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Eukaryotic	   initiation	   factors	   (eIFs)	   govern	   assembly	   of	   ribosomes	   on	   nascent	   mRNAs	   to	   be	  
translated.	  Many	  eIFs	  have	  been	  identified	  in	  proteomic	  screens	  which	  aim	  to	  identify	  proteins	  
that	  are	  subject	  to	  post-­‐translational	  modification	  by	  SUMO.	  Despite	  this,	  many	  remain	  to	  be	  
biochemically	   validated	  or	   functionally	   characterised.	   In	   this	  project,	   the	  DEAD-­‐box	  helicases	  
eIF4A1	  and	  eIF4A2	  were	  found	  to	  be	  SUMOylated	  on	  conserved	  lysine	  residues	  K216	  and	  K226	  
respectively	   using	   an	   in	   vitro	   SUMOylation	   assay	   and	   mass	   spectrometry.	   Additionally,	   the	  
SUMOylation	  of	  eIF4A2	  was	  found	  to	  increase	  in	  response	  to	  arsenite-­‐treatment	  (a	  treatment	  
known	  to	  induce	  stress	  granule	  formation	  in	  mammalian	  cells).	  Furthermore,	  mutation	  of	  K226	  
in	  eIF4A2	  affects	  the	  formation	  of	  stress	  granules.	  Further	  work	  will	  be	  required	  to	  determine	  
the	  potential	  effect	  of	  SUMOylation	  of	  eIF4A2	  on	  global	  translation.	  	  
Double-­‐strand	  breaks	  (DSBs)	  form	  some	  of	  the	  most	  deleterious	  and	  damaging	  lesions	  to	  DNA.	  
The	   DNA	   damage	   mediator,	   53BP1,	   governs	   the	   choice	   of	   repair	   method	   promoting	   error	  
prone	  non-­‐homologous	  end	  joining	  over	  homologous	  recombination.	  In	  this	  project,	  two	  novel	  
phosphorylation	   sites	   within	   the	   N-­‐terminus	   of	   53BP1	   were	   identified.	   Phosphorylation	   of	  
these	  residues	  is	  critical	  for	  the	  localisation	  of	  TopBP1	  to	  sites	  of	  damage.	  Pulse-­‐labelling	  cells	  
with	  traceable	  nucleotide	  analogues	  reveals	  that	  failure	  to	  phosphorylate	  these	  residues	  also	  
results	   in	  a	   failure	   to	   sustain	  a	  G1/S-­‐phase	  checkpoint	  when	  DSBs	  are	  present.	  These	   results	  
indicate	   that	   53BP1	   integrates	   two	   elements	   of	   the	   stress	   response-­‐	   choice	   of	   DSB	   repair	  
pathway	  and	  cell-­‐cycle	  regulation.	  Further	  work	  will	  elucidate	  the	  exact	  mechanism	  requiring	  
both	  53BP1	  and	  TopBP1	  to	  maintain	  the	  G1/S-­‐phase	  checkpoint.	  	  
53BP1	   is	   a	   reader	   of	   the	   histone	   code,	   recognising	   both	   methylation	   and	   ubiquitination	   of	  
histones	   through	   distinct	   domains.	   In	   this	   project,	   the	   BRCT2	   domains	   at	   the	   C-­‐terminus	   of	  
53BP1	  were	  shown	  to	  recognise	  a	  third	  post-­‐translational	  mark,	  phosphorylation.	  By	  analysing	  
the	  dependence	  on	  phosphorylation	  of	   the	   localisation	  of	   the	  BRCT2	   domains	   in	   isolation	   to	  
laser-­‐induced	  DNA	  damage	  alongside	  structural	  and	  biochemical	  data,	   it	  was	  shown	  that	   the	  
BRCT2	   domains	   interact	   directly	   with	   ΥH2AX	   in	   vitro	   and	   in	   vivo.	   Although	   not	   essential	   for	  
localisation	  to	  DNA	  damage,	  abolition	  of	  this	  interaction	  results	  in	  a	  persistence	  of	  ΥH2AX	  foci	  
at	  ‘late’	  time	  points	  representing	  the	  heterochromatic	  fraction	  of	  breaks.	  Furthermore,	  it	  was	  
shown	  that	   this	  defect	   is	  propagated	  by	  a	   failure	   to	   localise	   the	  activated	  checkpoint	  kinase,	  
ATM.	  Further	  investigation	  will	  be	  required	  to	  determine	  the	  mechanism	  underlying	  the	  repair	  




4E-­‐BP1	   eIF4E-­‐	  binding	  protein	  1	  
4E-­‐H	   eIF4E-­‐homolog	  
53BP1	   Tumour	  suppressor	  p53-­‐binding	  protein	  1	  
8-­‐oxoG	   8-­‐oxo-­‐7,8-­‐dihydro-­‐guanine	  
9-­‐1-­‐1	  complex	   Rad9-­‐Rad1-­‐Hus1	  
A-­‐site	   Aminoacyl	  site	  
AAD	   ATR	  activation	  domain	  
Ago	   Argonaute	  proteins	  
alt-­‐NHEJ	   Alternative	  NHEJ	  (a.k.a	  MMEJ)	  
APE1	   Apurinic/apyrimidinic	  endonuclease	  1	  
APLF	   Aprataxin	  and	  PNK-­‐like	  factor	  
APS	   Ammonium	  persulfate	  
ARE	   Adenine	  and	  uracil-­‐rich	  elements	  
ARE-­‐BPs	   ARE-­‐binding	  proteins	  
ATM	   Ataxia	  telangiectasia	  mutated	  
ATP	   Adenosine	  triphosphate	  
ATR	   Ataxia	  telangiectasia	  mutated	  and	  Rad3	  related	  
ATRIP	   ATR-­‐interacting	  protein	  
BER	   Base	  excision	  repair	  
BLAST	   Basic	  local	  alignment	  search	  tool	  
BLM	   Bloom	  syndrome	  helicase	  
BRCA	   Breast	  cancer	  susceptibility	  protein	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BRCT	   BRCA1	  C-­‐terminal	  	  
BrdU	   Bromodeoxyuridine	  
BSA	   Bovine	  serum	  albumin	  
BTR	   BLM,	  TopoIIIα,	  RM1	  and	  RM2	  
CaCl2	   Calcium	  chloride	  
CAF1	   Chromatin	  assembly	  factor	  1	  
CAK	   CDK-­‐activating	  kinase	  
CCR4	   Chemokine	  (C-­‐C	  motif)	  receptor	  4	  
cdc	   cell	  division	  cycle	  
CDK	   Cyclin-­‐dependent	  kinase	  
cDNA	   complementary	  DNA	  	  
CENPF	   Centromere	  protein	  F	  
CENT2	   Centrin	  2	  
CHD3	   Chromodomain-­‐helicase-­‐DNA-­‐binding	  protein	  3	  
Chk2	   Checkpoint	  kinase	  2	  
CPD	   Cyclobutane-­‐pyrimidine	  dimer	  
CPE	   Cytoplasmic	  polyadenylation	  element	  
CPEB	   CPE-­‐binding	  proteins	  
CPK	   Creatine	  phosphokinase	  
CRISPR	   Clustered	  regulatory	  interspaced	  short	  palindromic	  repeats	  
CrPV	   Cricket	  paralysis	  virus	  
CS	   Cockayne	  syndrome	  
CSR	   Class-­‐switch	  recombination	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CtBP	   C-­‐terminal	  binding	  protein	  
CtIP	   CtBP-­‐interacting	  protein	  
CuSO4	   Copper	  Sulfate	  
Cy5	   Cyanine	  5	  
DAPI	   4',6-­‐diamidino-­‐2-­‐phenylindole	  
Dcp	   Decapping	  protein	  	  
DDR	   DNA	  damage	  response	  
DEAD	   Glutamate-­‐aspartate-­‐alanine-­‐glutamate	  
DHJ	   Double	  Holliday	  Junction	  
DIS3	   chromosome	  disjunction	  
DMEM	   Dulbecco's	  modified	  eagles	  medium	  
DNA	  	   Deoxyribonucleic	  acid	  
DNA-­‐PK	   DNA-­‐dependent	  protein	  kinase	  
dNTPs	   deoxynucleotide	  
DSB	   Double	  strand	  break	  
dsDNA	  	   Double-­‐stranded	  DNA	  	  
DTT	   Dithioreitol	  
E2F-­‐1	   E2F	  transcription	  factor	  1	  
EDC4	   Enhancer	  of	  decapping	  4	  
EDTA	   Ethylenediaminetetraacetic	  acid	  
EdU	   5-­‐ethynyl-­‐2'-­‐deoxyuridine	  
EGTA	   Ethylene	  glycol	  tetraacetic	  acid	  
eIF	   eukaryotic	  initiation	  factor	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eIF4E-­‐T	   eIF4E-­‐transporter	  
EJC	   Exon	  junction	  complex	  
EME1	   Essential	  meiotic	  structure-­‐specific	  endonuclease	  1	  
EmGFP	   Emerald	  green	  fluorescent	  protein	  
eRF	   eukaryotic	  release	  factor	  
Exo1	   Exonuclease	  1	  
EXPAND1	   Multiple	  myeloma	  1	  (a.k.a	  MUM1)	  
FACS	   Fluorescence	  activated	  cell	  sorting	  
FAN1	   Fanconi	  anaemia-­‐associated	  nuclease	  1	  
FANC	   Fanconi	  anaemia	  associated	  
FAT	   FRAP,	  ATM,	  TRRAP	  
FATC	   C-­‐terminal	  FAT	  domain	  
FCS	   Fetal	  calf	  serum	  
FEN1	   Flap	  endonuclease	  1	  
FHA	   Forkhead-­‐associated	  
FITC	   Fluoroscein	  
FoxM1	   Forkhead	  box	  protein	  M1	  
G3BP1	   GTPase-­‐activating	  protein	  (SH3-­‐domain)	  binding	  protein	  1	  
G418	   G418	  disulfate	  
GAP	   GTPase-­‐activating	  protein	  
GAR	   Glycine-­‐arginine	  rich	  
GCN	   General	  control	  nonderepressible	  
GDP	   Guanosine	  diphosphate	  
	  	  
9	  
GEF	   Guanine	  nucleotide	  exchange	  factor	  
GEN1	   Flap	  endonuclease	  GEN1	  homolog	  1	  
GFP	   Green	  fluorescent	  protein	  
GG-­‐NER	   Global	  genome	  NER	  
gRNA	   guideRNA	  
GST	   Glutathione	  S-­‐transferase	  
GTP	   Guanosine	  triphosphate	  
H2A	   Histone	  H2A	  
H2AX	   Histone	  H2A	  variant	  X	  
H4K20me	   methylation	  of	  histone	  H4	  on	  lysine-­‐20	  
H4K20me2	   dimethylation	  of	  histone	  H4	  on	  lysine-­‐20	  
HA	   Haemagglutinin	  
HAT	  	   Histone	  acetyl	  transferase	  
HCV	   Hepatitus	  C	  virus	  
HDR	   Homology-­‐directed	  repair	  
HEAT	  	  
Huntingtin,	  elongation	  factor	  3,	  a	  subunit	  of	  protein	  
phosphatase	  2	  and	  TOR1	  
HEPES	   4-­‐(2-­‐hyroxyethyl)-­‐1-­‐piperaxineethanesulfonic	  acid	  
His	   Histidine	  
HP1	   Heterochromatin	  protein	  1	  
HR	   Homologous	  recombination	  
HRP	   Horseradish	  peroxidase	  
TERT	   Telomerase	  reverse	  transcriptase	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TTP	   Tristetraprolin	  
HU	   Urea	  elution	  buffer	  
ICL	   Interstrand	  crosslink	  
IPTG	   Isopropyl	  β	  -­‐D-­‐1-­‐thiogalactopyranoside	  
IR	   Ionising	  radiation	  
IRES	   Internal	  ribosome	  entry	  site	  
IRIF	   Ionising	  radiation-­‐induced	  foci	  
ISRIB	   Integrated	  stress	  response	  inhibitor	  
ITAFs	   IRES-­‐trans-­‐activating	  factors	  
JMJD2A	   Lysine-­‐specific	  demethylase	  4A	  (aka	  KDM4A)	  
KAP-­‐1	   Kruppel-­‐associated	  box	  (KRAB)-­‐associated	  protein	  1	  
KCl	   Potassium	  chloride	  
KOAc	   Potassium	  Acetate	  
Ku	   Heterodimeric	  complex	  that	  binds	  broken	  DNA	  end	  
L3MBTL1	   L(3)Mbt-­‐like	  1	  	  
LB	   Lysogeny	  Broth	  
LC-­‐MS/MS	   Liquid	  chromatography	  tandem	  mass	  spectrometry	  
Lys-­‐C	   Endoproteinase	  Lys-­‐C	  
m/z	   Mass	  to	  charge	  ratio	  
MAPK	   Mitogen-­‐activated	  protein	  kinase	  
MCM	   Minichromosome	  maintenance	  protein	  complex	  
MDC1	   Mediator	  of	  DNA	  damage	  checkpoint	  1	  
MeCN	   Acetonitrile	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MEF	   Mouse	  embryonic	  fibroblast	  
MGMT	   O6-­‐methylguanine-­‐DNA	  methyltransferase	  
MgSO4	   Magnesium	  sulfate	  
miRNA	   Micro-­‐RNA	  
MLH1	   MutL	  homolog	  1	  
MMEJ	   microhomology	  mediated	  end	  joining	  (aka	  alt-­‐NHEJ)	  
MMR	   Mismatch	  repair	  
MMSET	   Multiple	  myeloma	  SET	  domain	  
MnCl2	   Manganese	  chloride	  
MNK-­‐1	  	   MAPK-­‐interacting	  kinase	  
MOPS	   3-­‐(N-­‐morpholino)propanesulfonic	  acid	  
Mre	   Meiotic	  recombination	  
MRN	   Mre11-­‐Rad50-­‐Nbs1	  
mRNA	   messenger	  RNA	  
mRNAseq	   mRNA	  sequencing	  
MSH	   MutS	  homolog	  
mTOR	   mammalian	  Target	  of	  Rapamycin	  
mTORC1	   mTOR	  complex	  1	  
MUS81	   MUS81	  structure-­‐specific	  endonuclease	  subunit	  
Na2HPO4	   Disodium	  phosphate	  
NaAc	   Sodium	  acetate	  
NaCl	   Sodium	  chloride	  
NaF	   Sodium	  fluoride	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NaOH	   Sodium	  hydroxide	  
NER	   Nucleotide	  excision	  repair	  
NETN	   NaCl/EDTA/Tris-­‐HCl/NP-­‐40	  
NH4HCO3	   Ammonium	  bicarbonate	  
NHEJ	   Non	  homologous	  end	  joining	  
NMD	   Non-­‐sense	  mediated	  decay	  
NOT	   Component	  of	  the	  CCR4-­‐NOT	  deadenylation	  complex	  
NPM1	   Nucleophosmin	  1	  
OD	   Oligomerisation	  domain	  
OGG1	   8-­‐oxoG	  DNA	  glycosylase	  1	  
ORF	   Open	  reading	  frame	  
P-­‐bodies	   Processing	  bodies	  
P-­‐site	   Peptidyl	  site	  
p53	   Tumour	  protein	  	  
PABP	   Poly	  (A)-­‐binding	  protein	  
PAIP1	   PABP-­‐interacting	  protein	  1	  
PAIP2	   PABP-­‐interacting	  protein	  2	  
PAM	   Protospacer	  adjacent	  motif	  
PAR	   Poly	  ADP-­‐ribose	  
PARN	   Poly	  (A)	  ribonuclease	  
PARP	   Poly	  ADP-­‐ribose	  polymerase	  
PBS	   Phosphate	  buffered	  saline	  
PCNA	   Proliferating	  cell	  nuclear	  antigen	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PDCD4	   Programmed	  cell	  death	  protein	  4	  
PI3K	   Phosphatidylinositol	  3-­‐kinase	  
PIAS	   Protein	  inhibitor	  of	  activated	  STAT	  
PIKK	   Phosphatidylinositol	  kinase-­‐like	  kinases	  
PIP	   PCNA-­‐interacting	  protein	  
PML	   Promeylocytic	  leukaemia	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PML-­‐NB	   PML-­‐Nuclear	  bodies	  
PMS2	   Postmeiotic	  segregation	  increased	  2	  
PNK	   Polynucleotide	  kinase	  
POH1	   Proteasome	  26S	  subunit,	  non	  ATPase	  14	  
pol	   Polymerase	  
PPI	   Pyrophosphate	  
PRD	   PIKK-­‐regulatory	  domain	  
PRMT1	   Protein	  arginine	  methyltransferase	  1	  
PTB	   Polypyrimidine-­‐tract	  binding	  protein	  
PTC	   Premature	  termination	  codon	  
PTIP	   Pax	  transactivation	  domain-­‐interacting	  protein	  
PTM	   Post-­‐translational	  modification	  
RAD	   Radiation	  sensitive	  
Rb	   Retinoblastoma	  protein	  
RbCl	   Rubidium	  chloride	  
RECQ5	   RECQ5	  DNA	  helicase	  
RFC	   Replication	  factor	  C	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RHINO	   Rad9-­‐Rad1-­‐Hus1	  interacting	  nuclear	  orphan	  
RIF1	   Replication	  timing	  regulatory	  factor	  1	  
RNA	   Ribonucleic	  acid	  
RNAi	   RNA	  interference	  
RNF	   Ring	  finger	  protein	  
RNP	   Ribonucleoproteins	  
ROS	   Reactive	  oxygen	  species	  
RPA	   Replication	  protein	  A	  
S	   Svedberg	  units	  (Ribosomal	  subunits)	  
SDS	   Sodium	  dodecyl	  sulphate	  
SDS-­‐PAGE	   SDS-­‐polyacrylamide	  gel	  electrophoresis	  
SDSA	   Synthesis	  dependent	  strand	  annealing	  
SENP	   Sentrin-­‐specific	  protease	  
SETDB	   Histone-­‐lysine	  N-­‐methyltransferase	  
SG	   Stress	  granules	  
SIM	   SUMO-­‐interacting	  motif	  
siRNA	   small	  interfering	  RNA	  
SIRT1	   Silent	  mating	  type	  information	  regulation	  2	  homolog	  1	  
Siz2	   SAP	  and	  mIZ-­‐finger	  domain	  
sld	   DNA	  replication	  regulator	  
SLX	   Synthetic	  lethal	  of	  unknown	  (X)	  function	  
SMG1	  




Srs2	   Suppressor	  of	  Rad6	  
SSBR	   Single-­‐strand	  break	  repair	  
ssDNA	   Single-­‐stranded	  DNA	  	  
ssODN	   Single-­‐stranded	  oligonucleotide	  
SUMO	   Small	  ubiquitin-­‐like	  modifier	  
SUV39	   Histone	  H3	  lysine-­‐9	  methyltransferase	  
TBE	   Tris/Borate/EDTA	  buffer	  
TC	   Ternary	  complex	  
TCR	   Transcription-­‐coupled	  repair	  
TdT	   deoxyribonucleotidyl	  transferase	  
TE	   Tris	  EDTA	  solution	  
TEMED	   Tetramethylethylenediamine	  
TFA	   Trifluoroacetic	  acid	  
TFIIH	   Transcription	  initiation	  factor	  IIH	  
TIA-­‐1	   T-­‐cell	  internal	  antigen	  1	  
TLS	   Translesion	  synthesis	  
TMZ	   Temozolomide	  
TopBP1	   Topoisomerase	  IIβ-­‐binding	  protein	  1	  
TRITC	   Tetramethylrhodamine	  
tRNA	   Transfer	  RNA	  
TRRAP	  
Transformation/transcription	  domain-­‐associated	  family	  
member	  
UBA	   Ubiquitin	  activating	  enzyme	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Ubc	   Ubiquitin	  conjugating	  enzyme	  
UBM	   Ubiquitin	  recognition	  motif	  
UBZ	   Ubiquitin-­‐binding	  zinc	  finger	  
UDR	   Ubiquitin-­‐dependent	  domain	  
uORF	   Upstream	  ORFs	  
Upf	   Regulator	  of	  non-­‐sense	  transcripts	  
USP7	   Ubiquitin-­‐specific	  processing	  protease	  7	  
UTR	   Untranslated	  region	  
UV	   Ultra	  violet	  
UV-­‐DBB	   UV-­‐radiation-­‐DNA	  damage-­‐binding	  protein	  
UVA	   Ultraviolet	  A	  
UVSSA	   UV-­‐stimulated	  scaffold	  protein	  A	  
V(D)J	   Variable,	  diversity	  and	  joining	  
VEGF	   Vascular	  endothelial	  growth	  factor	  
XBP1	   X-­‐box	  binding	  protein	  1	  
XIAP	   X-­‐linked	  inhibitor	  of	  apoptosis	  
XLF	  
a.k.a	  Non	  homologous	  end	  joining	  factor	  1	  (NHEJ	  1),	  
Cernunnos	  
XP	   Xeroderma	  pigmentosum	  	  
XRCC4	   X-­‐ray	  repair	  cross-­‐complementing	  protein	  4	  
XRN1	   exoribonuclease	  1	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In	  mammalian	  cells	  post-­‐translational	  modifications	  govern	  many	  aspects	  of	  protein	  form	  and	  
function.	  Crucially,	  these	  modifications	  are	  rapid	  and	  have	  the	  potential	  to	  quickly	  reprogram	  
the	   physiology	   of	   the	   cell	   when	   needed.	   Alongside	   maintaining	   cellular	   homeostasis,	   post-­‐
translational	  modifications	  regulate	  the	  response	  to	  cellular	  stress.	  The	  causes	  of	  cellular	  stress	  
take	  many	   forms,	   from	  oxidative	   stress	   to	   ultraviolet	   light,	   from	   ionising	   radiation	   to	   amino	  
acid	  starvation.	   In	  all	   cases,	   the	  ability	  of	   the	  cell	   to	   tolerate	   these	  stresses	   is	  propagated	  by	  
cascades	  of	  post-­‐translational	  modifications	  that	  occur	  as	  a	  result.	  These	  serve	  as	  the	  chemical	  
messages	   and	   intra-­‐cellular	   switches	   that	   can	   alter	   gene	   expression,	   translation,	   genomic	  
integrity	  and	  cell-­‐cycle	  control.	  	  
1.1	  Post-­‐translational	  modification	  
Post-­‐translational	   modifications	   (PTMs)	   allow	   cells	   to	   respond	   to	   changes	   in	   both	   the	  
intracellular	   and	   extracellular	   environment.	   They	   mediate	   the	   chemical	   messages	   between	  
protein	   sensors	  and	  effectors,	  often	   referred	   to	  as	   cascades,	   to	  maintain	  homeostasis	  under	  
advantageous	   conditions	   and	   to	   reprogram	   the	   cell	   for	   survival	   under	   disadvantageous	  
conditions.	  Most	  importantly,	  PTMs	  are	  rapid	  and	  reversible	  allowing	  the	  cell	  to	  respond	  to	  the	  
ever-­‐changing	  cellular	  environment	  [11].	  	  
PTMs	   function	   by	   altering	   the	   properties	   of	   proteins	   within	   the	   cell.	   For	   example,	   they	   can	  
directly	   alter	   the	   enzymatic	   activity	   of	   a	   target	   protein,	   potentially	   via	   the	   induction	   of	   a	  
conformational	   change	   in	  a	  protein’s	   structure.	  Alternatively,	  PTMs	  can	  enhance	  or	  suppress	  
protein-­‐protein	   interactions,	   alter	   subcellular	   localisation	   or	   affect	   cellular	   abundance	   of	  
proteins	  by	  targeting	  them	  for	  proteasomal	  degradation	  [12-­‐14].	  	  
Given	   that	   over	   200	   types	  of	   PTM	  have	  been	   identified	   and	   that	   individual	   proteins	  may	  be	  
modified	  by	  more	  than	  one	  type	  of	  modifications	  on	  several	  amino	  acids,	  this	  creates	  a	  difficult	  
challenge	   to	   identify	   and	   characterise	   these	   networks	   [11].	   Additionally,	   as	   many	   of	   these	  
modifications	   have	   yet	   to	   be	   functionally	   characterised	   it	   becomes	   necessary	   to	   isolate	   and	  
determine	   which	   individual	   PTMs	   are	   critical	   for	   facilitating	   particular	   functions.	   Mass	  
spectrometry	   has	   accelerated	   the	   identification	   of	   PTMs,	   yet	   many	   remain	   to	   be	   validated	  
biochemically	   and	   their	   function	   determined	   [15].	   Table	   1.1	   summarises	   examples	   of	  
regulation	  by	  phosphorylation,	  ubiquitination	  and	  SUMOylation.	  These	  examples	  are	  explained	  
in	  more	  detail	  throughout	  this	  section.	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Table	  1.1	  Examples	  of	  regulation	  by	  phosphorylation,	  ubiquitination	  and	  SUMOylation.	  	  
Protein	   Cellular	  response	   PTM	   References	  
4E-­‐BP	   Suppression	  of	  global	  translation	  	   phosphorylation	   [13]	  
Rb	   G1-­‐S	  phase	  cell-­‐cycle	  progression	  	   phosphorylation	   [16]	  
-­‐	   Targeting	  proteins	  for	  proteasomal	  
degradation	  
ubiquitination	   [17]	  
NPM1	   Suppression	  of	  centrosome	  
expansion	  	  
SUMOylation	   [18]	  
PML	   PML	  nuclear	  bodies	  	   SUMOylation	   [19]	  
SUMO-­‐PML	   Degradation	  of	  PML	  nuclear	  bodies	   ubiquitination	   [20]	  
XBP1	  
FoxM1	  
Regulation	  of	  transcription	  factors	   SUMOylation	   [21,	  22]	  
	  
1.1.1	  Phosphorylation	  
Phosphorylation	   is	   a	   common	   PTM	   that	   plays	   important	   roles	   in	   regulating	   the	   cell-­‐cycle	   as	  
well	  as	   responses	   to	  metabolic	  and	  genotoxic	   stresses.	  Enzymes	   that	  phosphorylate	  proteins	  
are	  referred	  to	  as	  kinases.	  Many	  kinases	  exist	  within	  cells	  and	  although	  one	  kinase	  may	  dictate	  
the	   phosphorylation	   of	   overlapping	   protein	   networks,	   in	   mammalian	   cells	   the	   three	   most	  
commonly	  phosphorylated	  residues	  are	  serine,	  threonine	  and	  tyrosine	  [23].	  	  
The	  phosphatidylinositol	  3-­‐kinase-­‐related	  protein	  kinases	  (PIKKs)	  are	  a	  family	  of	  kinases	  which	  
modulate	   cellular	   metabolism	   and	   checkpoint	   signalling	   in	   response	   to	   DNA	   damage.	   PIKKs	  
phosphorylate	   serine	   or	   threonine	   residues	   followed	   by	   a	   glutamine	   residue	   (SQ/TQ	  motifs)	  
[24].	   The	   six	   PIKKs	  present	   in	  mammalian	   cells	   are	  mammalian	   target	   of	   rapamycin	   (mTOR),	  
Transformation/transcription	   domain-­‐associated	   protein	   (TRRAP),	   Suppressor	   with	  
morphological	   defects	   on	   genitalia	   family	   member	   (SMG1),	   Ataxia	   telangiectasia-­‐mutated	  
(ATM),	   Ataxia	   telangiectasia-­‐mutated	   and	   Rad3-­‐related	   (ATR)	   and	   DNA-­‐dependent	   protein	  
kinase	  catalytic	  subunit	  (DNA-­‐PKcs).	  This	  family	  of	  protein	  kinases	  all	  have	  comparable	  domain	  
architecture	   include	   N-­‐terminal	   Huntingtin,	   elongation	   factor	   3,	   a	   subunit	   of	   protein	  
phosphatase	  2	  and	  TOR1	  (HEAT)	  repeats.	  Adjacent	  to	  the	  HEAT	  repeats	  is	  a	  FRAP,	  ATM,	  TRRAP	  
(FAT)	  domain	  followed	  by	  the	  kinase	  domain,	  a	  PIKK-­‐	  regulatory	  domain	  (PRD)	  and	  a	  C-­‐terminal	  
FAT	  domain	  (FATC)	  [25].	  	  
Predominantly,	   mTOR	   governs	   global	   translation.	   By	   hyperphosphorylating	   4E-­‐BP1,	   which	  
would	   otherwise	   inhibit	   eIF4E	   availability	   in	   the	   cell,	   mTOR	   promotes	   cap-­‐dependent	  
translation	  [13].	  TRRAP	  is	  a	  core	  component	  of	  Histone	  acetyl	  transferase	  (HAT)	  complexes	  and	  
regulates	   PTM	  of	   chromatin	   via	   histone	   tails	   [26].	   SMG1	   is	   recruited	   to	  mRNAs	   during	  Non-­‐
sense	  mediated	  decay	  (NMD)	  and	  is	  incorporated	  into	  Stress	  granules	  (SGs)	  [27,	  28].	  The	  DNA	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damage	   response	   kinases	   ATM,	   ATR	   and	   DNA-­‐PKcs	   propagate	   signalling	   at	   double-­‐strand	  
breaks	  (DSBs),	  regions	  of	  single-­‐stranded	  DNA	  (ssDNA)	  and	  during	  DSB	  repair,	  respectively	  [29-­‐
31].	  	  	  
Cyclin-­‐dependent	   kinases	   (CDKs)	   regulate	   progression	   through	   the	   cell-­‐cycle	   by	  
phosphorylating	   protein	   targets	   on	   serine/threonine	   residues	   adjacent	   to	   a	   proline	   residue	  
(S/TP	  motif)	   [32].	   CDK	   activity	   is	   regulated	   throughout	   the	   cell-­‐cycle	   by	   the	   availability	   and	  
binding	  of	  cyclins	  to	  stimulate	  kinase	  activity.	  For	  example,	  in	  G1-­‐phase	  mammalian	  cells	  cyclin	  
D	  levels	  increase	  promoting	  kinase	  activity	  of	  CDKs	  4	  and	  6,	  whereas	  towards	  S-­‐phase	  levels	  of	  
cyclin	   E	   increase,	   stimulating	   the	   activity	   of	   CDK2	   [33,	   34].	   CDK2	  proceeds	   to	   phosphorylate	  
retinoblastoma	  (Rb),	  which	  releases	  the	  transcription	  factors	  E2F-­‐1	  to	  promote	  the	  G1-­‐S	  phase	  
transition	   [16].	   The	   downstream	   effect	   of	   activation	   of	   this	   kinase	   relies	   not	   only	   on	   the	  
phosphorylation	  of	  the	  protein	  targets	  but	  also	  the	  ability	  for	  the	  domains	  of	  other	  proteins	  to	  
recognise	   and	   bind	   to	   the	   phosphorylated	   serine/threonine	   residues.	   This	   requires	   the	  
phospho-­‐binding	   capacity	   by	   distinct	  molecular	  motifs	   such	   as	   Forkhead-­‐associated	   domains	  
and	  BRCA1	  C-­‐terminal	  (BRCT)	  domains	  to	  name	  but	  a	  few	  [35].	  	  
1.1.2	  Ubiquitination	  
Compared	   to	   phosphorylation,	   ubiquitination	   is	   a	   large	   PTM	   comprising	   the	   addition	   of	   an	  
~8.5kDa	   to	  a	   lysine	   residue	  by	   covalent	   linkage	   [15,	   36].	  Ubiquitination	   is	   required	   for	  many	  
functions	   within	   the	   cell,	   including	   the	   DNA	   damage	   response	   and	   targeting	   proteins	   for	  
degradation	  by	  the	  proteasome.	  	  
Unlike	   phosphorylation,	   four	   proteins	   are	   required	   to	   catalyse	   the	   ubiquitination	   of	   target	  
proteins,	   including	   a	   deubiquitinating	   enzyme	   required	   for	   the	   generation	   of	   the	   mature	  
ubiquitin	   protein	   from	   its	   protein	   precursor	   [37].	   	   Initially,	   ubiquitin	   is	   attached	   to	   an	   E1	  
ubiquitin-­‐activating	   enzyme	   in	   an	   ATP-­‐dependent	   manner	   via	   the	   formation	   of	   a	   thioester	  
bond.	   In	  mammalian	   cells,	   two	   ubiquitin-­‐activating	   enzymes	   have	   been	   identified	  UBA1	   and	  
UBA6,	  with	  UBA1	  being	   required	   for	  53BP1	   IRIF	   formation	   in	   response	   to	  DNA	  damage	   [38].	  
Ubiquitin	  is	  then	  transferred	  to	  an	  E2	  ubiquitin-­‐conjugating	  enzyme.	  Although	  there	  are	  many	  
E2	   ubiquitin-­‐conjugating	   enzymes	   in	   mammalian	   cells,	   Ubc13	   has	   been	   identified	   as	   an	  
important	  mediator	  in	  the	  propagation	  of	  the	  DNA	  damage	  response	  [39].	  Lastly,	  the	  ubiquitin	  
complex	   is	  directed	   to	  and	   transferred	   to	   the	   target	  protein	  by	  an	  E3	  ubiquitin	   ligase,	  which	  
bridges	  interactions	  between	  the	  E2-­‐ubiquitin	  complex	  and	  the	  target	  protein.	  As	  a	  result,	  it	  is	  
the	  E3	  ubiquitin	  ligases	  that	  provide	  target	  specificity	  for	  the	  ubiquitination	  machinery	  [40].	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As	  with	  phosphorylation,	  the	  generation	  and	  abolition	  of	  protein-­‐protein	  interactions	  by	  PTM	  
requires	  both	  the	  modified	  protein	  and	  a	  specialised	  recognition	  motif.	  Many	  motifs	  have	  been	  
identified	   including	   Ubiquitin-­‐recognition	   motifs	   (UBMs)	   and	   Ubiquitin-­‐binding	   zinc	   finger	  
(UBZ)	  domains,	  both	  of	  which	  feature	  in	  the	  Y-­‐family	  DNA	  polymerases	  utilised	  in	  translesion	  
synthesis	  (TLS)	  [41,	  42].	  	  
1.1.3	  SUMOylation	  
Small	  Ubiquitin-­‐like	  Modifier	  (SUMO)	  is	  a	  post-­‐translational	  modification	  that	  is	  essential	  for	  a	  
number	  of	  cellular	  processes	  from	  regulating	  transcription,	  DNA-­‐damage	  repair	  and	  controlling	  
the	  cellular	  response	  to	  stress.	  	  
There	  are	  four	  isoforms	  of	  SUMO	  in	  mammalian	  cells,	  SUMO1,	  SUMO2,	  SUMO3	  and	  SUMO4.	  
SUMO2	   and	   3	   share	   approximately	   97%	  homology,	  whereas	   SUMO1	   shares	   only	   about	   47%	  
homology	  with	  SUMO2/3	   [43].	  All	  SUMOs	  are	  synthesised	  as	   inactive	  precursor	  proteins	  and	  
have	  to	  be	  cleaved	  by	  specific	  cysteine	  isopeptidases,	  referred	  to	  as	  sentrin-­‐specific	  proteases	  
(SENPs),	   in	   order	   to	   yield	   the	   active	   protein	   that	   can	   then	  be	   conjugated	   to	   a	   target	   onto	   a	  
lysine	   residue	   [44].	   SUMO4	  however,	   lacks	   the	   residue	   required	   for	   cleavage	   to	  produce	   the	  
active	  protein	  and	  as	  a	  result	  cannot	  be	  conjugated	  to	  target	  proteins	  [45].	  Similar	  to	  ubiquitin,	  
SUMO2/3	  are	   capable	  of	   forming	  SUMO	  chains	  on	   target	  proteins	  due	   to	  an	  available	   lysine	  
residue	  (K11)	  present	  on	  both	  mammalian	  SUMO2	  and	  3	  [46].	  However,	  as	  SUMO1	  lacks	  this	  
lysine	   residue,	   only	   one	   SUMO1	  molecule	   can	  modify	   a	   target	   protein,	   alternatively	   SUMO1	  
can	  act	  as	  a	  chain	  terminator	  of	  a	  polySUMOylated	  target	  [43].	  	  
1.1.3.1	  Mechanism	  of	  SUMOylation	  and	  deSUMOylation	  
The	   mechanism	   by	   which	   SUMOylation	   occurs	   is	   comparable	   to	   that	   of	   ubiquitination	   of	  
substrates.	   Following	   activation	   of	   the	   SUMO	   molecule	   by	   SENPs	   to	   reveal	   a	   C-­‐terminal	  
diglycine	  residue,	  SUMO-­‐GG	  forms	  a	  thioester	  bond	  with	  an	  E1	  SUMO	  activating	  enzyme	  (SAE)	  
formed	  of	  a	  heterodimeric	  complex	  SAE1	  and	  SAE2.	  SUMO	  is	  then	  transferred	  to	  an	  E2	  SUMO	  
conjugating	   enzyme,	  Ubc9.	   From	   there,	   SUMO	   can	   either	   be	   directly	   conjugated	   to	   a	   target	  
protein	   containing	   SUMO	   consensus	   motif	   marked	   by	   a	   ψKxE	   motif,	   where	   ψ	   marks	   a	  
hydrophobic	  residue	  [43].	  Alternatively,	  an	  E3	  SUMO	  ligase	  may	  be	  utilised	  to	  conjugate	  SUMO	  
to	  non-­‐consensus	  lysine	  residues	  (figure	  1.1).	  Although	  only	  one	  E2	  SUMO	  conjugating	  enzyme	  
has	   been	   identified	   in	  mammalian	   cells,	  many	   E3	   ligases	   continue	   to	   be	   identified.	   Recently	  
TRIM28/KAP1,	   was	   found	   to	   catalyse	   SUMOylation	   of	   a	   DNA	   G-­‐quadruplex	   binding	   protein	  
specifically,	  nucleophosmin	  (NPM1)	  resulting	  in	  re-­‐localisation	  to	  the	  centrosome	  required	  for	  
the	  maintenance	  of	   genomic	   integrity	   [18].	  Conversely,	   the	  SUMO	  E3	   ligase,	  PIAS1	  has	  been	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demonstrated	   to	   bind	   to	   and	   mediate	   the	   SUMOylation	   of	   many	   targets	   that	   regulate	  
transcription	   [47].	   The	   SUMO	   E3	   ligases	   provide	   specificity	   to	   the	   SUMOylation	   machinery	  
directing	  the	  post-­‐translational	  modification	  to	  specific	  subsets	  of	  targets	  within	  the	  cell.	  	  
SUMOylation	   is	   a	   highly	   dynamic	   way	   of	   regulating	   protein	   function	   with	   waves	   of	  
SUMOylation	   occurring	   in	   response	   to	   cellular	   stress.	   Regulating	   deSUMOylation	   of	   protein	  
targets	   is	   just	   as	   important	   and	   requires	   the	   same	   group	  of	   enzymes	   that	   cleave	   the	   SUMO	  
precursor	   to	   yield	   the	   conjugation-­‐competent	   isoform.	   Six	   SENPs	   exist	   in	   mammalian	   cells;	  
SENP1,	   2	   and	   5	   are	   required	   for	   the	   maturation	   of	   SUMO,	   SENP1	   is	   also	   predominantly	  
involved	   in	   deSUMOylation.	   SENP6	   and	   SENP7	   facilitate	   deSUMOylation	   of	   polySUMOylated	  
target	  proteins	  [43,	  44].	  	  











Figure	  1.1	  Mechanism	  of	  SUMOyla8on.	  SUMO	  is	  processed	  to	  the	  mature	  form	  
by	  SENP	  proteases.	  SUMO	  is	  a?ached	  to	  an	  E1	  SUMO	  acAvaAng	  enzyme,	  then	  
passed	  to	  an	  E2	  SUMO	  conjugaAng	  enzyme.	  SUMO	  is	  conjugated	  to	  the	  target	  
protein	  either	  directly	  or	  via	  an	  E3	  SUMO	  ligase.	  SENP	  proteases	  also	  mediate	  
the	  deconjugaAon	  of	  SUMO	  from	  target	  proteins.	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1.1.3.2	  Diverse	  functions	  of	  SUMO	  
SUMO	   can	   act	   through	   a	   range	   of	   mechanisms,	   either	   by	   altering	   subcellular	   localisation,	  
altering	   protein-­‐protein	   interactions	   or	   promoting	   protein	   degradation.	   The	   role	   of	   SUMO	  
varies	   depending	   upon	   the	   specific	   process	   involved,	   for	   example	   S.	   cerevisiae	   PCNA	   is	  
SUMOylated	  during	  DNA	  replication.	  SUMOylated	  PCNA	  is	  then	  able	  to	  recruit	  Srs2	  through	  a	  
SUMO-­‐interacting	   motif	   (SIM),	   which	   supresses	   Rad51	   filament	   formation	   and	   homologous	  
recombination	  (HR)	  [48].	  	  
SUMO	   can	   also	   alter	   numerous	   protein-­‐protein	   interactions	   of	   large	   complexes	   by	   way	   of	  
group	   modification.	   Group	   modification	   by	   SUMO	   was	   proposed	   following	   analysis	   of	   the	  
ability	  of	  cells	  to	  repair	  DNA	  damage	  by	  HR.	  Following	  resection	  of	  the	  DNA	  ends,	  Siz2,	  an	  E3	  
SUMO	   ligase,	   catalyses	   the	   SUMOylation	   of	   a	   cluster	   of	   proteins	   involved	   in	   the	   repair	  
pathway.	   The	   researchers	   noted	   that,	   typically,	   deletion	   of	   one	   or	   two	   of	   the	   SUMOylation	  
sites	   in	   this	   pathway	   yielded	   only	   very	  mild	   HR	   defects	   and	   proposed	   that	   SUMOylation	   of	  
other	   proteins,	   along	   with	   SUMO-­‐interacting	   partners	   containing	   SIMs	   was	   sufficient	   to	  
continue	  to	  repair	  the	  DNA	  breaks.	  Furthermore,	  only	  deletion	  of	  the	  E3	  SUMO	  ligase	  directly	  
prevented	  SUMOylation	  and	  SUMOylation-­‐dependent	  repair	  [49].	  	  
Another	   well-­‐studied	   example	   of	   protein	   group	   SUMOylation	   is	   in	   Promyelocytic	   nuclear	  
bodies	   (PML-­‐NBs).	   PML-­‐NBs	   are	   nuclear	   aggregates	   that	   form	   in	   response	   to	   cellular	   stress	  
[19].	  PML	  protein	  has	  been	  shown	  to	  be	  SUMOylated	  on	  several	  residues	  and	  contains	  a	  SIM.	  
Despite	  this,	  mutation	  of	  the	  acceptor-­‐lysine	  residues	  or	  of	  the	  SIM	  does	  not	  prevent	  PML-­‐NB	  
formation	  [50].	  PML	  has	  intrinsic	  E3	  SUMO	  ligase	  activity	  and	  comparable	  to	  the	  loss	  of	  Siz2	  in	  
the	   DNA	   damage	   response,	   loss	   of	   PML	   results	   in	   a	   failure	   to	   form	   PML-­‐NBs	   indicating	   its	  
central	   role	   in	  catalysing	  SUMOylation	  of	  partner	  proteins	   [19,	  20].	  Partner	  proteins	  can	  also	  
be	  recruited	  to	  PML-­‐NBs	  through	  SIMs	  allowing	  group	  modification	  to	  hold	  these	  large	  nuclear	  
structures	  together.	  Furthermore,	  PML-­‐NBs	  have	  been	  demonstrated	  to	  facilitate	  the	  isolation	  
and	  degradation	  of	  misfolded	  proteins,	  firstly	  by	  SUMOylating	  and	  re-­‐localising	  the	  proteins	  to	  
PML-­‐NBs.	   Following	   incorporation	   into	   PML-­‐NBs,	   the	   proteins	   are	   targeted	   for	   proteasomal	  
degradation	  by	  RNF4-­‐dependent	  ubiquitination	  [20].	  	  	  
The	   ubiquitination	   of	   SUMOylated-­‐substrates	   is	   catalysed	   by	   a	   special	   subset	   of	   ubiquitin	  
ligases	   that	  contain	  SIMs	  known	  as	  SUMO-­‐targeted	  ubiquitin	   ligases	   (STUbLs).	  A	  well-­‐studied	  
example	   is	  RNF4,	  which	   targets	  SUMOylated	  PML	  and	  associated	  proteins	   for	  degradation	   in	  
PML-­‐nuclear	  bodies	  [20,	  51].	  RNF4	  binds	  to	  SUMO-­‐chains	  utilising	  two	  SIMs	   located	  with	  the	  
N-­‐terminus	  and	  functions	  as	  a	  dimer	  [52,	  53].	  	  
	  	  
33	  
SUMOylation	   is	   also	   capable	   of	   modulating	   the	   cellular	   response	   to	   stress	   by	   regulating	  
transcription.	   It	   is	   commonly,	   reported	   that	   several	   transcription	   factors	   are	   negatively	  
regulated	   by	   SUMOylation	   [54].	   However,	   deSUMOylation	   can	   also	   be	   utilised	   to	   positively	  
regulate	  transcription	  factors,	  for	  example	  endoplasmic	  reticulum	  (ER)	  stress	  or	  the	  unfolded-­‐
protein	  response	  results	  in	  deSUMOylation	  of	  the	  transcription	  factor	  XBP1	  [21].	  Recently,	  the	  
SUMO	  protease	  SENP6	  was	  demonstrated	  to	  activate	  the	  transcription	  factor,	  FoxM1,	  via	  the	  
removal	  of	  SUMO	  to	  promote	  cell	  growth	  [21].	  	  
Post-­‐translational	  modification	  by	  SUMO	  governs	  the	  ability	  of	  cells	  to	  tolerate	  different	  forms	  
of	   stress,	   facilitating	   HR	   in	   response	   to	   DNA	   damage	   and	   reprogramming	   transcription	   to	  
highlight	  a	   few	  examples	   [48,	  55].	  Regulation	  by	  SUMO	   is	  highly	  complex,	   involving	  different	  
isoforms	   of	   SUMO	   capable	   of	   forming	   several	   intermediates	   alongside	   cross-­‐talk	   with	   other	  
post-­‐translational	   modifications	   such	   as	   ubiquitin	   [56].	   Finally,	   SUMO	   is	   capable	   of	  
orchestrating,	   maintaining	   and	   disassembling	   large	   protein	   complexes	   by	   facilitating	   group	  
protein-­‐protein	   interactions	   [49].	  As	  a	  result,	   it	   is	  quite	   likely	   that	   the	  ramifications	  of	  SUMO	  
extend	  beyond	  the	  current	  understanding	  to	  other	  critical	  cellular	  processes	  in	  which	  the	  role	  
of	  SUMO	  has	  yet	  to	  be	  elucidated.	  	  
1.1.3.3	  Identification	  of	  the	  SUMO	  proteome	  
A	   number	   of	   approaches	   exist	   to	   study	   the	   SUMO	   proteome	   (reviewed	   in	   [43]).	   Primarily,	  
these	   rely	   on	   the	   isolation	   of	   SUMO	   and	   its	   SUMOylated	   targets	   using	   several	   different	  
approaches,	  followed	  by	  identification	  of	  the	  target	  proteins	  and	  modified	  residues	  using	  liquid	  
chromatography-­‐tandem	   mass	   spectrometry	   (LC-­‐MS/MS).	   Classically,	   SUMOylated	   proteins	  
have	  been	   isolated	  by	  exogenously	   introducing	  a	  variant	  of	  SUMO	  with	  either	  an	  affinity-­‐tag	  
that	   can	   be	   used	   to	   directly	   purify	   SUMOylated	   substrates	   or	   by	   using	   an	   antibody-­‐specific	  
epitope	  such	  as	  Flag	  [57,	  58].	  Using	  these	  approaches,	  SUMOylated	  proteins	  are	  then	  purified	  
under	   denaturing	   conditions.	   This	   ensures	   that	   only	   proteins	   covalently	   modified	   on	   lysine	  
residues	   co-­‐purify/immunoprecipitate	   with	   SUMO	   and	   exclude	   protein-­‐protein	   interactions	  
that	  rely	  on	  natively	  folded	  structures	  such	  as	  SIMs.	  	  
Additionally,	   following	   lysis	   of	   cells	   and	   prior	   to	   denaturation	   of	   proteins,	   SENP-­‐specific	  
inhibitors	   are	   also	   added	   to	   prevent	   deSUMOylation	   of	   proteins	   during	   the	   purification	  
process.	  The	  processing	  of	  samples	  for	  analysis	  by	  mass	  spectrometry	  requires	  digestion	  of	  the	  
polypeptide	  chains	  by	  peptidases	  such	  as	  trypsin	  [58].	  This	  generates	  small	  peptide-­‐chains	  that	  
can	  be	  easily	  ionised	  and	  detected	  by	  the	  mass	  spectrometer.	  However,	  digestion	  with	  trypsin	  
generates	  a	   short	  peptide	   from	   the	   target	  protein	  with	  a	   long	  peptide	   side-­‐chain	   if	   SUMO	   is	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present,	   making	   it	   difficult	   to	   detect.	   As	   a	   result,	   the	   introduction	   of	   an	   arginine	   or	   lysine	  
residue	  close	  to	  the	  C-­‐terminus	  of	  SUMO	  generates	  a	  shorter	  peptide	  branch	  conjugated	  to	  a	  
lysine	  residue	  if	  the	  substrate	  is	  SUMOylated	  [22].	  These	  modifications	  are	  much	  easier	  for	  the	  
mass	  spectrometer	  to	  detect	  by	  searching	  for	  a	  characteristic	  shift	  in	  the	  mass	  to	  charge	  ratio	  
(m/z)	   produced	   by	   the	   additional	   diglycine	   residue.	   SUMOylated	   residues	   can	   be	   identified	  
without	  the	  introduction	  of	  a	  lysine	  residue	  prior	  to	  the	  diglycine	  motif,	  either	  by	  searching	  for	  
a	   larger	   side-­‐group	   covalently	   attached	   to	   lysine	   or	   by	   using	   a	   different	   combination	   of	  
peptidases,	  such	  as	  Trypsin	  and	  Lys-­‐C	  [3].	  	  
SUMOylated	   substrates	   can	   also	   be	   purified	   without	   the	   introduction	   of	   an	   exogenously	  
expressed	   SUMO.	   This	   is	   advantageous	   as	   overexpression	   of	   SUMO	   could	   affect	   the	  
homeostatic	   mechanisms	   regulating	   SUMOylation	   and	   deSUMOylation	   in	   the	   cell	   making	   it	  
difficult	   to	  study	  SUMOylation	  patterns	   in	   response	   to	  stress	   for	  example.	  To	  overcome	  this,	  
SUMO	  and	   its	   substrates	   can	  be	   immunoprecipitated	  directly	   from	   cell	   lysates	   using	   specific	  
antibodies	  or	   alternatively,	   SIM-­‐traps	   can	  be	  used	   [2,	   4].	   SIM-­‐traps	  utilise	   recognition	  motifs	  
contained	   in	   some	   proteins	   to	   precipitate	   polySUMOylated	   targets	   by	   exploiting	   native	  
protein-­‐protein	   interactions.	   However,	   this	  method	   of	   purification	   is	   likely	   to	   generate	   false	  
positive	   candidates	   given	   the	   networks	   of	   interactions	   facilitated	   by	   group	   modification	   by	  
SUMO.	  	  
1.2	  Initiating	  translation	  in	  Eukaryotic	  cells	  
1.2.1	  Cap-­‐dependent	  Translation	  initiation	  
Translation	   is	   the	   process	   by	   which	   nascent	   mRNAs	   transcripts	   are	   read	   by	   ribosomes	   to	  
synthesise	  proteins.	  Translation	  is	  composed	  of	  three	  distinct	  stages,	  initiation,	  elongation	  and	  
termination.	  Firstly,	  translation	  initiation	  involves	  the	  loading	  of	  ribosomal	  subunits	  on	  to	  the	  
mRNA	   to	   be	   translated	   [1].	   Secondly,	   the	   elongation	   step	   comprises	   the	   extension	   of	   the	  
polypeptide	   chain	   by	   decoding	   the	   codon	   sequence.	   Finally,	   termination	   of	   the	   polypeptide	  
chain	   requires	   the	   recognition	   of	   a	   stop	   codon	   by	   the	   translation	   machinery,	   releasing	   the	  
ribosomes	   from	   the	  mRNA	   and	   yielding	   a	   newly	   synthesised	   polypeptide	   [59].	   Following	   on	  
from	  its	  generation,	  the	  polypeptide	  chain	  may	  require	  additional	  processing	  such	  as	  folding,	  
cleavage	  or	  post-­‐translational	  modification	   to	   form	   the	  active	  protein	   required	   to	  perform	  a	  
specific	  function	  within	  the	  cell	  [60].	  The	  initiation	  stage	  of	  translation	  is	  commonly	  thought	  of	  
as	  the	  major	  regulatory	  stage	  of	  cap-­‐dependent	  translation	  and	  is	  essentially	  rate	  limiting	  for	  
global	  protein	  synthesis.	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The	   basic	   mechanism	   of	   translation	   initiation	   can	   be	   thought	   of	   as	   the	   generation	   of	   two	  
distinct	   complexes	   firstly,	   the	   preparation	   of	   the	   ribosomal	   subunit	   and	   secondly,	   the	  
activation	   of	   the	   mRNA	   to	   be	   translated	   (figure	   1.2).	   Preparation	   of	   the	   ribosomal	   subunit	  
requires	  the	  isolation	  of	  the	  40S	  subunit	  from	  the	  60S	  subunit.	  Even	  in	  the	  absence	  of	  mRNA	  
these	  ribosomal	  subunits	  are	  cycling	   in	  a	  dynamic	  equilibrium	  between	  the	  80S	  complex	  (i.e.	  
both	  subunits	  assembled)	  and	  the	  dissociated	  40S	  and	  60S	  subunits	  [1].	  In	  order	  for	  translation	  
to	   progress,	   the	   dissociated	   40S	   subunit	  must	   be	   stabilised	   in	   the	   dissociated	   form	   to	   allow	  
association	  with	  the	  mRNA	  to	  be	  translated.	  	  
The	   40S	   subunit	   is	   maintained	   in	   the	   dissociated	   state	   by	   association	   with	   several	   other	  
factors.	   As	   these	   factors	   are	   involved	   in	   the	   initiation	   of	   eukaryotic	   translation	   they	   are	  
referred	  to	  as	  eukaryotic	  initiation	  factors	  (eIFs).	  The	  binding	  of	  eIF1,	  eIF1A	  and	  eIF3	  stabilise	  
the	  dissociated	  40S	  ribosomal	  subunit.	  Both	  eIF1	  and	  eIF1A	  are	  required	  to	   induce	  an	   ‘open-­‐
latch’	  conformation	   in	   the	  structure	  of	   the	  40S	  subunit	   to	  allow	  access	   to	   the	  mRNA	  binding	  
channel	   [61].	   The	   cryo-­‐EM	   structure	   of	   eukaryotic	   initiation	   factor	   eIF3	   reveals	   a	   large	  
multicomponent	  complex	   formed	  of	  both	  core	  components	  and	  accessory	   factors.	  There	  are	  
13	   subunits	   in	   total	   that	  make	   up	   eIF3	   referred	   to	   as	   eIF3a-­‐m.	   The	   core	   subunits	   comprise	  
eIF3a,	   -­‐c,	   -­‐e,	   -­‐k,	   -­‐l,	   -­‐m,	   -­‐f	   and	   -­‐h.	   The	   proteins	   eIF3b,	   -­‐d,	   -­‐g,	   -­‐i	   and	   -­‐j	  make	   up	   the	   accessory	  
factors	  [62].	  
The	  maintenance	  of	  the	  40S	  ribosomal	  subunit	  permits	  the	  association	  of	  the	  ternary	  complex	  
(TC)	  along	  with	  eIF5.	  The	  TC	  is	  composed	  of	  eIF2	  bound	  to	  the	  initiator	  tRNAMet	  (charged	  with	  
an	   initiator	   methionine	   residue).	   The	   TC	   complex	   associates	   with	   the	   assembled	   smaller	  
ribosomal	  subunit	  to	  form	  the	  43S	  pre-­‐initiation	  complex	  [1].	  	  
The	  second	  component	  required	  for	  the	  initiation	  of	  translation	  is	  the	  activation	  of	  the	  mRNA	  
to	  be	  translated.	  This	  requires	  the	  formation	  of	  the	  eIF4F	  complex	  associated	  with	  the	  mRNA.	  
The	  eIF4F	   complex	   is	   composed	  of	   three	  proteins,	   eIF4G-­‐	  a	   large	  molecular	   scaffold	  protein,	  
eIF4E-­‐	   a	   protein	   that	   binds	   the	   7-­‐methylguanosine	   cap	   of	   the	  mRNA	   directly	   and	   eIF4A-­‐	   an	  
ATP-­‐dependent	   RNA	   helicase.	   Along	  with	   the	   eIF4F	   complex,	   poly(A)-­‐binding	   protein	   (PABP)	  
binds	  to	  the	  polyadenylated	  tail	  of	  the	  mRNA	  transcript	  [1,	  63].	  	  
The	   molecular	   scaffold	   protein	   eIF4G	   contains	   binding	   domains	   for	   eIF4E,	   eIF4A,	   eIF3	   and	  
PABP.	   Interactions	   between	   PABP	   and	   eIF4E	   are	   bridged	   by	   eIF4G.	   As	   a	   result,	   the	  mRNA	   is	  
circularised	  with	  both	  vulnerable	  RNA	  ends	  sequestered	  by	   ribonucleoproteins.	  This	  protects	  
the	   mRNA	   from	   degradation	   by	   exoribonucleases,	   requiring	   either	   deadenylation	   and	   de-­‐
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capping	  prior	  to	  degradation	  [64].	  Following	  the	  activation	  of	  the	  mRNA	  and	  the	  preparation	  of	  
the	  43S	  complex,	  the	  two	  associate	  together	  to	  load	  the	  mRNA	  into	  the	  RNA	  binding	  channel	  
of	   the	   ribosomal	   subunit	   to	   form	   the	   48S	   ribosomal	   subunit.	   This	   recruitment	   requires	  
interaction	  between	  eIF4G	  and	  three	  subunits	  of	  eIF3,	  -­‐c,	  -­‐d	  and	  -­‐e	  [65].	  	  
The	  assembled	  complex	  then	  proceeds	  to	  scan	  the	  5’	  end	  of	  the	  mRNA	  for	  the	  start	  codon.	  The	  
scanning	   of	   the	   5’	   untranslated	   region	   (UTR)	   of	   the	  mRNA	   requires	   factors,	   eIF1	   and	   eIF1A.	  
These	   factors,	   eIF1	   and	   eIF1A,	   antagonise	   the	   hydrolysis	   of	   the	   GTP-­‐bound	   eIF2	   when	   the	  
correct	   start	   codon	   does	   not	   occupy	   the	   peptidyl-­‐site	   (P-­‐site)	   of	   the	   40S	   ribosomal	   subunit	  
[66].	   Once	   the	   start	   codon	   occupies	   the	   P-­‐site,	   eIF1A	   stabilises	   the	   complementation	   of	   the	  
codon	  by	  the	  tRNA.	  This	  causes	  a	  conformational	  change	  resulting	  in	  eIF1	  dissociation,	  which	  
permits	   the	   hydrolysis	   of	   eIF2-­‐GTP	   to	   GDP	   stimulated	   by	   eIF5	   [67,	   68].	   This	   changes	   the	  
conformation	   of	   the	   40S	   ribosomal	   subunit,	   closing	   the	   molecular	   ‘latch’	   and	   locking	   the	  
ribosome	  onto	   the	  mRNA.	   This	   results	   in	   the	  dissociation	  of	   the	   eukaryotic	   initiation	   factors	  
allowing	  the	  association	  of	  the	  60S	  subunit	  to	  form	  the	  complete	  80S	  ribosome.	  Further	  GTP	  
hydrolysis	   by	   eIF5B	   is	   required	   for	   its	   dissociation	   from	   the	   primed	   80S	   ribosome	   [69,	   70].	  
Elongation	  then	  proceeds	  with	  the	  delivery	  of	  amino	  acids	  charged	  to	  tRNAs	  that	  complement	  
the	   codons	   in	   the	  mRNA	   to	   the	   aminoacyl-­‐site	   (A-­‐site)	   of	   the	   ribosome.	   From	   this	   point	   the	  
polypeptide	  chain	  is	  extended	  to	  form	  the	  primary	  structure	  of	  the	  protein.	  	  
Figure	   1.2	   Overview	   of	   transla8on	   ini8a8on	   and	   regula8on	   of	   the	   eIF4F	  
complex.	   (Adapted	   from	   [118])	   The	   black	   line	   represents	   capped	   and	  




1.2.2	  Response	  to	  stress	  via	  post-­‐translational	  modifications	  
Post-­‐translational	   modifications	   (PTMs)	   regulate	   many	   of	   the	   components	   required	   for	   the	  
initiation	  of	  translation.	  Table	  1.2	  details	  examples	  of	  several	  PTMs	  that	  govern	  rates	  of	  global	  
translation	  and	  are	  described	  in	  more	  detail	  throughout	  this	  section.	  
Table	  1.2	  Examples	  of	  post-­‐translational	  modifications	  governing	  metabolic	  responses	  to	  
stress.	  	  
Protein	   Cellular	  response	   PTM	   References	  
eIF2α	   Suppression	  of	  global	  translation	  	   phosphorylation	   [12]	  
4E-­‐BP1	   Increased	  global	  translation	  	   phosphorylation	   [13]	  
eIF4E	   Suppression	  of	  global	  translation	  	   phosphorylation	   [71]	  
PDCD4	   Suppression	  of	  eIF4A-­‐dependent	  
translation	  
phosphorylation	   [72]	  
PAIP1	   Increased	  48S	  complex	  formation	   phosphorylation	   [73]	  
PAIP2	   Increased	  PABP-­‐binding	  by	  PAIP2	  
degradation	  
ubiquitination	   [63]	  
G3BP1	   Suppression	  of	  SG	  formation	   phosphorylation	   [74]	  
eIF4E	   Stabilisation	  of	  the	  eIF4F	  complex	   SUMOylation	   [75]	  
eIF4G	   Response	  to	  stresses	  that	  induce	  
SGs	  
SUMOylation	   [76]	  
	  
Global	   cap-­‐dependent	   translation	   is	   regulated	   via	   the	   formation	   of	   the	   43S	   pre-­‐initiation	  
complex	   and	   the	   activation	   of	   the	  mRNA.	   The	   formation	   of	   both	   complexes	   is	   regulated	   by	  
post-­‐translational	  modifications.	   In	   the	   case	   of	   the	   43S	   pre-­‐initiation	   complex,	   the	   ability	   of	  
eIF2	  to	  bind	  the	  initiator	  tRNAMet	  is	  modulated	  by	  a	  GTP/GDP	  molecular	  switch.	  The	  initiation	  
factor	   eIF2	   only	   binds	   the	   tRNAMet	   when	   guanosine	   triphosphate	   (GTP)	   is	   bound	   [1].	   The	  
exchange	  of	  GDP	  to	  GTP	   is	  catalysed	  by	   the	  guanine	  exchange	   factor,	  eIF2B.	  However,	  when	  
eIF2	   is	   phosphorylated	   on	   Ser51	   within	   the	   α	   subunit,	   phosphorylated	   eIF2	   bound	   to	   GDP	  
becomes	  a	  potent	  inhibitor	  of	  eIF2B	  [12].	  Inhibition	  of	  eIF2B	  prevents	  re-­‐priming	  of	  eIF2	  with	  
GTP	  and	  prevents	  the	  formation	  of	  the	  TC.	  Ultimately,	  phosphorylation	  of	  eIF2	  is	  a	  very	  rapid	  
way	   of	   shutting	   down	   cap-­‐dependent	   translation	   reducing	   the	   availability	   of	   eIF2-­‐GTP	   and	  
preventing	   the	   formation	   of	   the	   TC	   and	   the	   formation	   of	   the	   43S	   pre-­‐initiation	   complex.	  
Importantly,	  eIF2	   is	   targeted	  by	  a	  number	  of	  kinases	  that	  are	  activated	  by	  particular	  stresses	  
such	  as	  GCN2,	  which	  in	  turn	  is	  activated	  in	  response	  to	  amino	  acid	  starvation	  [77].	  
Alternatively,	  global	  translation	  can	  be	  regulated	  at	  the	  level	  of	  mRNA	  activation	  by	  affecting	  
the	  formation	  of	  the	  eIF4F	  complex.	  A	  small	  group	  of	  proteins	  compete	  with	  eIF4G	  for	  binding	  
with	   the	   7-­‐methylguanosine	   cap	   binding	   protein,	   eIF4E.	   These	   proteins	   are	   called	   eIF4E-­‐
binding	  proteins	  (4E-­‐BPs).	  A	  well-­‐characterised	  example	  of	  regulation	  by	  4E-­‐BPs	  in	  response	  to	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stress	   is	   through	   4E-­‐BP1,	   which	   preferentially	   binds	   to	   eIF4E	   when	   4E-­‐BP1	   is	   hypo-­‐
phosphorylated	   state	   preventing	   eIF4E	   binding	   to	   eIF4G	   and	   assembling	   the	   eIF4F	   complex.	  
Under	  normal	  conditions,	  4E-­‐BP1	   is	  hyper-­‐phosphorylated	  by	  mTORC1	   (mammalian	   target	  of	  
rapamycin	   complex	   1)	   kinase,	   thereby	   preventing	   binding	   to	   eIF4E	   and	   allowing	   initiation	   of	  
translation	  to	  proceed	  unhindered.	  However,	  under	  stress	  conditions,	  mTORC1	  kinase	  activity	  
is	  supressed	  leading	  to	  global	  sequestration	  of	  eIF4E	  and	  suppression	  of	  global	  translation	  [78].	  	  
The	   mRNA	   cap	   binding	   protein,	   eIF4E,	   is	   another	   example	   of	   a	   protein	   that	   can	   be	  
phosphorylated.	   It	   is	   phosphorylated	   directly	   by	  MAPK-­‐interacting	   kinase	   (MNK-­‐1),	   which	   is	  
recruited	  through	  the	  C-­‐terminal	  region	  of	  eIF4G	  [71],	  a	  region	  recently	  shown	  to	  be	  subject	  to	  
another	  post-­‐translational	  modification,	  SUMOylation	  [76].	  Phosphorylation	  of	  eIF4E	  serves	  to	  
inhibit	   the	   translation	  of	   capped	  mRNAs	  containing	  an	  RNA	   loop	  structure	  within	   the	  5’	  UTR	  
[71].	   Additional	   regulation	   at	   the	   level	   of	   eIF4E	   is	   introduced	   by	   eIF4E2/4E-­‐H,	   a	   homolog	   of	  
eIF4E	  capable	  of	  weak	  association	  with	  the	  capped	  mRNA	  but	  not	  able	  to	  interact	  with	  eIF4G.	  
Recently,	  4E-­‐H	  was	  demonstrated	  to	   interact	  with	  eIF4E-­‐binding	  protein	  (4E-­‐T),	  a	  component	  
of	  the	  mRNA	  degradation	  machinery	  [79,	  80]	   linking	  both	  translational	  repression	  and	  mRNA	  
degradation.	  	  
The	  third	  component	  of	  the	  eIF4F	  complex,	  eIF4A,	  is	  also	  subject	  to	  regulation.	  The	  DEAD-­‐box	  
helicase,	  eIF4A1,	  is	  required	  for	  the	  43S	  pre-­‐initiation	  complex	  to	  scan	  through	  secondary	  and	  
tertiary	  RNA	  structures	  located	  within	  the	  5’	  UTR	  of	  mRNAs.	  The	  unwinding	  of	  RNA	  structures	  
by	  eIF4A1	  requires	  hydrolysis	  of	  ATP,	  which	  is	  stimulated	  when	  eIF4A	  binds	  to	  eIF4G	  and	  a	  co-­‐
factor	   such	   as	   eIF4B	   or	   eIF4H	   [81].	   Modulating	   the	   activity	   of	   eIF4A	   has	   the	   ability	   to	   re-­‐
program	   the	   cell	   by	   altering	   the	   selectivity	   regarding	   which	   mRNA	   will	   be	   translated.	  
Programmed	  cell	  death	  protein	  4	  (PDCD4)	  binds	  to	  eIF4A	  and	  inhibits	  its	  incorporation	  into	  the	  
eIF4F	  complex.	  PDCD4	   is	  phosphorylated	  by	  p70S6	  Kinase,	  which	   is	  activated	  downstream	  of	  
mTORC1.	  When	   PDCD4	   is	   phosphorylated	   it	   binds	   to	   eIF4A	   sequestering	   it	   from	   associating	  
with	   the	   eIF4F	   complex	   [72].	   Interestingly,	   ribosome	   footprinting	   of	   cells	   treated	   with	  
silvestrol,	  an	  inhibitor	  of	  eIF4A,	  reveals	  a	  requirement	  for	  eIF4A	  to	  translate	  mRNA	  transcripts	  
containing	  G-­‐quadruplex	  RNA	  structures	  contained	  within	  the	  5’	  UTR.	  Furthermore,	  analysis	  of	  
mRNAs	  containing	  sequences	  predicted	  to	   form	  G-­‐quadruplexes	   indicates	  their	  prevalence	   in	  
oncogenic	  mRNAs,	  such	  as	  those	  encoding	  transcription	  factors	  [82].	  Ultimately,	  translation	  of	  
eIF4A-­‐dependent	  mRNAs	  may	  be	  critical	  for	  promoting	  cell	  survival	  under	  cellular	  stress.	  	  
Furthermore,	  there	  are	  three	  isoforms	  of	  eIF4A,	  eIF4A1,	  -­‐2	  and	  -­‐3.	  eIF4A1	  and	  2	  both	  have	  RNA	  
helicase	  activity.	  eIF4A3	  forms	  part	  of	  the	  exon	  junction	  complex	  and	  is	  involved	  in	  non-­‐sense	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mediated	   decay,	   a	   quality	   control	   mechanism	   required	   for	   the	   degradation	   of	   mRNAs	  
containing	   a	   premature	   stop	   codon	   [83].	   Downregulation	   of	   eIF4A1	   results	   in	   increased	  
transcription	  of	  eIF4A2.	  Despite	  this	  apparent	  compensatory	  response,	  eIF4A2	  cannot	  rescue	  
the	  translational	  defect	  caused	  by	  downregulation	  of	  eIF4A1	  [84].	   Indicating	  that	  eIF4A1	  and	  
eIF4A2	   serve	   different	   functions	   within	   the	   cell.	   This	   is	   the	   case,	   as	   eIF4A2	   has	   been	  
demonstrated	  to	  be	  required	  for	  miRNA-­‐mediated	  gene	  silencing	  [85].	  	  	  
Eukaryotic	   translation	   initiation	   can	   also	   be	   regulated	   by	   the	   availability	   of	   poly	   (A)	   binding	  
protein	   (PABP).	   Two	   co-­‐factors,	   PABP-­‐interacting	   proteins,	   PAIP1	   and	   PAIP2,	   have	   opposing	  
effects	   on	   translation	   initiation	   despite	   binding	   the	   same	   cellular	   target.	   PAIP1	   promotes	  
translation	   by	   binding	   to	   both	   PABP	   and	   eIF3g	   to	   promote	   formation	   of	   the	   48S	   complex.	  
Furthermore,	   the	   PAIP1-­‐eIF3g	   interaction	   is	   thought	   to	   be	   phosphorylation	   dependent,	  
requiring	   active	   mTORC1	   and	   S6	   kinases	   for	   interaction	   [73].	   Conversely,	   PAIP2-­‐binding	   of	  
PABP	  blocks	   the	  conformational	  change,	   revealed	  by	  single-­‐molecule	   fluorescence	  resonance	  
energy	   transfer	   (smFRET),	   required	   for	   PABP	   to	   associate	   with	   the	   poly	   (A)	   tail	   [63].	  
Additionally,	   PAIP2	   is	   itself	   is	   targeted	   for	   proteosomal	   degradation	   by	   another	   PTM,	  
ubiquitination	  catalysed	  by	  EDD,	  an	  E3	  ubiquitin	  ligase	  [86].	  
Although,	   many	   of	   the	   modifications	   identified	   in	   response	   to	   stress	   suppress	   global	  
translation,	   suppression	   of	   cap-­‐dependent	   translation	   promotes	   an	   alternative	   set	   of	  
translation	  mechanisms	  to	  take	  over,	  which	  facilitate	  the	  translation	  of	  a	  specialised	  subset	  of	  
mRNAs	  that	  help	  the	  cell	  tolerate	  stress	  and	  promote	  survival.	  	  
1.2.3	  Mechanisms	  of	  Cap-­‐independent	  translation	  
Following	  the	  induction	  of	  cellular	  stress	  and	  the	  suppression	  of	  global	  cap-­‐dependent	  protein	  
synthesis	   a	   number	   of	   physiological	   changes	   occur	   within	   the	   cell.	   Post-­‐translational	  
modifications	   facilitate	   the	   switching	   between	   cap-­‐dependent	   to	   cap-­‐independent	  
mechanisms	  of	  translation.	  Despite	  the	  suppression	  of	  the	  majority	  of	  mRNA	  translation,	  there	  
are	  some	  mRNAs	  that	  remain	  either	  unaffected	  or	  which	  are	  even	  up-­‐regulated	  in	  response	  to	  
cellular	  stress,	  such	  as	  VEGF	   (vascular	  endothelial	  growth	  factor)	   [1].	  There	  are	  currently	  two	  
methods	  of	  maintaining	   translation	  under	   conditions	  where	  either	  eIF2	   is	  phosphorylated	  or	  
the	   components	   of	   the	   eIF4F	   complex	   are	   scarce.	   Some	  mRNAs,	   such	   as	  GCN4,	   contain	   up-­‐
stream	  open	  reading	  frames	  (uORFs).	  uORFs	  are	  elements	  contained	  within	  the	  5’	  UTR	  of	  the	  
mRNA	   that,	   under	   normal	   physiological	   conditions,	   suppress	   the	   synthesis	   of	   the	   active	  
protein.	   Under	   these	   conditions,	   the	   scanning	   ribosome	   initiates	   translation	   at	   one	   of	   the	  
decoy	   ORFs.	   Following	   translation	   of	   the	   uORFs	   the	   majority	   of	   ribosomes	   would	   then	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dissociate	   from	   the	  mRNA	   before	   reaching	   the	   start	   codon	   for	   the	  GCN4	   ORF.	   Under	   stress	  
conditions	  for	  example,	  where	  the	  availability	  of	  the	  TC	  are	   low,	  the	  ribosome	  scans	  through	  
the	  uORFs	  without	   initiating	  translation	  and	  only	   initiates	   translation	   further	  downstream,	  at	  
the	   GCN4	   ORF	   [87].	   As	   a	   result,	   protein	   synthesis	   of	   the	   transcriptional	   activator,	   GCN4	   is	  
increased	  when	  eIF2	  is	  phosphorylated.	  	  	  	  
Alongside	   the	   use	   of	   uORFs	   to	   initiate	   translation	  when	   global	   cap-­‐dependent	   translation	   is	  
supressed,	   translation	   can	   be	   initiated	   via	   an	   internal	   ribosome	   entry	   site	   (IRES).	   These	   are	  
formed	  by	  extensive	  secondary	  structures	  located	  within	  the	  5’	  UTR	  of	  a	  subset	  of	  cellular	  and	  
viral	  mRNAs	  that	  bypass	  the	  requirement	  for	  some	  or	  all	  initiation	  factors.	  IRESs	  guide	  the	  40S	  
ribosomal	   subunit	   with	   the	   initiator	   tRNAMet	   directly	   to	   the	   start	   codon.	   IRES-­‐dependent	  
translation	  was	  firstly	  identified	  in	  the	  Picornavirus,	  which	  has	  an	  RNA	  genome	  lacking	  a	  5’	  cap.	  
Despite	   the	   absence	   of	   eIF4E	   the	   Picornavirus	   RNA	   is	   still	   translated,	   thereby	   bypassing	   the	  
eIF4E-­‐dependent	   regulation	  of	   translation	   [88].	   Since	   their	   initial	   identification,	   several	  other	  
viral	  IRESs	  have	  been	  identified	  alongside	  some	  cellular	  mRNAs	  such	  as	  XIAP	  (X-­‐linked	  inhibitor	  
of	   apoptosis)	   and	   VEGF,	   mentioned	   earlier	   [89].	   Each	   IRES	   demonstrates	   a	   different	  
requirement	  for	  eukaryotic	  initiation	  factors.	  For	  example,	  Hepatitis	  C	  virus	  (HCV)	  bypasses	  the	  
requirement	   for	   the	  eIF4F	   complex,	   only	   requiring	   eIF2	   and	  eIF3	   to	   initiate	   translation	   in	   an	  
eIF5B-­‐dependent	   manor	   [90-­‐92].	   The	   Cricket	   paralysis	   virus	   (CrPV)	   does	   not	   require	   any	  
initiation	  factors	  or	  even	  the	  initiator	  tRNAMet	  to	  translate	  viral	  protein.	  The	  Cryo-­‐EM	  structure	  
of	   the	   elongating	   ribosome	   on	   the	   CrPV	   reveals	   that	   translation	   initiation	   is	   bypassed	  
altogether	  [92].	  	  
Additionally,	  a	  number	  of	  co-­‐factors	   facilitate	  cap-­‐dependent	  translation	  via	   IRES	  called	   IRES-­‐
transactivating	  factors	  (ITAFs).	  Polypyrimidine-­‐tract	  binding	  protein	  (PTB)	  is	  an	  ITAF,	  which	  has	  
divergent	  functions	  within	  the	  cytoplasm	  and	  the	  nucleus.	  In	  the	  nucleus,	  PTB	  functions	  in	  pre-­‐
mRNA	  splicing	  whereas	  in	  the	  cytoplasm,	  PTB	  facilitates	  IRES-­‐mediated	  translation	  by	  binding	  
to	  and	  stabilising	  secondary	  RNA	  structures	  [93].	  
RNA	  G-­‐quadruplexes	  are	  proposed	  to	  be	  inhibitory	  to	  cap-­‐dependent	  translation,	  requiring	  an	  
RNA	  helicase	  for	  efficient	  removal	  of	  these	  structures	  to	  promote	  translation.	  Furthermore,	  an	  
RNA	   G-­‐quadruplex	   was	   shown	   to	   be	   required	   for	   IRES-­‐mediated	   translation	   of	   VEGF	   mRNA	  
suggesting	  that	  these	  structures	  also	  may	  form	  part	  of	  the	  IRES	  [82,	  94].	  Additional	  complexity	  
is	   revealed	   by	   the	   stabilisation	   of	   the	   RNA	   G-­‐quadruplex	   by	   extending	   the	   guanine	  
ribonucleotide	   stretches	   had	   an	   inhibitory	   effect	   on	   IRES-­‐mediated	   translation	   [95].	   Overall,	  
this	   suggests	   a	   spectrum	   of	   translation	   initiation	   efficiencies	   governed	   by	   the	   complexity	   of	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RNA	  structures	  within	  the	  5’	  UTR	  of	  each	  mRNA.	  Additionally,	   indicating	  that	  each	  mRNA	  can	  
be	   translationally	   activated	   or	   repressed	   depending	   on	   the	   availability	   of	   eIFs	   in	   the	   cellular	  
environment.	  
1.3	  mRNA	  stability,	  P-­‐bodies	  and	  stress	  granules	  
Having	  reviewed	  how	  global	  mRNA	  translation	  is	  regulated	  by	  post-­‐translational	  modifications	  
in	  response	  to	  stress,	   it	   is	  also	  critical	   to	  consider	  what	  happens	  to	  the	  mRNA	  when	   it	   is	  not	  
being	   translated.	   Ultimately,	   the	   cell	   faces	   a	   choice	   as	   to	  whether	   to	   store	   the	  mRNA	   or	   to	  
degrade	  it.	  	  
1.3.1	  mRNA	  stability	  and	  degradation	  
Degradation	  of	  mRNA	  occurs	  primarily	  through	  the	  deadenylation	  of	  the	  3’	  end	  of	  the	  mRNA.	  
Poly	   (A)	   binding-­‐specific	   ribonucleases,	   CAF1/CCR4/NOT	   complex	   and	   poly	   (A)	   ribonuclease	  
(PARN)	  all	  act	  to	  remove	  the	  poly	  (A)	  tail	  from	  mRNA	  resulting	  in	  the	  de-­‐circularisation	  of	  the	  
mRNA	  making	  it	  susceptible	  to	  decapping	  and	  degradation	  by	  ribonucleases	   [96].	  Removal	  of	  
the	  7-­‐methylguanosine	  cap	   is	  catalysed	  by	  the	  decapping	  complex	  Dcp1/Dcp2,	  the	  molecular	  
scaffold	  EDC4	  (enhancer	  of	  decapping	  4)	  and	  XRN1	  [97].	  Following	  the	  removal	  of	  both	  the	  3’	  
poly	  (A)	  tail	  and	  the	  5’	  cap,	  the	  mRNA	  can	  be	  degraded	  in	  either	  the	  5’	  to	  3’	  direction	  by	  XRN1	  
or	   in	   the	   3’	   to	   5’	   direction	   by	   hDIS3	   associated	   with	   the	   exosome	   [98].	   Additionally,	   some	  
mRNAs	  can	  be	  targeted	  by	  directly	  endoribonucleases,	  which	  bypass	  the	  requirement	  for	  both	  
deadenylation	  and	  decapping	  to	  allow	  5’	  to	  3’	  and	  3’	  to	  5’	  mRNA	  degradation	  [99]	  (figure	  1.3).	  	  
As	   a	   result,	   targeting	   of	   deadenylases	   to	   the	   mRNA	   is	   a	   critical	   step	   in	   regulating	   mRNA	  
turnover.	   Recruiting	   the	   deadenylation	   complex	   to	   mRNAs	   can	   occur	   through	   several	  
mechanisms.	  Adenine	  and	  uracil-­‐rich	  elements	  (AREs)	  located	  within	  the	  3’	  UTR	  of	  the	  mRNA	  
are	  capable	  of	  recruiting	  a	  range	  of	  ARE-­‐binding	  proteins	  (ARE-­‐BPs),	  such	  as	  TTP	  which	  recruits	  
the	   CCR4/NOT	   deadenylation	   complex	   [100].	   Alternatively,	   deadenylases	   can	   be	   recruited	  
through	  miRNA-­‐mediated	  mechanisms	  whereby,	  following	  translational	  repression	  the	  miRISC	  
complex	   then	   recruits	   the	   CAF1/CCR4/NOT1	   complex	   [101].	   Recent	   investigation	   of	   the	  
stability	   of	   TP53	   mRNA	   reveals	   functional	   interplay	   between	   miRNA-­‐dependent	   and	   ARE-­‐
dependent	   recruitment	   of	   PARN	   for	  mRNA	   decay	   [102].	   Deadenylases	   can	   also	   be	   recruited	  
through	   a	   specialised	   mRNA	   quality	   control	   mechanism,	   nonsense-­‐mediated	   decay	   (NMD).	  
When	  pre-­‐mRNAs	  are	  spliced	  an	  exon-­‐junction	  complex	  (EJC)	  is	  deposited	  just	  upstream	  of	  the	  
exon-­‐exon	   junction.	   If	   the	  mRNA	  contains	  a	  premature	   termination	   codon	   (PTC)	  with	  an	  EJC	  
downstream,	  the	  eukaryotic	  release	  factors	  (eRFs)	  recruit	  UPF1,	  UPF2,	  UPF3	  and	  UPF3B,	  which	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interact	  with	   the	  downstream	  EJC.	   This	   facilitates	   the	   recruitment	  of	   the	  mRNA	  degradation	  
machinery	  [103,	  104].	  	  














Figure	  1.3	  Overview	  of	  mRNA	  degrada8on	  pathways.	  The	  black	   line	  represents	  
capped	   and	   polyadenylated	   mRNA.	   Brown	   circle	   represents	   the	   exosome	   and	  
Dis3	  is	  marked	  in	  red	  as	  the	  catalyAc	  subunit.	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1.3.2	  mRNA	  regulation	  Processing	  bodies	  
Following	  translational	  repression	  mRNAs	  can	  enter	  processing	  bodies	  (P-­‐bodies).	  P-­‐bodies	  are	  
cytoplasmic	   aggregates	   that	   serve	   as	   processing	   centres	   for	   mRNA.	   They	   can	   facilitate	  
remodelling,	   storage,	   recycling	   and	   degradation	   of	   mRNA.	   P-­‐bodies	   contain	   an	   array	   of	  
proteins	   required	   for	   the	   translational	   repression	   such	   as	   eIF4E-­‐T	   and	   CPEBs	   that	   supress	  
translation	   through	   interactions	   with	   elements	   in	   the	   3’	   UTR	   of	   mRNAs	   [96].	   P-­‐bodies	   also	  
contain	   components	   required	   for	   both	   miRNA-­‐mediated	   suppression	   including	   GW182	   and	  
Argonaute	  protein	  2	  (Ago2)	  and	  nonsense-­‐mediated	  decay	  along	  with	  the	  deadenylation	  and	  
decapping	  machinery	  [105,	  106].	  	  
1.3.3	  Stress	  granules	  
Alternatively,	   following	   exposure	   to	   cellular	   stress,	   mRNAs	   can	   be	   incorporated	   into	   stress	  
granules	  (SGs).	  SGs	  are	  large	  cytoplasmic	  aggregates	  that	  form	  in	  response	  to	  stresses	  such	  as	  
oxidative	   stress	   and	   commonly	   act	   via	   eIF2	   phosphorylation-­‐dependent	   inhibition	   of	   global	  
cap-­‐dependent	  translation	  [107].	  The	  composition	  of	  SGs	  is	  distinguished	  from	  P-­‐bodies	  by	  the	  
presence	   eIFs	   and	   the	   40S	   ribosomal	   subunit.	   As	   a	   result,	   it	   is	   thought	   that	   if	   translation	  
initiation	   stalls,	   the	  mRNA	  will	   be	   targeted	   to	   SGs	   [108].	   The	   formation	   of	   SGs	   requires	   the	  
activity	   of	   two	   accessory	   proteins,	   T-­‐cell	   internal	   antigen	   1	   (TIA-­‐1)	   and	   GTPase-­‐activating	  
protein	  (SH3-­‐domain)	  binding	  protein	  1	  (G3BP1)	  (figure	  1.4).	  Interestingly,	  phosphorylation	  of	  
G3BP1	   prevents	   the	   formation	   of	   stress	   granules	   by	   preventing	   oligomerisation	   indicating	  
further	  control	  of	  translational	  suppression	  by	  post-­‐translational	  modifications	  [74].	  	  
Formation	  of	  stress	  granules	  occurs	  as	  a	  result	  of	  downregulating	  global	  translation	  of	  mRNAs	  
commonly	  as	  a	  result	  of	  eIF2	  phosphorylation.	  However,	  a	  number	  of	  stresses	   induce	  SG	  can	  
formation	  the	  absence	  of	  eIF2	  phosphorylation	  [109,	  110].	  Factors	  that	  affect	  the	  ability	  of	  the	  
eIF4F	   complex	   to	   form,	   such	   as	   small-­‐molecular	   inhibitors	   or	   direct	   depletion	   of	   eIF4A	   or	  
accessory	   factors	   eIF4B	   and	   eIF4H	   result	   in	   the	   formation	   of	   stress	   granules	   [111,	   112].	  
Disruption	  of	  factors	  acting	  downstream	  of	  eIF4F	  complex	  assembly	  i.e.	  eIF5B	  and	  60S	  subunit	  
association	  do	  not	   induce	  SG	  formation	  suggesting	  that	  the	  targeting	  of	  mRNA	  to	  SGs	  occurs	  
early	   the	   during	   initiation	   step	   [112].	   Interestingly,	   the	   type	   of	   stress	   introduced	   appears	   to	  
affect	  the	  composition	  of	  the	  SGs.	  For	  example,	  a	  recent	  small-­‐molecular	   inhibitor,	   ISRIB	  was	  
identified	   that	   inhibited	  SG	   formation	  of	   sodium	  arsenite-­‐	  and	   thapsigargin-­‐induced	  SGs,	  but	  
not	   those	   induced	   by	   pateamine	   A,	   suggesting	   that	   multiple	   mechanisms	   exist	   to	   promote	  
stress	  granule	  formation	  following	  inhibition	  of	  translation	  [107].	  	  










Figure	   1.4	  Overview	  of	   Stress	  Granules	   and	   P-­‐bodies.	  P-­‐bodies	   are	   shown	   in	  
red.	  Stress	  granules	  are	  shown	  in	  green.	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Following	  the	  removal	  of	  the	  stressor,	  the	  cell	  can	  choose	  to	  reinitiate	  translation,	  to	  continue	  
to	   store	   the	   mRNA	   or	   degrade	   it	   [96].	   Additional	   processing	   of	   the	   mRNA	   requires	   mRNP	  
remodelling	   that	   requires	   components	   found	   in	   both	   SGs	   and	   P-­‐bodies.	   Under	   certain	  
conditions,	  SGs	  and	  P-­‐bodies	  have	  been	  demonstrated	  to	  fuse	  together	  in	  the	  cell.	  It	  is	  thought	  
that	  this	  allows	  an	  exchange	  of	  mRNAs	  and	  mRNPs	  to	  permit	  additional	  processing	  of	  mRNAs	  
[113,	  114].	  	  	  
Ultimately,	   the	   formation	   of	   SGs	   directly	   involves	   factors	   involved	   in	   translation	   initiation.	  
Although	  canonical	  stress	  granules	  form	  in	  response	  to	  eIF2	  phosphorylation,	  a	  number	  of	  eIF2	  
phosphorylation-­‐independent	   mechanisms	   exist	   to	   form	   non-­‐canonical	   SGs	   in	   response	   to	  
different	   stresses.	   Non-­‐canonical	   SG	   formation	   is	   propagated	   by	   inhibition	   of	   eIF4F	   complex	  
formation	   either	   by	   depleting	   individual	   components	   or	   by	   using	   specific	   inhibitors.	   Further	  
work	  is	  required	  to	  establish	  how	  components	  of	  the	  eIF4F	  complex	  are	  regulated	  in	  response	  
to	  different	  stresses	  and	  determine	  whether	  or	  not	  these	  affect	  the	  ability	  to	  form	  SGs.	  	  
1.4	  SUMOylation	  and	  the	  initiation	  of	  translation	  
The	  identification	  of	  SUMOylated	  substrates	  has	  been	  of	  keen	  interest	  for	  many	  years.	  Studies	  
looking	   at	   the	   global	   SUMO	   proteome	   have	   primarily	   illustrated	   the	   wide	   range	   of	   cellular	  
targets	  within	  the	  cell	  that	  govern	  different	  processes	  and	  in	  particular	  the	  response	  to	  cellular	  
stress	   [4,	   6].	   Furthermore,	   validation	   and	   characterisation	  of	   the	   role	  of	   SUMO	   in	   regulating	  
many	  of	  these	  newly	  identified	  protein	  targets	  remains	  to	  be	  established.	  	  
1.4.1	  eIF	  SUMOylation	  
Intriguingly,	   numerous	   eukaryotic	   initiation	   factors	   have	   been	   identified,	   including	   all	   of	   the	  
components	  of	  the	  eIF4F	  complex,	  in	  proteomic	  screens	  both	  in	  mammalian	  cells	  and	  in	  other	  
organisms	   including	   D.	   melanogaster	   (see	   table	   1.3).	   Despite	   their	   identification,	   few	  
SUMOylated	  eIFs	  have	  been	  validated	  and	   investigated	   further	   to	  determine	   the	  role,	   if	  any,	  
that	  SUMO	  has	  on	  their	  function.	  The	  mRNA	  cap-­‐binding	  protein	  eIF4E	  has	  been	  shown	  to	  be	  
SUMOylated	  on	  5	  lysine	  residues	  and	  the	  introduction	  of	  an	  unSUMOylatable	  mutant	  into	  cells	  
impairs	  eIF4F	  assembly	  but	  not	   cap-­‐binding	   suggesting	   that	  SUMO	  stabilises	   the	  eIF4E-­‐eIF4G	  
interaction	  [75].	  Furthermore,	  the	  unSUMOylatable	  eIF4E	  mutant	  impairs	  translation	  of	  stress	  
response	  mRNAs	  [75].	  More	  recently,	  the	  molecular	  scaffold	  protein,	  eIF4G	  was	  shown	  to	  be	  
SUMOylated	   on	   two	   residues	  within	   the	   C-­‐terminus,	  with	   one	   site	   located	  within	   the	   eIF4A	  
binding	  domain	  and	  the	  other	  in	  the	  MNK-­‐1-­‐binding	  domain	  [76].	  Additionally,	  SUMOylation	  of	  
eIF4G	   in	  S.	   pombe	  was	   increased	   following	   treatment	  with	   KCl	  which	   induces	   stress	   granule	  
formation	  [76].	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Table	  1.3	  eIFs	  identified	  in	  proteomic	  screens	  for	  SUMOylated	  substrates.	  
Protein	   SUMO	   Type	  of	  Screen/purification	  method	   References	  
EIF1α	   Rat	  SUMO-­‐3	   Immunoprecipitation	  of	  HA-­‐SUMO3	   [6]	  
EIF2A	  Subunit	  1	   Hs	  SUMO-­‐1	   Purification	  by	  crosslinking	  cysteine	  to	  beads	   [3]
EIF2α	   Drosophila	  SUMO	   Dual	  purification	  of	  
His-­‐Flag-­‐SUMO	  
[115]	  
EIF2B	  Subunit	  β	   Hs	  SUMO-­‐1/2	   Purification	  of	  His-­‐SUMO	   [58]	  
EIF2B	   Plant	  SUMO	   Purification	  of	  
His-­‐SUMO1	  
[116]	  
EIF2	  Subunit	  γ	   Drosophila	  SUMO	   Dual	  purification	  of	  
His-­‐Flag-­‐SUMO	  
[115]	  
EIF3A	   Hs	  SUMO-­‐1	   Purification	  by	  crosslinking	  cysteine	  to	  beads	   [3]	  
EIF3B	   Hs	  SUMO-­‐1	   Purification	  by	  crosslinking	  cysteine	  to	  beads	   [3]
EIF3C	   Hs	  SUMO-­‐1/2	   Purification	  of	  His-­‐SUMO	   [58]	  
EIF3D	   Rat	  SUMO-­‐3	   Immunoprecipitation	  of	  HA-­‐SUMO3	   [6]	  
EIF3E	   Hs	  SUMO-­‐1/2	   Purification	  of	  His-­‐SUMO	   [58]	  
EIF3I	   Sp	  Smt3	   Immunoprecipitation	  of	  ProtA-­‐Smt3	   [57]	  
eIF3M	   Hs	  SUMO-­‐1	   Immunoprecipitation	  of	  endogenous	  
SUMO1	  
[2]	  
EIF3X	   Hs	  SUMO-­‐2	   Purification	  by	  crosslinking	  cysteine	  to	  beads	   [3]
EIF4AI	   Drosophila	  SUMO	   Dual	  purification	  of	  
His-­‐Flag-­‐SUMO	  
[115]	  
Rat	  SUMO-­‐3	   Immunoprecipitation	  of	  HA-­‐SUMO3	   [6]	  
Hs	  SUMO-­‐2	   Purification	  by	  polySUMO	  by	  SIM-­‐trap	   [4]	  
EIF4AII	   Hs	  SUMO-­‐1	   Immunoprecipitation	  of	  endogenous	  
SUMO1	  
[5]	  
EIF4E	   Hs	  SUMO-­‐1	   Purification	  of	  His-­‐SUMO1	   [75]	  
EIF4GI	   Hs	  SUMO-­‐1/2	   Purification	  by	  polySUMO	  SIM-­‐trap	  
immunoprecipitation	  of	  endogenous	  SUMO1	  
[4,	  5]	  
eIF5A	   Hs	  SUMO-­‐1/2	   Immunoprecipitation	  of	  endogenous	  
SUMO1	  
[2]	  
PABP1	   Hs	  SUMO-­‐1	  
Sc	  SUMO	  
Purification	  by	  crosslinking	  cysteine	  to	  beads	   [3,	  117]	  
PABP4	   Hs	  SUMO-­‐1	   Purification	  by	  crosslinking	  cysteine	  to	  beads	   [3]
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(Adapted	   from	   [118]:	   Table	   shows	   SUMOylated	   eukaryotic	   translation	   initiation	   factors	  
identified	   in	   proteomic	   screens,	   Hs=Human,	   Sp=Schizosaccharomyces	   pombe,	  
Sc=Saccharomyces	  cerevisiae,	  Plant=Arabidopsis	  thaliana).	  
Taken	   together	   these	   data	   suggest	   a	   potential	   role	   for	   SUMOylation	   of	   eIFs	   in	   regulating	  
translation	  potentially	  linking	  the	  response	  to	  cellular	  stress	  with	  the	  formation	  of	  cytoplasmic	  
stress	   granules.	   As	   SUMOylated	   eIF4E	   and	   eIF4G	   have	   been	   identified,	   it	   remains	   to	   be	  
elucidated	   as	   to	   whether	   the	   third	   component	   of	   the	   eIF4F	   complex,	   the	   ATP-­‐dependent	  
helicase,	  eIF4A,	  can	  be	  SUMOylated	  and	  if	  so,	  what	  role	  this	  serves	  within	  mammalian	  cells.	  	  	  
1.5	  Genotoxic	  stress	  and	  the	  response	  to	  DNA	  damage	  
Many	  types	  of	  DNA	  lesions	  arise	  as	  a	  consequence	  of	  genotoxic	  stress.	  The	  persistence	  of	  DNA	  
lesions	  is	  highly	  detrimental,	  driving	  genomic	  instability,	  facilitating	  loss	  of	  genetic	  material	  and	  
promoting	   incorporation	  of	  mutations,	  which	  may	   lead	   to	  genetic	  disorders	   including	   cancer	  
[119].	   Genotoxic	   stress	   can	   originate	   from	   either	   endogenous	  mechanisms,	   such	   as	   reactive	  
oxygen	   species	   (ROS)	  or	  exposure	   to	  exogenous	   factors	   such	  as	   alkylating	  agents,	  ultraviolet	  
(UV)	   light	   and	   ionising	   radiation	   (IR).	   Both	   types	   of	   cellular	   stress	   are	   capable	   of	   generating	  
characteristic	   DNA	   lesions	   that	   require	   specialised	   mechanisms	   for	   their	   repair,	   collectively	  
termed	   the	   DNA	   damage	   response	   (DDR).	   An	   extensive	   network	   of	   post-­‐translational	  
modifications	   orchestrates	   the	   DDR,	   and	   these	   modifications	   serve	   to	   enable	   DNA	   repair,	  
dictate	  DNA	  repair	  pathway	  choice	  and	  activate	  cell-­‐cycle	  controls.	  The	  following	  sections	  will	  
briefly	  describe	   the	  mechanisms	  of	   repair	   including	  examples	  of	  PTMs	   (summarised	   in	  Table	  
1.4)	   that	   regulate	   the	   repair	   process,	   followed	   by	   more	   a	   more	   detailed	   overview	   of	   the	  
Double-­‐strand	  break	  (DSB)	  repair	  pathway.	  	  
Table	  1.4	  Examples	  of	  post-­‐translational	  modifications	  governing	  repair	  pathways	  associated	  
with	  genotoxic	  stress.	  	  
Protein	   Cellular	  Response	   PTM	   References	  
PCNA	   Recruitment	  of	  translesion	  synthesis	  
polymerases	  
ubiquitination	   [120]	  
PCNA	   Suppression	  of	  Rad51	  filament	  
formation	  
SUMOylation	   [48]	  
MutSα	   Nuclear	  localisation	  of	  MMR	  repair	  
factor	  
phosphorylation	   [121]	  
OGG1	   Increased	  base	  excision	  activity	   phosphorylation	   [122]	  
APE1	   Increased	  DNA-­‐binding	  capability	   acetylation	   [123]	  
XPC	   Increased	  DNA-­‐lesion	  recognition	   ubiquitination	   [124]	  
FANCI/D2	   Controlled	  collapse	  of	  stalled	  
replication	  forks	  




1.5.1	  Mismatch	  Repair	  (MMR)	  
An	  example	  of	  endogenously	  generated	  changes	  is	  during	  DNA	  replication,	  whereby	  replicative	  
polymerases	   can	   facilitate	   the	   incorporation	   of	   an	   incorrect	   DNA	   base	   causing	   a	   mismatch.	  
These	  events	  are	  rare	  and	  even	  when	  a	  mistake	  is	  made	  the	  replicative	  polymerases	  pol	  δ	  and	  
pol	  ε	  are	  capable	  of	  proofreading	  the	  newly	  synthesised	  DNA	  sequence	  via	  3’	  nuclease	  activity	  
of	   these	   polymerases	   [126].	   Mutations	   that	   affect	   the	   exonuclease	   activity	   of	   these	  
polymerases	   cause	   an	   increase	   in	   misincorporation	   rates	   and	   result	   in	   an	   increased	  
predisposition	  to	  cancer	  [127].	   If	  DNA	  mismatches	  are	  not	  corrected	  by	  the	  polymerases,	  the	  
cell	  can	  employ	  a	  specialised	  mechanism	  to	  identify	  and	  repair	  mismatches,	  termed	  mismatch	  
repair	  (MMR).	  DNA	  mismatches	  are	  recognised	  by	  an	  MSH2-­‐MSH6	  heterodimer,	  which	  recruits	  
PMS2	  and	  MLH1.	  PCNA	  stimulates	  PMS2	  and	  MLH1	  to	  produce	  a	  nick	  in	  the	  DNA.	  The	  strand	  
containing	   the	   mismatch	   is	   either	   removed	   by	   the	   exonuclease,	   Exo1	   or	   displaced	   by	   the	  
progressing	  polymerase,	  which	  resynthesizes	   the	  oligonucleotide	   to	   traverse	   the	  gap.	  Finally,	  
the	  ends	  of	   the	  DNA	   fragments	  are	   ligated	   together	   to	   complete	   the	   repair	  process	   [128].	   If	  
DNA	  mismatches	   are	   not	   corrected	  before	   the	   next	   round	  of	   replication,	   a	  mutation	  will	   be	  
incorporated.	  
The	   DNA	   mismatch	   recognition	   machinery,	   MSH2-­‐MSH6	   also	   referred	   to	   as	   the	   MutSα	  
complex,	   is	   subject	   to	   post-­‐translational	   modification	   by	   phosphorylation.	   Failure	   to	  
phosphorylate	  MutSα	  impairs	  MMR	  by	  affecting	  its	  nuclear	  localisation	  [121].	  
1.5.2	  Base	  Excision	  Repair	  (BER)	  
Reactive	   oxygen	   species	   (ROS),	   generated	   through	   cellular	   respiration,	   are	   capable	   of	  
generating	   many	   different	   DNA	   lesions	   including	   8-­‐oxo-­‐7,8-­‐dihydro-­‐guanine	   (8-­‐oxoG).	   ROS-­‐
induced	   8-­‐oxoG	   is	   one	   of	   the	   best-­‐characterised	  DNA	   lesions.	   8-­‐oxoG	   can	   base	   pair	  with	   an	  
adenine	  nucleotide	  during	  replication,	  and	  if	   it	  remains	  unrepaired	  it	  can	  lead	  to	  a	  G:C	  to	  A:T	  
transversion.	  As	  a	  result,	  it	  is	  important	  that	  these	  types	  of	  lesions	  are	  effectively	  repaired.	  The	  
cell	  employs	  a	   repair	  mechanism	  to	   recognise,	   remove	  and	  correct	   the	  damaged	  base	  called	  
base-­‐excision	  repair	  (BER).	  BER	  of	  8-­‐oxoG	  requires	  the	  human	  8-­‐oxo-­‐guanine	  DNA	  glycosylase	  
1	   (hOGG1)	  protein	   that	   specifically	   recognises	   the	   lesion,	   flips	  out	   the	  base	  and	  catalyses	   its	  
removal.	   Removal	   of	   guanine	   generates	   an	   apurinic	   base	  within	   the	   DNA	   strand.	   Additional	  
processing	   by	   Apurinic/apyrimidinic	   endonuclease	   1	   (APE1)	   is	   required.	   APE1	   cuts	   the	   DNA	  
backbone	  to	  generate	  a	  3’	  hydroxyl	  group	  in	  the	  sugar-­‐phosphate	  backbone,	  thereby	  allowing	  
the	   incorporation	   of	   a	   guanine	   nucleotide	   by	   polβ,	  which	   can	   then	   be	   ligated	   into	   the	   DNA	  
backbone	   [129,	   130].	   Interestingly,	   OGG1	   is	   post-­‐translationally	   regulated,	   whereby	  
phosphorylation	  by	  the	  serine/threonine	  kinase	  Cdk4	  increases	  its	  activity	  [122].	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DNA	  lesions	  can	  also	  be	  endogenously	  generated	  by	  deamination	  of	  5-­‐methycytosine	  to	  uracil	  
by	   cytidine	   deaminases	   or	   by	   spontaneous	   depurination	   of	   adenine	   and	   guanine	   bases	   to	  
generate	  an	  apurinic	  site	  [131,	  132].	  The	  removal	  of	  uracil	  from	  DNA	  requires	  BER	  via	  the	  use	  
of	  uracil	  DNA	  glycosylase	  to	  generate	  an	  apyrimidinic	  nucleotide.	  However,	  repair	  of	  apurinic	  
sites	  generated	  by	  depurination	  of	  bases	  can	  proceed	  directly	  to	  AP	  endonuclease-­‐dependent	  
processing	  of	  the	  break	  before	  replacement	  of	  the	  nucleotide	  by	  polβ	  [133].	  APE1	  is	  regulated	  
by	  several	  post-­‐translational	  modifications.	  Acetylation	  of	  APE1	  enhances	  its	  ability	  to	  bind	  to	  
DNA,	   conversely	   phosphorylation	   and	   subsequent	   ubiquitination	   of	   APE1	   target	   it	   for	  
proteasomal	  degradation	  [123,	  134].	  	  	  
1.5.3	  Nucleotide	  Excision	  Repair	  (NER)	  
Nucleotide	   excision	   repair	   facilitates	   the	   repair	   of	   a	   number	   of	   DNA	   lesions	   that	   distort	   the	  
DNA	  helix	  structure,	  including	  ultraviolet	  (UV)	  light-­‐induced	  photoproducts.	  The	  most	  common	  
DNA	   lesions	   generated	   by	   exposure	   to	   UV	   light	   are	   cyclobutane-­‐pyrimidine	   dimers	   (CPDs).	  
There	  are	   two	  ways	   in	  which	   the	  NER	  machinery	   can	   recognise	  DNA	   lesions.	  Global	   genome	  
NER	  (GG-­‐NER)	  scans	  the	  genome	  for	  lesions,	  which	  distort	  the	  DNA	  helix.	  Following	  recognition	  
of	   a	   lesion	   by	   XPC,	   RAD32,	   RAD32B,	   CETN2	   and	   UV-­‐radiation-­‐DNA	   damage-­‐binding	   protein	  
(UV-­‐DBB)	   [135],	   the	   transcription	   initiation	   factor	   IIH	   (TFIIH)	   complex	   is	   recruited	   to	   the	   site	  
containing	  the	  lesion.	  Recently,	  it	  was	  demonstrated	  that	  binding	  of	  the	  CDK-­‐activating	  kinase	  
(CAK)	   module	   to	   TFIIH	   inhibits	   its	   intrinsic	   DNA	   binding	   capability,	   allowing	   XPC	   to	   direct	  
recruitment	   of	   TFIIH	   to	   NER	   specific	   substrates.	   Once	   recruited,	   the	   CAK	   module	   then	  
dissociates	   from	  TFIIH	   [136,	   137].	  Once	   TFIIH	   is	   recruited	   it	   opens	   up	   the	  DNA	   structure	   for	  
further	  processing.	  XPF	  and	  XRCC1	  commit	  to	  repair	  by	  NER	  by	  making	  an	  incision	  into	  the	  5’	  
side	  of	   the	   lesion.	  XPG	  generates	  an	   incision	  on	   the	  3’	   side	  of	   the	   lesion	  allowing	   the	   lesion-­‐
containing	   DNA	   strand	   to	   be	   excised	   [135].	   The	   region	   of	   single-­‐stranded	   DNA	   (ssDNA)	  
generated	  is	  protected	  by	  replication	  protein	  A	  (RPA).	  DNA	  polymerase	  fills	  the	  gap	  generated	  
before	  DNA	  ligases	  seals	  the	  sugar-­‐phosphate	  backbone	  to	  complete	  the	  repair	  process	  [138].	  
Furthermore,	   the	   association	  of	   XPC	  with	   the	  DNA	   lesion	   is	   enhanced	  by	  polyubiquitination,	  
which	  is	  catalysed	  by	  the	  E3	  ubiquitin	  ligase	  activity	  of	  its	  binding	  partner,	  UV-­‐DBB	  [124].	  
A	   second	   mechanism	   exists	   for	   the	   recognition	   of	   DNA	   lesions	   requiring	   NER	   in	   highly	  
transcribed	   genes.	   Transcription-­‐coupled	   repair	   (TCR)	   allows	   the	   recruitment	   of	   the	   NER	  
machinery	  directly	   to	   the	   stalled	  RNA	  polymerase	   (RNA	  polII):	   this	   requires	  CSA,	  CSB,	  UVSSA	  
and	  USP7	  [139].	  Following	  recognition	  of	  the	  lesion,	  NER	  continues	  as	  before	  with	  the	  excision	  
of	  the	  lesion-­‐containing	  DNA	  strand	  before	  gap	  filling	  and	  ligation	  [135].	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Some	   rare	   genetic	   disorders	   are	   associated	  with	  mutations	   in	   genes	   encoding	  NER	   and	   TCR	  
proteins.	  Xeroderma	  Pigmentosum	  (XP)	  results	  from	  mutations	  in	  XP	  proteins	  required	  for	  NER	  
and	  results	  in	  hypersensitivity	  to	  UV	  light	  in	  patients.	  Likewise,	  mutations	  in	  CSB	  or	  CSA	  result	  
in	   Cockayne	   syndrome	   (CS),	   which	   is	   characterised	   by	   hypersensitivity	   to	   UV	   light	   and	  
neurodegeneration	   [135].	   Interestingly,	   CSB	   also	   has	   a	   ubiquitin-­‐binding	   domain,	   which	   if	  
deleted,	  produces	  a	  CS-­‐like	  phenotype	  despite	  still	  being	  recruited	  to	  damage	  sites,	  indicating	  
a	  role	  for	  post-­‐translational	  modification	  in	  TCR	  [140].	  	  
1.5.4	  Direct	  reversal	  of	  DNA	  damage	  
The	   formation	   of	   O6-­‐methylguanine	   by	   alkylating	   agents	   such	   as	   temozolomide	   (TMZ)	   can	  
result	  in	  incorrect	  base	  pairing	  during	  replication.	  A	  specialised	  methyltransferase	  termed	  O6-­‐
methylguanine-­‐DNA	  methyltransferase	  (MGMT)	  removes	  the	  methyl	  group	  from	  guanine	  and	  
in	   doing	   so	   the	   protein	   becomes	   non-­‐functional	   i.e.	   each	  MGMT	  molecule	   can	   only	   remove	  
one	  methyl	  group	  from	  a	  damaged	  base.	  As	  a	  result,	  epigenetic	  control	  of	  MGMT	  expression	  
governs	   sensitivity	   of	   cancerous	   cells	   to	   alkylating	   agents	   such	   as	   TMZ	   [141].	   Furthermore,	  
targeting	   of	   MGMT	   using	   O6-­‐benzylguanine,	   an	   MGMT	   inhibitor,	   sensitises	   cells	   to	   DNA	  
alkylating	  agents	  [142].	  
1.5.5	  Translesion	  Synthesis	  
DNA	   lesions	   that	   are	   present	   during	   replication	   can	   cause	   replication	   to	   slow,	   stall,	   or	   if	  
unresolved,	   even	   cause	   the	   replication	   fork	   to	   collapse.	  As	   a	   result,	   it	   is	   critical	   that	   the	   cell	  
repairs	  or	  resolves	  these	  lesions	  prior	  to	  the	  following	  round	  of	  DNA	  replication.	  An	  additional	  
mechanism	   enables	   the	   replicative	   polymerase	   to	   continue	   through	   DNA	   lesions	   at	   the	  
expense	   of	   likely	   incorporating	  mutations	   into	   the	   newly	   synthesised	   DNA	   strand.	   A	   unique	  
subset	  of	  polymerases	  can	  be	  utilised	  by	  the	  cell	  to	  bypass	  the	  DNA	  lesion	  during	  replication.	  
The	   normal	   replicative	   polymerases	   display	   high	   fidelity	   and	   high	   processivity	   and	   are	  
specialised	   for	   replicating	   large	   regions	  of	  DNA	  accurately	  whereas	   the	  Y-­‐family	  polymerases	  
possess	   a	   larger	   active	   site	   allowing	   the	   incorporation	   of	   nucleotides	   opposite	   DNA	   lesions.	  
These	   polymerases	   are	   recruited	   to	   the	   replication	   fork	   through	   interactions	   with	   mono-­‐
ubiquitinated	   Proliferating	   Cell	   Nuclear	   Antigen	   (PCNA)	   via	   PCNA-­‐interacting	   protein	   (PIP)	  
boxes	   and	   ubiquitin-­‐binding	   motifs	   [42,	   120].	   PCNA	   can	   be	   SUMOylated	   and	   ubiquitinated.	  
When	  SUMOylated,	  PCNA	  recruits	  Srs2	  through	  a	  SIM	  to	  suppress	  Rad51	  filament	  formation,	  
further	  highlighting	  the	  diverse	  role	  of	  functions	  directed	  by	  post-­‐translational	  modification	  of	  
proteins	  [48].	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Some	  DNA	  lesions	  require	  more	  than	  one	  repair	  pathway	  to	  correct	  certain	  types	  of	  damage.	  
Interstrand	   crosslinks	   (ICLs)	   occur	   between	   the	   two	   anti-­‐parallel	   strands	   of	   DNA.	  
Chemotherapeutic	   agents	   commonly	   generate	   ICLs,	   which	   are	   highly	   toxic	   to	   cells	   if	  
unrepaired.	   The	   repair	   of	   ICLs	   occurs	   during	   S-­‐phase	   and	   is	   triggered	   by	   the	   stalling	   of	   the	  
replication	  fork.	  When	  the	  replication	  fork	  stalls,	  endonucleases	  are	  required	  to	  ‘unhook’	  one	  
of	  the	  strands	  containing	  the	  ICL,	  thereby	  resulting	  in	  the	  controlled	  collapse	  of	  the	  replication	  
fork	   and	   the	   generation	   of	   a	   DSB.	   A	   TLS	   polymerase	   is	   required	   to	   read	   through	   the	   lesion	  
containing	  the	   ICL.	  The	  DSB	  can	  then	  be	  resolved	  by	  homologous	  recombination	   (HR)	  before	  
restarting	   the	   replication	   fork.	   Resolution	   of	   ICLs	   requires	   FANC	   proteins,	   associated	   with	  
Fanconi	   anaemia	   (FA).	   It	   is	   currently	   thought	   that	   the	   monoubiquitinated	   FANCI-­‐FANCD2	  
complex	  directly	  binds	  to	  the	  DNA	  structure	  produced	  by	  replication	  forks	  colliding	  with	  an	  ICL	  
and	  that	  this	  complex	  recruits	  the	  specific	  endonucleases	  such	  as	  Fanconi-­‐associated	  nuclease	  
1	  (FAN1)	  [125].	  	  
1.5.6	  Single-­‐strand	  break	  repair	  (SSBR)	  
Different	  repair	  processes	  exist	  for	  the	  resolution	  of	  single-­‐	  and	  double-­‐stranded	  DNA	  breaks.	  
Single-­‐strand	  breaks	  (SSBs)	  can	  be	  generated	  by	  ROS	  as	  mentioned	  earlier,	  or	  as	  intermediates	  
in	   BER.	   SSBs	   are	   recognised	   by	   direct	   binding	   and	   activation	   of	   PARP-­‐1,	   which	   proceeds	   to	  
PARylate	  proteins	  in	  the	  regions	  of	  the	  lesion	  including	  itself	  [143].	  Following,	  PARylation	  PARP	  
dissociates	   from	   the	   region	   of	   the	   break	   allowing	   the	   association	   of	   end	   processing	   factors.	  
Due	   to	   the	   variation	   in	   the	   DNA	   ends	   produced	   (which	   is	   dependent	   upon	   the	   source	   of	  
damage),	   the	   cell	   has	   to	   process	   the	   DNA	   ends	   to	   produce	   a	   3’	   hydroxyl	   group	   and	   a	   5’	  
phosphate.	   This	   process	   can	   require	   a	   number	   of	   proteins	   including	   APE1	   endonuclease,	  
utilised	  in	  BER.	  After	  the	  preparation	  of	  the	  DNA	  ends,	  gap-­‐filling	  by	  a	  polymerase	  can	  occur.	  
Additional	   complexity	   is	   introduced	   by	   the	   ability	   of	   the	   polymerase	   to	   displace	   the	   5’	  
nucleotides	   to	  create	  a	  5’	  DNA	   flap,	  known	  as	   ‘long-­‐patch’	   repair.	  The	  5’	  DNA	   flap	  has	   to	  be	  
removed	  by	  FEN1	  endonuclease.	  Finally,	  the	  incorporated	  base	  or	  bases	  are	  ligated	  into	  DNA	  
strand	  by	  DNA	  ligase	  IIIα	  [144].	  
1.6	  DSB	  recognition	  
Double-­‐strand	  breaks	  (DSBs)	  in	  DNA	  form	  some	  of	  the	  most	  deleterious	  lesions	  to	  the	  genome,	  
potentially	   resulting	   in	   gross	   chromosomal	   loss	   or	   translocations	   [7].	   DSBs	   are	   generated	   by	  
ionising	  radiation,	  the	  collapse	  of	  replication	  forks	  or	  as	  part	  of	  cell-­‐type	  specific	  functions	  such	  
as	  V(D)J	  recombination	  in	  lymphocytes	  [145].	  The	  recognition	  of	  the	  DSB	  site	  requires	  PTM	  of	  a	  
number	   of	   targets	   to	   enable	   the	   recruitment	   of	   additional	   DSB	   repair	   mediators.	   Table	   1.5	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summarises	  examples	  of	  PTMs	  that	  occur	  at	  DSB	  sites.	  These	  examples	  are	  explained	  in	  more	  
detail	  in	  this	  section.	  	  
Table	  1.5	  Examples	  of	  PTMs	  that	  occur	  at	  DSB	  sites.	  
Protein	   Cellular	  response	   PTM	   References	  
H2AX	   Recruitment	  of	  MDC1	   phosphorylation	   [146]	  
ATM	   Activation	  of	  ATM	  kinase	  activity	   phosphorylation	   [147]	  
H2A	   Recruitment	  of	  53BP1	   ubiquitination	   [9]	  
Mre11	   Regulation	  of	  nucleolytic	  activity	   phosphorylation	   [148]	  
The	  initial	  step	  in	  repairing	  DNA	  DSBs	  is	  the	  recognition	  and	  marking	  of	  the	  break	  site.	  DSBs	  are	  
primarily	  recognised	  by	  the	  heterotrimeric	  complex	  MRN.	  MRN	  is	  composed	  of	  three	  subunits,	  
MRE11,	   RAD50	   and	   NBS1.	   DNA	   binding	   by	   the	   MRN	   complex	   is	   facilitated	   by	   the	   ‘closed’	  
conformation	   induced	   by	   Rad50	   bound	   to	   ATP.	   Mre11	   is	   a	   3’	   to	   5’	   endo-­‐exonuclease	   that	  
mediates	   the	   interaction	  of	   the	  MRN	  complex	  with	   the	  broken	  DNA	  ends.	  The	   ‘closed’	  MRN	  
conformation	  suppresses	  the	  nuclease	  activity	  of	  Mre11	  to	  prevent	  unwarranted	  resection	  of	  
broken	  DNA	  ends	  [149].	  	  
Recruitment	  of	   the	  MRN	  complex	   to	   the	  DNA	  ends	   serves	  as	  a	   recruitment	  platform	   for	   the	  
DNA	   damage	   sensing	   PI3-­‐kinase,	   Ataxia	   telangiectasia	   mutated	   (ATM).	   ATM	   is	   recruited	  
through	   interactions	   with	   the	   C-­‐terminal	   tail	   of	   Nbs1	   [147].	   In	   its	   inactive	   form	   ATM	   is	   a	  
homodimer,	   but	   activation	   of	   the	   kinase	   stimulates	   autophosphorylation	   of	   serine-­‐1981	   and	  
the	   kinase	   becomes	   a	  monomeric.	  Once	   recruited	   to	  DSBs,	   ATM	  proceeds	   to	   phosphorylate	  
the	   histone	   variant	   H2AX	   on	   serine-­‐139,	   to	   produce	   a	   form	   termed	   γH2AX	   [146].	   γH2AX	   is	  
widely	  accepted	  as	  a	  marker	  of	  DSBs	  within	  cells	  and	  is	  used	  to	  recruit	  DDR	  proteins	  to	  the	  site	  
of	  DNA	  damage	  [150].	  	  
Mediator	  of	  DNA	  damage	  checkpoint	  protein	  1	  (MDC1)	  interacts	  directly	  with	  γH2AX	  through	  
its	   BRCA1	   C-­‐terminal	   (BRCT)	   domains	   [151].	   MDC1	   recruits	   another	   MRN	   complex	   through	  
phosphorylation-­‐dependent	   interactions	   between	   NBS1	   and	   the	   Forkhead-­‐associated	   (FHA)	  
domain	  of	  MDC1	  [152].	  The	  additional	  recruitment	  of	  MRN	  localises	  and	  activates	  more	  ATM	  
resulting	  in	  the	  spreading	  of	  the	  γH2AX	  signal	  along	  the	  chromatin	  flanking	  the	  break	  site	  [153]	  
(figure	  1.5).	  	  
Following	  the	  marking	  of	  the	  break	  site	  by	  the	  generation	  of	  γH2AX	  along	  the	  chromatin,	  both	  
histone	  H2A	  and	  H2AX	  are	  subject	  to	  further	  post-­‐translational	  modification	  by	  ubiquitin.	  Ring	  
finger	  protein	  8	  (RNF8),	  an	  ubiquitin	  E3	  ligase,	  is	  rapidly	  localised	  to	  sites	  of	  DNA	  damage	  and	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proceeds	   to	  polyubiquitinate	  histone	  H2A	  and	  H2AX	   via	   an	   E2	  ubiquitin	   conjugating	   enzyme	  
UBC13.	  The	  generation	  of	  K63-­‐linked	  ubiquitin	  chains	  facilitates	  the	  recruitment	  of	  a	  second	  E3	  
ubiquitin	  ligase,	  RNF168	  [154].	  RNF168	  proceeds	  to	  monoubiquitinate	  H2A	  and	  H2AX	  on	  K15,	  
which	   along	   with	   histone	   4	   K20-­‐dimethylation	   (H3K9me2),	   is	   recognised	   the	   DNA	   damage	  
mediator	  53BP1	  [155]	  (figure	  1.6).	  	  
Recently,	  Mre11	  has	  been	  demonstrated	  to	  direct	  repair	  pathway	  choice	  by	  initiating	  the	  end	  
resection	   of	   broken	   DNA	   ends.	   Once	   recruited	   to	   sites	   of	   double	   strand	   breaks,	  Mre11	   can	  
make	  an	  incision	  adjacent	  to	  the	  DSB	  and	  then	  resect	  DNA	  back	  towards	  the	  break	  site	  in	  the	  
3’	   to	   5’	   direction.	   The	   endonucleolytic	   incision	   is	   viewed	   as	   a	   licencing	   step	   for	   progression	  
towards	   homology	   directed	   repair	   (HDR).	   Subsequent	   activity	   by	  Mre11,	   Exo1	   and	   CtIP	   are	  
required	   for	   5’	   to	   3’	   resection	   away	   from	   the	  break	   in	  order	   to	  promote	  homology	  directed	  
repair	   (HDR).	   Furthermore,	   inhibition	   of	   either	   the	   exonuclease	   or	   endonuclease	   activity	   of	  
Mre11	   confers	   a	   HDR	   defect	   and	   forces	   cells	   to	   repair	   DSBs	   by	   NHEJ	   [156].	   Recently,	   two	  
phosphorylation	   sites	   in	   Mre11,	   S676	   and	   S678,	   were	   identified	   as	   ATM	   phosphorylation	  
targets.	   Failure	   to	   phosphorylate	   these	   residues	   also	   results	   in	   defective	   HDR.	   Furthermore,	  
un-­‐phosphorylatable	  Mre11	  results	   in	  aberrant	  control	  of	  end	  resection	  by	  Exo1,	   resulting	   in	  
excessive	  resection,	  as	  measured	  by	  an	  increase	  RPA	  focus	  intensity	  [148].	  	  
Figure	   1.5	   Mechanism	   of	   DSB	   recogni8on	   (γH2AX signal spreading along 
chromatin). dsDNA	   (blue)	   is	   wrapped	   around	   nucleosomes	   (organge).	   MRN	   
complex	   (red,	   green	   and	   purple	   circles	   labelled	   ‘M’,	   ‘R’	   and	   ‘N’)	   recognises	   
broken	  DNA	  ends.	  MMSET methyltransferase (pink) methylates histone H4 (blue 
circle labeled ‘Me’). Phosphorylation of histone H2AX (red circle labeled ‘P’).'
Figure	  1.6	  Mechanism	  of	  DSB	  recogni8on	  (recruitment	  of	  53BP1). UbiquiAn	  E3	  
ligases	  RNF8	  and	  RNF168	  ubiquiAnate	  histone	  H2A	   (yellow	  circle	   labelled	   ‘Ub’	  
histone).	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1.7	  DSB	  repair	  pathways	  
Following	  on	   from	   the	   recognition	   and	  marking	  of	   the	  DSB	   site	  by	   various	  post-­‐translational	  
modifications	   and	   the	   subsequent	   recruitment	   of	   mediator	   proteins,	   the	   DNA	   ends	   can	   be	  
processed	   to	   allow	   repair	   of	   the	   break.	   Predominantly,	   four	   repair	  mechanisms	   exist	  within	  
cells	   to	   repair	   these	   types	  of	   lesions,	   three	  of	  which	   require	   resection	  and	   the	  generation	  of	  
ssDNA	  overhangs	  as	  a	  prerequisite	  for	  repair.	  	  
1.7.1	  Non-­‐homologous	  end	  joining	  (NHEJ)	  
NHEJ	  is	  one	  of	  the	  most	  prevalent	  repair	  pathways	  utilised	  by	  cells	  to	  repair	  DSBs.	  NHEJ	  can	  be	  
employed	  throughout	  the	  cell-­‐cycle	  as	  it	  does	  not	  rely	  on	  the	  availability	  of	  a	  sister	  chromatid	  
for	  use	  as	  a	  template	  for	  repair.	  Essentially,	  NHEJ	  involves	  re-­‐ligation	  of	  the	  broken	  DNA	  ends.	  
However,	   if	   the	  broken	  ends	   are	   resected	  by	  nucleases	  prior	   to	   re-­‐ligation,	   a	   loss	  of	   genetic	  
material	   is	   incurred.	   As	   a	   result	   NHEJ	   is	   viewed	   as	   a	   highly	   error-­‐prone	  mechanism	   of	   DNA	  
repair.	  	  
DSB	   repair	   by	   NHEJ	   requires	   the	   recognition	   of	   the	   broken	   DNA	   ends	   by	   the	   heterodimeric	  
Ku70/Ku80	  complex	  [157].	  The	  Ku	  complex	  serves	  as	  a	  binding	  platform	  for	  other	  factors.	  DNA	  
protein	   kinase	   catalytic	   subunit	   (DNA-­‐PKcs)	   is	   then	   recruited	  and	   together	  with	  Ku	  bound	   to	  
DNA,	   collectively	   forms	   the	  active	  PI3-­‐kinase,	  DNA-­‐PK	   [158].	  DNA-­‐PK	   is	   capable	  of	   forming	  a	  
synapse	   between	   the	   two	   broken	   ends,	   holding	   them	   within	   proximity	   to	   one	   another.	  
Synapsis	  also	  protects	  the	  DNA	  ends	  from	  nucleases,	  which	  could	  cause	  deletion	  of	  bases	  prior	  
to	  repair	  [31].	  Recruitment	  of	  XRCC4,	  DNA	  ligase	  IV	  is	  promoted	  by	  APLF	  and	  together	  with	  XLF	  
the	   complex	   re-­‐ligates	   the	   broken	   DNA	   ends	   back	   together	   to	   complete	   the	   repair	   process	  
[159] (figure	  1.7).
Genotoxic	   stresses	   that	   induce	  DSBs	   can	   produce	  DNA	   breaks	  with	   single	   strand	   overhangs.	  
Under	  these	  circumstances	  the	  cell	  is	  forced	  to	  employ	  specific	  nucleases,	  such	  as	  Artemis,	  to	  
remove	  the	  overhang	  from	  these	  breaks	  prior	  to	  ligation	  [160].	  Artemis	  is	  recruited	  following	  
phosphorylation	  DNA-­‐PK	  by	  ATM	  [161].	  X-­‐family	  polymerases	  can	  fill	  gaps	  generated	  by	  DNA	  
end	   processing	   without	   the	   need	   for	   a	   template.	   In	   NHEJ,	   terminal	   deoxyribonucleotidyl	  
transferase	  (TdT),	  pol	  μ	  or	  pol	  λ	  are	  required	  for	  gap	  filling	  [162].	  
Figure	   1.7	   Repair	   of	   DSBs	   by	   NHEJ.	   Broken	   DNA	   ends	   are	   recognised	   by	   the	  
Ku70/Ku80	  heterodimer	  (red	  and	  green	  ovals).	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1.7.2	  Microhomology-­‐mediated	  end	  joining	  (MMEJ)	  
MMEJ,	  also	  known	  as	  alternative-­‐NHEJ	  (alt-­‐NHEJ),	  requires	  recognition	  of	  the	  broken	  DNA	  ends	  
by	   PARP-­‐1	   instead	   of	   the	   Ku	   heterodimer	   (used	   in	   classical-­‐NHEJ)	   [163].	   Following	   this,	   the	  
broken	   DNA	   ends	   are	   resected	   by	   Mre11	   and	   CtIP,	   to	   generate	   two	   single-­‐stranded	   3’	  
overhangs.	   The	   overhangs	   generated	   in	   this	   process	   are	   used	   as	   substrates	   for	   either	  HR	  or	  
MMEJ	  [164].	  Unlike	  HR,	  Pol	  θ	  binds	  to	  3’	  overhangs	  and	  is	  thought	  to	  use	  a	  unique	  helicase-­‐like	  
domain	   to	   promote	   microhomology	   binding	   between	   the	   two	   sets	   of	   overhangs	   [165].	  
Following	   binding,	   Pol	   θ	   extends	   each	   of	   the	   DNA	   strands	   using	   the	   other	   overhang	   as	   a	  
template.	   Following	   extension	   the	   DNA	   ends	   can	   be	   ligated	   together.	   Due	   to	   the	   use	   of	  
resection	  to	  facilitate	  microhomology	  search	  MMEJ	  will	  generate	  errors	  and	  only	  accounts	  for	  
the	  repair	  of	  a	  small	  subset	  of	  DNA	  breaks	  [166]	  (figure	  1.8).	  	  	  
Search	  for	  microhomology	  
following	  resecAon	  of	  DNA	  ends	  
Polθ	  	  
Loss	  of	  geneAc	  material	  
Figure	  1.8	  Repair	  of	  DSBs	  by	  MMEJ.	  Thin	  blue	  strand	  represents	  resected	  DNA	  
ends.	   Black	   verAcal	   dashes	   indicate	   regions	   of	   microhomology	   between	  
resected	  DNA	  strands.	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1.7.3	  Homologous	  recombination	  (HR)	  
HR	  is	  a	  specialised	  repair	  pathway	  limited	  to	  S-­‐	  and	  G2-­‐phase	  cells	  due	  to	  the	  requirement	  of	  
the	   sister	   chromatid	   for	   use	   as	   a	   template	   for	   repair.	   Due	   to	   the	   use	   of	   an	   exact	   copy	   as	   a	  
template,	  this	  type	  of	  repair	  is	  error-­‐free	  [167].	  	  
Repair	  by	  HR	  requires	  extensive	  end	  resection	  of	  the	  broken	  DNA	  ends	  initiated	  by	  Mre11	  and	  
extended	   by	   the	   5’	   to	   3’	   exonucleases,	   Exo1	   and	   CtIP	   [156,	   168].	   The	   single	   stranded	   3’	  
overhangs	   generated	   are	   prevented	   from	   forming	   unwanted	   secondary	   structures	   by	   the	  
association	  of	  RPA	  [169].	  RPA	  is	  then	  removed	  from	  the	  ssDNA	  and	  replaced	  by	  Rad51.	  Rad51	  
forms	   a	   filament	   on	   the	   ssDNA,	   which	   is	   mediated	   by	   the	   Shu	   complex	   in	   yeast,	   which	  
comprises	  several	  Rad51	  paralogues	  and	  BRCA2	  [170].	  	  
Following	   Rad51	   filament	   formation	   the	   cell	   initiates	   the	   search	   for	   the	   homologous	   region.	  
Two	   features	   of	   Rad51	   nucleofilaments	   permit	   efficient	   searching	   for	   homology:	   firstly	   the	  
nucleofilament	  has	  the	  ability	  to	  slide	  a	  short-­‐range	  (approximately	  16	  bases)	  along	  the	  sister	  
strand	   [171].	   Secondly,	   nucleofilaments	   can	   bridge	   interactions	   with	   several	   non-­‐contigous	  
sequences	  on	  the	  sister	  strand,	  allowing	  homology	  search	  over	  a	  large	  distance	  simultaneously	  
[172].	   Upon	   identification,	   Rad51	   mediates	   base	   pairing	   between	   the	   3’	   overhang	   and	   the	  
sister	   chromatid.	   Base	   pairing,	   facilitated	   by	   Rad54,	   results	   in	   the	   displacement	   of	   the	  
complementing	   DNA	   strand	   of	   the	   sister,	   generating	   a	   D-­‐loop	   structure	   [173].	   Polymerases	  
extend	  the	  crossed	  strands	  and	  fill	   in	  the	  gaps	  to	  form	  a	  secondary	   intermediate	  known	  as	  a	  
double-­‐Holliday	  junction	  (DHJ)	  [174]	  (figure	  1.9).	  	  
Resolution	  of	  DHJs	  can	  give	  rise	  to	  either	  crossover	  or	  non-­‐crossover	  events	  depending	  upon	  
the	   orientation	   of	   incisions	   made	   at	   the	   junction.	   Three	   endonuclease	   complexes	   mediate	  
these	  incisions,	  GEN1,	  MUS81-­‐EME1	  and	  SLX1-­‐SLX4.	  Interestingly,	  MUS81-­‐EME1	  and	  SLX1-­‐SLX4	  
have	  been	  demonstrated	  to	  work	  together	  with	  the	  former	  complex	  generating	  a	  nick	   in	  the	  
DNA,	   which	   can	   then	   be	   efficiently	   processed	   by	   SLX1-­‐SLX4	   [175,	   176].	   Importantly,	  
suppression	  of	  potential	  crossover	  events	  requires	  the	  BTR	  complex	  (BLM,	  TopoIIIα,	  RM1	  and	  
RM2),	  which	  suppresses	  both	  crossover	  and	  non-­‐crossover	  events	  by	  promoting	  dissolution	  of	  
the	  DHJ	   [177].	   Furthermore,	  MUS81-­‐EME1	  and	  SLX1-­‐SLX4	  association	   requires	  CDK1	  activity,	  
indicating	   a	   role	   for	   post-­‐translational	  modification	   in	   promoting	   potential	   crossover	   events	  
[178].	  	  
Strand	  invasion	  of	  Rad51	  ﬁlament	  
and	  D-­‐loop	  displacement	  following	  
DNA	  end	  resecAon	  
DHJ	  formaAon	  
ResoluAon	  of	  DHJ	  to	  yield	  a	  
crossover	  or	  non-­‐crossover	  event	  
Figure	  1.9	  Repair	  of	  DSBs	  by	  HR.	  The	  invading	  ssDNA	  strand	  (red)	  displaces	  the	  
5’-­‐3’	  strand	  of	  the	  sister	  chromaAd.	  Red	  and	  green	  lines	  indicate	  extension	  of	  of	  
the	  invading	  strand	  using	  the	  opposite	  strand	  as	  a	  repair	  template.	  	  
64	  
1.7.4	  Synthesis	  dependent	  strand	  annealing	  (SDSA)	  
SDSA	  permits	  the	  resolution	  of	  DSBs	  using	  the	  sister	  chromatid	  as	  a	  template	  without	  the	  risk	  
of	  generating	  a	  crossover	  event.	  As	  with	  HR,	  SDSA	  requires	  the	  resection	  of	  DNA	  ends,	  Rad51	  
filament	   formation,	   D-­‐loop	   displacement	   and	   the	   extension	   of	   the	   invading	   nucleofilament.	  
Instead	  of	  utilising	  endonucleases	  or	  the	  BTR	  complex	  to	  resolve	  the	  structure,	  RECQ5	  helicase	  
displaces	   Rad51	   from	   the	   nucleofilament	   [179].	   The	   newly	   synthesised	   DNA	   segment	   is	   re-­‐
annealed	  to	  the	  original	  strand	  to	  complete	  the	  sequence.	  DNA	  polymerases	  are	  then	  required	  
to	  fill	  the	  gap	  generated	  as	  a	  result.	  Finally,	  the	  DNA	  ends	  are	  ligated	  together	  to	  complete	  the	  
repair	  process	  [175]	  (figure	  1.10).	  	  
Strand	  invasion	  and	  D-­‐loop	  displacement	  
following	  end	  resecAon	  
Gap	  ﬁlling	  by	  polymerases	  
Figure	  1.10	  Repair	  of	  DSBs	  by	  SDSA.	  The	  red	  line	  indicates	  the	  extension	  of	  the	  
invading	   strand	   using	   the	   sister	   chromaAd	   as	   a	   repair	   template.	   Following	  
extension,	   the	   newly	   synthesised	   strand	   is	   ligated	   to	   the	   original	   chromaAd	  
while	  a	  polymerase	  ﬁlls	  the	  gap	  generated	  (do?ed	  line).	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1.8	  Role	  of	  p53-­‐binding	  protein	  1	  (53BP1)	  
1.8.1	  Structure	  and	  recruitment	  of	  53BP1	  to	  DNA	  	  
The	   DNA	   damage	   mediator	   protein	   53BP1	   has	   a	   number	   of	   distinct	   domains	   that	   mediate	  
recognition	   and	   recruitment	   to	   sites	   of	   DNA	   damage,	   along	  with	   regions	  mediating	   protein-­‐
protein	   interactions	   that	   are	   critical	   for	   influencing	   the	   repair	   pathway	   choice	   and	   for	   the	  
activation	  of	  associated	  checkpoint	  kinase	  signalling	  pathways.	  	  
The	   ‘core’	   focus-­‐forming	   region	   of	   53BP1	   comprises	   the	   oligomerisation	   domain	   (OD),	   a	  
glycine-­‐arginine	   rich	   (GAR)	  motif,	   a	   tandem	  Tudor	  domain	  and	   the	  ubiquitination-­‐dependent	  
recruitment	  (UDR)	  domain.	  As	  well	  as	  these	  domains,	  53BP1	  also	  contains	  a	   large	  N-­‐terminal	  
region	   containing	   28	   SQ/TQ	  phosphorylation	  motifs,	  which	   are	   capable	   of	  mediating	   several	  
phosphorylation-­‐dependent	   protein-­‐protein	   interactions	   and	   lastly,	   at	   the	   C-­‐terminus,	   there	  
are	  tandem	  BRCA1	  C-­‐terminal	  (BRCT)	  domains	  [8]	  (figure	  1.11).	  	  
The	  GAR	  domain	  was	  initially	  identified	  by	  immunoprecipitation	  of	  substrates	  with	  antibodies	  
recognising	  methylated	  MRE11	   in	  which	  53BP1	  was	   identified.	   It	  was	  observed	  that	  53BP1	   is	  
methylated	  by	  PRMT1	  within	   the	  GAR	  domain	  and	   it	  was	   then	  proposed	   that	   this	   region	  co-­‐
operated	  with	  the	  Tudor	  domains	  to	  mediate	  the	  recruitment	  of	  53BP1	  to	   ionising	  radiation-­‐
induced	  foci	  (IRIF)	  as	  pre-­‐treatment	  with	  methylase	  inhibitors	  prevented	  recruitment	  of	  53BP1	  
to	  sites	  of	  damage.	  Conversely,	  cells	  expressing	  53BP1	  with	  a	  mutant	  GAR	  domain	  were	  able	  to	  
localise	   to	   damage	   normally	   [180].	   This	   indicates	   a	   potential	   role	   for	   negative	   regulation	   of	  
recruitment	  of	  53BP1	  to	  IRIF	  by	  methylation.	  	  
The	  tandem	  Tudor	  domains	  of	  53BP1	  specifically	  recognise	  and	  bind	  to	  di-­‐methylated	  histone	  
H4	  on	  lysine-­‐20	  (H4K20me2).	  This	  interaction	  is	  critical	  for	  localisation	  of	  53BP1	  to	  sites	  of	  DNA	  
damage.	  Recruitment	  of	   53BP1	   to	   IRIF	   via	   the	  Tudor	  domains	   is	   predominantly	   governed	  by	  
methyltransferases	  MMSET	  and	  SETDB8,	  which	  have	  been	  shown	  to	  concentrate	  their	  activity	  
at	  sites	  of	  DNA	  damage	  [181,	  182].	  However,	  as	  histone	  methylation	  is	  observed	  ubiquitously	  
throughout	   the	   genome,	   it	   is	   also	   proposed	   that	   epitope	  masking	   by	   L3MBTL1,	   JMJD2A	   and	  
polyubiquitin	   antagonises	   the	   recruitment	   of	   53BP1.	   Following	   the	   generation	   of	   DSBs,	  
methylated	  histones	  are	  unmasked	  facilitating	  53BP1	  recruitment	  [183-­‐185].	  Furthermore,	  the	  
oligomerisation	   of	   53BP1,	   via	   the	   OD	   domains,	   is	   required	   for	   its	   efficient	   recognition	   of	  
methylated	  histones	  by	  the	  Tudor	  domains	  and	  for	  efficient	  recruitment	  into	  IRIF	  [186].	  	  
An	   additional	   level	   of	   complexity	   is	   introduced	   by	   the	   identification	   of	   the	   UDR	   domain,	  
through	  which	  53BP1	  recognises	  mono-­‐ubiquitinated	  H2A	  and	  H2AX	  on	  lysine-­‐15	  [155],	  which	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is	  a	  DNA	  damage	  specific	  modification	  generated	  by	  the	  E3	  ubiquitin	  ligase	  RNF168	  [187].	  The	  
ubiquitin-­‐binding	  activity	  of	  RNF168	  was	  shown	  to	  be	  critical	  to	  for	  the	  retention	  of	  53BP1	  to	  
sites	  of	  DNA	  damage	  [188].	  Mutation	  of	  the	  UDR	  domain	  prevents	  focus	  formation	  by	  53BP1	  
indicating	   a	   co-­‐operative	   role	   for	   both	   ubiquitin	   and	   methylation	   recognition	   in	   localising	  
53BP1	   to	   sites	  of	  DNA	  damage.	  Ubiquitin-­‐dependent	  accumulation	  of	  53BP1	   to	   sites	  of	  DNA	  
damage	   facilitated	   by	   the	   E3	   ligases	   RNF8	   and	   RNF168	   is	   directly	   antagonised	   by	   the	   de-­‐
ubiquitinating	  enzyme,	  POH1,	  a	  component	  of	  the	  proteasome	  [184].	  	  
The	  SQ/TQ	  motifs	  are	  phosphorylation	  motifs	  located	  within	  the	  N-­‐terminus	  of	  53BP1,	  many	  of	  
which	  are	  phosphorylated	  by	   the	  PI3-­‐kinase	  ATM	  following	   its	  activation.	  Phosphorylation	  of	  
these	   sites	  mediate	   further	   phospho-­‐specific	   protein	   interactions	  with	   proteins	   such	   as	   Rif1	  
and	  PTIP,	  both	  of	  which	  have	  been	  shown	  to	  facilitate	  the	  downstream	  effects	  of	  53BP1	  (i.e.	  
limiting	  DNA	  end	   resection	  and	   fusion	  of	  unprotected	   telomeres)	   [189-­‐191].	  However,	  many	  
non-­‐SQ/TQ	  motif	   residues	  within	   the	  N-­‐terminus	   of	   53BP1	  may	   also	   be	   phosphorylated	   and	  
have	  yet	   to	  be	   characterised.	   Furthermore,	   the	   replication-­‐licensing	   factor	   and	  DNA	  damage	  
response	   mediator	   TopBP1	   (Topoisomerase	   IIβ-­‐binding	   protein	   1)	   is	   recruited	   to	   breaks	   by	  
53BP1,	   through	   its	  N-­‐terminus,	   in	   a	   phosphorylation-­‐dependent	  manner	   [192].	   Interestingly,	  
this	   particular	   interaction	   is	   also	   cell-­‐cycle	   specific,	   integrating	   both	   damage	   response	  
signalling	  and	  cell-­‐cycle	  control	  [193].	  
Classically,	   BRCT	   domains	   are	   thought	   of	   as	   phosphorylation-­‐dependent	   binding	   modules,	  
which	  mediate	  protein-­‐protein	   interactions	  between	  a	  phosphorylated	  peptide	  and	  the	  BRCT	  
containing	   protein.	   However,	   the	   BRCT	   domains	   of	   53BP1	   can	   mediate	   a	   number	   of	  
phosphorylation-­‐independent	   interactions.	   The	   tumour	   suppressor	   protein	   p53	   interacts	  
directly	  with	  the	  BRCT	  domain	  of	  53BP1	  in	  a	  phosphorylation-­‐independent	  manner	  [194,	  195].	  
The	  BRCT	  domains	  also	  interact	  with	  Rad50	  in	  complex	  with	  Mre11	  and	  can	  also	  interact	  with	  
the	  chromatin	  remodelling	  protein	  EXPAND1	  [196,	  197].	  In	  S.	  pombe	  Crb253BP1	  and	  S.cerevisiae	  
Rad953BP1,	   the	  BRCT	  domains	  have	  been	  shown	   to	  mediate	  phosphospecific	   interactions	  with	  
γH2A.1	   and	   γH2A	   respectively	   [198,	   199].	  Whether	   or	   not	   the	   BRCT	   domains	   of	   53BP1	   are	  
capable	   of	   mediating	   phosphorylation-­‐dependent	   protein	   interactions	   remains	   to	   be	  
















































































































































































































































































































1.8.2	  Functions	  of	  53BP1	  
53BP1	   mediates	   several	   important	   functions	   in	   response	   to	   DNA	   damage.	   Firstly,	   53BP1	  
regulates	  the	  repair	  pathway	  choice,	  favouring	  error	  prone	  NHEJ	  over	  HR	  by	  antagonising	  the	  
resection	  of	  broken	  DNA	  ends	   [190].	  Secondly,	  53BP1	   transduces	   the	  DNA	  damage	   response	  
requiring	   ATM-­‐dependent	   phosphorylation	   of	   its	   N-­‐terminal	   domain	   in	   order	   to	   mediate	  
interactions	   with	   downstream	   factors	   required	   for	   its	   function	   [200].	   Furthermore,	   the	  
activation	   of	   ATM	   serves	   as	   a	   critical	   signalling	   node,	   transducing	   the	   damage	   signal	   via	  
phosphorylation	   to	   a	   vast	   number	  of	   downstream	  mediators	   and	  effector	   proteins	   including	  
Chk2,	   which	   induces	   cell-­‐cycle	   arrest	   [201].	   Thirdly,	   the	   reorganisation	   of	   the	   chromatin	  
structure	   in	   the	   region	   surrounding	   the	   DSB,	   often	   considered	   as	   a	   barrier	   to	   the	   repair	  
process,	   requires	   53BP1	   and	   the	   damage	   response	   kinase	   ATM	   [202,	   203].	   The	   53BP1-­‐
dependent	  reorganisation	  of	  chromatin	  has	  been	  studied	  further	  by	  analysing	  the	  mobility	  of	  
unprotected	  telomeres,	  it	  has	  been	  demonstrated	  that	  53BP1	  is	  required	  for	  long-­‐range	  NHEJ	  
and	   to	   reorganise	   chromatin	   structure	   to	   allow	   increased	   telomere	   mobility	   (a	   feature	  
proposed	   to	   explain	   increased	   telomere	   fusions	   observed	   in	   TRF2-­‐/-­‐	   conditional	   knock-­‐out	  
cells)	   [204].	   In	   lymphocytes,	   53BP1	   and	   its	   downstream	   effectors	   have	   been	   shown	   to	   be	  
required	   for	   Class-­‐Switch	   Recombination	   (CSR)	   and	   V(D)J	   (Variable-­‐Diversity-­‐Joining)-­‐
recombination	  which	  are	  vital	  for	  the	  establishment	  of	  the	  immune	  system	  [205,	  206].	  	  
53BP1	   functions	   in	   the	   repair	   pathway	   choice	   by	   antagonising	   the	   resection	   of	   broken	   DNA	  
ends	  promoted	  by	  BRCA1.	   In	  S-­‐	  and	  G2-­‐phase	  cells,	  BRCA1	  displaces	  53BP1	   from	  DSB	  site	   in	  
order	  to	  permit	  end	  resection	   initiated	  by	  CtIP	  and	  promote	  Homology-­‐directed	  repair	   (HDR)	  
[207,	  208].	  Both	  53BP1	  and	  BRCA1	  elicit	  mutual	  antagonism	  of	  one	  another	  that	  is	  propagated	  
by	  the	  recruitment	  of	  downstream	  factors.	  53BP1	  recruits	  Rif1	  through	  phosphorylated	  SQ/TQ	  
motifs	   within	   its	   N-­‐terminus	   [190].	   Loss	   of	   Rif1	   phenocopies	   loss	   of	   53BP1	   at	   unprotected	  
telomeres	   by	   preventing	   telomere	   fusions	   and	   failing	   to	   prevent	   end	   resection	   [190].	  
Conversely,	  BRCA1	  has	  recently	  been	  shown	  to	  recruit	  an	  E3	  ubiquitin	  ligase,	  UHRF1,	  through	  
its	   BRCT	   domain	   in	   order	   to	   polyubiquitinate	   Rif1	   and	   promote	   DNA	   end	   resection	   [209].	  
Downstream	  of	  the	  activity	  of	  BRCA1	  at	  IRIF,	  53BP1	  is	  repositioned	  from	  the	  core	  of	  the	  focus	  
to	  the	  periphery	  [208].	  The	  physical	  repositioning	  of	  53BP1	  from	  the	  core	  of	  IRIF	  is	  achieved	  in	  
two-­‐phases.	  Firstly,	  by	  expansion	  of	  the	  53BP1	  focus	  followed	  by	  formation	  of	  a	  53BP1-­‐devoid	  
core,	   the	   latter	   of	   which	   requires	   the	   de-­‐ubiquitinating	   protein	   POH1,	   which	   has	   previously	  
been	   shown	   to	   antagonise	   RNF8/RNF168-­‐dependent	   polyubiquitination	   and	   recruitment	   of	  
53BP1	   [184,	  210].	   The	  mechanism	  by	  which	  53BP1	   IRIF	  expand	   is	  of	   keen	   interest	   and	   likely	  
reflects	  the	  initial	  selection	  and	  DSB	  processing	  required	  for	  the	  progression	  to	  HDR.	  Alongside	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the	  requirement	  for	  POH1	  to	  remove	  polyubiquitin	  chains	  from	  the	  core	  of	  IRIF,	  the	  expansion	  
of	   53BP1	   IRIF	   requires	   BRCA1,	   CtIP	   and	   a	   number	   of	   chromatin	   repressive	   factors	   including	  
Heterochromatin	   Protein	   1	   (HP1),	   the	   histone	   methyltransferases	   SETDB1	   and	   SUV39	   [210,	  
211].	   This	   suggests	   the	   repositioning	   of	   53BP1	   requires	   the	   ability	   to	   modulate	   a	   highly	  
dynamic	  chromatin	  environment.	  	  
Targeting	   proteins	   that	   govern	   DNA	   repair	   pathway	   choice	   have	   proved	   to	   be	   valuable	  
therapeutic	  targets.	  BRCA1-­‐deficient	  cells	  fail	  to	  repair	  DSBs	  by	  HR	  and	  as	  a	  subsequently	  cells	  
resort	  to	  error	  prone	  and	  potentially	  mutagenic	  NHEJ	  for	  repair	  [212].	  PARP	  inhibitors,	  such	  as	  
Olaparib,	  have	  been	  very	  successful	  in	  sensitising	  BRCA1-­‐deficient	  cells	  to	  ionising	  radiation	  by	  
blocking	  the	  NHEJ	  repair	  pathway,	  creating	  a	  synthetic	  lethality	  with	  the	  failure	  to	  perform	  HR	  
conferred	   by	   the	   loss	   of	   BRCA1	   [213].	   Interestingly,	   loss	   of	   53BP1	   was	   found	   to	   confer	  
resistance	   to	   PARPi	   by	   restoring	   the	   ability	   for	   cells	   to	   perform	  HR	   [213].	   The	   resistance	   to	  
PARPi	   has	   been	   utilised	   to	   identify	   proteins	   that	   co-­‐operate	   with	   53BP1	   to	   prevent	   end	  
resection.	  For	  example,	   loss	  of	  PTIP	  confers	  resistance	  to	  PARPi	   indicating	  that	   it	  co-­‐operates	  
with	   53BP1	   to	   block	   HR	   [213].	   PTIP	   is	   recruited	   to	   sites	   of	   DNA	   damage	   through	   ATM-­‐
dependent	   phosphorylation	   sites	   located	  within	   the	  N-­‐terminus	   of	   53BP1	   [213].	   Unlike	   Rif1,	  
PTIP	  only	  appears	  to	  require	  the	  first	  8	  SQ/TQ	  motifs	   for	   its	  53BP1-­‐dependent	   function.	  PTIP	  
also	  appears	  to	  be	  critical	  in	  order	  to	  limit	  end	  resection	  and	  to	  prevent	  fusion	  of	  unprotected	  
telomeres	  [213].	  Recently,	  PTIP	  has	  been	  shown	  to	  recruit	  the	  endonuclease	  Artemis	  to	  sites	  of	  
damage	   in	   a	   phosphorylation-­‐dependent	   manor	   and	   that	   remarkably,	   depletion	   of	   Artemis	  
results	   in	   PARPi	   resistance	   in	   BRCA1-­‐deficient	   cells	   [214].	   This	   suggests	   that	   a	   key	   factor	   in	  
protecting	  broken	  DNA	  ends	  from	  resection	  by	  nucleases	  is	  the	  generation	  of	  blunt	  DNA	  ends.	  
Recent	   investigation	  has	   also	   identified	  REV7,	   a	   component	  of	   polymerase	   ζ,	   as	   a	   key	   factor	  
acting	  downstream	  of	  53BP1	   in	  protecting	  broken	  DNA	  ends,	   it	  has	  been	  demonstrated	   that	  
loss	  of	  REV7	  restores	  HR	  and	  confers	  resistance	  to	  PARPi	  [215].	  	  
53BP1	  is	   involved	  in	  mediating	  the	  cell-­‐cycle	  checkpoint	  responses	  following	  DNA	  damage.	   In	  
the	  absence	  of	  53BP1	  cells	  activate	  but	  fail	  to	  maintain	  a	  G2-­‐M	  checkpoint	  arrest	  that	  would	  
otherwise	   be	   propagated	   through	   sustained	   ATM-­‐mediated	   phosphorylation	   of	   Chk2	   [29].	  
Interestingly,	  in	  cells	  lacking	  Rif1,	  resection	  of	  DSBs	  leads	  to	  increased	  ATR	  activation	  following	  
the	   generation	  of	   ssDNA	   [190].	  One	  might	   expect	   that	   53BP1	  would	   indirectly	   suppress	  ATR	  
activation	  given	  its	  role	  in	  preventing	  resection	  and	  the	  generation	  of	  ssDNA.	  However	  this	  is	  
not	   the	   case,	   as	   53BP1	   is	   also	   required	   for	   ATR	   activation	   in	   order	   to	   establish	  G2-­‐M	  phase	  
checkpoint	   arrest	   [216].	   Additionally,	   53BP1	   may	   also	   be	   required	   for	   G1-­‐phase	   arrest	   and	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preventing	  S-­‐phase	  entry	  while	  DNA	  damage	  is	  present.	  The	  establishment	  of	  the	  G1-­‐S	  phase	  
checkpoint	  requires	  both	  53BP1	  and	  TopBP1	  [193].	  	  
53BP1	   is	   required	   for	   repair	   of	   DNA	   DSBs	   located	   in	   regions	   of	   heterochromatin.	   The	  
heterochromatinised	  fraction	  of	  DSBs	  accounts	  for	  approximately	  10-­‐15%	  of	  breaks	  generated	  
following	   exposure	   to	   ionising	   radiation.	   The	   resolution	   of	   these	   breaks	   specifically	   requires	  
the	  BRCT	  domains	   of	   53BP1,	  with	   the	   loss	   of	   these	   domains	   resulting	   in	   impaired	  MRN	  and	  
pATM	   (pSer1981)	   localisation	   [202].	   Furthermore,	   the	   repair	   of	   heterchomatinised	   DSB	  
requires	  ATM-­‐dependent	  phosphorylation	  of	  the	  repressor	  of	  transcription,	  KRAB-­‐1	  associated	  
protein	   1	   (KAP-­‐1)	   to	   promote	   chromatin	   relaxation	   [202].	   The	   association	   of	   KAP-­‐1	   with	  
chromatin	  is	  regulated	  by	  phosphorylation	  of	  serine-­‐824	  [217].	  When	  KAP-­‐1	  is	  SUMOylated,	  it	  
recruits	  the	  nucleosome	  remodeler,	  CHD3	  [218].	  Although	  phosphorylation	  of	  KAP-­‐1	  does	  not	  
directly	  affect	  its	  SUMOylation,	  it	  changes	  the	  conformation	  of	  the	  binding	  region,	  preventing	  
the	   association	   of	   CHD3	   with	   KAP-­‐1.	   Ultimately,	   phosphorylation	   of	   KAP-­‐1	   rapidly	   displaces	  
CHD3	  from	  chromatin	  to	  permit	  chromatin	  relaxation	  [203].	  The	  ability	  of	  KAP-­‐1	  to	  associate	  
with	   CHD3	   to	   modulate	   the	   repair	   of	   heterochromatic	   breaks	   is	   also	   regulated	   by	  
polySUMOylation	   as	   the	   SUMO	   protease,	   SENP7,	   is	   required	   to	   relax	   chromatin	   to	   permit	  
repair	   by	   HR	   [218].	   	   Despite	   determining	   the	   downstream	   events	   requiring	   the	   activated	  
pATM,	  it	  remains	  to	  be	  established	  as	  to	  why	  deletion	  of	  the	  BRCT	  domains	  of	  53BP1	  results	  in	  
a	   failure	   to	   localise	   both	   MRN	   and	   pATM	   to	   DSBs.	   Further	   characterisation	   of	   the	   specific	  
interactions	   mediated	   by	   the	   BRCT	   domains	   will	   be	   required	   to	   address	   this	   question.	  
Furthermore,	   the	   chromatin	   remodeler,	   EXPAND1	   interacts	   with	   in	   a	   phosphorylation-­‐
independent	   manner	   through	   the	   BRCT	   domain	   of	   53BP1	   [197].	   EXPAND1	   associates	   with	  
chromatin	   through	   histone	   H3	   using	   its	   PWWP-­‐domain.	   These	   interactions	   have	   also	   been	  
shown	   to	   be	   required	   for	   the	   relaxation	   of	   chromatin	   surrounding	   DSBs	   and	   impacts	   upon	  
sensitivity	  of	  cells	  to	  ionising	  radiation	  [197].	  	  
A	   number	   of	   research	   groups	   have	   demonstrated	   the	   extent	   to	   which	   53BP1	   governs	  
chromatin	  mobility.	  By	  using	  fluorescently	  labelled	  TRF1,	  it	  has	  been	  shown	  that	  loss	  of	  53BP1	  
prevents	   the	   increased	   telomere	  mobility	   observed	   at	   unprotected	   telomeres	   and	   that	   this	  
mobility	  also	  requires	  ATM	  kinase	  [204].	  The	  requirement	  for	  53BP1	  to	  mobilise	  chromatin	  is	  
also	   applicable	   at	   DSBs	   and	   requires	   the	   nuclear	   envelope-­‐bound	   LINC	   complex	   to	   promote	  
chromatin	  reorganisation	  to	  facilitate	  repair	  [219].	  This	  is	  a	  pivotal	  study	  as	  it	  suggests	  that	  the	  
part	  of	  the	  driving	  force	  required	  to	  globally	  alter	  chromatin	  organisation	  may	  originate	  from	  
the	  microtubules	  in	  the	  cytoplasm.	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Finally,	  the	  role	  of	  53BP1	  in	  the	  cell	  is	  not	  limited	  to	  repair	  of	  DSBs,	  checkpoint	  signalling	  and	  
chromatin	  mobility	  as	  detailed	  above,	  but	  also	  extends	  to	  the	   immune	  system.	   In	  specialised	  
cells,	   53BP1	   has	   been	   shown	   to	   be	   required	   for	   CSR,	   a	   process	   by	   which	   B-­‐cells	   switch	  
immunoglobulin	   isotype	   by	   generating	   a	   controlled	   DSB	   [205].	   Despite	   the	   requirement	   for	  
both	  Rif1	  and	  PTIP	  for	  long-­‐range	  end	  joining	  of	  telomeres,	  failure	  to	  recruit	  PTIP	  (but	  not	  Rif1)	  
by	   mutation	   of	   the	   N-­‐terminus	   of	   53BP1	   does	   not	   affect	   CSR	   indicating	   that	   only	   Rif1	   is	  
required	   for	   this	   specialised	  process	   [213].	  Alongside	  CSR,	  V(D)J-­‐recombination	   (required	   for	  
maturation	   of	   B	   and	   T	   cells	   as	   well	   as	   diversification	   of	   antibodies)	   was	   also	   found	   to	   be	  
perturbed	  in	  53BP1	  deficient	  lymphocytes	  although,	  it	  remains	  to	  be	  established	  which	  factors	  
acting	  downstream	  of	  53BP1	  are	  required	  for	  this	  process	  [206].	  	  
1.8.3	  Role	  of	  TopBP1	  
TopBP1	  is	  a	  large	  molecular	  scaffold	  protein	  that	  contains	  9	  BRCT	  domains	  that	  mediate	  many	  
protein-­‐protein	  interactions	  [220]	  (figure	  1.12).	  As	  such,	  it	  has	  roles	  throughout	  the	  cell	  cycle,	  
including	   the	   initiation	   of	   replication,	   the	   repair	   of	   DNA	   damage,	   transcriptional	   control,	  
mediating	   checkpoint	   signalling	   and	   cell	   cycle	   arrest	   [221].	   Predominantly,	   TopBP1	  has	  been	  
characterised	   as	   a	   critical	   factor	   required	   for	   the	   initiation	   of	   replication.	   In	   S.	   cerevisiae,	  
Dpb11TopBP1	   bridges	   interactions	   between	   the	   replication	   pre-­‐loading	   complex	   through	   Sld2	  
and	  MCM	  helicase	  via	  Sld3	  and	  cdc45	   to	   form	  the	  active	  helicase	   [222].	   In	  mammalian	  cells,	  
Treslin	  mediates	  the	  interaction	  of	  TopBP1	  with	  cdc45	  and	  the	  MCM	  complex,	  and	  as	  a	  result	  
depletion	  of	  Treslin	  causes	  defective	  DNA	  replication	  [223].	  	  
Under	   conditions	   of	   replicative	   stress	   TopBP1	   activates	   the	   checkpoint	   kinases	   ATR.	  
Deacetylation	   of	   TopBP1	   by	   SIRT1	   facilitates	   suppression	   of	   replication	   origin	   firing	   [224].	   In	  
order	  to	  mediate	  its	  checkpoint	  activity,	  TopBP1	  contains	  a	  conserved	  ATR-­‐activation	  domain	  
(AAD)	  located	  between	  BRCT	  domains	  6	  and	  7	  [225].	  During	  replicative	  stress,	  the	  replication	  
fork	   stalls	   at	   the	   site	  of	  damage,	  which	   causes	   the	   region	  of	   ssDNA	  on	   the	   lagging	   strand	   to	  
become	  coated	  in	  RPA.	  RPA	  recruits	  ATR-­‐interacting	  protein	  (ATRIP),	  which	  then	  recruits	  ATR	  
kinase	  to	  the	  site	  of	   replicative	  stress.	  The	  heterotrimeric	  sliding	  clamp	  complex,	  Rad9-­‐Rad1-­‐
Hus-­‐1	   (9-­‐1-­‐1)	   is	   loaded	   onto	   the	   DNA	   by	   the	   Rad17-­‐RFC	   complex	   [226].	   TopBP1	   is	   then	  
recruited	  to	  the	  stalled	  replication	  fork	  by	  interactions	  between	  TopBP1	  BRCT	  domains	  0,	  1-­‐2	  
and	   the	   phosphorylated	   C-­‐terminus	   of	   Rad9	   of	   the	   9-­‐1-­‐1	   complex	   [227].	   Rad9-­‐Rad1-­‐Hus1	  
interacting	   nuclear	   orphan	   (RHINO)	   binds	   to	   both	   the	   9-­‐1-­‐1	   complex	   and	   TopBP1	   to	   fully	  
activate	  ATR	  [228].	  The	  ATR-­‐activation	  domain	  of	  TopBP1	  contacts	  the	  PI3K	  regulatory	  domain	  
(PRD)	  of	  ATR	  to	  stimulate	  its	  activity	  [229].	  Activated	  ATR	  kinase	  phosphorylates	  a	  number	  of	  
downstream	  targets	  including	  the	  checkpoint	  kinase	  Chk1	  to	  promote	  intra	  S-­‐phase	  checkpoint	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arrest	   [230].	   Recently,	   ATR-­‐dependent	   Chk1	   signalling	   was	   demonstrated	   to	   require	   post-­‐
translational	  modification	  of	  ATRIP	  by	  SUMO2/3.	  Generation	  of	  an	  unSUMOylatable	  mutant	  by	  
mutation	   of	   two	   lysine	   residues	   impaired	   localisation	   of	   ATRIP	   to	   sites	   of	   replicative	   stress	  
[231].	  	  
Interestingly,	  it	  was	  recently	  proposed	  that	  the	  MRN	  complex	  is	  responsible	  for	  recruitment	  of	  
TopBP1	   to	   stalled	   replication	   forks,	   although	   the	  downstream	  activation	  of	  ATR	   still	   requires	  
the	  9-­‐1-­‐1	  complex	  [232].	  Furthermore,	  it	  has	  been	  demonstrated	  that	  early	  MRN	  recruitment	  
to	  IR-­‐induced	  damage	  occurs	  independently	  of	  MDC1,	  through	  interactions	  with	  Rad17	  [233].	  
It	   will	   of	   future	   interest	   to	   determine	   whether	   Rad17	   is	   required	   for	   MRN	   and	   TopBP1	  
recruitment	  to	  stalled	  replication	  forks.	  
Unusually,	   TopBP1	   has	   also	   been	   identified	   as	   a	   transcriptional	   repressor.	   Its	   role	   in	  
suppressing	   the	   transcriptional	   activity	  of	   E2F1	   requires	  oligomerisation	  of	   TopBP1,	  which	   in	  
turn	   is	   governed	   by	   phosphorylation	   of	   serine-­‐1159	   [234].	   TopBP1	   also	   has	   a	   role	   in	  
suppressing	  the	  transcriptional	  activity	  of	  the	  tumour	  suppressor,	  p53	  [235].	  	  
TopBP1	  also	  mediates	   interactions	  with	  BLM	  helicase	  a	   component	  of	   the	  BTR	  complex	   that	  
suppresses	   crossover	   events	   during	   HR.	   Previously,	   TopBP1	   had	   been	   demonstrated	   to	  
regulate	   the	   stability	   of	   BLM	   [236],	   although	   this	   now	  appears	   not	   to	  be	   the	   case	   as	   virally-­‐
induced	  degradation	  of	  TopBP1	  does	  not	  influence	  the	  stability	  of	  BLM	  [237].	  Despite	  this,	  the	  
TopBP1-­‐BLM	   interaction	   is	   required	   for	   maintenance	   of	   genome	   stability	   as	   measured	   by	  
increased	  sister	  chromatid	  exchanges	   (SCEs)	   [237].	  Additionally,	  TopBP1	   is	   required	   for	  V(D)J	  
recombination	   in	   lymphocytes	   [145].	   The	   mechanism	   by	   which	   TopBP1	   regulates	   the	   BLM	  
helicase	  in	  the	  resolution	  of	  DHJs	  remains	  to	  be	  established.	  
In	   S.	   pombe,	   Rad4TopBP1	   has	   been	   demonstrated	   to	   interact	   in	   a	   phosphorylation-­‐dependent	  
manner	  with	  Crb253BP1	  [238].	  In	  humans,	  TopBP1	  is	  recruited	  to	  53BP1	  through	  BRCT	  domains	  
0,	  1-­‐2	  and	  4-­‐5	   in	  G1-­‐phase.	  This	   contrasts	  with	  S-­‐phase,	  as	   recruitment	  of	  TopBP1	   to	   stalled	  
DNA	  replication	  forks	  requires	  BRCT	  domains	  0,	  1-­‐2	  and	  7-­‐8.	  Furthermore,	   in	  stable	  cell	   lines	  
expressing	   TopBP1	   lacking	   BRCT	   domains	   4-­‐5	   a	   G1-­‐S	   checkpoint	   defect	   is	   observed,	  
comparable	   to	   that	   observed	   by	   depletion	   of	   53BP1	   or	   TopBP1	   alone	   [193].	  Moreover,	   G1-­‐
phase	   cells	   are	   sensitised	   to	   IR-­‐induced	   killing	   following	   treatment	   with	   an	   ATR	   inhibitor,	  
indicating	   a	   potential	   role	   for	   ATR-­‐dependent	   checkpoint	   signalling	   in	   G1-­‐phase	   cells	   [239].	  
Additionally,	  TopBP1	  BRCT	  domain	  5	  has	  been	  shown	  to	   interact	  with	  phosphorylated	  MDC1	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[240].	   As	   a	   result,	   further	   work	   will	   be	   required	   to	   determine	   which	   sets	   of	   interactions	  
mediated	  by	  these	  domains	  are	  required	  for	  checkpoint	  activation.	  	  	  
Due	   to	   the	   complex	   interactions	   mediated	   by	   TopBP1	   and	   given	   its	   diverse	   functions,	   it	   is	  
difficult	   to	   dissect	   the	   importance	   of	   individual	   interactions	   mediated	   by	   this	   protein.	   For	  
example,	   deletion	   of	   a	   single	   set	   of	   BRCT	   domains	   may	   result	   in	   the	   abolition	   of	   several	  
interactions.	   As	   a	   result,	   it	   becomes	   necessary	   to	   examine	   the	   binding	   target	   to	   determine	  
which	   specific	   interactions	   are	   required	   for	   its	   function	   and	   in	   the	   case	   of	   BRCT	   domains,	  
whether	  they	  are	  phosphorylation-­‐dependent.	  	  














































































































The	   overall	   aim	   of	   this	   project	   was	   to	   investigate	   mechanisms	   associated	   with	   the	   roles	   of	  
certain	  post-­‐translational	  modifications	  in	  response	  to	  stresses,	  including	  response	  to	  arsenite	  
and	  ionising	  radiation.	  	  
Firstly,	   following	   the	   identification	  of	  many	  eukaryotic	   initiation	   factors	   in	  proteomic	  screens	  
undertaken	  to	  identify	  SUMOylated	  substrates,	  the	  initial	  aim	  of	  the	  project	  was	  to	  determine	  
whether	   the	   eukaryotic	   initiation	   factor	   4A,	   a	   component	   of	   the	   eIF4F	   complex,	   is	   a	   true	  	  	  	  
SUMOylation	   target	   in	   vivo.	   If	   so,	   the	   aim	   was	   then	   to	   identify	   the	   residue(s)	   that	   is/are	  
SUMOylated,	   and	   finally,	   by	   mutating	   the	   SUMOylated	   residue(s),	   to	   characterise	   the	  
intracellular	   role	   of	   this	  modification	   and	   to	  determine	  whether	   it	   forms	  part	   of	   the	   cellular	  
response	  to	  stress.	  
Secondly,	  following	  the	  identification	  of	  two	  phosphorylated	  residues	  within	  the	  N-­‐terminus	  of	  
53BP1	  that	  interact	  with	  TopBP1	  BRCT	  domain	  0,	  1-­‐2	  and	  4,	  5	   in	  vitro,	  the	  aim	  of	  this	  project	  
was	  to	  determine	  whether	   these	  sites	  are	  phosphorylated	   in	  vivo.	   If	   so,	   the	  aim	  was	  then	  to	  
determine	  whether	   failure	   to	  phosphorylate	   these	   residues	  disrupts	   the	   interaction	  between	  
53BP1	   and	   TopBP1.	   Finally,	   by	   generating	   an	   unphosphorylatable	  mutant	   of	   53BP1,	   the	   aim	  
was	   to	   characterise	   the	   role	   of	   the	   53BP1-­‐TopBP1	   interaction	   in	  mediating	   the	   response	   to	  
genotoxic	  stress.	  
Thirdly,	  following	  identification	  of	  a	  phosphorylation	  specific	  interaction	  between	  recombinant	  
53BP1-­‐BRCT	  domains	  and	  a	  γH2AX	  phospho-­‐peptide,	  the	  aim	  was	  then	  to	  determine	  whether	  
this	  interaction	  occurs,	   in	  vivo,	   in	  mammalian	  cells.	  By	  making	  specific	  point	  mutations	  within	  
the	  BRCT	  domain,	   the	  project	   then	   aimed	   to	   identify	   the	  downstream	  effects	   of	   a	   failure	   to	  
mediate	   this	   interaction	   and	   whether	   it	   is	   required	   to	   mediate	   the	   response	   to	   genotoxic	  
stress.	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2.	  Materials	  and	  Methods	  
2.1	  Bacterial	  Methods	  




5g/l	  Yeast	  extract	  
LB	  Agar	  plates	  
10g/l	  Tryptone	  
10g/l	  NaCl	  
5g/l	  Yeast	  extract	  
15g/l	  Agar	  
2.1.2	  Antibiotics	  
Bacterial	  plasmids	  contained	  resistance	  genes	  to	  a	  range	  of	  antibiotics.	  Antibiotics	  were	  added	  
to	  the	  media	  prior	  to	  use.	  Stock	  concentrations	  of	  antibiotics	  were	  stored	  at	  -­‐20⁰C.	  	  
Table	  2.1	  Bacterial	  antibiotics	  and	  concentrations	  used.	  
Antibiotic	   Stock	  concentration	  (mg/ml)	   Final	  concentration	  (µg/ml)	  
Ampicillin	   100	   100	  
Kanamycin	   100	   100	  
Chloramphenicol	   34	  in	  ethanol	   34	  
	  
2.1.3	  E.	  coli	  strains	  
NM522	  E.	  coli	  strain	  was	  used	  for	  all	  bacterial	  based	  methodologies	  excluding	  cultures	  used	  for	  
DNA	  midi-­‐preps	  and	  protein	  overexpression.	  	  
F'	  proA+B+	  lacIq	  Δ(lacZ)M15/	  Δ(lac-­‐proAB)	  glnV	  thi-­‐1	  Δ(hsdS-­‐mcrB)5	  	   (NEB)	  
DH5α	  E.	  coli	  strain	  was	  used	  for	  bacterial	  culture	  for	  DNA	  midi-­‐preps.	  	  
	   F-­‐	  80dlacZ	  M15	   (lacZYA-­‐argF)	  U169	   recA1	   endA1hsdR17(rk-­‐,	  mk+)	   phoAsupE44	   -­‐thi-­‐1	  
gyrA96	  relA1	   (MCLAB)	  
BL21	   C+	   E.	   coli	   strain	   was	   used	   for	   culturing	   bacteria	   for	   protein	   overexpression	   and	  
purification.	  	  




E.	   coli	   transformation	  was	   carried	   out	   by	   thawing	   the	   cells	   on	   ice.	   2ng	   of	   plasmid	  DNA	  was	  
added	  to	  100µl	  of	  competent	  cells	  and	  incubated	  on	  ice	  for	  20	  minutes.	  	  After	  this	  incubation	  
the	  cells	  were	  heat	  shocked	  at	  37°C	  for	  90	  seconds.	  1ml	  of	  LB	  was	  added	  to	  the	  cells	  before	  
returning	  them	  to	  the	  37°C	  for	  a	  further	  60	  minutes.	  After	  the	  second	  incubation	  the	  cells	  were	  
collected	  by	  centrifugation	  at	  3,000rpm	  for	  3	  minutes	  and	  most	  of	  the	  supernatant	  removed.	  
Approximately	  100µl	  of	  the	  remaining	  supernatant	  was	  used	  to	  re-­‐suspend	  the	  cell	  pellet	  and	  
cells	   were	   plated	   onto	   pre-­‐warmed	   and	   dried	   LB	   agar	   plates	   containing	   the	   appropriate	  
antibiotic.	  	  
2.1.5	  Competent	  cell	  preparation	  
TRNS1	  
	   100mM	  RbCl	  
	   50mM	  MnCl2•4H2O	  
	   10mM	  CaCl2•2H2O	  
	   35mM	  Sodium	  Acetate	  
	   6.6%	  Glycerol	  
	   Adjusted	  to	  pH	  5.8	  using	  0.2M	  acetic	  acid	  and	  filtered	  through	  a	  0.22µm	  filter.	  
TRNS2	  
100mM	  RbCl	  
	   10mM	  CaCl2•2H2O	  
	   10mM	  MOPS	  
	   6.6%	  Glycerol	  
	   Adjusted	  to	  pH	  6.8	  using	  potassium	  hydroxide	  and	  filtered	  through	  a	  0.22µm	  filter.	  
A	  single	  colony	  of	  NM522	  cells	  were	  cultured	  overnight	   in	  5ml	  of	  LB	  at	  37°C	  with	  shaking	  at	  
180rpm.	  This	  culture	  was	  then	  used	  to	  inoculate	  1l	  of	  LB	  and	  incubated	  for	  a	  further	  2-­‐4	  hours	  
at	  37°C	  with	  shaking	  at	  180rpm.	  The	  culture	  was	  grown	  to	  an	  optical	  density	  of	  between	  0.5-­‐
0.6	  as	  determined	  by	  spectrophotometric	  measurements	  taken	  at	  595nm.	  Once	  the	  cells	  had	  
reached	   the	   optimum	   density	   the	   culture	   was	   cooled	   on	   ice	   for	   approximately	   60	   minutes	  
before	   being	   collected	   by	   centrifugation	   at	   5,000rpm	   for	   5	  minutes	   at	   4°C.	   The	   supernatant	  
was	  discarded	  and	  the	  pelleted	  cells	  were	  re-­‐suspended	  in	  25ml	  of	  TRNS1	  and	  incubated	  on	  ice	  
for	  60	  minutes.	  Cells	  were	  collected	  again	  by	  centrifugation	  at	  5,000rpm	  for	  5	  minutes	  at	  4°C.	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After	  the	  supernatant	  was	  removed	  the	  cells	  were	  re-­‐suspended	  in	  12ml	  of	  TRNS2	  solution	  and	  
incubated	   on	   ice	   for	   a	   further	   hour.	   Finally,	   the	   cells	  were	   pipetted	   into	   300µl	   aliquots	   and	  
were	  snap	  frozen	  in	  liquid	  nitrogen	  before	  being	  stored	  at	  -­‐80°C	  ready	  for	  use.	  	  	  
2.1.6	  Blue/White	  colony	  selection	  
Blue/White	   colony	   selection	  was	  used	   to	   select	   for	   colonies	   that	  had	   successfully	   integrated	  
the	  DNA	   insert	   into	   the	   pGEM-­‐T	   Easy	   plasmid	   backbone.	   Ligation	   into	   the	   linearized	   cloning	  
vector	  disrupts	  the	  LacZα	  peptide	  ORF,	  resulting	  in	  white	  colonies	  on	  agar	  plates	  containing	  X-­‐
GAL	   and	   IPTG	   along	  with	   the	   ampicillin	   selection	  marker.	   X-­‐GAL	   is	   an	   analogue	   of	   galactose	  
that	  can	  be	  metabolised	  by	  β-­‐galactosidase	  and	   isopropyl	  β-­‐D-­‐1-­‐thiogalactopyranoside	  (IPTG)	  
is	  used	  to	  induce	  the	  expression	  of	  the	  lacZ	  gene.	  	  
2.1.7	  Bacterial	  protein	  expression	  
BL21	  C+	  E.	  coli	  were	  inoculated	  into	  1l	  of	  LB	  media	  and	  allowed	  to	  grow	  at	  37°C	  for	  ~5	  hours	  
until	  they	  reached	  an	  optical	  density	  of	  between	  0.5-­‐0.6.	  Cells	  were	  then	  placed	  on	  ice	  for	  30	  
minutes	   before	   adding	   IPTG	   to	   a	   final	   concentration	   of	   0.2mM.	   Induced	   cells	   were	   then	  
incubated	  overnight	  at	  16°C.	  Cells	  were	  harvested	  by	  ultracentrifugation	  at	  4°C	  and	  the	  pellet	  
was	  collected	  and	  frozen	  at	  -­‐20°C	  until	  purification.	  
2.2	  DNA	  Methods	  
2.2.1	  Qiagen	  Minipreps	  	  
Cells	  from	  a	  10ml	  bacterial	  culture	  were	  collected	  by	  centrifugation	  at	  3000rpm	  for	  5	  minutes	  
at	  4°C.	  The	  supernatant	  was	  removed	  and	  the	  cell	  pellet	  was	  re-­‐suspended	  in	  250µl	  of	  buffer	  
P1	  containing	  RNAse	  A.	  250µl	  of	  buffer	  P2	  was	  added	  and	  mixed	  by	  inversion.	  350µl	  of	  buffer	  
N3	  was	  added	  and	  mixed	  by	   inversion	  to	  precipitate	  protein	  from	  the	  solution.	  The	  resultant	  
mixture	  was	  centrifuged	  at	  13,000rpm	  for	  10	  minutes	  at	  room	  temperature.	  The	  supernatant	  
was	   then	   transferred	   to	   QIAprep	   spin	   column	   and	   passed	   through	   the	   column	   by	  
centrifugation	   at	   13,000rpm	   for	   1	   minute.	   The	   flow-­‐through	   was	   then	   discarded	   before	  
washing	   the	   column	  with	   500µl	   of	   PB	   buffer.	   A	   second	  wash	  was	   performed	   this	   time	  with	  
buffer	   PE,	   which	   precipitates	   the	   DNA	   from	   solution.	   As	   before	   the	   flow	   through	   was	  
discarded.	  The	  column	  was	   centrifuged	  again	  without	   the	  addition	  of	  any	  buffers	   to	   remove	  
excess	  buffer	  from	  the	  filter	  within	  the	  column.	  Finally,	  50µl	  of	  H2O	  was	  added	  to	  the	  column	  
and	   incubated	   at	   room	   temperature	   for	   2	   minutes.	   Eluted	   DNA	   was	   collected	   into	   a	   clean	  
Eppendorf	  tube	  by	  centrifugation.	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2.2.2	  DISH	  Minipreps	  
DISH	  minipreps	  were	  used	  to	  screen	  white	  colonies	  from	  white/blue	  selection	  plates	  for	  the	  
integration	  of	  the	  DNA	  insert	  into	  pGEM-­‐T	  easy	  cloning	  vector.	  	  
DISH1	  
	   50mM	  Glucose	  
	   10mM	  EDTA	  
	   25mM	  Tris	  (pH	  8.0)	  
DISH2	  
	   0.2mM	  NaOH	  
	   1%	  SDS	  
DISH3	  
	   3M	  KOAc	  
	   8M	  Glacial	  Acetic	  acid	  
TE	  
	   10mM	  Tris-­‐HCl	  pH	  8.0	  
	   1mM	  EDTA	  
2ml	   Cultures	   were	   grown	   for	   a	   period	   of	   4	   to	   5	   hours	   before	   being	   transferred	   to	   a	  
microcentrifuge	   tube	   and	   spun	   down.	   The	   supernatant	   was	   removed	   leaving	   just	   the	   cell	  
pellet,	  which	  was	  then	  re-­‐suspended	  in	  100µl	  of	  DISH1	  solution.	  200µl	  of	  DISH2	  solution	  was	  
then	  added	  to	  the	  tube	  to	  lyse	  the	  cells.	  Finally	  300µl	  of	  ice-­‐cold	  DISH3	  solution	  was	  added	  to	  
precipitate	  proteins	  from	  the	  solution.	  The	  resultant	  mixture	  was	  centrifuged	  for	  5	  minutes	  at	  
13,000rpm.	  	  
Once	  the	  debris	  had	  been	  pelleted,	  the	  supernatant	  was	  transferred	  to	  a	  new	  microcentrifuge	  
tube	  containing	  an	  equal	  volume	  of	  phenol	   chloroform.	  The	  solutions	  were	  mixed	  and	  again	  
centrifuged	   at	   13,000rpm	   for	   5	   minutes.	   The	   top	   layer	   was	   transferred	   to	   a	   new	  
microcentrifuge	  tube	  containing	  1ml	  of	  100%	  ethanol.	  This	  was	  mixed	  and	  left	  for	  30	  minutes	  
to	  allow	  the	  precipitation	  of	  DNA	  from	  the	  solution.	  The	  DNA	  was	  isolated	  by	  centrifugation	  as	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before	  and	  the	  supernatant	  removed.	  The	  pelleted	  DNA	  was	  dried	  in	  a	  vacuum	  desiccator	  for	  5	  
minutes	  before	  resuspension	  in	  50µl	  of	  TE.	  	  
2.2.3	  Qiagen	  Midipreps	  
100ml	   of	   LB	   was	   inoculated	   with	   DH5α	   cells	   from	   a	   smaller	   pre-­‐culture	   and	   containing	   the	  
plasmid	   to	   be	   propagated.	   	   The	   culture	   was	   grown	   overnight	   at	   37°C	   and	   harvested	   by	  
centrifugation	   the	   following	  morning.	  After	   the	   removal	  of	   the	   LB	  media	   the	  bacterial	   pellet	  
was	  resuspended	  in	  4ml	  of	  buffer	  P1	  containing	  RNase	  A.	  Buffer	  P2	  was	  added	  and	  incubated	  
at	   room	  temperature	   for	  5	  minutes	   to	   lyse	   the	  cells.	  Buffer	  P3	  was	  added	   to	  precipitate	   the	  
proteins	   from	   solution.	   The	   mixture	   was	   then	   centrifuged	   at	   4,000rpm	   for	   30	   minutes	   to	  
remove	  cell	  debris	  from	  the	  solution.	  	  
A	  QiaTip	  was	  equilibrated	  with	  4ml	  of	  buffer	  QBT	  before	  the	  addition	  of	   the	  cell	   lysate.	   	  The	  
lysate	  passed	  through	  the	  column	  by	  gravity	  flow.	  The	  tip	  was	  then	  washed	  with	  20ml	  of	  buffer	  
QC	  before	  eluting	   the	  plasmid	  DNA	   from	  the	   tip	   in	  buffer	  QF.	  The	  elution	  was	  collected	   in	  a	  
clean	   falcon	   tube.	   The	   DNA	   was	   precipitated	   from	   solution	   with	   the	   addition	   of	   3.5ml	   of	  
isopropanol.	  The	  tube	  was	  then	  centrifuged	  at	  4,000rpm	  for	  45	  minutes.	  The	  supernatant	  was	  
carefully	  removed	  and	  the	  DNA	  pellet	  was	  resuspended	  in	  1ml	  of	  70%	  ethanol	  and	  transferred	  
to	  a	  microcentrifuge	  tube.	  The	  solution	  was	  centrifuged	  for	  10	  minutes	  at	  13,000rpm	  and	  the	  
supernatant	   was	   again	   removed.	   The	   pellet	   was	   then	   dried	   in	   a	   vacuum	   desiccator	   for	   10	  
minutes	  before	  resuspension	  in	  100µl	  of	  TE	  buffer.	  	  
The	   concentration	   of	   plasmid	   midipreps	   was	   determined	   using	   a	   nano-­‐drop	  
spectrophotometer.	  Plasmid	  midipreps	  produced	  DNA	  concentrations	  ranging	  from	  1-­‐2µg/µl.	  
2.2.4	  Ethanol	  precipitation	  
Solutions:	  
	   3M	  NaAc	  
	   100%	  Ethanol	  (-­‐20⁰C)	  
	   70%	  Ethanol	  (Room	  temperature)	  
Sodium	  acetate	  was	  added	  to	  the	  sample	  equal	  to	  1/10	  of	  the	  total	  volume	  of	  the	  sample.	  The	  
sample	  was	  mixed	  by	  vortex.	  Two	  volumes	  of	  100%	  ethanol	  were	  added	  to	  the	  sample	  before	  
mixing	  and	  centrifugation	  at	  13,000rpm	  for	  10	  minutes.	  The	  supernatant	  was	  removed	  and	  the	  
pelleted	  DNA	  was	   re-­‐suspended	   in	  500µl	  of	  70%	  ethanol.	  The	  sample	  was	  again	  centrifuged,	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supernatant	   removed	  and	  pellet	  dried	   in	   a	   vacuum	  desiccator	   for	  10	  minutes.	   The	  DNA	  was	  
then	  re-­‐suspended	  in	  water	  or	  an	  appropriate	  buffer.	  	  
2.2.5	  Agarose	  Gel	  electrophoresis	  
1x	  TBE	  buffer:	  
100mM	  Tris	  base	  
100mM	  Boric	  acid	  
2mM	  EDTA	  
6x	  Loading	  dye:	  
2.5%	  Ficoll-­‐400	  
11mM	  EDTA	  
3.3mM	  Tris-­‐HCl	  (pH7.6)	  
0.017%	  SDS	  
0.015%	  Bromophenol	  blue	  
30%	  Glycerol	  
DNA	  samples	  were	  analysed	  by	  agarose	  gel	  electrophoresis.	  Most	  DNA	  samples	  were	  run	  on	  a	  
0.8%	  agarose	  gel.	  The	  gel	  was	  prepared	  by	  the	  addition	  of	  1.6g	  of	  agarose	  to	  200ml	  of	  1x	  TBE	  
buffer.	  The	  resultant	  mixture	  was	  heated	  to	  melt	  the	  agarose	  before	  being	  allowed	  to	  cool	  at	  
room	  temperature.	  Before	  the	  gel	  had	  set	  10µl	  of	  ethidium	  bromide	  was	  added	  to	  the	  mixture	  
before	  pouring	  into	  a	  prepared	  gel	  tray	  complete	  with	  a	  gel	  comb.	  The	  gel	  was	  allowed	  to	  set	  
at	  room	  temperature	  for	  approximately	  20	  minutes.	  Once	  set	  the	  gel	  was	  submerged	  in	  a	  gel	  
tank	   containing	  1x	  TBE	  buffer.	   Sample	  buffer	  was	  added	   to	  each	  of	   the	  DNA	   samples	  at	   the	  
appropriate	  concentration	  before	  running	  for	  approximately	  30	  minutes	  –dependent	  upon	  the	  
mass	  of	  the	  DNA	  in	  the	  sample.	  With	  ethidium	  bromide	  intercalated	  between	  the	  bases	  of	  the	  
DNA	  the	  sample	  was	  visualised	  by	  excitation	  with	  ultraviolet	  light.	  	  
2.2.6	  Site-­‐directed	  Mutagenesis	  
Mutagenesis	   primers	  were	  designed	   to	  mutate	   as	   few	  bases	   as	  possible	  while	   still	   achieving	  
the	  required	  codon	  change.	  Depending	  on	  the	  number	  of	  bases	  to	  be	  changed	  flanking	  regions	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of	  homology	  were	  included	  varying	  in	  length	  and	  ending	  with	  a	  cytosine	  or	  guanine	  base.	  The	  
primers	  were	  diluted	  to	  100pmol/µl	  concentration.	  
A	  typical	  PCR	  reaction	  was	  set	  up	  as	  follows:	  
5µl	  KOD	  hot	  start	  DNA	  polymerase	  buffer	  
1.5mM	  MgSO4	  
50ng	  DNA	  Template	  
0.2mM	  dNTPs	  
0.3μM	  Forward	  primer	  
0.3μM	  Reverse	  primer	  
0.02U/µl	  KOD	  hot	  start	  DNA	  polymerase	  
Each	  reaction	  was	  made	  up	  to	  a	  total	  volume	  of	  50µl	   in	  distilled	  water.	  The	  reaction	  was	  run	  
for	  between	  20	  and	  30	   cycles	   as	  well	   as	   at	   a	   range	  of	   annealing	   temperatures	   ranging	   from	  
40°C	   to	  60°C	   to	  optimise	  DNA	  product	   synthesis.	   Extension	   time	  was	  also	  altered	   relative	   to	  
the	  size	  of	  the	  template	  plasmid.	  	  
After	   the	   reaction	   the	   DNA	   product	   was	   digested	   with	   DpnI,	   which	   recognises	   methylated	  
residues	  only	  found	  on	  the	  template	  strand.	  The	  remaining	  product	  can	  then	  be	  transformed	  
into	  competent	  cells	  to	  propagate	  the	  DNA	  allowing	  for	  subsequent	  sequence	  analysis.	  	  
2.2.7	  Sequencing	  
DNA	  sequencing	  was	  carried	  out	  by	  Sourcebioscience.	  	  
2.2.8	  PCR	  amplification	  
A	  typical	  PCR	  reaction	  was	  set	  up	  as	  follows:	  
5µl	  KOD	  hot	  start	  DNA	  polymerase	  buffer	  
1.5mM	  MgSO4	  
50ng	  DNA	  template	  
0.2mM	  dNTPs	  
0.3μM	  Forward	  primer	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0.3μM	  Reverse	  primer	  
0.02U/µl	  KOD	  hot	  start	  DNA	  polymerase	  
Each	  reaction	  was	  made	  up	  to	  a	  total	  volume	  of	  50µl	   in	  distilled	  water.	  The	  reaction	  was	  run	  
for	  between	  20	  and	  30	  cycles	  as	  well	  as	  a	  range	  of	  annealing	  temperatures	  ranging	  from	  40°C	  
to	  60°C	  to	  optimise	  DNA	  product	  synthesis.	  Extension	  time	  was	  also	  altered	  relative	  to	  the	  size	  
of	  the	  DNA	  to	  be	  amplified.	  
2.2.9	  Restriction	  digestion	  
A	  typical	  restriction	  digest	  was	  set	  up	  as	  follows:	  
5µl	  of	  10x	  Cutsmart	  restriction	  digest	  buffer	  
1µg	  of	  DNA	  
10U/µl	  of	  Restriction	  enzyme	  	  
The	   reaction	   was	   carried	   out	   in	   a	   total	   volume	   of	   50µl	   for	   the	   duration	   of	   1	   hour	   at	   37°C.	  
Restricted	   DNA	   fragments	   were	   analysed	   by	   agarose	   gel	   electrophoresis	   to	   confirm	   the	  
efficiency	  of	  the	  digest.	  
2.2.10	  DNA	  gel	  extraction	  
DNA	  fragments	  were	  purified	  from	  agarose	  gels	  firstly	  by	  careful	  excision	  of	  the	  DNA	  fragment	  
using	  a	  clean	  blade	  and	  a	  UV	  light	  box.	  The	  excised	  fragment	  was	  transferred	  to	  an	  Eppendorf	  
tube.	   300µl	   of	   Easypure®	   Salt	   solution	   along	  with	   50µl	   of	  Melt	   solution	  were	   added	   to	   the	  
sample	  which	  was	   then	   incubated	  at	  50°C	   for	   approximately	  10	  minutes	  until	   the	  gel	  pieces	  
had	   completely	  melted.	   8µl	   of	   Easypure	  DNA	  binding	  beads	  were	   added	   to	   the	  mixture	   and	  
incubated	  at	   room	   temperature	   for	  5	  minutes.	  Centrifugation	  was	  used	   to	   isolate	   the	  beads	  
bound	   to	   the	   purified	   DNA	   fragment.	   A	   series	   of	   2	   further	   washes	   were	   used	   to	   remove	  
residual	   melted	   agarose	   and	   contaminants.	   Finally	   the	   beads	   were	   re-­‐suspended	   in	   20µl	   of	  
water	  to	  elute	  the	  DNA	  from	  the	  beads.	  	  
Purified	  fragment	  concentration	  was	  determined	  by	  nanodrop	  spectrophotometry.	  	  
2.2.11	  Ligations	  
Purified	   digested	   fragments	   were	   ligated	   into	   destination	   vectors	   using	   quick	   ligase.	   Below	  
shows	  a	  typical	  ligation	  reaction:	  




10µl	  of	  2x	  Quick	  ligase	  buffer	  
5%	  Quick	  ligase	  
*concentration	  of	  DNA	  insert	  was	  calculated	  using	  a	  molar	  ratio	  of	  3:1	  (insert:vector).	  
The	  reaction	  was	  carried	  out	  in	  a	  total	  volume	  of	  20µl	  for	  15	  minutes	  at	  room	  temperature.	  5µl	  
of	   the	   ligation	   mixture	   was	   transformed	   into	   competent	   cells	   and	   plated	   on	   agar	   plates	  
containing	  the	  appropriate	  antibiotic.	  	  
2.2.12	  Cloning	  
DNA	   fragments	   were	   cloned	   by	   PCR	   amplification	   with	   the	   addition	   of	   appropriate	  
endonuclease	   restriction	   sites	   for	   both	   the	  5’	   and	  3’	   ends	  of	   the	  designed	  primers.	   The	  PCR	  
product	   was	   analysed	   by	   agarose	   gel	   electrophoresis	   and	   purified	   using	   the	   agarose	   gel	  
extraction	  protocol	  to	  remove	  the	  DNA	  template	  from	  the	  mixture.	  	  
The	   purified	   fragment	   was	   ligated	   into	   an	   intermediate	   destination	   vector	   (pGEM-­‐T	   easy)	  
before	  transformation	  into	  competent	  cells.	  White/blue	  colony	  selection	  was	  used	  to	  establish	  
whether	  the	  colonies	  formed	  had	  integrated	  the	  insert	  into	  the	  vector.	  Clones	  were	  validated	  
by	  restriction	  digest	  and	  sequencing.	  More	  of	  the	  insert	  was	  digested	  from	  the	  pGEM-­‐T	  vector	  
and	   ligated	   into	   the	   destination	   vector.	   The	   destination	   vector	   had	   been	   digested	   with	   the	  
same	   restriction	   enzymes	   and	   pre-­‐treated	   with	   calf	   intestinal	   phosphatase	   to	   prevent	   re-­‐
ligation	  of	  the	  vector	  to	  itself.	  	  
Finally	   colonies	  were	   screened	   the	   following	   day	   using	   gel	   electrophoresis	   and	   validated	   by	  
sequencing.	  	  
2.2.13	  Designing	  guide	  RNAs/ssODN	  template	  for	  CRISPR	  
Guide	   RNAs	   were	   designed	   using	   a	   function	   build	   into	   Benchling®.	   Oligonucleotides	   were	  
identified	  by	   searching	   for	   20	  base	  pair	   sequences	   adjacent	   to	   a	  protospacer	   adjacent	  motif	  
(PAM)	   site	  marked	   by	   5’	   NGG	   3’.	   Oligonucleotides	   were	   scored	   for	   both	   on-­‐target	   and	   off-­‐
target	   effect	   probabilities.	   The	   3	   highest	   scoring	   (i.e.	   highest	   on-­‐target	   with	   the	   lowest	   off-­‐
target	  scores)	  in	  a	  defined	  region	  were	  used	  to	  test	  cutting	  efficiency.	  	  
The	  DNA	  oligonucleotides	  had	  additional	  bases	  added	  to	  the	  5’	  and	  3’	  ends	  of	  each	  to	  create	  
sticky	  ends	   (red)	   that	  would	  anneal	   to	   the	  ends	  generated	  by	  cutting	   the	  pSpCas9	  backbone	  
and	  to	  facilitate	  cloning.	  For	  example	  to	  target	  exon	  10	  of	  the	  TP53BP1	  gene:	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5’	  CACCGGGACTGCTAGGAACGATAAA	  3’	  
	  	  	  	  	  	  	  	  	  	  3’	  CCCTGACGATCCTTGCTATTTCAAA	  5’	  	  
	  
Once	  the	  oligonucleotides	  had	  been	  cloned	  into	  the	  pSpCas9	  plasmid	  it	  would	  synthesize	  the	  
gRNA	  along	  with	  Cas9	   in	  mammalian	  cells.	  DNA	  oligonucleotides	  were	  ordered	  from	  Eurofins	  
Genomics®.	  	  
2.2.14	  Cloning	  DNA	  oligonucleotides	  into	  pSpCas9(BB)-­‐neo	  
The	   synthesised	   DNA	   oligonucleotides	   were	   suspended	   in	   distilled	   water	   to	   a	   final	  
concentration	   of	   100pmol/µl.	   The	   oligonucleotides	   were	   incubated	   with	   T4	   Polynucleotide	  
kinase	  to	  phosphorylate	  the	  5’	  and	  3’	  ends	  prior	  to	  ligation.	  Finally,	  the	  oligonucleotides	  were	  
heated	  and	  cooled	  gradually	  to	  allow	  the	  complementary	  strands	  to	  anneal.	  	  
Table	  2.2	  Example	  reaction	  for	  the	  preparation	  of	  the	  heteroduplex	  DNA.	  	  
Component	  	   Volume	  
gRNA	  top	   1µl	  (100pmol)	  
gRNA	  bottom	   1µl	  (100pmol)	  
10x	  T4	  PNK	  buffer	  with	  ATP	   1µl	  	  
T4	  Polynucleotide	  Kinase	  
(10,000U/ml)	  
1µl	  	  
H2O	   6µl	  
A	  10µl	  total	  reaction	  volume	  was	  then	  subjected	  to	  the	  following	  program	  in	  a	  PCR	  machine.	  	  
Temperature	   Time	  
37°C	   30	  minutes	  
95°C	   5	  minutes	  
25°C	   >5ᵒc/min	  
The	  newly	  formed	  heteroduplex	  DNA	  was	  diluted	  1:200	  with	  distilled	  water	  before	  setting	  up	  
the	  ligation	  reaction	  with	  the	  Cas9	  vector.	  	  
Table	  2.3	  Example	  reaction	  for	  the	  ligation	  of	  the	  guide	  into	  the	  Cas9	  vector.	  
Component	   Volume	  
pSpCas9(BB)-­‐neo	   1µl	  (100ng)	  
Diluted	  oligonucleotide	  duplex	   2µl	  
10x	  Fastdigest	  Buffer	   2µl	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Dithriothreitol	  (DTT)	  (10mM)	   1µl	  
ATP	  (10mM)	   1µl	  
Fastdigest	  BpiI	   1µl	  
T7	  DNA	  ligase	   0.5µl	  
H2O	   11.5µl	  
The	  ligation	  mix	  was	  subjected	  to	  the	  following	  program	  on	  a	  PCR	  machine.	  	  
Temperature	   Time	  
37°C	   5	  minutes	  
21°C	   5	  minutes	  
Cycle	  above	  6	  times	   	  
Hold	  at	  4ᵒc	   	  
Next,	  PlasmidSafe®	  exonuclease	  was	  used	  to	  digest	  any	  remaining	  linearised	  pSpCas9	  vector.	  	  
Table	  2.4	  Example	  reaction	  for	  the	  digestion	  of	  unligated	  backbone	  vector.	  
Component	  	   Volume	  
Ligation	  mix	   11µl	  
10x	  PlasmidSafe	  buffer	   1.5µl	  
10mM	  ATP	   1.5µl	  
PlasmidSafe	  exonuclease	   1µl	  
The	  digestion	  mix	  was	  then	  subjected	  to	  the	  following	  program	  on	  a	  PCR	  machine.	  	  
Temperature	  	   Time	  
37°C	   30	  minutes	  
70°C	   30	  minutes	  
Finally,	   5µl	   of	   the	   final	  mix	  was	   transformed	   into	   100µl	   of	   competent	   bacterial	  NM522.	   The	  
following	  day	  colonies	  were	  selected	  for	  validation	  by	  sequencing	  using	  the	  U6	  forward	  primer.	  	  
2.2.15	  Mammalian	  Genomic	  miniprep	  
The	   Cas9-­‐gRNA	   constructs	   were	   transfected	   into	   cells	   using	   an	   appropriate	   transfection	  
method.	   The	   cells	   were	   incubated	   for	   a	   further	   5	   days,	   on	   the	   2nd	   day	   the	   media	   was	  
supplemented	  with	  1mg/ml	  G418	  disulfate	  antibiotic	  to	  select	  for	  transformed	  cells.	  Following	  
this	  the	  cells	  were	  collected	  by	  trypsinisation	  and	  centrifugation.	  	  
Genomic	  preps	  were	  obtained	  using	  Sigma	  GenElute™	  Mammalian	  Genomic	  DNA	  miniprep	  kit	  
following	  the	  manufacturer’s	  protocol.	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2.2.16	  Gibson	  assembly	  fusion	  of	  PCR	  fragments	  
Gibson	   Assembly	   was	   used	   to	   create	   generate	   a	   53BP1	   repair	   template	   to	   incorporate	  
EmeraldGFP	  gene	  at	  the	  N-­‐terminus	  of	  53BP1.	  The	  repair	  template	  included	  homology	  arms	  of	  
500	  bases	  upstream	  and	  500	  bases	  downstream	  of	  the	  start	  codon.	  EmGFP	  was	  included	  after	  
the	   start	   codon	   in	  exon	  1	  of	  53BP1.	  The	   repair	   template	  was	   cloned	   into	  pUC19,	   a	  bacterial	  
cloning	  vector.	  	  
Primers	   for	   Gibson	   Assembly	   were	   designed	   using	   the	   online	   NEBuilder	   tool	   (New	   England	  
Biolabs).	  Primers	  were	  designed	  to	  create	  overlapping	  homology	  between	  the	  PCR	  products	  to	  
be	  fused	  together.	  	  
The	   homology	   arms	   were	   then	   amplified	   using	   PCR	   of	   U2OS	   genomic	   DNA.	   EmGFP	   was	  
amplified	   from	  a	   template	   vector	   and	  pUC19	  was	   linearized	  with	  EcoRI	   restriction	  digestion.	  
The	   PCR	   products	   and	   target	   vector	   were	   gel	   purified	   to	   remove	   template	   DNA	   (i.e.	   either	  
genomic	  or	  undigested	  vector).	  	  
The	  gel	  purified	  DNA	  fragments	  were	  supplemented	  at	  a	  vector:	  insert	  ratio	  of	  1:1	  before	  the	  
addition	  of	  the	  Gibson	  Assembly	  master	  mix.	  The	  maser	  mix	  contained	  all	   three	  components	  
required	   for	   the	   reaction	   (an	   exonuclease,	   a	   polymerase	   and	   a	   ligase).	   The	   reaction	   was	  
incubated	  for	  60	  minutes	  at	  37°C.	  After	   incubation,	  2µl	  of	   the	  final	  mixture	  was	  transformed	  
into	   competent	   bacteria	   and	   plated	   onto	   agar	   plates	   containing	   ampicillin	   (ampicillin-­‐
resistance	  gene	  contained	  by	  pUC19	  vector).	  	  
The	  reaction	  generated	  ~300	  bacterial	  colonies.	  10	  where	  picked,	  cultured	  before	  isolating	  the	  
DNA	  using	  a	  Qiagen	  miniprep	  kit.	  Purified	  DNA	  was	  analysed	  by	  agarose	  gel	  electrophoresis.	  2	  
out	  of	  the	  10	  colonies	  screened	  contained	  the	  4.4Kb	  product	  rather	  than	  pUC19	  alone	  (3.3Kb).	  
Sequencing	   by	   Sourcebioscience	   was	   then	   used	   to	   validate	   the	   generation	   of	   the	   repair	  
templates.	  	  
2.3	  Protein	  Methods	  	  
2.3.1	  Nickel	  affinity	  purification	  from	  bacteria	  
Binding	  buffer:	  
	   5mM	  imidazole	  
500mM	  NaCl	  
20mM	  Tris	  HCl	  (pH	  7.0)	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Protease	  cocktail	  inhibitors	  
Wash	  buffer:	  
	   20mM	  imidazole	  
500mM	  NaCl	  
20mM	  Tris	  HCl	  (pH	  7.0)	  
Elution	  buffer:	  
	   500mM	  imidazole	  
500mM	  NaCl	  
20mM	  Tris	  HCl	  (pH7.0)	  
The	  pellet	  was	  thawed	  in	  15ml	  of	  binding	  buffer	  followed	  by	  sonication	  at	  amplitude	  27%	  for	  2	  
minutes	   in	   5	   second	   pulses.	   Cell	   debris	  was	   removed	   by	   centrifugation	   at	   15,000rpm	   for	   20	  
minutes.	  1ml	  of	  nickel	  agarose	  or	  cobalt	  resin	  was	  equilibrated	  in	  binding	  buffer	  before	  being	  
added	  to	  the	  lysate.	  After	  1	  hour	  of	  incubation	  at	  4⁰C,	  the	  lysate	  was	  run	  through	  a	  column	  and	  
washed	  with	  10ml	  of	  wash	  buffer.	  Purified	  protein	  was	  eluted	  by	  addition	  of	  300µl	  of	  elution	  
buffer	  into	  a	  clean	  microcentrifuge	  tube.	  Samples	  were	  stored	  in	  10%	  glycerol,	  snap	  frozen	  and	  
stored	  at	  -­‐80°C.	  
2.3.2	  GST-­‐tagged	  protein	  purification	  
NETN	  buffer:	  
	   0.5%	  NP-­‐40	  
	   20mM	  Tris	  pH	  8.0	  
	   100mM	  NaCl	  
	   1mM	  EDTA	  
Wash	  buffer:	  
	   100mM	  Tris	  pH	  8.0	  




	   100mM	  Tris	  pH	  8.0	  
	   120mM	  NaCl	  
	   20mM	  Glutathione	  
The	  pelleted	  bacteria	  were	  re-­‐suspended	  in	  15ml	  of	  NETN	  buffer	  with	  protease	  inhibitors.	  The	  
suspension	  was	   then	   sonicated	  on	   ice	   at	   27%	  amplitude	   for	  5	   second	  pulses	   for	   a	   total	   of	   1	  
minute.	  	  The	  homogenous	  mixture	  was	  then	  centrifuged	  at	  4°C	  at	  15,000rpm	  for	  20	  minutes	  to	  
remove	   cell	   debris.	   The	   supernatant	  was	   then	   allowed	   to	   flow	   through	   a	   column	   containing	  
GST	  beads	  previously	  equilibrated	   in	  NETN	  buffer.	  Once	  the	  supernatant	  had	  passed	  through	  
the	  column	   it	  was	  washed	  3x	  with	  10ml	  of	  wash	  buffer.	  Finally,	  protein	  was	  eluted	   from	  the	  
beads	   in	   5x	   300µl	   aliquots	   in	   elution	   buffer.	   The	   purified	   protein	   was	   snap	   frozen	   in	   10%	  
glycerol	  and	  stored	  at	  -­‐80°C	  until	  use.	  
2.3.3	  Nickel	  affinity	  purification	  from	  Mammalian	  cells	  (denaturing	  conditions)
	   	  
Buffer	  A:	  	  
6M	  guanidinium	  hydrochloride	  
100mM	  sodium	  dihydrophosphate	  
10mM	  Tris-­‐HCl	  pH8	  
Buffer	  C:	  	  
8M	  urea	  
100mM	  sodium	  dihydrophosphate	  
10mM	  Tris-­‐HCl	  pH	  6.3	  
HU	  Buffer:	  	  
8M	  urea	  
200mM	  Tris-­‐HCl	  pH6.8	  
1mM	  EDTA	  
5%	  w/v	  SDS	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0.1%	  bromophenol	  blue	  
1.5%	  w/v	  DTT	  
Cells	  were	   lysed	   using	   1.85M	  NaOH/7.5%	  β-­‐mercaptoethanol.	   Protein	  was	   then	   precipitated	  
using	  20%	  TCA.	  The	  mixture	  was	  then	  centrifuged	  and	  the	  supernatant	  was	  removed	  to	  retain	  
the	   denatured	   proteins.	   The	   pelleted	   protein	   was	   re-­‐suspended	   in	   Buffer	   A	   and	   allowed	   to	  
solubilise	  for	  a	  further	  hour.	  20µl/sample	  aliquots	  of	  nickel	  agarose	  were	  equilibrated	  in	  Buffer	  
A	  with	  0.05%	  Tween.	  Nickel	  beads	  were	  added	  to	  the	  protein	  solution	  and	  incubated	  overnight	  
at	  4°C.	  The	  following	  morning	  the	  samples	  were	  washed	  twice	  more	  with	  Buffer	  A,	  a	   further	  
four	  washes	  with	   Buffer	   C	   and	   two	  more	   times	  with	   Buffer	   C	  with	   0.05%	   tween	   and	   50mM	  
Imidazole.	  After	  the	  final	  wash	  the	  nickel	  beads	  were	  re-­‐suspended	   in	  42µl	  of	  HU	  buffer	  and	  
boiled	  for	  5	  minutes	  to	  elute	  bound	  protein.	  Samples	  were	  centrifuged	  and	  run	  on	  SDS-­‐PAGE	  
as	  above.	  	  
2.3.4	  Concentrating	  protein	  samples	  
Protein	   samples	   were	   concentrated	   using	   centrifugal	   filters	   from	   Milipore®.	   Samples	   were	  
spun	   at	   3,000rpm	   for	   variable	   lengths	   of	   time	   dependent	   on	   the	   degree	   of	   concentration	  
required.	  	  
2.3.5	  Bradford	  Assay	  
Bradford	  assay	  was	  performed	  using	  a	  pre-­‐made	  5x	  concentration	  solution.	  The	  reagent	  was	  
diluted	   and	   1ml	   was	   added	   to	   each	   cuvette.	   1µl	   of	   the	   protein	   sample	   was	   added	   to	   the	  
cuvette	  before	  inverting	  with	  parafilm.	  The	  resultant	  absorption	  at	  595nm	  was	  compared	  to	  a	  
standard	   curve	   of	   a	   known	   set	   of	   concentrations	   of	   bovine	   serum	   albumin	   to	   calculate	   the	  
concentration	  of	  the	  protein	  sample.	  	  
2.3.6	  SDS-­‐PAGE	  
5x	  Sample	  buffer:	  




0.01%	  Bromophenol	  Blue	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4x	  Separating	  gel	  buffer:	  
1.5M	  Tris-­‐HCl	  pH	  8.8	  
0.4%	  SDS	  
4x	  Stacking	  gel	  buffer:	  
0.5M	  Tris-­‐HCl	  pH	  6.8	  
0.4%	  SDS	  
10%	  Separating	  gel:	  
33%	  Protogel	  (0.8%	  Acrylamide)	  	  
25%	  Separating	  gel	  buffer	  
0.1%	  Ammonium	  Persulfate	  (APS)	  
0.001%	  TEMED	  
6%	  Stacking	  gel:	  
20%	  Protogel	  
12.5%	  Stacking	  gel	  buffer	  
0.25%	  APS	  
0.0005%	  TEMED	  
Samples	  for	  analysis	  by	  SDS-­‐PAGE	  were	  prepared	  by	  the	  addition	  of	  sample	  buffer	  to	  the	  final	  
1x	   concentration.	   Samples	   were	   then	   boiled	   for	   5	   minutes	   using	   a	   heating	   block	   and	  
centrifuged	  at	  13,000rpm	  for	  5	  minutes	  before	  being	   loaded	   into	  the	  gel.	  The	  gel	  was	  run	  at	  
150V	  for	  approximately	  1	  hour.	  	  
2.3.7	  Coomassie	  staining	  
The	   presence	   of	   protein	   bands	   was	   detected	   using	   Coomassie	   InstantBlue	   stain.	   10ml	   was	  
added	  to	  a	  petri	  dish	  containing	  the	  polyacrylamide	  gel	  and	  incubated	  for	  60	  minutes	  at	  room	  
temperature	  on	  an	  orbital	  shaker.	  Blue	  protein	  bands	  present	  within	  the	  gel	  could	  then	  excised	  
and	  prepared	  for	  mass	  spectrometry.	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2.3.8	  Western	  Blotting	  
Semi-­‐dry	  transfer	  buffer:	  
	   48mM	  Tris-­‐base	  
	   39mM	  Glycine	  
	   0.04%	  SDS	  
	   20%	  Methanol	  
2	  x	  6	  pieces	  of	  filter	  paper	  were	  cut	  to	  the	  same	  size	  as	  the	  polyacrylamide	  gel	  and	  soaked	  in	  
semi-­‐dry	   transfer	  buffer.	  A	  section	  of	  PVDF	  transfer	  membrane	  was	  also	  cut	   to	  a	  similar	   size	  
and	   soaked	   in	  methanol.	  The	  gel	  was	  placed	  carefully	  on	   top	  of	   the	   transfer	  membrane	  and	  
sandwiched	  between	  the	  two	  sets	  of	  soaked	  filter	  paper	  in	  the	  semi-­‐transfer	  tank.	  The	  transfer	  
was	  run	  at	  150mA	  for	  between	  35-­‐50	  minutes	  dependent	  upon	  the	  size	  of	   the	  protein	  to	  be	  
investigated.	  
After	  the	  transfer	  had	  completed	  the	  membrane	  was	  removed	  and	  incubated	  for	  30	  minutes	  in	  
4%	  (w/v)	  milk	  in	  PBS	  on	  an	  orbital	  shaker.	  The	  primary	  antibody	  was	  then	  added	  directly	  to	  the	  
milk	  solution	  to	  the	  desired	  concentration	  before	  incubating	  overnight	  at	  4°C.	  	  
The	  next	  morning	  the	  primary	  antibody	  solution	  was	  removed	  and	  the	  transfer	  membrane	  was	  
washed	   3x	   in	   PBS-­‐Tween	  with	   each	  wash	   lasting	   between	   5-­‐10	  minutes.	   After	  washing,	   the	  
appropriate	   secondary	   antibody	   coupled	   to	   horseradish	   peroxidase	   (HRP)	   was	   added	   to	   4%	  
milk	   in	   PBS	   and	   incubated	  with	   the	  membrane	   for	   1	   hour.	   After	   this	   incubation	   period	   the	  
membrane	   was	   washed	   3	   times	   as	   before,	   followed	   by	   1	   additional	   wash	   in	   PBS	   without	  
tween.	  	  
2.3.9	  Chemilluminescence	  	  detection	  
The	   transfer	   membrane	   was	   then	   incubated	   with	   2ml	   of	   Pierce	   western	   blotting	   substrate.	  
Chemilluminescence	  was	  analysed	  by	  exposing	   the	  membrane	   to	  an	  Amersham	  hyperfilm	  X-­‐
ray	   film	   and	   developed	   in	   a	   Xograph	   film	   developer.	   X-­‐ray	   film	   exposure	   times	  were	   varied	  
from	  4	  seconds	  to	  60	  minutes	  to	  optimise	  clarity	  of	  bands	  present.	  	  
2.3.10	  Immunoprecipitation	  
Immunoprecipitation	  was	  performed	  using	  Sigma	  HA-­‐immunoprecipitation	  kit.	  Cells	  were	  lysed	  
using	   Sigma	   lysis	   buffer.	   Sigma	   Lysis	   buffer	   was	   supplemented	   with	   additional	   inhibitors	   to	  
prevent	  protein	  degradation	  and	  de-­‐phosphorylation.	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Lysis	  buffer	  was	  supplemented	  with:	  
	   2mM	  EGTA	  
	   50mM	  NaF	  
	   0.1mM	  Sodium	  vanadate	  	  
	   25mM	  β-­‐glycerolphosphate	  
	   150mM	  NaCl	  
	   PhosStop®	  phosphatase	  inhibitor	  cocktail	  
	   Protease	  inhibitor	  cocktail	  with	  EDTA	  
The	   cells	  were	   incubated	   for	   15	  minutes	   at	   room	   temperature	  with	   1	  ml	   of	   the	   lysis	   buffer	  
before	  scraping	   the	  cells	   into	  a	  microcentrifuge	   tube.	  Following	   this	   the	  cells	  were	  sonicated	  
for	  5	  second	  pulses	  at	  amplitude	  27%	  for	  1	  minute.	  1µl	  of	  Benzonase	  and	  1µl	  of	  2M	  MgCl2	  was	  
added	  to	  the	  lysates	  and	  incubated	  for	  60	  minutes	  on	  ice.	  Treated	  lysates	  were	  transferred	  to	  
a	   spin	   column	   before	   the	   addition	   of	   10µl	   of	   the	   HA-­‐	   antibody	   resin.	   The	   mixture	   was	  
incubated	  overnight	  at	  4°C	  on	  a	  rotating	  wheel.	  	  
The	  following	  morning	  the	  column	  was	  spun	   in	  a	  microcentrifuge	  at	  4°C	  to	  remove	  unbound	  
protein	   from	   the	  HA-­‐	   resin.	   The	   resin	  was	  washed	   a	   further	   6	   times	   in	   1	   x	   IP	   buffer.	   The	   IP	  
buffer	  was	  also	  supplemented	  with	  additional	  inhibitors.	  	  
IP	  buffer	  was	  supplemented	  with:	  	  
	  	   2mM	  EGTA	  
	   50mM	  NaF	  
	   0.1mM	  Sodium	  vanadate	  	  
	   25mM	  β-­‐glycerolphosphate	  
	   150mM	  NaCl	  
	   PhosStop®	  phosphatase	  inhibitor	  cocktail	  
	   Protease	  inhibitor	  cocktail	  with	  EDTA	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One	   final	   wash	   was	   performed	   with	   0.1%	   IP	   buffer	   before	   the	   addition	   of	   100µl	   Laemmli	  
buffer.	  The	  samples	  were	  boiled	  for	  5	  minutes	  in	  a	  heating	  block	  before	  eluting	  the	  protein	  by	  
centrifugation	   into	   a	   clean	   microcentrifuge	   tube.	   Samples	   were	   analysed	   by	   SDS-­‐PAGE	   and	  
Western	  Blot.	  
2.3.11	  In	  vitro	  SUMOylation	  Assay	  
Protein	  components	  for	  the	  in	  vitro	  assay	  were	  prepared	  by	  purifying	  protein	  from	  a	  1l	  culture	  
of	  E.	  coli	  as	  described	  above.	  Purified	  protein	  was	  snap	  frozen	  in	  10%	  glycerol	  and	  stored	  at	  -­‐
80°C	  ready	  for	  use.	  
The	  in	  vitro	  assay	  was	  prepared	  with	  the	  controls	  shown	  below.	  Components	  added	  are	  in	  µl.	  
Table	  2.5	  Shows	  an	  example	  set	  up	  for	  the	  in	  vitro	  SUMOylation	  assay.	  
Reaction	  Tube	  No.	   1	   2	   3	   4	   5	   6	   7	   8	  
	  	   eIF4A	   No	  
SAE	  
Assay	  	   A+	  
pli1	  
eIF4A	   eIF4A+	  
Pli1	  
eIF4A	   eIF4A+Pli1	  
Substrate	   10	   10	   	  	   	  	   10	   10	   20	   20	  
10x	  Buffer	   	  	   4	   4	   4	   4	   4	   4	   4	  
E2	  (Ubc9/Hus5)	  [1.5mg/ml]	   	  	   2	   2	   2	   2	   2	   2	   2	  
Sumo-­‐GG	  (Pmt3)	  [5mg/ml]	   	  	   4	   4	   4	   4	   4	   4	   4	  
E1	  (SAE;	  Rad31/Fub2)	  
[0.5mg/ml]	  
	  	   	  	   4	   4	   4	   4	   4	   4	  
CPK	  [3.5mg/µl]	   	  	   2	   2	   2	   2	   2	   2	   2	  
PPI	  [0.12	  mg/µl]	   	  	   2	   2	   2	   2	   2	   2	   2	  
E3	  (pli1)	  [1.5mg/ml]	   	  	   	  	   	  	   2	   	  	   2	   	  	   2	  
Water	   30	   16	   22	   20	   12	   10	   2	   0	  
The	  reaction	  mix	  was	  incubated	  at	  30°C	  for	  2	  hours	  before	  the	  direct	  addition	  of	  8µl	  of	  5xSDS	  
sample	  buffer.	  Samples	  were	  then	  run	  on	  SDS-­‐PAGE.	  	  
2.3.12	  In-­‐gel	  trypsin	  digestion	  
Bands	   were	   cut	   from	   the	   SDS-­‐PAGE	   gel	   and	   de-­‐stained	   by	   washing	   gel	   pieces	   in	   25mM	  
NH4HCO3	  in	  50%	  MeCN	  (acetonitrile)	  solution.	  This	  was	  repeated	  3	  times	  to	  remove	  Coomassie	  
stain	   and	  dehydrate	   the	   gel	   pieces.	   The	   gel	   pieces	  were	   then	   reduced	  by	   addition	  of	   10mM	  
DTT	  in	  25mM	  NH4HCO3	  and	  incubation	  at	  50°C	  for	  45	  minutes.	  This	  solution	  was	  then	  replaced	  
with	  50mM	  iodoacetamide	   in	  25mM	  NH4HCO3	  and	   incubated	  for	  a	   further	  45	  minutes	   in	  the	  
dark	  for	  alkylation	  to	  occur.	  Samples	  were	  then	  digested	  with	  trypsin	  (10ng/µl)	  overnight.	  The	  
	  	  
96	  
following	  day	  peptides	  were	  recovered	  in	  5%	  tetrafluoroacetic	  acid	  (TFA)	  to	  a	  final	  volume	  of	  
~8µl.	  Samples	  were	  then	  stored	  at	  -­‐20°C	  until	  analysis	  by	  mass	  spectrometry.	  
2.3.13	  Mass	  spectrometry	  
Protein	  samples	  were	  analysed	  by	  SDS-­‐PAGE.	  Bands	  of	  interest	  were	  excised	  and	  digested	  with	  
trypsin	   following	   the	   ‘in-­‐gel’	   digestion	   protocol	   outlined	   above.	   Peptides	   were	   analysed	   by	  
liquid	   chromatography	   tandem	   mass	   spectrometry	   (LC-­‐MS/MS)	   in	   which	   digested	   peptides	  
were	   eluted	   in	   order	   of	   mass	   and	   ionised	   by	   electrospray	   ionisation	   before	   acceleration,	  
deflection	  and	  finally	  detection.	  Mass	  to	  charge	  ratios	  were	  plotted	  and	  the	  resultant	  spectra	  
was	  BLAST	  searched	  against	  a	  database	  of	  known	  eukaryotic	  proteins	  using	  Mascot	  Daemon	  
software.	  The	  software	  was	  also	  used	  to	  identify	  a	  shift	  in	  mass	  corresponding	  to	  that	  of	  Lysine	  
conjugated	  to	  di-­‐glycine	  to	  signify	  a	  modified	  residue.	  	  	  
2.4	  Mammalian	  Tissue	  culture	  methods	  
2.4.1	  Media	  
Mammalian	   cell	   lines	   used	   were	   cultured	   in	   Dulbecco’s	   Modified	   Eagle’s	   Medium	   (DMEM).	  
Media	   was	   supplemented	   with	   10%	   fetal	   calf	   serum	   (FCS).	   L-­‐glutamine	   along	   with	  
penicillin/streptomycin	  was	  also	  added	  to	  the	  media	  prior	  to	  use.	  	  
2.4.2	  Antibiotics	  
G418	  was	   used	   to	   select	   for	  mammalian	   cells	   that	   had	   integrated	   a	   plasmid	   containing	   the	  
neomycin	  resistance	  gene.	  	  
2.4.3	  Cell	  lines	  
Table	  2.6	  details	  the	  cell	  lines	  used	  in	  experiments.	  
Cell	  Line	   Special	  requirements	  
HeLa	   	  
U2OS	   	  
U2OS-­‐DR-­‐GFP	   U2OS	  cell	  line	  with	  an	  integrated	  cassette	  that	  
produces	  a	  GFP	  signal	   if	  DSB	  repair	  occurs	  by	  
HR.	  Contains	  an	  I-­‐SceI	  restriction	  site.	  
HeLa	  YFP-­‐BRCT	  WT	   HeLa	  cell	   line	  with	  an	   integrated	  YFP	  plasmid	  
containing	   the	   BRCT	   domains	   of	   53BP1.	  
Culture	  in	  400µg/µl	  G418.	  
HeLa	  YFP-­‐BRCT	  R1811E	   HeLa	  cell	   line	  with	  an	   integrated	  YFP	  plasmid	  
containing	   the	   BRCT	   domains	   of	   53BP1.	  
Culture	  in	  400µg/µl	  G418.	  
+/+	  H2AX	  Mouse	  Embryonic	  Fibroblast	  (MEF)	   	  





0.0025%	  (w/v)	  in	  PBS	  was	  filter	  sterilised	  using	  a	  0.22µm	  filter.	  	  
Cells	   were	   cultured	   in	   T175	   flasks.	   Cells	   were	   trypsinised	   firstly	   by	   the	   removal	   of	   media	  
containing	  FCS.	  The	  cells	  were	  then	  washed	  with	  10ml	  of	  PBS.	  After	  removal	  of	  the	  PBS,	  10ml	  
of	   trypsin	  solution	  was	  added.	  The	  trypsin	  was	   incubated	  for	  5	  minutes	  to	  allow	  digestion	  of	  
the	  adhesive	  proteins	  utilised	  by	  the	  cells.	  Media	  containing	  serum	  was	  added	  to	  the	  cells	  to	  
ablate	  the	  activity	  of	  the	  trypsin.	  The	  cells	  were	  then	  counted	  and	  collected	  by	  centrifugation	  
before	  re-­‐suspension	  in	  new	  media.	  Finally	  the	  cells	  were	  seeded	  into	  a	  new	  flask	  to	  passage	  
the	  cells	  and/or	  seeded	  for	  experiments	  in	  35mm	  dishes.	  	  
2.4.5	  Cell	  counting	  
The	  number	  of	  cells	  per	  ml	  of	  media	  was	  calculated	  using	  a	  haemocytometer.	  	  
2.4.6	  Total	  cell	  extracts	  
Total	  cell	  extracts	  were	  prepared	  by	  addition	  of	  50µl	  of	  1xSDS-­‐Sample	  buffer	  to	  a	  35mm	  plate.	  
Cells	  were	  then	  removed	  by	  scraping	  and	  transferred	  to	  an	  Eppendorf	  tube.	  The	  samples	  were	  
sonicated	  at	  amplitude	  27%	  for	  30	  seconds	  in	  5	  second	  pulses.	  Samples	  were	  then	  boiled	  and	  
centrifuged	  ready	  for	  analysis	  by	  SDS-­‐PAGE.	  	  
2.4.7	  RNA	  interference	  
SiRNA	  oligonucleotides	  were	  obtained	  from	  Life	  Technologies.	  	  
RNA	  oligonucleotide	  transfections	  were	  set	  up	  as	  follows	  for	  each	  plate:	  	  
50µl	  OptiMEM	  (Serum	  free	  media)	  
5µl	  Hiperfect	  transfection	  reagent	  
2µl	  of	  20µM	  siRNA	  oligonucleotides	  	  
The	  solution	  was	  mixed	  and	  incubated	  at	  room	  temperature	  for	  10	  minutes	  to	  allow	  complex	  
formation.	  Cells	  were	   trypsinised	  as	  described	  above	  and	  2x105	   cells	  were	   seeded	  per	  plate.	  
The	  cells	  were	  reverse	  transfected	  (i.e.	  while	  still	  in	  suspension)	  with	  the	  prepared	  transfection	  
solution.	  siRNA	  oligonucleotides	  were	  diluted	  to	  a	  final	  concentration	  of	  20nM.	  Typically	  cells	  
were	  incubated	  for	  a	  further	  48	  hours	  to	  allow	  RNA	  interference	  (RNAi)	  to	  occur.	  The	  efficacy	  
of	   RNAi	   was	   assessed	   by	   both	   western	   blot	   analysis	   and	   immunofluorescence	   where	  
appropriate.	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2.4.8	  Mammalian	  cell	  transfection	  (calcium	  phosphate)	  
2x	  HBS	  
	   0.0162%	  NaCl	  (w/v)	  
	   0.0004%	  Na2HPO4	  7H2O	  (w/v)	  
	   0.013%	  HEPES	  (w/v)	  
	   Adjusted	  to	  pH	  7.0	  
2M	  CaCl2	  
The	   calcium	   phosphate	   transfection	   method	   was	   used	   to	   transfect	   HEK293	   cells.	   Prior	   to	  
transfection	  the	  cells	  were	  trypsinised	  and	  seeded	  at	  low	  confluency	  (20-­‐30%)	  on	  10cm	  plates	  
two	  hours	  before	  transfection	  to	  allow	  the	  cells	  to	  re-­‐attach	  to	  the	  plate.	  	  
For	   the	   transfection,	   2x	   HBS	   was	   thawed	   at	   room	   temperature	   before	   preparing	   the	  
CaCl2/HBS/DNA	  mixture.	   For	   each	   10cm	   dish,	   10µg	   of	   DNA	  was	   diluted	   in	   500µl	   of	   244mM	  
CaCl2.	   The	   DNA/CaCl2	   was	   then	   added	   dropwise	   to	   500µl	   of	   2xHBS.	   Finally,	   the	   prepared	  
mixture	  was	  added	  dropwise	  evenly	  to	  the	  media	  of	  the	  10cm	  plate	  and	  incubated	  at	  37°C	  for	  
24	  hours.	  The	  media	  was	  changed	  the	  following	  day	  and	  the	  cells	  were	  cultured	  for	  a	  further	  
60	  hours	  before	  being	  lysed.	  
2.4.9	  Mammalian	  cell	  transfection	  (lipid-­‐based)	  
After	  incubating	  cells	  with	  the	  siRNA	  transfection	  reagent	  the	  cells	  were	  washed	  with	  PBS	  and	  
new	  media	  added.	  Cells	  were	  then	  transfected	  with	  plasmids	  constructs	  containing	  either	  the	  
wild	  type	  protein	  or	  a	  mutant	  version.	  	  
Plasmid	  transfections	  were	  set	  up	  as	  follows	  for	  each	  plate:	  
50µl	  OptiMEM	  
2.75µl	  Nanojuice	  transfection	  booster	  
1.5µl	  Nanojuice	  core	  transfection	  reagent	  
1.5µg	  Plasmid	  DNA	  
Reagents	  were	  briefly	  vortexed	  before	  the	  addition	  of	  the	  plasmid	  DNA.	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2.4.10	  Mammalian	  cell	  transfection	  (Electroporation)	  
Due	  to	  the	  requirement	  for	  high	  transfection	  efficiency,	  electroporation	  was	  performed	  using	  
Invitrogens’	  NEON®	  transfection	  system.	  Cells	  were	  trypsinised	  and	  counted.	  2x105	  cells	  were	  
transfected	  per	  plate.	  Cells	  were	  isolated	  and	  pelleted	  before	  re-­‐suspension	  in	  buffer	  R.	  500µg	  
of	   plasmid	  DNA	  was	   added	   to	   the	   cell	   suspension.	   The	   cell	   suspension	  was	  drawn	  up	   into	   a	  
NEON	  transfection	  tip	  before	  placing	  in	  a	  cuvette	  containing	  electrolytic	  buffer.	  The	  cells	  were	  
electroporated	  at	  a	  set	  voltage,	  time	  and	  number	  of	  pulses	  recommended	  for	  each	  cell	  type	  by	  
the	  manufacturer’s	  database.	  	  
Finally,	   the	   cells	   were	   expelled	   from	   the	   pipette	   tip	   into	   a	   35mm	   plate	   containing	   2ml	   of	  
media.	   The	   following	   day	   the	   transfection	   efficiency	   was	   assessed	   using	   a	   GFP	   reporter	  
construct.	   Typically	   transfection	   efficiencies	   higher	   than	   95%	   were	   achieved	   using	   this	  
protocol.	  	  
2.4.11	  Irradiation	  
In	  order	   to	  generate	  DNA	  DSBs	   cells	  were	  exposed	   to	  gamma	   radiation	   from	  a	  Caesium-­‐137	  
source.	  	  
For	   larger	   samples,	   for	   example	   those	   in	   96-­‐well	   plates,	   an	   X-­‐ray	   machine	   was	   used	   to	  
generate	  DNA	  damage.	  
2.4.12	  Fluorophores	  
Fluorophores	  used	  for	  immunofluorescence	  experiments	  include:	  
DAPI	  –	  Blue	  
	  FITC	  –	  Green	  	  
Cy3	  –	  Orange	  	  
Cy5	  –	  Far	  Red	  
The	   graph	   below	   illustrates	   the	   excitation	   and	   emission	   spectra	   of	   each	   fluorophore.	   The	  
distribution	   of	   the	   spectra	   allows	   the	   use	   of	   all	   4	   fluorophore	   channels	   in	   one	   experiment.	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2.4.13	  Immunofluorescence	  
Mammalian	  cells	  were	  cultured	  on	  glass	  coverslips.	  Following	  RNAi	  and	  plasmid	  transfections	  
cells	  were	   treated	  as	   indicated	  and	  processed	  by	  either	   fixation	  using	  4%	  paraformaldehyde	  
before	  permeabalisation	  with	  0.1%	  Triton	  X100	  or	  the	  reverse	  for	  triton	  extraction.	  Methanol	  
fixation	  was	  used	   for	   immunofluorescence	  experiments	   staining	   for	  TopBP1.	  Coverslips	  were	  
washed	  with	  PBS	  three	  times	  between	  each	  step.	  Antibodies	  were	  diluted	  in	  4%	  Bovine	  serum	  
albumin	  (BSA)	  in	  PBS	  to	  assay	  specific	  concentrations	  ranging	  from	  1:1000	  to	  1:100	  (see	  table	  
below	   for	   further	   details)	   and	   incubated	   on	   the	   glass	   coverslips	   for	   1	   hour	   at	   room	  
temperature.	  	  
Table	  2.7	  Details	  the	  antibodies	  and	  concentrations	  used	  in	  experiments.	  
Primary	  Antibody	   Dilution	  factor	  for	  IF	   Host	  
α-­‐HA	   1:200	   Mouse	  monoclonal	  
α-­‐53BP1	   1:400	   Rabbit	  polyclonal	  
α-­‐pATM	  (S1981)	   1:400	   Rabbit	  monoclonal	  
α-­‐NBS1	   1:1,000	   Rabbit	  polyclonal	  
α-­‐γH2AX	  (S139)	   1:400	   Rabbit	  polyclonal	  
α-­‐	  γH2AX	  (S139)	   1:800	   Mouse	  monoclonal	  
α-­‐BRCA1	   1:100	   Rabbit	  polyclonal	  
α-­‐TopBP1	   1:1,000	   Rabbit	  polyclonal	  
After	  the	  primary	  antibody	  was	  removed	  the	  coverslips	  were	  washed	  3	  more	  times	  with	  PBS	  
before	   the	   addition	   of	   the	   secondary	   antibody	   coupled	   to	   a	   fluorophore.	   The	   secondary	  
antibody	   was	   diluted	   in	   4%	   BSA	   and	   incubated	   on	   the	   coverslips	   for	   30	   minutes	   at	   room	  
temperature.	   The	   secondary	   antibody	   was	   removed	   by	   3	   further	   washes	   in	   PBS	   before	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mounting	  the	  coverslips	  onto	  slides	  with	  Prolong	  gold	  mounting	  media	  with	  DAPI.	  Slides	  were	  
left	   overnight	   at	   4°C	   to	   allow	   the	  mounting	  media	   to	   set.	   Immunofluorescence	   slides	   were	  
imaged	  using	  an	  Imsol	  Deltavision	  IX70	  microscope.	  	  
2.4.14	  ScanR	  
Analysis	   of	   foci	   co-­‐localisation	   was	   achieved	   using	   ScanR	   microscopy.	   Initially	   cells	   were	  
cultured	  as	  before	  on	  35mm	  dishes.	  Cells	  were	  seeded	  at	  2x105	  cells	  per	  well	  and	  were	  reverse	  
transfected	   with	   53BP1	   siRNA	   oligonucleotides.	   Cells	   were	   incubated	   for	   24	   hours	   before	  
washing	  with	  PBS	  and	  transfection	  with	  plasmid	  constructs	  containing	  either	  wild-­‐type	  53BP1	  
or	   one	  of	   the	   serine/threonine	  mutants.	   Cells	  were	   incubated	   for	   a	   further	   24	   hours	   before	  
being	   trypsinised	  and	  re-­‐seeded	  onto	  a	  96-­‐well	   scanR	  plate.	  Cells	  were	  seeded	  at	  2x104	  cells	  
per	  well.	  	  
The	   following	   day	   cells	   were	   exposed	   to	   8Gy	   of	   IR	   using	   an	   X-­‐ray	   machine.	   The	   cells	   were	  
allowed	  to	  recover	  for	  4	  hours	  before	  fixation	  using	  -­‐20°C	  methanol	  for	  15	  minutes.	  Cells	  were	  
processed	   for	   immunofluorescence	   as	   before	   using	   antibodies	   for	   TopBP1	   and	   HA	   at	   their	  
appropriate	   concentrations.	   Primary	   antibodies	   were	   incubated	   for	   1	   hour	   and	   secondary	  
antibodies	   for	   30	   minutes	   at	   room	   temperature.	   Finally	   cells	   were	   stained	   with	   DAPI	   at	   a	  
5µg/ml	  concentration	  for	  10	  minutes	  at	  room	  temperature.	  	  
Analysis	   by	   scanR	  microscopy	  was	   assisted	   by	  Dr	   V.	   Savic	   (University	   of	   Sussex).	   6x6	   images	  
were	   taken	  per	  well.	  DAPI	   intensity	   stain	  was	  analysed	   to	  produce	  a	  cell	   cycle	  profile	  on	   the	  
contents	  of	  each	  well.	  The	  resulting	  images	  were	  analysed	  for	  both	  53BP1	  and	  TopBP1	  foci.	  Co-­‐
localisation	  was	  assessed	  by	  the	  production	  of	  a	  database	   listing	  the	  X,Y	  coordinates	  of	  each	  
focus	   along	   with	   its	   size	   only	   in	   G1	   cells.	   G1	   phase	   cells	   were	   scored	   for	   either	   having	   co-­‐
localised	  foci	  or	  not.	  
2.4.15	  Homologous	  recombination	  assay	  
A	  U2OS	   cell	   line	  with	   an	   integrated	   plasmid	   cassette	  was	   used	   to	   analyse	   changes	   in	   global	  
homologous	   recombination	   (HR).	   The	   integrated	   cassette	   contains	   an	   inactive	  GFP	  molecule	  
due	   to	   a	   direct	   repeat	   (DR)	   adjacent	   to	   an	   I-­‐SceI	   restriction	   site.	  When	   an	   I-­‐SceI	   expressing	  
plasmid	   is	   transfected	   into	   these	   cells	   it	   generates	   one	   DSB	   per	   cell.	   Downstream	   of	   the	  
inactive	  GFP	  is	  a	  C-­‐terminal	  fragment	  capable	  of	  being	  used	  as	  a	  template	  to	  restore	  the	  GFP	  to	  
the	  active	   form	   i.e.	  without	   the	  DR.	   If	   the	   repair	  occurs	  by	  homologous	   recombination	  using	  
the	  downstream	  template	  a	  GFP	  signal	  is	  produced.	  Un-­‐repaired	  breaks	  or	  breaks	  repaired	  by	  
non-­‐homologous	  end	  joining	  (NHEJ)	  do	  not	  produce	  any	  GFP	  signal.	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U2OS	   DR-­‐GFP	   cells	   were	   treated	   as	   before	   by	   depleting	   endogenous	   53BP1	   using	   RNAi.	   48	  
hours	   after	   reverse	   transfection	   with	   the	   siRNA	   oligonucleotides	   the	   cells	   were	   transfected	  
with	   either	   the	   wild-­‐type	   53BP1	   or	   one	   of	   the	   mutants	   alongside	   an	   I-­‐SceI	   plasmid.	   After	  
transfection	  the	  cells	  were	  incubated	  for	  a	  further	  48	  hours	  to	  allow	  for	  the	  induction	  of	  a	  DSB	  
and	  to	  allow	  time	  for	  repair	  to	  occur.	  After	  the	  incubation	  period	  the	  cells	  were	  trypsinised	  and	  
analysed	  by	  fluorescence	  activated	  cell	  sorting	  (FACS).	  	  
2.4.16	  Fluorescence	  activated	  cell	  sorting	  	  
U2OS-­‐DR-­‐GFP	  (direct	  repeat)	  cells	  were	  seeded	  onto	  35mm	  dishes	  and	  transfected	  with	  siRNA	  
oligonucleotides	   targeting	   53BP1.	   48	   hours	   later	   cells	   were	   transfected	   with	   both	   siRNA	  
resistant	  constructs	  alongside	  a	  pCBASceI	  construct	  designed	  to	  create	  a	  double	  strand	  break	  
in	   the	   DR-­‐GFP	   construct.	   Cells	   that	   repair	   the	   damage	   using	   homologous	   recombination	  
produce	  and	  active	  GFP	  signal.	  	  
To	  analyse	  the	  samples	  by	  FACS	  the	  cells	  were	  trypsinised	  from	  35mm	  dishes	  and	  centrifuged	  
before	  being	  concentrated	   into	  500µl	  of	  PBS	  with	  1mM	  EDTA.	  Cells	  were	  vortexed	  briefly	   to	  
prevent	   clumping.	   Once	   the	   fluidics	   had	   pressurised	   and	   the	   lasers	   were	   at	   an	   operational	  
temperature	  the	  samples	  could	  then	  be	  analysed	  for	  GFP	  fluorescence.	  	  
2.4.17	  Generation	  of	  stable	  transfected	  cell	  lines	  
Stable	   cell	   lines	  were	   generated	   by	   initially	   seeding	   2x105	   HeLa	   cells	   per	   35mm	   dish	   before	  
transfecting	  the	  cells	  when	  they	  had	  reached	  approximately	  70-­‐80%	  confluence.	  The	  plasmid	  
transfected	  contained	  a	  resistance	  neomycin	  resistance	  gene	  that	  confers	  resistance	  to	  G418	  
disulfate.	   48	   hours	   after	   the	   initial	   transfection	   the	   cells	   were	   checked	   for	   transfection	  
efficiency	  under	  a	  fluorescent	   light	  microscope.	  After	  checking	  the	  transfection	  efficiency	  the	  
media	   was	   changed	   and	   supplemented	   with	   700µg/ml	   of	   G418.	   The	   cells	   were	   continually	  
treated	  with	  media	  containing	  this	  selection	  marker	  at	  this	  concentration	  for	  a	  further	  14	  days.	  	  
Cells	  that	  had	  failed	  to	  retain	  and	  integrate	  the	  plasmid	  had	  undergone	  apoptosis	  and	  surviving	  
colonies	   were	   all	   expressing	   the	   protein	   of	   interest.	   After	   the	   initial	   selection	   the	   G418	  
concentration	  was	  decreased	  to	  400µg/ml.	  	  
Due	   to	   the	   nature	   of	   the	   following	   experiments	   the	   cell	   line	   was	   cultured	   as	   a	   polyclonal	  
population	  with	  a	  range	  of	  different	  expression	  profiles.	  	  
2.4.18	  Cross-­‐sectional	  analysis	  of	  foci	  
1x105	  HeLa	   cells	  were	   seeded	  per	  plate	  and	   reverse	   transfected	  with	   siRNA	  oligonucleotides	  
targeting	  53BP1.	  48	  hours	  later	  the	  cells	  were	  either	  left	  untransfected	  or	  transfected	  with	  the	  
wild-­‐type	   protein	   or	   one	   of	   the	  mutant	   constructs.	   The	   cells	  were	   then	   exposed	   to	   ionising	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radiation.	  Mock-­‐treated	  and	  wild-­‐type	  cells	  were	  exposed	  to	  3Gy	  while	  mutants	  were	  exposed	  
to	   1Gy	   to	   generate	   similar	   foci	   numbers	   after	   8	   hours.	   8	   hours	   post-­‐IR	   exposure	   cells	   were	  
fixed	  in	  4%	  paraformaldehyde	  and	  permeablised	  using	  0.1%	  Triton	  X100.	  Cells	  were	  processed	  
for	  immunofluorescence	  staining	  for	  BRCA1	  and	  53BP1	  for	  mock-­‐treated	  and	  si53BP1	  whereas	  
the	   wild-­‐type	   and	   mutant	   constructs	   were	   stained	   for	   BRCA1	   and	   HA.	   Coverslips	   were	  
mounted	  on	  glass	  slides	  using	  prolong	  gold	  mounting	  media	  containing	  DAPI.	  	  
A	   series	   of	   non-­‐overlapping	   de-­‐convolved	   z-­‐stack	   images	   were	   obtained	   using	   an	   IMSOL	  
Deltavision	   IX70	   inverted	  microscope.	   20	   images	   were	   taken	   per	   stack	   with	   a	   z	   distance	   of	  
0.2µm	  between	  each	  image.	  Each	  image	  was	  subjected	  to	  10	  de-­‐convolution	  cycles.	  
Intensity	   profiles	   were	   measured	   across	   individual	   foci	   using	   SoftworXs	   image	   analysis	  
software.	  Profiles	  of	  20	  foci	  were	  generated	  per	  slide.	  Intensity	  values	  were	  normalised	  to	  the	  
highest	   intensity	   read	  on	   that	   particular	   channel.	   The	   average	  of	   the	   relative	   foci	   intensities	  
were	  plotted	  with	  error	  bars	  representing	  1	  standard	  deviation.	  	  
2.4.19	  Laser	  track	  micro-­‐irradiation	  and	  spinning	  disc	  confocal	  microscopy	  
2x105	  HeLa	  cells	  were	  seeded	  onto	  MatTek	  35mm	  glass	  bottom	  dishes	  and	  reverse	  transfected	  
with	  siRNA	  oligonucleotides	  for	  53BP1.	  48	  hours	   later	  cells	  were	  transfected	  with	  YFP-­‐tagged	  
constructs	  containing	  either	  the	  tandem	  BRCT	  domains	  of	  53BP1	  fused	  to	  a	  nuclear	  localisation	  
signal	  (NLS)	  one	  of	  the	  mutants	  or	  just	  the	  YFP-­‐NLS.	  Cells	  were	  incubated	  for	  a	  further	  16	  hours	  
before	  the	  addition	  of	  Hoechst	  34580	  diluted	  to	  a	  final	  concentration	  of	  10µg/ml.	  The	  Hoechst	  
stain	   was	   allowed	   to	   intercalate	   with	   the	   DNA	   for	   20	   minutes	   at	   37°C.	   Following	   pre-­‐
sensitisation	  with	  Hoechst	  a	  405nm	  wavelength	  laser	  was	  used	  to	  generate	  DSBs.	  Fluorescence	  
intensity	  on	  the	  488nm	  scanning	  laser	  was	  tracked	  over	  2	  minutes.	  Slidebook6	  reader	  software	  
was	  used	  to	  quantify	   the	  change	   in	   intensity	  normalised	   to	  an	  un-­‐damaged	  control.	  Tracking	  
experiments	   were	   repeated	   3	   times	   and	   the	   average	   plotted	   with	   error	   bars	   showing	   1	  
standard	  deviation.	  	  
For	  experiments	  using	  MEFs	  cells	  were	  seeded	  at	  1x106	  cells	  per	  well	  and	  incubated	  with	  siRNA	  
for	  only	  24	  hours	  before	  transfection.	  	  
2.4.20	  EdU/BrdU	  dual	  pulse	  labelling	  to	  assess	  G1-­‐S	  phase	  entry	  
1x105	   U2OS	   cells	   were	   seeded	   and	   reverse	   transfected	   as	   previously	   described	   with	   siRNA	  
oligonucleotides	  targeting	  53BP1.	  Following	  a	  48	  hour	  incubation	  period	  the	  cells	  were	  washed	  
and	   transfected	   using	   Nanojuice®	   transfection	   reagents	   using	   the	   protocol	   described	  
previously.	   16	   hours	   following	   the	   transfection	   the	   cells	   were	   pre-­‐incubated	   with	   EdU-­‐
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containing	  media	   for	  1	  hour	  at	  37°C.	   The	   cells	  were	   then	  washed	   twice	  with	  PBS	   to	   remove	  
residual	  EdU	  before	  irradiation	  with	  2Gy	  of	  ionising	  radiation	  using	  a	  caesium137	  source.	  After	  
irradiation	  the	  cells	  were	  supplemented	  with	  media	  containing	  another	  nucleotide	  analogue,	  
BrdU.	  The	  cells	  were	  incubated	  for	  a	  further	  7	  hours	  before	  fixation	  and	  permeabalisation	  for	  
ClickiT	  chemistry	  and	  immunofluorescence.	  	  
The	  DNA	  was	  denatured	  by	  adding	  2ml	  of	  4M	  HCl	  to	  each	  well	  followed	  by	  incubation	  for	  20	  
minutes	   at	   room	   temperature.	   This	   is	   critical	   to	   allow	   the	   BrdU	   antibody	   to	   bind	   its	   target.	  
Following	   on	   from	   this	   the	   cells	   were	   washed	   five	   times	   using	   a	   neutralising	   buffer	  
(phosphate/citric	   acid	  buffer).	   The	   cells	  were	  washed	  a	   further	   two	   times	  using	  a	  PBS/	  0.1%	  
Triton	  X100/	  1%	  BSA	  (antibody-­‐stain)	  solution.	  	  
Table	  2.8	  Details	  preparation	  of	  the	  ClickiT	  reaction.	  
Reagent	   Amount	  (v/v)	  
1x	  ClickIt	  EdU	  reaction	  buffer	   86%	  
CuSO4	   0.4%	  
Alexa	  Fluor	  647	  azide	   0.025%	  
10x	  ClickIt	  EdU	  buffer	  additive	   10%	  
Total	  volume	   10ml	  
	  
500µl	   of	   the	   ClickiT	  mixture	  was	   added	   to	   each	  well	   and	   incubated	   for	   30	  minutes	   at	   room	  
temperature	   in	   the	  dark.	   Following	  on	   from	   this	   the	   cells	  were	  washed	   two	   times	  using	   the	  
antibody-­‐stain	  solution.	  After	  washing,	  the	  anti-­‐BrdU	  and	  anti-­‐HA	  antibodies	  were	  diluted	  into	  
the	  antibody	  stain	  solution	  and	  100µl	  was	  spotted	  onto	  each	  of	  the	  coverslips.	  The	  coverslips	  
were	  incubated	  for	  a	  further	  60	  minutes	  at	  room	  temperature.	  After	  incubation,	  the	  antibodies	  
were	   washed	   off	   the	   coverslips	   three	   times	   with	   the	   antibody	   stain	   solution.	   A	   secondary,	  
fluorophore	  coupled	  antibody,	  was	  used	   to	   stain	   for	   the	  HA	   tag	  and	  was	   incubated	  with	   the	  
coverslips	  for	  a	  further	  30	  minutes	  at	  room	  temperature.	  	  
Finally,	  the	  secondary	  antibody	  was	  washed	  off	  the	  coverslips	  a	  further	  three	  times	  using	  the	  
antibody	  stain	  solution.	  Note	  that	  the	  BrdU	  antibody	  does	  not	  require	  a	  secondary	  antibody	  as	  
the	  primary	  antibody	   is	  already	  coupled	   to	  alexa	   fluor	  488.	  The	  coverslips	  were	  washed	   two	  
further	   times	   in	   PBS	   before	  mounting	   onto	   glass	   slides	   using	   Prolong	   gold	  mounting	  media	  
with	  DAPI.	  	  
2.4.21	  Dilution	  and	  clonal	  expansion	  of	  mammalian	  cells	  for	  CRISPR	  
Following	   transfection	   with	   the	   Cas9	   containing	   the	   targeting	   gRNA	   and	   incubation	   G418	  
disulfate	   for	   5	   days,	   the	   polyclonal	   cells	   were	   trypsinised	   and	   serially	   diluted	   to	   a	   final	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concentration	  of	  1	  cell/ml.	  200µl	  of	  the	  diluted	  cell	  solution	  was	  added	  to	  each	  well	  of	  a	  96-­‐
well	   plate	   and	   cultured	   for	   3-­‐weeks	   or	   until	   each	   well	   became	   confluent.	   Cells	   were	   then	  
cultured	  on	  larger	  plates	  and	  screened	  for	  deletion	  of	  the	  targeted	  gene.	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3.	  Investigating	  the	  role	  of	  SUMOylation	  of	  eukaryotic	  translation	  
initiation	  factors	  (eIFs)	  
3.1	  Introduction	  
The	   eukaryotic	   initiation	   factors,	   eIF4A1	   and	   eIF4A2,	   belong	   to	   the	   RNA	   DEAD-­‐box	   helicase	  
family.	   Despite	   their	   striking	   structural	   conservation	   these	   helicases	   have	   distinct	   roles	   in	  
regulating	  cellular	  metabolism	  [84].	  eIF4A1	  has	  been	  shown	  to	  directly	  impact	  upon	  translation	  
by	   affecting	   the	   ability	   of	   the	   assembling	   ribosome	   to	   traverse	   secondary	   structures	   located	  
within	  the	  5’	  UTR	  of	  the	  mRNA	  [241].	  Conversely,	  eIF4A2	  has	  been	  shown	  to	  be	  required	  for	  
miRNA-­‐mediated	  mRNA	  silencing	  [85,	  242].	  
The	   RNA	   helicase	   activity	   of	   eIF4A1	   has	   been	   shown	   to	   be	   highly	   inefficient	   and	   dependent	  
upon	   interactions	  with	   other	   initiation	   factors	   such	   as	   eIF4G	   and	   eIF4B	   to	   promote	   efficient	  
unwinding	  activity	  [81,	  243,	  244].	  Consequently,	  post-­‐translational	  modification	  of	  this	  protein	  
holds	  the	  potential	  to	  tip	  the	  balance	  and	  globally	  alter	  translation	  either	  directly	  by	  altering	  its	  
helicase	   activity	  or	   indirectly	  by	   affecting	   its	   availability	  within	   the	   cell.	   Furthermore,	   eIF4A1	  
and	   eIF4A2	   have	   been	   identified	   in	   proteomic	   screens	   designed	   to	   identify	   SUMOylated	  
proteins	  [4,	  5].	  
3.2	  Results	  
3.2.1	  eIF4A1	  and	  eIF4A2	  are	  SUMOylated	  in	  vitro	  on	  K225	  and	  K226	  respectively	  
In	   order	   to	   test	   whether	   or	   not	   the	   translation	   initiation	   factors	   eIF4A1	   and	   eIF4A2	   can	   be	  
SUMOylated	  in	  vitro,	  6x	  His-­‐tagged	  eIF4A1	  and	  GST-­‐tagged	  eIF4A2	  proteins	  (plasmid	  constructs	  
provided	   by	   Professor	   Simon	   Morley)	   were	   expressed	   and	   affinity	   purified	   from	   bacteria.	  
Expression	   of	   the	   proteins	  was	   induced	   in	  Escherichia	   coli	   and	   then	   recombinant	  His-­‐eIF4A1	  
protein	  was	   affinity	   purified	   using	   nickel	   beads.	   Separately,	   glutathione-­‐coupled	   beads	  were	  
used	  to	  affinity	  purify	  GST-­‐tagged	  eIF4A2	  protein.	  The	  purified	  proteins	  were	  eluted	   in	  300μl	  
aliquots	  following	  protocols	  described	  in	  sections	  2.3.1	  and	  2.3.2.	  Purified	  protein	  eluates	  were	  
analysed	  by	  SDS-­‐PAGE	  and	  staining	  with	  Coomassie	  instant	  blue	  protein	  stain	  (figure	  3.1a	  and	  
b).	  	  
Purified	  eIF4A1	  ran	  at	  the	  expected	  molecular	  mass	  of	  ~46kDa.	  eIF4A2	  has	  a	  similar	  molecular	  
mass	   to	   that	   of	   eIF4A1,	   however	   due	   to	   the	   addition	   of	   a	   GST-­‐tag,	   its	  mass	   is	   increased	   by	  
approximately	   25kDa	   so	   that	   it	   migrates	   closer	   to	   ~61kDa	   as	   seen	   on	   the	   gel.	   Each	   eluted	  
fraction	   was	   divided	   into	   50µl	   aliquots	   in	   10%	   glycerol,	   snap	   frozen	   in	   liquid	   nitrogen	   and	  





































Figure	   3.1	   Aﬃnity	   puriﬁca8on	   of	   His-­‐eIF4A1	   and	   GST-­‐eIF4A2.	   a)	   Shows	  
coomassie	  stained	  polyacrylamide	  gel	  of	  aﬃnity	  puriﬁed	  His-­‐eIF4A1	  eluted	  from	  
nickel	  beads	  following	  expression	  in	  Escherichia	  coli.	  FT	  =	  Flow	  through.	  E2,	  E3	  =	  
EluAon	   fracAons.	   b)	   Coomassie	   stained	   polyacrylamide	   gel	   of	   aﬃnity	   puriﬁed	  
GST-­‐eIF4A2	  eluted	  from	  GST	  beads	  following	  expression	  in	  Escherichia	  coli.	  FT	  =	  
Flow	  through.	  E2,	  E3,	  E4	  =	  EluAon	  fracAons.	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Recombinant	  eIF4A1	  and	  eIF4A2	  were	   then	   tested	   for	   the	  ability	   to	  be	  SUMOylated	   in	  an	   in	  
vitro	  SUMOylation	  assay.	  This	  assay	  includes	  an	  E1	  activating	  enzyme	  (Rad31	  and	  Fub2)	  and	  an	  
E2	  conjugating	  enzyme	  (Hus5)	  with	  or	  without	  an	  E3	  ligase	  (Pli1).	  Additionally,	  it	  uses	  a	  SUMO	  
construct	  with	  an	  additional	   trypsin-­‐cleavage	  site.	  His-­‐SUMO-­‐tr-­‐GG	  has	  an	  additional	   trypsin-­‐
cleavage	  site	  (lysine	  residue)	  engineered	  immediately	  adjacent	  to	  the	  diglycine	  motif	  as	  used	  in	  
the	  identification	  of	  SUMOylation	  sites	  in	  eIF4G	  [76].	  This	  enables	  the	  generation	  of	  peptides	  
with	   a	   smaller	   mass/charge	   ratio	   (m/z)	   shift	   after	   trypsin	   digestion	   and	   improves	   target	  
identification	   by	  mass	   spectrometry.	   Following	   incubation	   with	   the	   SUMOylation	  machinery	  
the	  eIF4A	  proteins	  were	  analysed	  by	  SDS-­‐PAGE	  and	  Coomassie	  Instantblue®	  staining	  to	  identify	  
additional	  bands	  corresponding	  to	  SUMOylated	  species	  (figures	  3.2a	  and	  b).	  The	  conjugation	  of	  
SUMO	  to	  a	  modified	  lysine	  should	  produce	  a	  characteristic	  shift	  of	  20kDa	  or	  multiples	  thereof	  
for	  polySUMOylated	  products.	  	  
In	   vitro	   SUMOylation	   of	   recombinant	   eIF4A1	   protein	   did	   not	   produce	   any	   additional	   bands.	  
However	   the	   possibility	   remained	   that	   other	   proteins	   used	   in	   the	   assay	   with	   a	   comparable	  
relative	  mobility	  could	  mask	  a	  SUMOylated	  species.	  Additionally,	  the	  quantity	  of	  SUMOylated	  
protein	   could	   be	   such	   that	   the	   Coomassie	   staining	   might	   not	   detect	   smaller	   quantities	   of	  
modified	  proteins.	  As	  a	   result,	   the	   indicated	  segments	   (figure	  3.2a	  and	  b)	  were	  excised	   from	  
the	  gel	  and	  the	  protein	  digested	  with	  trypsin	  to	  produce	  short	  peptide	  sequences	  as	  illustrated	  
in	  figure	  3.3a.	  The	  resulting	  peptides	  were	  analysed	  by	  LC-­‐MS/MS	  using	  an	  LTQ-­‐Orbitrap	  mass	  
spectrometer.	  	  
In	   vitro	   SUMOylation	   of	   recombinant	   eIF4A2	   did	   show	   an	   additional	   band	   potentially	  
representing	  a	  SUMOylated	  product.	  The	  band	   identified	   (marked	  by	  *	  on	   figure	  3.2b)	  has	  a	  
higher	   relative	  mobility	   than	   expected	   for	   a	   SUMOylated	   species,	   running	   at	   approximately	  
58kDa	  rather	  than	  the	  expected	  86kDa.	  As	  before,	  the	  possibility	  remained	  that	  other	  proteins	  
included	  in	  the	  assay	  could	  also	  mask	  the	  presence	  of	  SUMOylated	  eIF4A2.	  Groups	  of	  bands,	  
excised	  in	  segments	  including	  that	  marked	  by	  *,	  were	  excised	  from	  the	  gel	  and	  analysed	  by	  LC-­‐
MS/MS.	  	  
The	  spectra	  generated	  were	  used	  to	  identify	  peptides	  cleaved	  by	  trypsin	  using	  Mascot	  daemon	  
software	  (i.e.	  peptides	  cleaved	  on	  the	  C-­‐terminal	  side	  of	  lysine	  and	  arginine	  residues).	  A	  basic	  
local	  alignment	  search	  tool	  (BLAST)	  was	  used	  to	  identify	  which	  protein	  the	  peptides	  belonged	  
to.	  The	  software	  was	  also	  able	   to	   identify	  post-­‐translational	  modifications	  characterised	  by	  a	  
shift	  in	  the	  m/z	  ratio.	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Mascot	   software	   was	   able	   to	   identify	   a	   single	   peptide	   within	   eIF4A1	   that	   showed	   a	  
characteristic	  mass	  shift	  (represented	  by	  di-­‐glycine	  conjugated	  to	  a	  lysine	  residue)(figure	  3.3b).	  
This	  peptide	  mapped	  to	  the	  N-­‐terminal	  region	  of	  eIF4A1	  at	  amino	  acid	  residue	  K225.	  Similarly,	  
a	  single	  SUMOylation	  site	  was	  identified	  in	  eIF4A2	  (figure	  3.3c).	  The	  modified	  lysine	  in	  eIF4A2,	  
K226,	  mapped	  to	  an	  equivalent	  region	  of	  eIF4A1,	  within	  the	  N-­‐terminal	  portion	  of	  the	  protein.	  	  	  
The	   positions	   of	   these	   SUMOylated	   residues	   were	   then	   identified	   on	   the	   available	   crystal	  
structures	   for	  both	  eIF4A1	  and	  eIF4A2	   [245,	   246]	   (figure	  3.4a	   and	  b).	   The	  modified	   residues	  
project	  out	  from	  the	  main	  structures	  on	  an	  alpha	  helix.	  This	  suggests	  that	  the	  sites	  would	  be	  
accessible	  for	  SUMOylation	  in	  vivo.	  
	   	  
Figure	  3.2	  In	  vitro	  SUMOyla8on	  of	  recombinant	  eIF4A1	  and	  eIF4A2.	  a)	  Shows	  a	  
coomassie-­‐stained	  polyacrylamide	  gel	  of	  samples	  run	  on	  a	  gel	   following	  the	   in	  
vitro	  SUMOylaAon	  assay	  of	  His-­‐eIF4A1	  (verAcal	  bars	  indicate	  bands	  excised	  for	  
analysis	   by	  mass	   spectrometry).	   +	  marks	   the	   addiAon	   of	   S.	   pombe	  E1	   (SUMO	  
acAvaAng	   enzyme,	   Rad31/Fub2	  heterodimer);	   E2	   (SUMO	  conjugaAng	   enzyme,	  
Hus5)	  and	  E3	  (SUMO	  ligase,	  Pli1).	  Arrows	  indicate	  the	  regions/bands	  excised	  for	  
mass	   spectrometric	   analysis.	  Arrows	   indicate	   segments	   containing	   the	   SUMO-­‐
modiﬁed	   form.	   b)	   In	   vitro	   SUMOylaAon	   of	   GST-­‐eIF4A2	   (verAcal	   bars	   indicate	  
regions	   analysed	   by	   mass	   spectrometry).	   Arrows	   indicate	   the	   regions/bands	  




Figure	   3.3	   eIF4A1	   and	   eIF4A2	   are	   SUMOylated	   in	   vitro	   on	   K225	   and	   K226	  
respec8vely.	  a)	  diagrammaAc	  representaAon	  of	  trypAc	  digesAon	  of	  SUMOylated	  
proteins	  to	  generate	  diglycine-­‐conjugated	  pepAdes.	  Figure	  shows	  cleavage	  of	  the	  
C-­‐terminal	   side	   of	   Lysine	   adjacent	   to	   diglycine.	   6x	   His	   =	   HisAdine	   tag.	   b)	  Mass	  
spectra	   showing	   the	   detecAon	  of	   the	   SUMOylated	   pepAde	   idenAﬁed	   in	   eIF4A1	  
following	   trypAc	   digesAon.	   c)	   Mass	   spectra	   showing	   the	   detecAon	   of	   the	  









Figure	   3.4	   SUMOyla8on	   sites	   iden8ﬁed	   using	   the	   in	   vitro	   SUMOyla8on	   assay	  
map	   to	   an	   external	   face	   of	   the	   available	   crystal	   structures	   of	   eIF4A1	   and	  
eIF4A2.	  a)	  Crystal	  structure	  of	  eIF4A1	  was	  obtained	  from	  the	  protein	  data	  bank	  
and	   adapted	   from	   [245]	   with	   the	   SUMOylated	   lysine	   (K225)	   highlighted	   in	  
magenta.	   b)	   Crystal	   structure	   of	   the	   N-­‐terminal	   porAon	   of	   of	   eIF4A2	   obtained	  
from	  the	  protein	  data	  bank	  and	  adapted	  from	  [246]	  with	  the	  SUMOylated	  lysine	  




3.2.2	  eIF4A1	  and	  eIF4A2	  are	  SUMOylated	  in	  vivo	  
After	   the	   identification	   of	   these	   SUMOylation	   sites	   in	   vitro	   using	   S.	   pombe	   purified	  
components,	   it	   was	   necessary	   to	   establish	   whether	   or	   not	   eIF4A1	   and	   eIF4A2	   are	   in	   fact	  
SUMOylated	  in	  vivo,	  in	  mammalian	  cells.	  
In	   order	   to	   analyse	   this,	   HeLa	   cells	   stably	   expressing	   His-­‐SUMO1	   and	   His-­‐SUMO2	   (kindly	  
provided	  by	  Prof.	  R	  Hay)	  were	  cultured	  and	  used	  for	  affinity	  purification	  studies.	  Nickel	  affinity	  
purification	  and	  Western	  blot	  analysis	  of	  His-­‐SUMO1	  and	  His-­‐SUMO2	  from	  these	  cells	  reveals	  a	  
range	  SUMO	  of	  conjugates	  with	  various	  molecular	  weights	  (figure	  3.5a).	  The	  SUMO	  conjugates	  
purified	  from	  these	  cells	  were	  probed	  for	  eIF4A	  and	  eIF4A2	  (figure	  3.5b)	  to	  reveal	  the	  presence	  
of	   SUMO1-­‐modified	   eIF4A	   and	   SUMO1-­‐	   and	   2-­‐modified	   eIF4A2.	   The	   specificities	   of	   the	   two	  
antibodies	   used	   in	   this	   assay	   were	   tested	   against	   recombinant	   proteins	   with	   the	   eIF4A	  
antibody	  reporting	  on	  both	  isoforms	  (eIF4A1	  and	  2)	  and	  the	  eIF4A2	  antibody	  solely	  reporting	  
on	  recombinant	  eIF4A2	  (Figure	  3.6a).	  Dr.	  Jirapas	  Jongjitwimol	  performed	  these	  experiments.	  	  
Despite	  there	  being	  no	  clear	  additional	  eIF4A	  species	  purified	  from	  the	  His-­‐SUMO2	  expressing	  
cells	  in	  figure	  3.5b	  the	  likelihood	  of	  eIF4A	  being	  modified	  by	  SUMO2/3	  is	  quite	  high	  given	  the	  
substantial	  shift	   in	  molecular	  weight	  observed	  for	  eIF4A	  purified	  from	  His-­‐SUMO1	  expressing	  
cells	  i.e.	  indicating	  the	  indicating	  the	  presence	  of	  a	  polySUMOylated	  species	  with	  SUMO1	  as	  a	  
chain	  terminator.	  This	  is	  supported	  by	  the	  fact	  that	  when	  the	  same	  affinity	  purified	  lysates	  are	  
analysed	   using	   the	   eIF4A2	   specific	   antibody	   a	  modified	   eIF4A2	   species	   is	   observed	   for	   both	  
SUMO1	  and	  SUMO2	  conjugates.	  	  
Having	  established	  that	  SUMOylated	  species	  of	  eIF4A2	  could	  be	  identified	  in	  mammalian	  cells,	  
it	   then	   became	   possible	   to	   test	   whether	   the	   amino	   acid	   residues	   identified	   by	   mass	  
spectrometry	   were	   indeed	   genuine	   sites	   targeted	   for	   post-­‐translational	   modification.	   The	  
modification	  of	  eIF4A2	  by	  SUMO1	  on	  K226	  was	  examined	  further	  as	  this	  modified	  species	  was	  
the	  one	  most	  easily	  identified	  by	  Western	  analysis.	  	  
By	  depleting	  the	  endogenous	  protein	  by	  RNAi	  and	  transfecting	  cells	  with	  flag-­‐eIF4A2	  and	  flag-­‐
eIF4A2(K226R)	   constructs,	   Dr.	   Jirapas	   Jongjitwimol	  was	   able	   to	   show	   that	  mutation	   of	   K226	  
abolishes	  SUMOylation	  of	  eIF4A2	  in	  cells	  expressing	  his-­‐SUMO1	  (figure	  3.6b).	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Figure	   3.5	   eIF4A1	   and	   eIF4A2	   are	   SUMOylated	   in	   vivo	   by	   SUMO1	   and	  
SUMO2/3.	   (Performed	   by	   Dr.	   Jiripas	   Jongjitwimol).	   HeLa	   cells	   either	   not-­‐
transfected	   (NT)	   or	   stably	   expressing	   his-­‐SUMO1	   (S1)	   and	   his-­‐SUMO2/3	   (S2)	  
were	  cultured	  and	  SUMOylated	  proteins	  were	  aﬃnity	  puriﬁed	  (AP)	  using	  Nickel	  
agarose	  beads.	  WCE	  =	  Whole	  cell	  extracts.	  a)	  Shows	  a	  western	  blot	  probed	  with	  
anA-­‐SUMO1	   and	   anA-­‐SUMO2/3	   anAbodies	   following	   aﬃnity	   puriﬁcaAon	   b)	  
Aﬃnity	  puriﬁed	  lysates	  were	  analysed	  by	  western	  blot	  for	  the	  presence	  of	  eIF4A	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Figure	   3.6	   eIF4A2	   is	   SUMOylated	   on	   K226	   in	   vivo.	   (Performed	   by	   Dr.	   Jiripas	  
Jongjitwimol).	   a)	   Western	   blot	   analysis	   of	   recombinant	   eIF4A1	   and	   eIF4A2	  
protein	  was	  used	  to	  demonstrate	  the	  speciﬁcity	  of	  eIF4A	  and	  eIF4A2	  anAbodies.	  
b)	  HeLa	  cells	  stably	  expressing	  his-­‐SUMO1	  (S1)	  cells	  were	  depleted	  of	  eIF4A2	  by	  
RNA	   interference	   over	   24	   hours	   before	   transfecAon	   with	   siRNA	   resistant	  
constructs	  expressing	  either	  wild-­‐type	  Flag-­‐myc-­‐eIF4A2-­‐wt	  or	  a	  K226R	  mutant.	  
Flag-­‐myc-­‐eIF4A2	  was	  immunoprecipitated	  from	  whole	  cell	  extracts	  (WCE)	  using	  
α-­‐Flag-­‐coupled	  agarose	  beads	  and	  IP-­‐lysates	  were	  analysed	  by	  western	  blot	  for	  
the	  presence	  of	  higher-­‐molecular	  weight	  species	  of	  eIF4A2.	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3.2.3	  Mutation	  of	  K226	  affects	  the	  formation	  of	  stress	  granules	  after	  treatment	  with	  
arsenite	  
Having	  demonstrated	   that	   the	  eukaryotic	   initiation	   factor	  eIF4A2	   is	   SUMOylated	  on	  K226	  by	  
SUMO1,	  we	  were	   interested	   to	  determine	  whether	   failure	   to	  post-­‐translationally	  modify	   this	  
residue	  results	  in	  an	  observable	  defect	  or	  cellular	  change.	  One	  of	  the	  roles	  of	  SUMOylation	  is	  
to	   regulate	   protein	   trafficking	   and	   localisation.	   For	   example,	   SUMOylation	   of	   PML	   promotes	  
the	   formation	   of	   PML	   bodies	   which	   are	   discrete	   nuclear	   protein	   aggregates	   that	   form	   in	  
response	  to	  cellular	  stress	  [19].	  
In	  contrast	  to	  the	  role	  of	  SUMO	  in	  controlling	  nuclear	  compartmentalisation	  we	  wanted	  to	  test	  
whether	  the	  same	  level	  of	  control	  could	  be	  exhibited	  by	  SUMO	  over	  cytoplasmic	  proteins	  i.e.	  
altering	   their	   sub-­‐cellular	   localisation	   and	   affecting	   their	   recruitment	   to	   cytoplasmic	  
aggregates.	   This	   is	   particularly	   relevant	   with	   respect	   to	   the	   cytoplasmic	   formation	   of	   stress	  
granules	   and	   processing	   bodies	   (P-­‐bodies).	   Stress	   granules	   form	  when	   translation	   is	   blocked	  
and	  is	  proposed	  to	  be	  a	  protective	  response	  leading	  to	  either	  the	  degradation	  or	  recycling	  of	  
mRNA	  [247].	  There	  are	  two	  mechanisms	  that	  are	  thought	  to	  facilitate	  the	  formation	  of	  stress	  
granules	   by	   phosphorylation	   of	   eIF2α,	   either	   by	   preventing	   its	   association	  with	   the	   charged	  
tRNA,	  or	  by	  targeting	  eIF4A1	  and	  eIF4G	  directly	  [247].	  As	  eIF4G	  has	  recently	  been	  shown	  to	  be	  
SUMOylated,	   investigating	   the	   role	   of	   SUMOylation	   of	   eIF4A2	   on	   stress	   granule	   formation	  
could	  provide	  a	  link	  between	  these	  two	  observations	  [76].	  	  
In	   order	   to	   test	   this,	   cells	   were	   transfected	   with	   siRNA	   oligonucleotides	   targeting	   eIF4A2.	  
Following	   transfection	   with	   the	   siRNAs,	   cells	   were	   then	   transiently	   transfected	   with	   either	  
wild-­‐type	  Flag-­‐eIF4A2	  or	  the	  K226R	  unSUMOylatable	  mutant.	  After	  expression	  of	  the	  plasmids	  
the	   cells	  were	   then	   treated	  with	   either	   ionising	   radiation	   to	   induce	  DNA	  damage	   or	   sodium	  
arsenite	  to	  induce	  oxidative	  stress,	  which	  in	  turn	  induces	  stress	  granule	  formation	  [248]	  (figure	  
3.7).	   The	   results	  provisionally	   indicated	   that	   the	   incorporation	  of	  eIF4A2	   into	   stress	  granules	  
was	  impaired	  when	  K226	  was	  mutated	  to	  arginine.	  To	  further	  investigate	  this	  we	  repeated	  the	  
experiment	  to	  model	  the	  volume	  of	  the	  stress	  granules	  using	  images	  taken	  across	  a	  z-­‐range.	  	  
Image	  analysis	  was	  performed	  by	  taking	  deconvolved	  z-­‐stacks	  images	  over	  a	  z-­‐plane	  of	  4µm	  at	  
0.05µm	   slices.	   10	   cells	   were	   imaged	   per	   sample	   with	   surface	  mapping	   and	   volume	   analysis	  
using	  Imaris	  microscopy	  software.	  Example	  surface	  mapping	  is	  shown	  in	  figure	  3.8a.	  	  
Immunofluorescence	  analysis	  of	   flag-­‐eIF4A2	  and	   flag-­‐eIF4A2(K226R)	   incorporation	   into	  stress	  
granules	   reveals	   that	   mutation	   of	   eIF4A2	   results	   in	   an	   increase	   in	   the	   number	   of	   stress	  
granules	  with	  smaller	  volumes	  following	  treatment	  with	  arsenite	  (figure	  3.8b	  and	  c).	   	  
Jirapas	  Jongjitwimol	  
Figure	   3.7	   Localisa8on	   of	   Flag-­‐eIF4A2	   wild-­‐type	   and	   K226R	   mutant	   in	  
response	   to	   diﬀerent	   stress	   condi8ons.	   (Performed	   by	   Dr.	   Jirapas	  
Jongjitwimol).	  HeLa	  cells	  were	  depleted	  of	  eIF4A2	  by	  transfecAon	  with	  siRNA	  
oligonucleoAdes.	  24	  hours	   following	  transfecAon,	  cells	  were	  transfected	  with	  
either	  wild-­‐type	  Flag-­‐eIF4A2	  or	  the	  K226R	  mutant.	  The	  cells	  were	  then	  either	  
leq	  untreated	  (UT),	  treated	  with	  1mM	  sodium	  arsenite	  (AR)	  for	  30	  minutes	  or	  
exposed	   to	  3Gy	  of	   ionising	   radiaAon	  and	  allowed	   to	   recover	   for	  30	  minutes.	  
Following	   treatment	   the	   cells	   were	   ﬁxed	   and	   immunostained	   for	   SUMO-­‐1	  
(green)	  and	  eIF4A2	  via	  a	  Flag	  anAbody	  (red).	  Yellow	  boxes	  indicate	  regions	  of	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Figure	  3.8	  Muta8on	  of	  K226	   results	  a	   larger	  popula8on	  of	   stress	  granules	  with	  
smaller	   volumes	   aber	   treatment	   with	   arsenite.	   HeLa	   cells	   were	   depleted	   of	  
eIF4A2	   by	   transfecAon	   with	   siRNA	   oligonucleoAdes.	   24	   hours	   following	  
transfecAon	  cells	  were	  transfected	  with	  either	  wild-­‐type	  Flag-­‐eIF4A2	  or	  the	  K226R	  
mutant	   followed	   by	   treatment	  with	   1mM	   sodium	   arsenite	   for	   30	  minutes.	   High	  
resoluAon	   z-­‐stack	   (z=4μm	   0.05μm/slice)	   images	   were	   taken	   and	   deconvolved	  
using	  Soqworx	  soqware	  suite.	  Cells	  were	  ﬁxed	  and	   immunostained	  with	  an	  anA-­‐
Flag	   anAbody.	   Volumetric	   analysis	  was	   carried	   out	   on	   120	   stress	   granules	   using	  
Imaris	   soqware.	   a)	   shows	   example	   images	   eIF4A2	   stress	   granules	   (green).	   Two-­‐
panels	   below	   shows	   idenAﬁcaAon	   of	   stress	   granules	   by	   surface	   mapping	   using	  
Imaris.	   b)	   Histogram	   showing	   the	   frequency	   of	   stress	   granule	   volumes	   (n=120	  
stress	  granules	  analysed	  for	  each	  sample).	  c)	  Box	  and	  whisker	  plot	  shows	  skewed	  
distribuAon	  of	  stress	  granule	  volumes	  median,	  upper	  and	  lower	  quarAles	  of	  stress	  
granule	  volumes	  (n=120).	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3.2.4	  Mutant	  eIF4A2	  forms	  smaller	  stress	  granules	  although	  eIF4A2	  and	  TIA1	  co-­‐
localise	  normally	  
Following	  on	  from	  the	  identification	  of	  a	  larger	  population	  of	  smaller	  eIF4A2	  stress	  granules	  in	  
cells	  transfected	  with	  the	  K226R	  mutant,	   it	  was	  necessary	  to	  determine	  whether	  the	  amount	  
of	  eIF4A2	  being	  incorporated	  into	  stress	  granules	  is	  reduced	  by	  this	  mutation	  or	  whether	  the	  
overall	  volume	  of	  the	  stress	  granules	  is	  affected.	  Additionally,	  it	  was	  necessary	  to	  confirm	  that	  
the	  cytoplasmic	  bodies	  to	  which	  eIF4A2	  was	  being	  incorporated	  are	  stress	  granules	  as	  opposed	  
to	  P-­‐bodies,	  which	  contain	  different	  translation	  factors	  and	  components.	  	  
In	  order	  to	  this,	  the	  above	  experiment	  was	  repeated	  with	  additional	  co-­‐immunostaining	  for	  a	  
known	   component	   of	   stress	   granules,	   TIA1	   [249].	   As	   before,	   high-­‐resolution	   z-­‐stack	   images	  
were	   taken	   and	   deconvolved	   before	   being	   analysed	   by	   Imaris.	   Flag-­‐eIF4A2	   co-­‐localises	   with	  
TIA1	   indicating	   that	   eIF4A2	   is	   incorporated	   into	   stress	   granules	   following	   treatment	   with	  
arsenite	   (figure	  3.9a).	  Co-­‐localisation	  of	  Flag-­‐eIF4A2	  and	  TIA1	  was	   further	  analysed	  by	   Imaris	  
software.	  The	  software	  calculates	  the	  fluorescence	  signal	  overlap	  between	  two	  channels	  above	  
a	  threshold.	  The	  threshold	  was	  determined	  by	  a	  non-­‐transfected	  control	  and	  would	  therefore	  
represent	   only	   transfected	   cells	   and	   not	   background	   fluorescence.	   Co-­‐localisation	   of	   Flag-­‐
eIF4A2	  and	  TIA1	  was	  not	  affected	  by	  mutation	  of	  K226	  to	  arginine	  indicating	  that	  SUMOylation	  
of	  K226	  is	  not	  required	  for	  recruitment	  of	  eIF4A2	  to	  stress	  granules	  (figure	  3.9b).	  
Finally,	   it	  was	  possible	  to	  analyse	  the	  average	  stress	  granule	  volume	  across	  all	  3	  experiments	  
for	   each	   sample.	   There	  was	   a	   slight	   decrease	   in	   stress	   granule	   volume	  between	   Flag-­‐eIF4A2	  
wild-­‐type	  and	  the	  K226R	  mutant	   indicating	  that	  despite	  the	  fact	   that	  SUMOylation	  of	  eIF4A2	  
was	   not	   absolutely	   required	   for	   localisation	   to	   stress	   granules,	   SUMOylated	   eIF4A2	   might	  
mediate	   interactions	   with	   other	   proteins	   located	   in	   stress	   granules	   which	   also	   may	   be	  
SUMOylated	  (figure	  3.9c).	  	  
	   	  
Figure	  3.9	  Muta8on	  of	  K226	  results	  in	  a	  slight	  reduc8on	  in	  overall	  stress	  granule	  
volume	   aber	   treatment	   with	   arsenite.	   HeLa	   cells	   were	   depleted	   of	   eIF4A2	   by	  
transfecAon	   with	   siRNA	   oligonucleoAdes.	   Following	   this	   cells	   were	   transfected	  
with	   either	   wild-­‐type	   Flag-­‐eIF4A2	   or	   the	   K226R	   mutant.	   Cells	   were	   ﬁxed	   and	  
stained	  for	  both	  Flag-­‐eIF4A2	  and	  TIA1.	  a)	  Example	  image	  showing	  high	  resoluAon	  
z-­‐stack	   (z=4μm	  0.05μm/slice)	   images	  deconvolved	  using	  Soqworx	  soqware	  suite.	  
b)	   Co-­‐localisaAon	   analysis	   was	   performed	   using	   Imaris	   soqware	   suite.	   Results	  
show	  percentage	  of	  overlapping	  ﬂuorescence	  signal	  averaged	  over	  3	  experiments.	  
c)	  Average	  stress	  granule	  volume	  per	  image	  was	  calculated	  by	  mapping	  surfaces	  to	  
ﬂuorescence	   signal	   using	   Imaris	   soqware	   suite.	   Average	   of	   3	   experiments.	   Error	  

























































































Using	   recombinant	  proteins	  purified	   from	  E.	   coli,	   it	  was	  demonstrated	   that	  both	  eIF4A1	  and	  
eIF4A2	   are	   SUMOylated	   in	   vitro	   using	   recombinant	   proteins	   affinity	   purified	   from	   E.	   coli.	  
Additionally,	  K225	  in	  eIF4A1	  and	  K226	  in	  eIF4A2	  were	  identified	  as	  SUMOylation	  sites	  using	  LC-­‐
MS/MS.	   There	   are	   some	   limitations	   to	   these	   results,	   one	   of	   the	   foremost	   being	   the	   use	   of	  
SUMOylation	  protein	  components	  purified	  from	  S.	  pombe.	   It	   is	  possible	  that	  the	  yeast	  SUMO	  
conjugation	  machinery	  is	  not	  representative	  of	  the	  specificity	  and	  individual	  complexity	  that	  is	  
present	  in	  mammalian	  cells.	  Mammals	  possess	  several	  SUMO	  E3	  ligases	  that	  are	  each	  capable	  
of	   dictating	   SUMO	   target	   specificity	   and	  which	  may	   result	   in	   SUMOylation	   of	   other	   lysine(s)	  
[250].	  	  	  
Consideration	   also	   has	   to	   be	   made	   for	   the	   ability	   of	   E.	   coli	   to	   correctly	   fold	   mammalian	  
proteins.	  In	  vitro	  SUMOylation	  artefacts	  could	  be	  identified	  by	  the	  incorrect	  folding/unmasking	  
of	   lysine	   residues	   not	   present	   on	   the	   external	   face	   of	   the	   protein	   structure.	   Although	   these	  
additional	  sites	  can	  be	  SUMOylated	  they	  are	  unlikely	  to	  represent	  genuine	  target	  sites	  due	  to	  
their	   location	   within	   the	   correctly	   folded	   protein.	   To	   answer	   this	   latter	   point,	   the	   sites	  
identified	   on	   both	   eIF4A1	   and	   eIF4A2	   map	   to	   an	   external	   face	   of	   the	   available	   crystal	  
structures	  of	  both	  eIF4A1	  and	  the	  N-­‐terminal	  domain	  of	  eIF4A2,	  supporting	  the	  conclusion	  that	  
they	  are	  true	  SUMOylation	  sites	  [245,	  246].	  	  
In	   order	   to	   confirm	   the	   in	   vitro	   results,	   we	   went	   on	   to	   show	   that	   SUMOylated	   isoforms	   of	  
eIF4A1	  and	  eIF4A2	   can	  be	   identified	   in	   vivo	   in	  mammalian	   cells	  by	  utilising	  HeLa	   cells	   stably	  
expressing	  His-­‐SUMO1	  and	  His-­‐SUMO2.	  One	  of	  the	  limitations	  of	  using	  these	  cell	  types	  is	  that	  
the	  overexpression	  of	  SUMO	  within	  the	  cell	  could	  dramatically	  alter	  the	  physiology	  of	  the	  cells.	  
However,	   analysis	   of	   these	   cell	   lines	   reveals	   a	   comparable	   level	   of	   protein	   expression	   and	  
minimal	   change	   to	   the	   quantity	   of	   SUMO	   conjugates	   [251,	   252].	   This	   likely	   reflects	   the	  
availability	  of	  the	  rate	  limiting	  SUMOylation	  machinery	  required	  for	  the	  conjugation	  of	  SUMO	  
to	   target	   proteins.	   However,	   the	   generation	   of	   stable	   cell	   lines	   relies	   on	   random	   genomic	  
integration	  of	  the	  His-­‐SUMO	  plasmid.	  This	  occurs	  without	  disruption	  to	  the	  endogenous	  SUMO	  
gene,	   the	   result	  of	  which	  produces	  a	  mixture	  of	  potentially	   competing	   tagged	  and	  untagged	  
protein	   being	   present	   within	   the	   cell.	   	   This	   could	   also	   be	   in	   part	   why	   we	   fail	   to	   observe	  
additional	  bands	  signifying	  eIF4A	  modification	  with	  SUMO2/3	   i.e.	   if	  His-­‐tagged	  SUMO2	   is	  not	  
expressed	  as	  highly	  as	  the	  endogenous	  SUMO2	  and	  SUMO3	  genes.	  	  
By	   focusing	  on	  SUMO1	  modification	  of	  eIF4A2	  we	  were	  able	   to	   show	  that	   the	   lysine	   residue	  
(K226)	   identified	   by	   mass	   spectrometry	   was	   the	   sole	   lysine	   residue	   SUMOylated	   in	   vivo	   by	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creating	  a	  un-­‐SUMOylatable	  mutant,	  K226R.	  Mutation	  of	  this	  residue	  results	  in	  an	  increase	  in	  
smaller	  stress	  granules	  after	  treatment	  with	  arsenite.	  Care	  has	  to	  be	  taken	  however	  to	  account	  
for	   the	   inevitable	   variation	   in	   over-­‐expression	   of	   the	   construct	   produced	   by	   transiently	  
transfecting	   cells	   with	   this	   construct.	   In	   order	   to	   account	   for	   the	   potential	   variation	   of	  
expression	  of	  eIF4A2	  by	  transient	  transfection,	  the	  stress	  granule	  volumes	  of	  TIA-­‐1	  were	  also	  
analysed,	   revealing	   that	   both	   eIF4A2	   and	   TIA-­‐1	   stress	   granule	   volumes	   decrease	   following	  
transfection	   with	   the	   eIF4A2-­‐K226R	   mutant.	   Alternatively,	   a	   larger	   scale	   experiment	   using	  
automated	  SCANR	  microscopy	  could	  be	  used	  to	  assess	  the	  volumes	  of	  a	  much	  larger	  samples	  
size.	  An	  additional	  advantage	  is	  that	  the	  volumes	  could	  be	  normalised	  to	  the	  total	  internal	  FITC	  
intensity	  within	  each	  of	  the	  transfected	  cells.	  This	  would	  allow	  us	  to	  account	  for	  the	  variation	  
in	  expression	  following	  transient	  transfection.	  
Finally,	  one	  might	  expect	   that	   if	   SUMOylation	  of	  eIF4A2	   is	   required	   for	   the	   re-­‐localisation	  of	  
eIF4A2	   to	   stress	   granules,	  over-­‐expression	  of	   an	  unSUMOylatable	  mutant	  would	   fail	   to	   form	  
stress	  granules	  altogether.	  This	  is	  not	  the	  case	  however	  as	  we	  still	  see	  that	  both	  TIA1,	  a	  known	  
component	  of	   stress	   granules	   and	  eIF4A2	   still	   localise	   to	  discrete	   cytoplasmic	  bodies.	   This	   is	  
likely	  to	  result	  from	  similarities	  with	  PML	  body	  formation,	  during	  which	  SUMO	  creates	  a	  large	  
binding	  surface	  and	  essentially	  acts	  like	  a	  ‘glue’	  to	  hold	  PML	  and	  its	  binding	  partners	  together	  
[49].	   If	   the	   same	   is	   true	   for	   stress	   granules	   we	   may	   continue	   to	   see	   recruitment	   to	   stress	  
granules	  while	  other	  eIFs	  within	  stress	  granules,	  such	  as	  eIF4G	  and	  eIF4E,	  are	  still	  modified.	  To	  
fully	  identify	  the	  role	  of	  SUMO	  in	  stress	  granule	  formation,	  it	  may	  be	  necessary	  to	  identify	  and	  
mutate	  all	  of	  the	  SUMOylation	  sites	  in	  the	  proteins	  contained	  in	  the	  eIF4F	  complex	  and	  analyse	  
the	  defects	  produced.	  However,	  due	  to	  the	  relatively	  minor	  defects	  observed	  by	  mutating	  the	  
SUMOylation	  site	  of	  eIF4A2	  alone,	  the	  direction	  of	  the	  project	  was	  switched	  at	  this	  point.	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4.	   Characterisation	  of	   the	  phospho-­‐specific	   interactions	  between	  
53BP1	  and	  TopBP1	  
4.1	  Introduction	  
The	   N-­‐terminus	   of	   53BP1	   contains	   28	   SQ/TQ	   phosphorylation	   site	   motifs	   [213].	  
Phosphorylation	   of	   53BP1	   within	   this	   region	   has	   been	   shown	   to	   mediate	   several	   protein-­‐
protein	   interactions,	   only	   a	   few	   of	   which	   have	   been	   demonstrated	   to	   be	   critical	   for	   the	  
function	   of	   53BP1.	   For	   example,	   the	   role	   of	   53BP1	   to	   promote	   repair	   by	  NHEJ	   relies	   on	   the	  
ability	  to	  protect	  broken	  DNA	  ends	  from	  being	  resected	  by	  nucleases.	  This	  is	  achieved	  through	  
a	   set	   of	   phospho-­‐specific	   interactions	   between	   the	   phosphorylated	   SQ/TQ	   motifs	   located	  
within	   N-­‐terminal	   region	   of	   53BP1	   and	   other	   proteins	   such	   as	   Rif1	   [190]	   and	   PTIP	   [213].	  
Additionally,	  in	  G1-­‐phase	  cells,	  53BP1	  has	  also	  been	  shown	  to	  interact	  with	  TopBP1	  [193]	  in	  a	  
phosphorylation-­‐dependent	  manner.	  These	  interactions	  appear	  to	  be	  at	  least	  partly	  conserved	  
between	  species	  as	  this	  phosphorylation-­‐dependent	  interaction	  has	  previously	  been	  observed	  
in	  Schizosaccharomyces	  pombe	  between	  Crb253BP1	  and	  Rad4TopBP1	  [238].	  	  
TopBP1	  is	  a	  BRCT-­‐containing	  protein	  that	  has	  9	  BRCT	  domains	  [220,	  221]	  (figure	  1.12)	  and	  acts	  
predominantly	   during	   S-­‐phase	   in	   the	   initiation	  of	  DNA	   replication	   [192,	   253].	   TopBP1	   is	   also	  
recruited	  to	  sites	  of	  replicative	  stress	  through	  interactions	  between	  the	  C-­‐terminus	  of	  the	  Rad9	  
subunit	  of	  the	  Rad9-­‐Hus1-­‐Rad1	  (9-­‐1-­‐1)	  complex	  [254].	   	  Localisation	  of	  TopBP1	   is	  required	  for	  
the	  activation	  of	  the	  checkpoint	  kinase,	  ATR	  [255].	  This	  activation	  requires	  the	  ATR	  activation	  
domain	  (AAD)	  located	  within	  the	  C-­‐terminal	  portion	  of	  TopBP1,	  just	  upstream	  of	  BRCT	  domains	  
7-­‐8	   [256].	   Despite	   its	   predominant	   function	   in	   S-­‐phase	   during	   replication,	   the	   role	   of	   the	  
recruitment	  of	  TopBP1	  to	  DSBs	  in	  G1-­‐phase	  cells	  remains	  largely	  uncharacterised	  and	  suggests	  
that	  TopBP1	  has	  additional,	  cell-­‐cycle	  dependent	  functions.	  	  	  
By	   cloning	   segments	   of	   TopBP1	   and	   analysing	   the	   co-­‐localisation	  with	   53BP1,	   Cescutti	   et	   al	  
demonstrated	  that	  the	  53BP1-­‐TopBP1	  interaction	  in	  G1-­‐phase	  is	  mediated	  by	  two	  sets	  of	  BRCT	  
domains	  within	  TopBP1,	  BRCT	  domains	  1-­‐2	  and	  4-­‐5	   [193].	  However	   in	  S-­‐	  and	  G2-­‐phase	  cells,	  
TopBP1	   localises	   at	   sites	   of	   damage	   through	   a	   separate	   combination	   of	   BRCT-­‐dependent	  
interactions:	   in	  S-­‐	  and	  G2-­‐phase	  cells	  TopBP1	  BRCT	  domains	  1-­‐2	  and	  7-­‐8	  are	  required	  for	  co-­‐
localisation	  of	  TopBP1	  with	  RPA	  [193].	  	  
4.1.1	   53BP1	   phosphopeptides,	   pSer366	   and	   pThr760,	   interact	   specifically	   with	  
BRCT	  domains	  4-­‐5	  and	  1-­‐2	  in	  vitro	  
Previous	   work	   from	   the	   Pearl	   laboratory	   identified	   the	   requirement	   for	   CDK-­‐dependent	  
phosphorylation	  of	  Crb253BP1	  to	  promote	  interaction	  with	  the	  BRCT	  domains	  of	  Rad4TopBP1	  [238].	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In	  order	  to	  identify	  the	  phosphorylation	  sites	  within	  the	  N-­‐terminus	  of	  53BP1	  that	  mediate	  the	  
phospho-­‐specific	   interaction	  with	  TopBP1,	  M.	  Day	   (Pearl	   Lab)	   identified	  a	   consensus	  peptide	  
sequence	   that	  was	   required	   to	  mediate	   the	  phosphorylation-­‐dependent	   interaction	  between	  
the	  N-­‐terminus	  of	  Crb253BP1	  and	  BRCT	  domains	  1,2	  of	  Rad4TopBP1.	  Using	  the	  consensus	  identified	  
in	  figure	  4.1a	  (where	  Φ	  is	  either	  alanine,	  valine,	  isoleucine,	  leucine	  or	  methionine	  and	  x	  is	  any	  
amino	  acid)	  M.Day	  identified	  four	  candidate	  phosphopeptides.	  M.	  Day	  performed	  fluorescence	  
polarisation	   experiments	   with	   each	   of	   the	   candidate	   phosphopeptides	   and	   recombinant	  
TopBP1-­‐BRCT	  domains.	  	  
Of	   the	   four	   candidate	   sites	   identified,	   two	   showed	   a	   specific	   interaction	   with	   the	   BRCT	  
domains	   of	   TopBP1	   (highlighted	   in	   green	   in	   figure	   4.1a).	   53BP1	   phosphoserine-­‐366	   peptide	  
specifically	   interacts	  with	  TopBP1	  BRCT	  domains	  4-­‐5	   (figure	  4.1b)	  and	  phosphothreonine-­‐670	  
peptide	  specifically	  interacts	  with	  TopBP1	  BRCT	  domains	  0,	  1-­‐2	  (figure	  4.1c).	  From	  these	  data,	  
dissociation	   constants	   (Kd)	  were	   calculated.	   The	   interaction	  between	  BRCTs	  4-­‐5	  and	  pSer366	  
has	   an	   affinity	   of	   31.35	  µM.	   The	   interaction	  between	  BRCTs	   0,	   1-­‐2	   and	  pThr670	  displayed	   a	  
much	  stronger	  affinity	  of	  1	  µM.	  






Figure	   4.1	   BRCT	   domains	   4-­‐5	   and	   BRCT	   domains	   0,	   1	   and	   2	   interact	   with	  
phospho-­‐serine	   366	   and	   phospho-­‐threonine	   670	   in	   vitro.	   a)	   Consensus	  
phosphopepAde	   moAfs	   are	   in	   bold.	   Four	   candidate	   phosphopepAdes	   from	  
53BP1	   predicted	   to	   interact	   with	   TopBP1-­‐BRCT1,2-­‐	   predicted	   phosphorylated	  
residue	   is	  highlighted	   in	   red.	  Phospho-­‐pepAdes	   found	  to	   interact	  with	  TopBP1	  
are	  highlighted	  in	  green.	  Fluorescence	  polarisaAon	  performed	  by	  M.	  Day	  (Pearl	  
lab)	   shows	   b)	   speciﬁc	   interacAon	   of	   a	   phospho-­‐serine	   366	   phosphopepAde	  
labelled	   with	   ﬂuoroscein	   when	   Atrated	   against	   BRCT	   domains	   4	   and	   5	   of	  
TopBP1.	   c)	   speciﬁc	   interacAon	   of	   a	   phospho-­‐threonine	   670	   phosphopepAde	  
labelled	  with	  ﬂuoroscein	  with	  BRCT	  domains	  0,	  1	  and	  2	  of	  TopBP1.	  Fluorescence	  
values	  below	  the	  do?ed	  line	  indicate	  non-­‐speciﬁc	  ﬂuorescence.	  	  	  
BRCT1	   	  	  	  	  	  Φ	  Φ	  Φ	  x	  x	  T/S	  P	  
BRCT2	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  Φ	  x	  x	  T/S	  P	  
Thr	  334	   	  G	  G	  C	  S	  L	  A	  S	  T	  P	  A	  T	  
Ser	  366	   	  S	  S	  D	  L	  V	  A	  P	  S	  P	  D	  A	  
Ser	  380	   	  	  	  T	  P	  F	  I	  V	  P	  S	  S	  P	  T	  E	  








4.2.1	  Ser366	  and	  Thr670	  of	  53BP1	  are	  phosphorylated	  in	  response	  to	  DNA	  damage	  
Having	   identified	   interactions	   between	   53BP1-­‐pSer366	   and	   pThr670,	   and	   TopBP1	   BRCTs	   4-­‐5	  
and	  0,	  1-­‐2	   in	  vitro	  using	  fluorescence	  polarisation,	  it	  was	  then	  necessary	  to	  establish	  whether	  
these	  residues	  are	  in	  fact	  phosphorylated	  in	  vivo.	  	  
In	  order	  to	  do	  this,	  custom	  rabbit	  polyclonal	  antibodies	  were	  generated	  by	  ImmunoKontact®	  to	  
target	   phosphorylated	   Ser366	   and	   phosphorylated	   Thr670	   phospho-­‐peptides.	   To	   test	   the	  
specificity	   of	   the	   antibodies,	   HeLa	   cells	   were	   either	   transfected	  with	   siRNA	   oligonucleotides	  
targeting	  53BP1	  or	   transfected	  with	   a	   non-­‐targeting	   control.	   48	  hours	   following	   transfection	  
the	  cells	  were	  either	  exposed	  to	  8Gy	  of	   ionising	  radiation	  or	   left	  untreated	  before	  incubating	  
for	   a	   further	   4	  hours.	  Whole	   cell	   extracts	  were	   prepared	  by	   lysing	   cells	   in	   SDS-­‐PAGE	   sample	  
buffer	   followed	  by	  sonication.	  The	   lysates	  were	  analysed	  by	  Western	  blot	   for	  53BP1,	   tubulin	  
and	  the	  two	  phospho-­‐specific	  antibodies.	  	  
The	   results	   indicated	   that	   both	   of	   the	   phospho-­‐specific	   antibodies,	   pSer366	   and	   pThr670,	  
recognise	   53BP1	   as	   shown	   by	   the	   absence	   of	   bands	   in	   cells	   depleted	   of	   53BP1	   (figure	   4.2).	  
Furthermore,	   both	   Ser366	   and	   Thr670	   only	   appear	   to	   be	   phosphorylated	   following	   DNA	  
damage	  suggesting	  that	  these	  interactions	  may	  form	  part	  of	  a	  DNA	  damage-­‐specific	  response.	  	  






































Figure	  4.2	  53BP1	  is	  phosphorylated	  on	  Serine-­‐366	  and	  Threonine-­‐670	  in	  
response	  to	  ionising	  radia8on.	  HeLa	  cells	  were	  reverse	  transfected	  with	  
either	  siRNA	  targeAng	  53BP1	  or	  a	  non-­‐targeAng	  control	  and	  incubated	  for	  
48	   hours.	   Aqer	   which,	   cells	   were	   exposed	   to	   8Gy	   IR	   and	   allowed	   to	  
recover	  for	  4	  hours	  before	  lysing	  the	  cells	  processing	  for	  western	  blozng	  
by	   sonicaAon.	   Whole	   cell	   extracts	   were	   analysed	   by	   Western	   blot	   and	  
probed	   for	   phospho-­‐Ser366,	   phospho-­‐Thr670,	   53BP1	   and	   tubulin.	  




4.2.2	  TopBP1	  fails	  to	  co-­‐immunoprecipitate	  with	  53BP1	  phospho-­‐binding	  site	  
mutants	  
After	  demonstrating	  that	   the	  phosphorylation	  sites	   that	   facilitate	   interaction	  between	  53BP1	  
and	  TopBP1	   in	   vitro	   are	  genuine	  phosphorylation	   sites	  used	   in	   vivo,	   it	  was	   important	   to	   test	  
whether	  failure	  to	  phosphorylate	  either	  of	  these	  sites	  disrupted	  the	  53BP1-­‐TopBP1	  interaction.	  	  
In	   order	   to	   do	   this,	  Dr	  O.	  Wilkinson	   (Watts	   Lab)	   used	   site-­‐directed	  mutagenesis	   to	   generate	  
unphosphorylatable	  mutants	   in	   a	  HA-­‐53BP1	   cDNA	  construct:	   a	   serine	   to	  alanine	   substitution	  
mutation	  at	  residue	  366	  (S366A)	  and	  a	  threonine	  to	  alanine	  mutation	  at	  residue	  670	  (T670A).	  A	  
double-­‐mutant	  was	  also	  made	  containing	  both	  S366	  and	  T670	  to	  alanine	  mutations	  (SATA).	  	  
HEK293	   cells	   were	   transfected	   by	   calcium	   phosphate	   transfection	   protocol.	   Following	  
transfection	  the	  cells	  were	  incubated	  for	  a	  further	  60	  hours.	  The	  cells	  were	  either	  exposed	  to	  
8Gy	  of	  ionising	  radiation	  using	  an	  X-­‐ray	  machine	  or	  left	  untreated.	  The	  cells	  were	  incubated	  for	  
4	   hours	   following	   irradiation	   before	   processing	   for	   immunoprecipitation.	   Samples	   were	  
analysed	  by	  Western	  blotting	  using	  anti-­‐HA	  (53BP1)	  and	  TopBP1.	  	  
TopBP1	  co-­‐immunoprecipitated	  with	  HA-­‐53BP1	   in	  cells	   transfected	  with	   the	  wild-­‐type	  53BP1	  
cDNA	   construct	   (figure	   4.3).	   This	   indicates	   that	   these	   two	   proteins	   interact	   in	   vivo	   in	  
mammalian	  cells.	  However,	  when	  the	  cells	  were	  transfected	  with	  either	  S366A,	  T670A	  or	  the	  
double-­‐mutant,	   the	   amount	   of	   TopBP1	   that	   co-­‐immunoprecipitates	   with	   53BP1	   is	   reduced.	  
Unexpectedly,	  TopBP1	  co-­‐immunoprecipitates	  with	  the	  wild-­‐type	  53BP1	  regardless	  of	  whether	  
the	  cells	  were	  exposed	  to	  ionising	  radiation	  prior	  to	  harvesting.	  The	  reason	  for	  this	  is	  not	  clear,	  
but	   could	  be	   indicative	  of	   stress	   induced	  by	   the	  overexpression	  of	   53BP1	  within	   these	   cells.	  
Overall,	  these	  results	  indicate	  that	  inability	  to	  phosphorylate	  either	  S366	  or	  T670,	  within	  the	  N-­‐
terminus	  of	  53BP1,	  impairs	  the	  interaction	  between	  53BP1	  and	  TopBP1.	  	  


















































Figure	   4.3	   Muta8on	   of	   S366	   or	   T670	   to	   alanine	   impairs	   co-­‐
immunoprecipita8on	  of	  HA-­‐53BP1	  and	  TopBP1.	  HEK293FT	  cells	  were	  cultured	  
and	  transfected	  with	  HA-­‐53BP1	  constructs	  (wild-­‐type	  or	  mutant)	  using	  calcium	  
phosphate	   protocol	   and	   incubated	   for	   a	   further	   60	   hours.	   Cells	   were	   then	  
exposed	   to	   9Gy	   IR	   and	   allowed	   to	   recover	   for	   4	   hours	   before	   lysis.	   IP	   was	  
performed	   using	   HA-­‐IP	   kit	   (Sigma)	   using	   provided	   buﬀers	   supplemented	  with	  
cocktail	   protease	   and	   phosphatase	   inhibitors.	   Samples	   were	   analysed	   by	  
Western	   blot	   for	   HA	   and	   TopBP1.	   *marks	   non-­‐speciﬁc	   anAbody	   binding	   of	  
TopBP1	  anAbody.	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4.2.3	  53BP1	  phosphorylation	  mutants	  fail	  to	  co-­‐localise	  with	  TopBP1	  following	  DNA	  
damage	  in	  G1-­‐phase	  cells	  
Having	  established	  that	  the	  mutation	  of	  either	  53BP1-­‐S366	  or	  -­‐T670	  decreases	  the	  interaction	  
between	   53BP1	   and	   TopBP1,	   it	   was	   then	   important	   to	   analyse	   the	   localisation	   of	   these	  
proteins	  within	  the	  cells.	  Firstly,	  it	  was	  necessary	  to	  identify	  whether	  either	  of	  these	  mutations	  
prevented	  53BP1	   from	   localising	   to	  sites	  of	  damage	  and	  secondly,	  whether	  TopBP1	  was	  also	  
still	   recruited	   to	   sites	   of	   DNA	   damage	   and	   if	   so,	   whether	   the	   two	   proteins	   co-­‐localised.	  
Additional	  markers	  were	  employed	  to	   identify	  G1-­‐phase	  cells	  prior	   to	  co-­‐localisation	  analysis	  
as	   previous	   investigation	   has	   demonstrated	   that	   the	   interaction	   of	   53BP1	   with	   TopBP1	   is	  
limited	  to	  G1-­‐phase	  cells	  [193].	  
In	   order	   to	   do	   this,	   immunofluorescence	   was	   performed	   on	   cells	   depleted	   of	   endogenous	  
53BP1	  and	  transfected	  with	  the	  HA	  (53BP1)	  cDNA	  constructs.	  Following	  on	  from	  transfection,	  
the	  cells	  were	  treated	  with	  8Gy	  of	  ionising	  radiation	  and	  left	  to	  recover	  for	  4	  hours,	  following	  
the	   experimental	   methods	   outlined	   by	   Cescutti	   et	   al	   [193],	   before	   analysis	   by	  
immunofluorescence.	   The	   cells	   were	   immuno-­‐stained	   for	   HA	   (53BP1),	   TopBP1	   and	   CENPF	   a	  
marker	  expressed	  only	  in	  S-­‐	  and	  G2-­‐phase	  cells.	  
The	   results	   demonstrate	   that	   the	   53BP1-­‐S366A	   or	   -­‐T670A	  mutants	   disrupt	   co-­‐localisation	   of	  
53BP1	  and	  TopBP1	   in	  G1-­‐phase	   cells	   (figure	  4.4).	   Perfect	   co-­‐localisation	  between	  53BP1	  and	  
TopBP1	   is	   observed	   following	   damage	   in	   cells	   transfected	   with	   the	   wild-­‐type	   53BP1	   cDNA.	  
Mutation	  of	  the	  phosphorylation	  site	  with	  the	  weaker	  affinity	  for	  TopBP1	  BRCTs	  4-­‐5,	  S366,	  still	  
appears	  to	  allow	  the	  formation	  of	  TopBP1	  foci.	  However,	  these	  do	  not	  co-­‐localise	  with	  53BP1.	  
In	  contrast,	  mutation	  of	  the	  phosphorylation	  site	  with	  the	  stronger	  affinity	  for	  TopBP1	  BRCTs	  0,	  
1-­‐2,	  T670,	  drastically	  impairs	  TopBP1	  focus	  formation	  in	  G1-­‐phase	  cells.	  


















DAPI	   HA-­‐53BP1	   TopBP1	   CENPF	   Merge	  
Figure	   4.4	   53BP1	   phosphoryla8on	   sites,	   S366	   and	   T670,	   are	   required	   for	   co-­‐
localisa8on	   of	   53BP1	  with	   TopBP1	   in	   G1-­‐phase	   cells.	  U20S	   cells	  were	   reverse	  
transfected	   with	   53BP1	   siRNA.	   48	   hours	   later	   cells	   were	   transfected	   with	   an	  
siRNA	   resistant	   construct	   containing	   either	   wild-­‐type	   HA-­‐53BP1	   or	   one	   of	   the	  
phosphorylaAon	   site	   mutants.	   16	   hours	   aqer	   this	   cells	   were	   exposed	   to	   8Gy	  
ionising	   radiaAon	   Cells	   were	   allowed	   to	   recover	   for	   4	   hours	   before	   ﬁxaAon	   in	  
methanol	  for	  20	  minutes	  and	  staining	  for	  HA,	  TopBP1	  and	  CENPF.	  Bo?om	  panel	  
shows	   example	   of	   G1-­‐phase	   cell	   idenAﬁcaAon	   by	   analysing	   cells	   negaAve	   for	  
CENPF.	  Scale	  bar	  =	  5	  μm.	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4.2.4	  Quantitative	  analysis	  of	  53BP1-­‐TopBP1	  co-­‐localisation	  using	  SCANR	  
microscopy	  	  	  
Given	  that	  the	  mutation	  of	  two	  phosphorylation	  sites	  in	  53BP1	  appears	  to	  affect	  co-­‐localisation	  
with	  TopBP1,	  it	  was	  important	  to	  further	  analyse	  this	  phenotype	  and	  quantify	  this	  defect.	  With	  
support	   from	   Dr.	   Velibor	   Savic	   (University	   of	   Sussex),	   SCANR	   automated	   microscopy	   was	  
employed	   to	   image	   and	   analyse	   large	   numbers	   of	   cells	   to	   further	   investigate	   the	   co-­‐
localisation.	   The	   same	   experimental	   set	   up	   was	   used	   as	   before:	   53BP1-­‐depleted	   cells	   were	  
transfected	  with	  the	  cDNA	  constructs	  and	  seeding	  them	  into	  a	  96-­‐well	  SCANR	  plate.	  Following	  
irradiation	  the	  cells	  were	  fixed	  and	  stained	  as	  before.	  	  
The	   SCANR	   microscope	   was	   programmed	   to	   take	   36x	   3-­‐channel	   images	   per	   well	   at	   a	   20x	  
magnification.	   Each	   image	   was	   analysed	   for	   total	   internal	   DAPI	   intensity	   to	   generate	   a	   cell	  
cycle	  profile	  to	  which	  each	  cell	  could	  then	  be	  characterised	  as	  either	  G1-­‐	  S-­‐	  or	  G2-­‐phase.	  This	  
would	  enable	  the	  isolation	  and	  analysis	  of	  just	  the	  G1-­‐phase	  population	  of	  cells.	  Following	  this,	  
each	  of	  the	  cells	  was	  analysed	  for	  53BP1	  and	  TopBP1	  foci	  based	  on	  a	  set	  of	  criteria	  determined	  
by	   analysing	   several	   example	   images.	   For	   example,	   the	   minimum	   and	   maximum	   size	   and	  
intensity	   of	   each	   focus	  was	   set	   to	   include	   as	  many	   foci	   as	   possible	   but	   also	   to	   exclude	   any	  
staining	  artefacts.	  Finally,	  the	  X	  and	  Y	  co-­‐ordinates	  along	  with	  their	  size	  and	  reference	  to	  which	  
cell	  they	  belong	  was	  exported.	  	  
Using	   this	   equipment	   and	  methodology	   it	   was	   possible	   to	   analyse	   over	   91,000	   cells	   over	   4	  
biological	   repeats	   in	   which	   over	   670,000	   TopBP1	   foci	   and	   over	   50,000	   53BP1	   foci	   were	  
identified.	  
In	   order	   to	   analyse	   such	   a	   vast	   array	   of	   data,	   G1-­‐phase	   population	   of	   cells	   were	   identified	  
based	  on	  the	  cell	  cycle	  profile	  generated	  before.	  Next,	  the	  transfected	  population	  of	  cells	  were	  
identified	  and	  plotted	  on	  X	  and	  Y	  co-­‐ordinates	  in	  Microsoft	  Excel	  along	  with	  the	  data	  for	  each	  
TopBP1	  and	  53BP1	  focus	  including	  the	  radius	  of	  each.	  From	  this	  it	  was	  possible	  to	  score	  each	  
G1-­‐phase	  transfected	  cell	  as	  to	  whether	  TopBP1	  and	  53BP1	  IRIF	  were	  co-­‐localised.	  	  
One	  of	  the	  limitations	  of	  this	  experimental	  format	  was	  the	  transfection	  efficiency	  in	  which	  the	  
number	  of	   transfected	  cells	   ranged	   from	  1	   to	  5%	  of	   the	   total	  population	  of	  cells.	   In	  order	   to	  
minimise	  the	  number	  of	  cells	  excluded	  from	  analysis	  based	  on	  the	  variable	  expression	  level	  of	  
53BP1,	  a	  cell	  was	  scored	  as	  having	  co-­‐localised	  foci	  if	  one	  or	  more	  53BP1	  foci	  overlapped	  with	  




Finally,	   over	   350	   cells	  were	   counted	   per	   sample	   and	   defined	   as	   either	   having	   or	   not	   having	  
53BP1-­‐TopBP1	   co-­‐localised	   foci.	   The	   results	   show	   that	   mutation	   of	   either	   S366	   or	   T670	   to	  
alanine	  disrupts	  the	  co-­‐localisation	  of	  53BP1	  and	  TopBP1	  in	  G1-­‐phase	  cells	  (figure	  4.5a	  and	  b).	  
As	  co-­‐localisation	  of	  53BP1	  and	  TopBP1	  has	  been	  demonstrated	  to	  be	  limited	  to	  G1-­‐phase	  cells	  
whereby	  in	  G2-­‐phase	  cells	  TopBP1	  co-­‐localises	  with	  RPA	  [193],	  G2-­‐phase	  cells	  transfected	  with	  
the	  wild-­‐type	  53BP1	  cDNA	  construct	  were	  also	  analysed	  for	  co-­‐localisation.	  Approximately	  18%	  
of	  the	  G2-­‐phase	  cells	  analysed	  were	  still	   scored	  as	  having	  co-­‐localised	  foci	  even	   in	  G2-­‐phase,	  
this	   gave	   an	   indication	   the	   background	   level	   of	   co-­‐localisation	   reported	   using	   these	  
parameters.	  Having	  analysed	  the	  background	  co-­‐localisation	  observed	  in	  G2-­‐phase	  cells,	  it	  can	  
be	  seen	  that	  mutation	  of	  53BP1-­‐S366	  and	  -­‐T670	  impairs	  co-­‐localisation	  of	  53BP1	  and	  TopBP1	  
to	  near	  background	  levels.	  
After	  having	  demonstrated	  that	  the	  co-­‐localisation	  of	  TopBP1	  to	  sites	  of	  DNA	  damage	  required	  
phosphorylation	   of	   53BP1	   on	   both	   S366	   and	   T670,	   it	   was	   necessary	   to	   test	   whether	   the	  
number	   of	   TopBP1	   foci	   was	   affected	   by	   the	   loss	   of	   53BP1.	   Provisionally,	   it	   looked	   as	   if	   the	  
number	  of	  TopBP1	  foci	  in	  these	  cells	  decreased	  as	  seen	  in	  figure	  4.4.	  	  
In	   order	   to	   further	   examine	   whether	   this	   was	   indeed	   the	   case,	   the	   SCANR	   data	   generated	  
above	  was	   used	   to	   calculate	   the	   average	   number	   of	   TopBP1	   foci	   identified	   per	   cell	   in	   both	  
mock-­‐treated	   cells	   and	   those	   transfected	   with	   siRNA	   oligonucleotides	   targeting	   53BP1.	  
Additionally,	  it	  was	  possible	  to	  segregate	  the	  populations	  of	  both	  G1-­‐	  and	  G2-­‐phase	  cells.	  The	  
results	   indicate	   that	   53BP1-­‐depleted	   G1-­‐phase	   cells	   have	   fewer	   TopBP1	   foci	   following	   DNA	  
damage	  than	  those	  mock-­‐treated	  (figure	  4.6).	  Additionally,	  it	  can	  also	  be	  seen	  that	  the	  number	  
of	  TopBP1	   foci	  per	   cell	   in	  G2-­‐phase	  cells	   remains	  unchanged	  between	   the	  mock-­‐treated	  and	  
53BP1-­‐depleted	   cells	   following	   damage.	   This	   serves	   to	   consolidate	   the	   notion	   that	   the	  
localisation	  of	  TopBP1	  in	  G1-­‐phase	  cells	  is	  at	  least	  in	  part	  a	  53BP1-­‐dependent	  event.	  	  
	   	  



































Figure	  4.5	  53BP1	  phosphoryla8on	  sites,	  S366	  and	  T670,	  are	  required	  for	  TopBP1	  
binding.	  U20S	   cells	  were	   reverse	   transfected	  with	  53BP1	   siRNA.	   24	  hours	   later	  
cells	   were	   transfected	   with	   an	   siRNA	   resistant	   construct	   containing	   wild-­‐type	  
HA-­‐53BP1	  or	  one	  of	   the	  BRCT	  mutants.	  24	  hours	  aqer	   this	  cells	  were	   re-­‐plated	  
into	   a	   96-­‐well	   SCANR	   plate	   and	   aqer	   a	   further	   24	   hours	  were	   exposed	   to	   8Gy	  
ionising	  radiaAon	  Cells	  were	  permi?ed	  to	  recover	  for	  4	  hours	  before	  staining	  for	  
HA	  and	  TopBP1.	  SCANR	  soqware	  was	  used	  to	  take	  36	   images	   	  per	  well	   	  at	  20x	  
magniﬁcaAon.	  a)	  shows	  example	  images	  taken	  by	  the	  SCANR	  microscope.	  b)	  Each	  
image	  was	   analysed	   for	   53BP1,	   TopBP1	   foci	   and	   DAPI	   intensity.	   DAPI	   intensity	  
was	  used	  to	  create	  cell	  cycle	  proﬁles	  and	  gate	   for	  G1	  phase	  cells.	  The	  resulAng	  
populaAon	  of	  cells	  were	  scored	  for	  co-­‐localisaAon	  (co-­‐localised	  foci	  ≥	  1	  per	  cell).	  
N>345	   transfected	  cells	  analysed	   for	  each	  sample	  over	  4	  experimental	   repeats.	  
Error	  bars	  represent	  1	  standard	  deviaAon.	  	  
Figure	  4.6	  Deple8on	  of	  53BP1	  reduces	  the	  number	  of	  TopBP1	  foci	  in	  G1	  phase	  
cells.	  U20S	  cells	  processed	  as	  in	  ﬁgure	  4.5	  were	  analysed	  by	  SCANR	  4	  hours	  aqer	  
exposure	   to	   8Gy	   ionising	   radiaAon	   either	   with	   or	   without	   prior	   depleAon	   of	  
53BP1	   by	   RNAi.	   36	   images	   per	  well	   were	   analysed	   to	   calculate	   the	   number	   of	  
TopBP1	   foci	   per	   cell	   in	   G1-­‐phase	   and	   G2-­‐phase	   cells	   based	   on	   DAPI	   intensity.	  
Once	   cells	   had	   been	   categorised	   the	   number	   of	   TopBP1	   foci	   per	   cell	   was	  










































4.2.5	  S366A	  and	  T670A	  mutants	  display	  altered	  cell	  cycle	  profiles	  
After	   having	  demonstrated	   that	   both	   53BP1-­‐S366	   and	   -­‐T670	   are	  phosphorylated	   in	   vivo	   and	  
that	   inability	   to	   phosphorylate	   53BP1	   results	   in	   a	   failure	   to	   co-­‐localise	   TopBP1	   in	   G1-­‐phase	  
cells,	  it	  was	  necessary	  to	  identify	  and	  characterise	  any	  physiological	  defect	  that	  may	  occur	  as	  a	  
consequence.	  	  
Previous	   work	   from	   Cescutti	   et	   al	   [193]	   demonstrated	   that	   both	   TopBP1	   and	   53BP1	   are	  
required	  for	  sustained	  G1-­‐S	  phase	  arrest	  of	  cells	  following	  DNA	  damage	  and	  that	  a	  stable	  cell	  
line	   expressing	   TopBP1	   lacking	   the	   BRCT	   domains	   4-­‐5	   also	   fails	   to	   sustain	   a	   G1-­‐S	   phase	  
checkpoint.	   In	   their	   study,	   they	   did	   not	   test	   mutant	   TopBP1	   lacking	   BRCT	   domains	   0,	   1-­‐2	  
although	  from	  our	  co-­‐immunoprecipitation	  and	  immunofluorescence	  data,	  it	  seems	  likely	  that	  
failure	  of	  53BP1	  to	  interact	  with	  TopBP1-­‐BRCT	  domains	  0,	  1-­‐2	  may	  also	  produce	  a	  comparable	  
defect.	  
In	   order	   to	   determine	   whether	   an	   inability	   to	   phosphorylate	   53BP1	   on	   either	   of	   these	  
phosphorylation	   sites	   results	   in	   a	   checkpoint	   defect,	   the	   SCANR	  data	  were	   re-­‐analysed.	   This	  
involved	   determination	   of	   the	   cell-­‐cycle	   status	   of	   each	   cell	   analysed	   based	   on	   total	   internal	  
DAPI	  intensity.	  The	  cell-­‐cycle	  status	  of	  each	  cell	  transfected	  with	  either	  wild-­‐type	  53BP1	  or	  one	  
of	   the	  mutants,	   could	   then	   be	   compared	   to	   determine	  whether	   there	  were	  more	   cells	   in	   a	  
particular	  phase	  of	  the	  cell-­‐cycle	  8	  hours	  following	  the	  introduction	  of	  DNA	  damage.	  Although	  
this	  would	  provide	  only	  a	  single	  snap-­‐shot	  of	  the	  cell	  cycle	  profiles	  following	  damage,	  it	  would	  
give	  some	   indication	  as	  to	  whether	  there	  was	  any	  alteration	   in	  the	  cell	  cycle	  profile	  with	  the	  
unphosphorylatable	   53BP1	  mutants.	   Additionally,	   in	   order	   to	   account	   for	   cells	   that	  may	   still	  
express	  the	  cDNA	  constructs	  but	  not	  necessarily	  form	  foci,	  total	  internal	  fluorescence	  intensity	  
was	   also	   measured	   for	   each	   cell.	   Fluorescence	   intensity	   above	   a	   threshold	   determined	   by	  
examining	  mock-­‐transfected	  cells	  was	  used	  to	  examine	  the	  transfected	  population	  of	  cells.	  	  
Following	   the	   introduction	   of	   DNA	  damage,	   it	  would	   be	   expected	   that	   cells	  would	   initiate	   a	  
cell-­‐cycle	  arrest.	   If	  a	  cell-­‐cycle	  checkpoint	  defect	   is	  present,	   in	  the	  hours	  following	   irradiation	  
the	   population	   of	   cells	   may	   be	   skewed	   towards	   either	   G1-­‐	   or	   G2-­‐	   phase	   depending	   on	   the	  
stage	  in	  which	  the	  cell-­‐cycle	  the	  defect	  occurs.	  By	  analysing	  the	  number	  of	  cells	  in	  each	  stage	  
of	   the	   cell-­‐cycle	   8	   hours	   following	   the	   introduction	   of	   DNA	   damage,	   cells	   transfected	   with	  
either	   the	  53BP1-­‐S366A	  or	   -­‐T670A	  mutant	  show	  altered	  cell	  cycle	  profiles	  characterised	  by	  a	  
larger	   G2-­‐phase	   population	   of	   cells	   compared	   to	   those	   cells	   transfected	   with	   the	   wild-­‐type	  
cDNA	   (figure	  4.7).	  The	   larger	  proportion	  of	  G2-­‐phase	  cells	  observed	   following	  damage	   in	   the	  
	  	  
137	  
samples	   transfected	  with	   the	  phosphorylation	  mutants,	   compared	   to	   those	   transfected	  with	  
the	  wild-­‐type	  53BP1,	  suggests	  that	  there	  is	  a	  cell-­‐cycle	  checkpoint	  defect.	  	  	  	  























Figure	   4.7	   53BP1	   phosphoryla8on	   mutants	   show	   altered	   cell	   cycle	   proﬁles.	  
U20S	   cells	   processed	   as	   in	   ﬁgure	   4.5	   were	   analysed	   by	   SCANR	   4	   hours	   aqer	  
exposure	  to	  8Gy	  ionising	  radiaAon.	  Only	  cells	  expressing	  either	  wild-­‐type	  53BP1	  
(WT)	  or	  the	  phosphorylaAon	  site	  mutants	  (S366A	  and	  T670A)	  were	  compared.	  36	  
images	  per	  well	  were	  analysed	  for	  DAPI	  intensity	  and	  total	  internal	  FITC	  intensity	  
to	  generate	  a	  cell	   cycle	  proﬁle	  of	   transfected	  cells.	  N>1325	  cells	  were	  analysed	  
per	   sample.	   Chart	   shows	   the	   proporAon	   of	   transfected	   cells	   4	   hours	   post	  
irradiaAon	  in	  each	  stage	  of	  the	  cell	  cycle	  (either	  G1,	  S	  or	  G2-­‐phase).	  	  
	  	  
139	  
4.2.6	  53BP1	  phosphorylation	  mutants	  fail	  to	  maintain	  the	  S-­‐phase	  entry	  checkpoint	  
following	  damage	  
To	   further	   investigate	   whether	   phosphorylation	   of	   53BP1	   was	   required	   for	   G1-­‐S	   cell	   cycle	  
arrest	   following	  damage,	   it	  was	  necessary	   to	  employ	  a	  more	  accurate	  assay	   to	   test	  whether	  
the	  cells	  could	  arrest	  in	  G1-­‐phase	  and	  prevent	  premature	  entry	  into	  S-­‐phase	  following	  damage.	  	  
In	  order	  to	  do	  this	  cells	  were	  treated	  as	  before	  by	  depleting	  endogenous	  53BP1	  in	  U2OS	  cells	  
before	  transfecting	  the	  cells	  with	  either	  wild-­‐type	  53BP1,	  53BP1-­‐S366A,	  -­‐T670A	  or	  the	  double	  
mutant.	  The	  cells	  were	  seeded	  at	  low	  confluence	  to	  allow	  them	  to	  continue	  cycling	  throughout	  
treatment.	  After	  transfection	  the	  cells	  were	  pulse-­‐labelled	  with	  the	  nucleotide	  analogue,	  EdU,	  
for	  1	  hour	  at	  37°C.	  This	  enabled	  the	  identification	  of	  cells	  that	  were	  already	  in	  S-­‐phase	  prior	  to	  
irradiation.	   Following	   EdU-­‐labelling,	   the	   cells	   were	   washed	   in	   PBS	   and	   irradiated.	   After	  
irradiation	   the	   cells	   were	   treated	   with	   media	   supplemented	   with	   a	   second	   nucleotide	  
analogue,	   BrdU,	   for	   a	   further	   7	   hours	   at	   37°C	   (figure	   4.8a).	   By	   utilising	   this	   series	   of	   pulse	  
labelling	  experiments	  it	  was	  possible	  to	  determine	  whether	  cells	  were	  progressing	  through	  G1	  
into	  S	  phase	  following	  damage.	  	  
Firstly,	  by	  examining	  the	  number	  of	  EdU-­‐negative	  cells	  (i.e.	  cells	  not	  already	  in	  S-­‐phase	  at	  the	  
time	  of	  irradiation)	  and	  BrdU	  positive	  cells	  (i.e.	  cells	  entering	  s-­‐phase	  following	  damage)	  it	  can	  
be	  seen	  that	  in	  mock-­‐treated	  cells	  exposed	  to	  2Gy	  ionising	  radiation	  there	  is	  a	  decrease	  in	  the	  
number	  of	  BrdU	  positive	  cells	  following	  ionising	  radiation,	  which	  is	   indicative	  of	  a	  G1-­‐S	  phase	  
arrest	   (figure	  4.8b).	   Furthermore,	  by	  depleting	  53BP1	  by	  RNAi	   comparable	  numbers	  of	  BrdU	  
positive	  cells	  can	  be	  observed	  in	  both	  the	  un-­‐treated	  and	  those	  exposed	  to	  ionising	  radiation,	  
confirming	  that	  these	  cells	  fail	  to	  sustain	  a	  G1-­‐S	  phase	  cell	  cycle	  arrest.	  This	  is	  consistent	  with	  
the	  observations	  made	  by	  Cescutti	  et	  al	  [193].	  	  
Having	   confirmed	   that	   there	   is	   a	   G1-­‐S	   phase	   checkpoint	   defect	   in	   a	   53BP1-­‐depleted	  
background,	  it	  was	  necessary	  to	  establish	  whether	  the	  cell-­‐cycle	  defect	  was	  attributable	  to	  the	  
phosphorylation	   sites	   identified	   earlier.	   To	   do	   this,	   the	   experiment	   was	   repeated	   with	   the	  
additional	  transfection	  of	  the	  53BP1-­‐depleted	  U2OS	  cells	  with	  either	  the	  wild-­‐type	  or	  mutant	  
cDNA	   constructs,	   either	   53BP1-­‐S366A,	   -­‐T670A	   or	   the	   double	   mutant.	   Additional	  
immunostaining	  for	  HA	  was	  used	  to	  identify	  transfected	  cells.	  	  
By	   analysing	   the	   transfected	   population	   of	   cells	   and	   assessing	   whether	   or	   not	   they	   had	  
incorporated	  the	  2nd	  DNA	   label,	   it	  was	  possible	   to	  see	  examples	  of	  cells	   transfected	  with	  the	  
mutant	   53BP1	   that	   continued	   into	   S-­‐phase	   despite	   the	   presence	   of	   damage	   (figure	   4.8c).	  
Furthermore,	   it	   was	   possible	   to	   quantify	   the	   number	   of	   EdU	   negative;	   BrdU	   positive	   cells	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transfected	   with	   either	   the	   wild-­‐type	   53BP1	   cDNA	   or	   the	   phosphorylation	   mutants	   as	   a	  
percentage	  of	  the	  total	  EdU	  negative	  cells	  (figure	  4.8d).	  These	  results	  demonstrate	  that	  53BP1-­‐
depleted	   cells	   expressing	   wild-­‐type	   53BP1	   are	   capable	   of	   sustaining	   G1	   arrest,	   whereas	   the	  
cells	   transfected	  with	   either	   53BP1-­‐S366A,	   -­‐T670A	   or	   the	   double	  mutant	   are	   not	   capable	   of	  
sustaining	  G1	  arrest	  (figure	  4.8e).	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+IR	   +IR	  Untreated	   Untreated	  
Figure	  4.8	  Phosphoryla8on	  of	  S366	  and	  T670	  are	  required	  for	  maintenance	  of	  the	  G1-­‐
S	   phase	   checkpoint.	   a)	   DiagrammaAc	   representaAon	   of	   treatment.	   U20S	   cells	   were	  
reverse	   transfected	  with	   53BP1	   siRNA.	   48	   hours	   later	   cells	  were	   transfected	  with	   an	  
siRNA	  resistant	  construct	  containing	  wild-­‐type	  HA-­‐53BP1	  or	  one	  of	  the	  phosphorylaAon	  
mutants.	   15	   hours	   later	   cells	   were	   incubated	   for	   1	   hour	   with	   EdU	   before	   washing,	  
irradiated	  with	  2Gy	   ionising	   radiaAon	  and	   the	  addiAon	  of	  BrdU	  and	  nocodazole.	  Cells	  
were	  incubated	  for	  a	  further	  7	  hours	  before	  ﬁxaAon	  and	  staining	  for	  HA,	  EdU	  and	  BrdU.	  
EdU+	  cells	  (Yellow)	  were	  ignored	  for	  analysis.	  S-­‐phase	  entry	  aqer	  damage	  was	  analysed	  
by	  counAng	  BrdU+	  cells	  (Green).	  b)	  shows	  eﬀect	  of	  siRNA	  depleAon	  of	  53BP1	  on	  G1-­‐S	  
phase	  entry	  by	   incorporaAon	  of	  BrdU	   following	  damage.	   c)	   shows	  example	   images	  of	  
BrdU	  incorporaAon	  in	  transfected	  cells.	  d)	  shows	  quanAﬁcaAon	  of	  EdU	  negaAve;	  BrdU	  
posiAve	  cells	  following	  IR	  with	  and	  without	  depleAon	  of	  53BP1.	  e)	  shows	  quanAﬁcaAon	  
of	  EdU	  negaAve;	  BrdU	  posiAve	  cells	   following	   IR	  with	  depleAon	  of	  endogenous	  53BP1	  
and	  transfecAon	  with	  either	  wild-­‐type	  or	  mutant	  53BP1.	  	  
Incubate	  with	  EdU	  
Wash	  cells,	  irradiate	  
and	  add	  BrdU	  































































4.2.7	  53BP1	  phosphorylation	  mutants	  show	  a	  ‘slow’	  kinetic	  repair	  defect	  
Having	   determined	   that	   mutation	   of	   either	   S366	   or	   T670	   within	   the	   N-­‐terminus	   of	   53BP1	  
confers	  a	  checkpoint	  defect,	   it	  was	  necessary	  to	  analyse	  whether	  these	  mutations	  result	   in	  a	  
failure	  to	  repair	  DNA	  breaks	  following	  DNA	  damage.	  	  
To	  investigate	  this,	  HeLa	  cells	  were	  reverse	  transfected	  with	  siRNA	  oligonucleotides	  targeting	  
53BP1	   as	   before.	   Following	   this,	   the	   cells	  were	   transfected	  with	   either	   the	  wild-­‐type	   53BP1	  
construct	   or	   one	   of	   the	   phosphorylation	   mutants.	   Cells	   were	   then	   exposed	   to	   5Gy	   ionising	  
radiation	  and	  allowed	  to	  recover	  for	  the	  indicated	  time	  before	  fixation	  and	  immunostaining	  for	  
HA	  (53BP),	  γH2AX	  and	  CENPF.	  The	  γH2AX	  foci	  were	  enumerated	  in	  cells	  negative	  for	  CENPF	  i.e.	  
cells	  in	  G1-­‐phase.	  	  
A	   repair	   defect	  was	  observed	  16	   and	  24	  hours	   following	   irradiation	   in	   cells	   transfected	  with	  
53BP1-­‐S366A,	   -­‐T670A	  or	   the	  double	  mutant	   (figure	  4.9).	  These	  cells	  appear	   to	   show	  a	   ‘slow’	  
kinetic	  repair	  defect.	  Previous	  investigations	  have	  shown	  these	  types	  of	  defects	  to	  result	  from	  
a	  failure	  to	  resolve	  complex	  breaks	  or	  those	  dependent	  on	  the	  chromatin	  environment	   [202,	  
203].	  	  






































Figure	  4.9	  53BP1	  phosphoryla8on	  mutants	  show	  a	  ‘slow’	  kine8c	  repair	  defect.	  
HeLa	  cells	  were	  reverse	  transfected	  with	  53BP1	  siRNA.	  48	  hours	  later	  cells	  were	  
transfected	  with	  an	  siRNA	  resistant	  construct	  containing	  wild-­‐type	  HA-­‐53BP1	  or	  
one	  of	  the	  phosphorylaAon	  mutants.	  16	  hours	  later	  cells	  were	  exposed	  to	  5Gy	  
ionising	  radiaAon	  and	  allowed	  to	  recover	  for	  the	  indicated	  Ame	  before	  staining	  
for	  HA,	  γH2AX	  and	  CENPF.	  The	  number	  of	  γH2AX	  foci	  per	  cell	  was	  enumerated	  
n=25	  CENPF	  negaAve	  cells.	  Graph	  shows	  average	  of	  3	  experiments.	  Error	  bars	  
represent	  1	  standard	  deviaAon.	  Horizontal	  blue	  bars	  show	  samples	  depleted	  of	  








4.2.8	  The	  late	  stage	  repair	  defect	  can	  be	  rescued	  by	  depletion	  of	  KAP-­‐1	  
KRAB-­‐associated	  protein	  1	  (KAP-­‐1)	  is	  a	  key	  regulator	  of	  chromatin	  structure	  and	  remodelling	  in	  
response	   to	   DNA	   damage.	   Previous	   investigation	   has	   indicated	   a	   role	   for	   pATM-­‐dependent	  
phosphorylation	  of	  KAP-­‐1	  on	  S824	   in	   facilitating	   the	   ‘slow’	  kinetic	   repair	  of	   complex	  or	  DSBs	  
[202,	  203].	  Phosphorylation	  of	  KAP-­‐1	  acts	  to	  promote	  chromatin	  relaxation	  and	  accessibility	  to	  
DSB	  sites.	  It	  was	  therefore	  decided	  to	  test	  whether	  the	  ‘slow’	  kinetic	  repair	  defect	  is	  due	  to	  an	  
inability	  to	  phosphorylate	  KAP-­‐1	  to	  promote	  chromatin	  relaxation.	  	  
To	  investigate	  this,	  HeLa	  cells	  were	  either	  depleted	  of	  53BP1	  as	  before	  or	  double-­‐depleted	  of	  
both	  53BP1	  and	  KAP-­‐1.	  As	  described	  above,	  siRNA	  resistant	  constructs	  were	  transfected	   into	  
either	   53BP1-­‐depleted	   or	   double-­‐depleted	   (si53BP1/siKAP1)	   backgrounds.	   Cells	   were	   then	  
exposed	  to	  3Gy	  ionising	  radiation,	  allowed	  to	  recover	  for	  the	  indicated	  time	  before	  fixing	  and	  
staining	   for	   HA	   (53BP1)	   and	   γH2AX.	   Finally,	   γH2AX	   foci	   were	   enumerated	   to	   indicate	   the	  
number	  of	  breaks	  remaining	  within	  the	  cell	  at	  that	  time.	  
Enumeration	   of	   γH2AX	   foci	   in	   cells	   double-­‐depleted	   of	   53BP1	   and	   KAP-­‐1	   reveals	   that	   the	  
additional	  depletion	  of	  KAP-­‐1	  bypasses	  the	  ‘slow’	  kinetic	  repair	  defect	  produced	  by	  depletion	  
of	  53BP1	  or	   transfection	  with	  53BP1-­‐S366A,	   -­‐T670A	  or	   the	  double	  mutant	   (figure	  4.10).	   This	  
indicates	   that	   these	   persistent	   DSBs	   result	   from	   a	   failure	   to	   repair	   breaks	   in	   regions	   of	  
heterochromatin.	  	  

























Figure	   4.10	   siRNA	  deple8on	   of	   KAP-­‐1	   rescues	   the	   ‘slow’	   kine8c	   repair	   defect	   in	  
53BP1	  phosphoryla8on	  mutants.	  HeLa	  cells	  were	   reverse	   transfected	  with	  53BP1	  
and/or	  KAP-­‐1	  siRNA.	  48	  hours	   later	  cells	  were	  transfected	  with	  an	  siRNA	  resistant	  
construct	   containing	   wild-­‐type	   HA-­‐53BP1	   or	   one	   of	   the	   BRCT	   mutants.	   16	   hours	  
later	   cells	  were	  exposed	   to	  3Gy	   ionising	   radiaAon	  and	  allowed	   to	   recover	   for	   the	  
indicated	   Ame	   before	   staining	   for	   HA	   and	   γH2AX.	   a)	  Western	   blot	   of	   whole	   cell	  
extracts	  showing	  siRNA	  depleAon	  of	  53BP1	  and	  KAP-­‐1.	  b)	  Graph	  shows	  the	  average	  
number	   of	   γH2AX	   foci	   per	   cell	   (average	   of	   3	   experiments,	   error	   bars	   show	   1	  




















































4.2.9	  53BP1	  phosphorylation	  mutants	  show	  normal	  repositioning	  of	  53BP1	  in	  S-­‐	  and	  
G2-­‐phase	  cells	  
Having	   identified	   that	   the	   53BP1	   phosphorylation	   site	  mutants,	   S366A	   and	   T670A,	   have	  G1,	  
G1/S	   checkpoint	   defects	   and	   fail	   to	   repair	   a	   fraction	   of	   the	   total	   number	   of	   breaks,	   it	   then	  
became	  necessary	  to	  determine	  if	  the	  defects	  observed	  were	  limited	  solely	  to	  G1-­‐phase	  cells.	  	  
53BP1	  plays	  a	  pivotal	  role	  in	  the	  choice	  of	  DSB	  repair	  mechanism-­‐	  favouring	  NHEJ	  over	  HR	  by	  
preventing	  resection	  of	  the	  broken	  DNA	  ends	  [190].	  53BP1	  does	  this	  by	  antagonising	  BRCA1	  in	  
S-­‐and	   G2-­‐phase	   cells	   [212].	   Previously	   it	   has	   been	   observed	   that	   53BP1	   is	   physically	  
repositioned	  to	  the	  periphery	  of	  the	  IRIF	  several	  hours	  following	  exposure	  to	  ionising	  radiation	  
and	  that	  this	  repositioning	  is	  critical	  for	  the	  progression	  to	  HR-­‐mediated	  repair	  [210].	  
In	   order	   to	   examine	  whether	   repositioning	   of	   53BP1	  was	   altered,	   the	   localisation	   of	   BRCA1	  
relative	   to	   53BP1	   was	   assessed	   in	   S-­‐	   and	   G2-­‐phase	   cells	   following	   the	   introduction	   of	   DNA	  
damage.	  This	  was	  achieved	  by	  exposing	  cells	  to	  3Gy	  ionising	  radiation	  before	  allowing	  them	  to	  
recover	  for	  a	  period	  of	  8	  hours.	  The	  cells	  were	  then	  fixed	  and	  immunostained	  for	  BRCA1	  and	  
53BP1.	  High-­‐resolution	  z-­‐stack	  images	  were	  taken	  on	  a	  z-­‐range	  of	  2µm	  at	  0.1µm	  intervals.	  The	  
images	  were	  deconvolved	  and	   IRIF	   intensity	  profiles	  were	  measured	  across	  both	  channels	   to	  
determine	  the	  relative	  distance	  of	  53BP1	  from	  BRCA1.	  	  	  	  
No	  repositioning	  defect	  was	  observed	  as	  the	  53BP1	  phosphorylation	  mutant	  proteins,	  53BP1-­‐
S366A,	  -­‐	  T670A	  and	  the	  double	  mutant	  were	  repositioned	  normally,	  relative	  to	  BRCA1,	  towards	  
the	  periphery	  of	   IRIF	   in	  S-­‐	  and	  G2-­‐phase	  cells	  (figure	  4.11).	  This	   indicates	  that	  this	  S-­‐	  and	  G2-­‐
phase	  specific	  function	  of	  53BP1	  does	  not	  require	  these	  phosphorylation	  sites.	  	  





























































Figure	   4.11	   53BP1	   phosphoryla8on	   site	  mutants	   show	   normal	   displacement	  
by	  BRCA1	  in	  G2	  cells.	  HeLa	  cells	  were	  reverse	  transfected	  with	  53BP1	  siRNA.	  48	  
hours	  later	  cells	  were	  transfected	  with	  an	  siRNA	  resistant	  construct	  containing	  
wild-­‐type	  HA-­‐53BP1	  or	  one	  of	  the	  BRCT	  mutants.	  16	  hours	  aqer	  this	  cells	  were	  
exposed	   to	   either	   3Gy	   (Mock	   and	  WT)	   or	   1Gy	   IR	   for	  mutants	   and	   allowed	   to	  
recover	   for	   8	   hours	   before	   staining	   for	   HA	   and	   BRCA1.	   High	   resoluAon,	  
deconvolved	   Z-­‐stack	   images	   were	   obtained.	   QuanAtaAve	   measurements	   of	  
intensity	  across	  foci	  were	  generated	  using	  soqWoRx	  soqware	  (n>20	  foci)	  error	  
bars	   show	  1	   standard	   deviaAon.	   VerAcal	   blue	   bars	   show	   samples	   depleted	   of	  









In	   vitro	   analysis	   of	   two	   phospho-­‐peptides	   from	   the	  N-­‐terminus	   of	   53BP1	   revealed	   a	   specific	  
interaction	   between	   phosphorylated	   53BP1	   and	   the	   BRCT	   domains	   of	   TopBP1.	   A	  
phosphoserine366-­‐containing	  53BP1	  peptide	  interacts	  with	  BRCT	  domains	  4-­‐5	  of	  TopBP1	  with	  
a	   dissociation	   constant	   of	   31.35μM.	   A	   second	   interaction	   was	   also	   identified,	   specifically	  
between	   a	   phosphothreonine670-­‐containing	   53BP1	   peptide	   and	   BRCT	   domains	   0,	   1-­‐2	   of	  
TopBP1.	   Interestingly,	   this	   second	   interaction	   had	   a	  much	   higher	   affinity	  with	   a	   dissociation	  
constant	   of	   1μM.	   Furthermore,	   it	   was	   possible	   to	   establish	   that	   these	   sites	   were	   genuine	  
phosphorylation	  targets	  and	  were	  phosphorylated	  in	  vivo	  following	  DNA	  damage	  using	  custom	  
antibodies	  generated	  against	  the	  phosphopeptides.	  	  
Western	  analysis	  of	  whole	  cell	  extracts	  taken	  from	  HeLa	  cells	  with	  and	  without	  RNAi	  depletion	  
of	  53BP1	   indicates	   that	  both	  of	   the	  custom	  antibodies	  are	  specific	   to	  53BP1.	  Further	  work	   is	  
required	  to	  test	  whether	  there	  is	  any	  cross-­‐reactivity	  with	  the	  un-­‐phosphorylated	  peptide.	  This	  
could	  be	  achieved	  by	  Western	  analysis	  of	  lysates	  pre-­‐treated	  with	  λ-­‐phosphatase.	  Despite	  this,	  
the	  lack	  of	  reactivity	  with	  lysate	  from	  HeLa	  cells	  without	  exposing	  the	  cells	  to	  ionising	  radiation	  
prior	   to	   lysing	   does	   indicate	   a	   degree	   of	   specificity.	   Finally,	   although	   these	   antibodies	   are	  
suitable	   for	   studying	   the	  phosphorylation	  of	  53BP1	  when	  proteins	   can	  be	   resolved	  based	  on	  
their	   molecular	   weight,	   non-­‐specific	   activity	   of	   the	   antibodies	   with	   proteins	   with	   a	   lower	  
molecular	   weight,	   revealed	   by	  Western	   analysis,	   indicate	   that	   these	   antibodies	  may	   not	   be	  
suitable	  for	  immunofluorescence-­‐based	  experiments.	  	  
By	  mutating	   either	   S366	  or	   T670	   to	   alanine,	   it	  was	   possible	   to	   demonstrate	   that	   inability	   to	  
phosphorylate	   either	   residue	   individually,	   affects	   the	   ability	   of	   TopBP1	   to	   co-­‐
immunoprecipitate	   with	   53BP1	   (figure	   4.3).	   TopBP1	   also	   co-­‐immunoprecipitates	   with	   HA-­‐
53BP1	   even	   in	   the	   absence	   of	   DNA	   damage.	   This	   contrasts	   with	   the	   results	   from	   figure	   4.2	  
which	  demonstrate	  that	  these	  residues	  are	  only	  phosphorylated	  following	  DNA	  damage.	  This	  
might	   occur	   as	   a	   result	   of	   excess	   HA-­‐53BP1	   overexpression	   of	   the	   cDNA	   constructs	   within	  
these	   cells.	   Calcium	   phosphate	   transfection	   of	   HEK293	   cells	   is	   optimised	   to	   allow	   for	   the	  
production	  of	   large	  quantities	  of	  protein.	  The	  overexpression	   itself	   could	  stress	   the	  cells	  and	  
result	   in	   increased	  phosphorylation	  of	   these	   residues.	   Further,	  Western	   analysis	   of	   total	   cell	  
extracts	   from	   these	   cells,	   probing	   for	   pSer-­‐366	   and	  pThr-­‐670	   could	  be	  used	   to	   test	  whether	  
overexpression	  of	  53BP1	  in	  increases	  53BP1	  phosphorylation	  in	  the	  absence	  of	  DNA	  damage.	  	  
Alternatively,	   it	   is	  also	  possible	   that	   there	   is	  a	  basal	   level	  of	  53BP1	  phosphorylation,	  perhaps	  
allowing	  53BP1	  and	  TopBP1	  to	  co-­‐operate	  within	  the	  cell,	  even	  in	  the	  absence	  DNA	  of	  damage.	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This	  seems	   less	   likely	  however,	  as	  there	  was	  no	   increase	  observed	   in	  the	  quantity	  of	  TopBP1	  
co-­‐immunoprecipitated	  from	  cells	  following	  exposure	  to	  ionising	  radiation	  compared	  to	  those	  
without	  damage.	  	  
The	  failure	  of	  53BP1	  phosphorylation	  site	  mutants	  to	  co-­‐localise	  with	  TopBP1	  was	  quantified	  
using	  SCANR	  microscopy.	  This	  automated	  approach	  allowed	  the	  analysis	  of	  a	  large	  number	  of	  
cells	   and	   foci	   across	   different	   channels.	   Additionally,	   by	   generating	   profiles	   based	   on	   total	  
internal	   DAPI	   staining	   intensity,	   the	   individual	   cell-­‐cycle	   status	   of	   each	   cell	   could	   be	  
determined.	  The	  data	  analysis	  using	   this	  method	  does	  have	   some	   limitations	  however,	   since	  
analysis	  of	  the	  number	  of	   foci	  generated	  per	  cell	   is	   likely	  to	  be	  an	  underestimate	  of	  the	  true	  
number,	  due	  to	  the	  way	  in	  which	  the	  data	  are	  analysed.	  A	  focus	  has	  to	  be	  defined	  by	  a	  clear	  
set	   of	   criteria	   i.e.	   minimum	   intensity,	   minimum	   area	   and	   maximum	   area	   based	   on	   the	  
exposure	   times	   for	   each	   image.	   These	   thresholds	   aim	   to	   prevent	   misinterpretation	   of	  
background	  fluorescence	  and	  concurrently,	  antibody	  staining	  artefacts	  from	  being	  interpreted	  
as	  additional	  foci.	  In	  order	  to	  prevent	  misidentification	  the	  thresholds	  are	  set	  slightly	  above	  the	  
minimum	  requirement	  for	  focus	  identification	  based	  on	  manual	  analysis	  of	  several	  images.	  The	  
assigned	   criteria	   are	   then	   applied	   to	   all	   of	   the	   images	   for	   analysis.	   The	   result	   is	   that	   some	  
weaker	  foci	  or	  larger,	  more	  intense	  foci	  may	  not	  have	  been	  accounted	  for.	  
Analysis	  of	  the	  number	  of	  transfected	  cells	  identified	  in	  each	  phase	  of	  the	  cell	  cycle	  reveals	  a	  
larger	   S-­‐	   and	   G2-­‐phase	   population	   of	   cells	   following	   DNA	   damage	   in	   cells	   transfected	   with	  
53BP1-­‐S366A	  and	   -­‐T670A.	  Although	   these	  data	   indicate	  a	  marked	  difference	   in	   the	  cell-­‐cycle	  
profiles	   4	   hours	   following	   DNA	   damage	   there	   are	   some	   limitations	   to	   these	   results.	   These	  
results	  only	  provide	  a	  single	  snapshot	  of	  cell-­‐cycle	  status	  following	  DNA	  damage.	  It	  is	  possible	  
that	   these	   cells	   had	   entered	   S-­‐phase	   prior	   to	   irradiation	   and	   had	   subsequently	   entered	  G2-­‐
phase	  by	  the	  time	  the	  cells	  were	  fixed.	  Additionally,	  G2-­‐phase	  cells	  were	  not	  prevented	  from	  
proceeding	   through	   mitosis	   during	   the	   experiment.	   Further	   controls	   would	   be	   needed	   to	  
confirm	  that	  the	  cell	  cycle	  changes	  occur	  specifically	  in	  response	  to	  DNA	  damage	  i.e.	  including	  
the	   cell	   cycle	   profiles	   of	   un-­‐irradiated	   controls.	   As	   a	   result,	   it	   was	   necessary	   to	   analyse	   this	  
phenotype	   in	   a	   more	   controlled	   environment.	   In	   order	   to	   do	   this,	   dual-­‐pulse	   labelling	  
experiments	  were	  employed	  to	  examine	  the	  G1-­‐S	  checkpoint.	  	  
Utilising	   the	   dual-­‐pulse	   labelling	   assay,	   it	   was	   possible	   to	   determine	   that	   consistent	   with	  
previous	  observations,	   loss	  of	  53BP1	  results	   in	  a	  failure	  to	  sustain	  the	  G1-­‐S	  phase	  checkpoint	  
[193].	   This	   experimental	   format	   allowed	   the	   identification	   only	   of	   cells	   that	   had	   entered	   S-­‐
phase	  following	  irradiation	  and	  allowed	  us	  to	  exclude	  the	  population	  of	  cells	  that	  had	  already	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entered	   S-­‐phase	   before	   irradiation,	   as	   determined	   by	   the	   incorporation	   of	   the	   first	   DNA	  
analogue	  EdU.	  Secondly,	   transfected	  cells	   could	  be	   identified	  by	   the	  presence	  of	  HA	   (53BP1)	  
foci	   for	   the	   wild-­‐type	   and	   mutant	   constructs.	   However,	   this	   experiment	   is	   limited	   as	  
transfected	  cells	  can	  only	  be	  identified	  in	  the	  presence	  of	  DNA	  damage	  i.e.	  the	  formation	  of	  HA	  
(53BP1)	   foci.	   Ideally,	   it	  would	   be	   necessary	   to	   identify	   transfected	   cells	   in	   the	   presence	   and	  
absence	  of	  damage	   to	  confirm	   that	   the	  cell-­‐cycle	  defect,	   caused	  by	  mutation	  of	  53BP1,	  only	  
occurs	   in	   response	   to	  DNA	  damage.	  This	   could	  be	  achieved	  using	   fluorescence	  activated	  cell	  
sorting	  to	  identify	  transfected	  cells	  irrespectively	  of	  HA-­‐53BP1	  IRIF	  formation.	  
With	   any	   cell-­‐cycle	   analysis	   the	   choice	   of	   cell	   line	   utilised	   is	   critical.	   Some	   cell	   lines,	   such	   as	  
HeLa	  cells,	  are	  very	  highly	  transformed	  and	  as	  a	  result	   intricate	  regulation	  of	  the	  cell	  cycle	   is	  
lost.	  In	  fact	  it	  is	  questionable	  as	  to	  whether	  HeLa	  cells	  display	  any	  cell-­‐cycle	  control	  at	  all.	  Often	  
this	   ability	   to	   regulate	   the	   cell	   cycle	   stems	   from	   mutated	   p53,	   a	   common	   feature	   in	  
cancerous/immortalised	   cell	   lines.	   In	   order	   to	   study	   the	   G1-­‐S	   phase	   checkpoint,	   U2OS	   cells	  
were	  used	  as	   they	  are	  a	   transfectable	   isogenic	   cell	   line	  with	  an	   intact	  p53	   response	  and	  are	  
capable	  of	  sustaining	  a	  G1-­‐S	  phase	  arrest	  following	  the	  introduction	  of	  DNA	  damage	  as	  shown	  
in	  Figure	  4.8a.	  	  
Although	  more	  representative	  than	  HeLa	  cells,	  U2OS	  cells	  might	  not	  accurately	  represent	  the	  
physiological	   response	   to	   damage.	   This	  may	   be	   better	   represented	   using	   different	   cell	   lines	  
such	   as	   hTERT-­‐immortalised	   retinal	   pigment	   epithelium	   (RPE)	   cells.	   These	   cells	   are	   more	  
physiologically	  representative	  of	  uncancerous	  cells	  and	  are	  immortalised	  via	  the	  expression	  of	  
telomerase	   allowing	   indefinite	   proliferation.	   Further	   analysis	   of	   several	   cell	   lines	   under	   the	  
same	  test	  conditions	  would	  help	  to	  confirm	  whether	  a	  cell-­‐cycle	  defect	  is	  occurring	  and	  would	  
negate	  any	  cell	  line-­‐specific	  traits	  that	  may	  affect	  the	  results.	  	  	  
Further	  work	  will	  be	  required	  to	  establish	  whether	  under	  these	  experimental	  conditions	  there	  
is	  a	   risk	   that	   the	  HeLa	  cells	  are	  still	   cycling	   following	  on	   from	  the	   introduction	  of	  damage.	   In	  
order	  to	  be	  confident	  that	  only	  G1-­‐phase	  cells	  were	  being	  analysed,	  CENPF	  a	  marker	  of	  S-­‐	  and	  
G2-­‐phase	  cells	  was	  used	  as	  a	  selection	  marker.	  Despite	  this,	  there	  is	  also	  the	  possibility	  that	  at	  
the	  longest	  time	  point	  i.e.	  24	  hours	  following	  irradiation,	  the	  cells	  may	  have	  continued	  through	  
the	  cell-­‐cycle.	  If	  that	  is	  the	  case,	  it	  is	  possible	  that	  cells	  that	  were	  analysed	  could	  have	  passed	  
through	  S-­‐,	  G2-­‐	  and	  M-­‐phase	  back	  to	  G1	  prior	  to	  the	  enumeration	  of	  foci.	  	  
In	  order	  to	  try	  and	  account	  for	  this	  a	  number	  of	  steps	  could	  be	  taken.	  Firstly,	  U20S	  or	  another	  
cell	   line	  capable	  of	  confluence	  arrest	  could	  be	  utilised	  for	  these	  experiments	  to	  analyse	  non-­‐
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cycling	   cells.	   Secondly,	   nocodazole	   could	   be	   used	   to	   block	   cells	   from	   cycling	   from	  G2-­‐phase	  
through	  mitosis	  and	  back	  through	  to	  G1-­‐phase.	  This	  could	  be	  performed	  in	  combination	  with	  
CENPF	  staining	  to	  identify	  only	  non-­‐cycling	  G1-­‐phase	  cells.	  	  
To	   further	   characterise	   the	   DNA	   DSBs	   that	   persist	   at	   late	   stages	   following	   irradiation,	   dual	  
depletion	   of	   KAP-­‐1	   and	   53BP1	   was	   demonstrated	   to	   bypass	   the	   53BP1-­‐dependent	   repair	  
kinetics	   indicating	   that	   this	   subset	   of	   breaks	   require	   phosphorylation	   of	   KAP-­‐1	   to	   allow	  
relaxation	  of	  heterochromatin	  in	  order	  to	  resolve	  these	  breaks.	  As	  before,	  care	  has	  to	  be	  taken	  
to	   account	   for	   any	   disruption	   to	   the	   cell	   cycle	   using	   these	   experimental	   formats	   and	  
additionally,	  to	  determine	  if	  depletion	  of	  KAP-­‐1	  has	  ramifications	  beyond	  repair	  of	  DSBs.	  	  
In	  order	  to	  account	  for	  this,	  dual-­‐depletion	  of	  53BP1	  and	  KAP-­‐1	  followed	  by	  a	  double	  knock-­‐in	  
of	  53BP1	   could	  be	  used	  with	  a	  phospho-­‐mimetic	   and	  un-­‐phosphorylatable	  mutant	  of	  KAP-­‐1.	  
This	   would	   determine	   whether	   the	   bypassing	   of	   the	   repair	   defect	   by	   depletion	   of	   KAP-­‐1	   is	  
synonymous	  with	  ATM-­‐dependent	  phosphorylation	  of	  KAP-­‐1.	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5.	  Determining	  the	  phospho-­‐specific	  interactions	  of	  the	  BRCA-­‐1	  C-­‐
terminal	  (BRCT)	  domains	  of	  53BP1	  
5.1	  Introduction	  
In	  a	  previous	  collaboration	  between	  the	  Watts	  and	  Pearl	   labs	   it	  was	  shown	  that	   in	  S.	  pombe,	  
the	   BRCT	   domains	   of	   Crb2,	   the	   orthologue	   of	   53BP1,	   interact	   directly	   with	   γH2A	   [205].	  
Conservation	  of	  this	  interaction	  is	  suggested	  by	  the	  fact	  that	  the	  S.	  cerevisiae	  orthologue	  Rad9,	  
also	  interacts	  with	  phosphorylated	  H2A	  [199].	  To	  build	  on	  this	  we	  wished	  to	  establish	  whether	  
mammalian	  53BP1	   is	   capable	  of	  mediating	   the	   same	   interaction	   and	   if	   so,	   to	   determine	   the	  
functional	  role	  of	  this	  interaction	  in	  DNA	  repair.	  	  
Previously,	  Noon	  et	  al	   [257]	  showed	  that	  deletion	  of	  the	  BRCT	  domains	  of	  53BP1	  results	   in	  a	  
‘slow’	  kinetic	  repair	  defect	  as	  shown	  by	  enumeration	  of γH2AX	  foci	  following	  exposure	  to	  IR.	  
These	  breaks	  are	  proposed	  to	  represent	  approximately	  15%	  of	  the	  total	  number	  of	  breaks	  i.e.	  
those	  generated	  in	  regions	  of	  heterochromatin.	  In	  order	  for	  the	  DNA	  repair	  machinery	  to	  gain	  
access	   to	   the	   break	   site	   and	   facilitate	   repair,	   extensive	   chromatin	   remodeling	   and	  
reorganization	   is	   required.	   As	   this	   phenotype	   was	   observed	   by	   deleting	   the	   entire	   region	  
encoding	   the	   BRCT	   domains	   it	   remained	   unclear	   as	   to	   which	   set(s)	   of	   specific	   interactions,	  
mediated	   by	   these	   domains,	   are	   required	   for	   the	   correct	   processing	   of	   complex	   breaks.	   For	  
example,	   the	   BRCT	   domains	   have	   been	   shown	   to	   mediate	   a	   phosphorylation-­‐independent	  
interaction	  with	  the	  tumor	  suppressor	  protein	  p53,	  as	  well	  as	  a	  phosphorylation-­‐independent	  
interaction	  with	  one	  of	  the	  heterotrimeric	  subunits	  of	  the	  MRN	  complex,	  Rad50	  [258,	  259].	  
Several	  groups	  have	  suggested	  that	  recruitment	  of	  53BP1	  to	  sites	  of	  DNA	  damage	  is	  dependent	  
on	  phosphorylation	  of	  H2AX.	  In	  the	  experiments	  performed	  by	  Ward	  et	  al,	  H2AX	  +/+	  and	  H2AX	  
-­‐/-­‐	  embryonic	  stem	  cells	  were	  transfected	  with	  either	  wild-­‐type	  H2AX	  or	  H2AX-­‐S139A	  mutant	  
(i.e.	   an	   unphosphorylatable	   H2AX	   mutant).	   As	   expected,	   they	   observed	   that	   formation	   of	  
53BP1	   foci	  had	  been	   restored	   in	   the	  H2AX	   -­‐/-­‐	   cells	   that	  had	  been	   transfected	  with	   the	  wild-­‐
type	  histone	  variant.	  However,	  mutant	  cells	  transfected	  with	  the	  H2AX-­‐S139A	  mutant	  failed	  to	  
form	   53BP1	   foci,	   potentially	   reflecting	   the	   requirement	   for	   γH2AX	   at	   early	   time-­‐points	  
following	  damage	  [260].	  More	  recently,	  Kocylowski	  et	  al	  used	  a	  similar	  experimental	  format	  to	  
dissect	  the	  role	  of	  ubiquitination	  in	  53BP1	  recruitment.	  They	  studied	  RNF8	  -­‐/-­‐	  MEFs,	  which	  fail	  
to	   ubiquitinate	   histone	   H2A	   and	   failed	   to	   form	   53BP1	   foci.	   By	   transfecting	   the	   cells	   with	   a	  
ubiquitin-­‐H2A	   fusion	   protein	   they	   were	   able	   to	   restore	   the	   ability	   to	   form	   53BP1	   foci.	  
Interestingly,	   introduction	  of	   the	  H2AX-­‐S139A	  mutation	   failed	   to	   rescue	   the	  defect	   in	  53BP1	  
focus	  formation	  despite	  the	  presence	  of	  ubiquitin	  [261].	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Both	  of	  these	  experiments	  suggest	  an	  as	  yet	  uncharacterised	  role	  for	  phosphorylated	  H2AX	  in	  
the	  localisation	  of	  53BP1	  into	  foci	  (i.e.	  other	  than	  methylation-­‐	  and	  ubiquitination-­‐dependent	  
recruitment	  through	  the	  Tudor	  and	  UDR	  domain	  of	  53BP1).	  Our	  aim	  was	  to	  establish	  whether	  
53BP1	  directly	  interacts	  with	  γH2AX	  through	  its	  tandem	  BRCT	  domains.	  	  
5.1.1	  Fluorescence	  polarisation	  reveals	  a	  phospho-­‐specific	  interaction	  between	  the	  
BRCT	  domains	  of	  53BP1	  and	  γH2AX	  
To	   begin	   to	   investigate	   the	   interaction	   of	   53BP1	   and	   γH2AX,	   Matthew	   Day	   (Pearl	   lab,	  
University	   of	   Sussex)	   performed	   fluorescence	   polarisation	  with	   a	   fluorescein-­‐coupled	   γH2AX	  
phosphopeptide	   titrated	  against	   concentrations	  of	  purified	   recombinant	  BRCT	  domains	   from	  
53BP1	  (figure	  5.1a).	  He	  found	  that	  there	  was	  a	  specific	  interaction	  between	  the	  BRCT	  domains	  
of	   53BP1	   and	   the	   γH2AX	   phosphopeptide.	   In	   addition	   to	   this,	   he	   was	   able	   to	   calculate	   a	  
dissociation	   constant	   of	   1.4µM	   for	   the	   interaction.	   He	   then	   went	   on	   to	   test	   whether	   this	  
interaction	  was	  dependent	  on	  the	  peptide	  being	  phosphorylated.	  Pre-­‐treatment	  of	  the	  γH2AX	  
phosphopeptide	  with	   λ-­‐phosphatase	  prior	   to	   in	  vitro	   analysis	   abolished	   its	   interaction.	   Since	  
H2AX	   is	   phosphorylated	   on	   S139	   in	   response	   to	   DNA	   damage	   [262],	   the	   significance	   of	   this	  
phosphorylation-­‐dependent	   interaction	   indicates	   a	   potential	   role	   for	   the	   interaction	   in	   the	  
DNA	  damage	  response	  and	  more	  specifically	  in	  response	  to	  DSBs.	  	  	  
M.	   Day	   went	   on	   to	   further	   test	   the	   specificity	   exhibited	   by	   the	   BRCT	   domains	   of	   53BP1	   by	  
performing	   the	   same	   experiment	   with	   another	   phosphopeptide,	   phospho-­‐KAP-­‐1.	   KAP-­‐1	   is	  
phosphorylated	   on	   S821	   by	   pATM	   in	   response	   to	   DNA	   damage	   and	   facilitates	   chromatin	  
remodelling	  to	  allow	  repair.	  The	  BRCT	  domains	  of	  53BP1	  showed	  no	  interaction	  with	  the	  KAP-­‐1	  
phosphopeptide	  (figure	  5.1b)	  indicating	  that	  the	  BRCT	  domains	  display	  at	  least	  some	  degree	  of	  
specificity.	  	  
It	   was	   proposed	   that	   the	   location	   of	   the	   ‘pSQEY’	   motif	   at	   the	   C-­‐terminal	   end	   of	   the	  
phosphopeptide	   might	   be	   important	   for	   dictating	   the	   specificity	   exhibited	   by	   the	   BRCT	  
domains.	   This	   contrasts	   with	   the	   KAP-­‐1	   phosphopeptide,	   in	   which	   three	   additional	   residues	  
follow	  the	   ‘pSQEL’	  motif,	   ‘SGG’	  masking	  the	  otherwise	  exposed	  carboxyl	  group.	   Interestingly,	  
amidation	  of	  the	  tyrosine	  or	  the	  addition	  of	  a	  single	  glycine	  residue	  at	  the	  C-­‐terminal	  side	  of	  
the	  γH2AX	  phosphopeptide	  significantly	  reduced	  the	  interaction	  of	  the	  BRCT	  domains	  of	  53BP1	  
with	   the	   phosphopeptide	   (figure	   5.1c).	   This	   indicates	   that	   the	   exposed	   C-­‐terminal	   carboxyl	  
group	  of	  the	  tyrosine	   is	   important	  for	  the	   interaction	  to	  occur	  and	   likely	  forms	  the	  basis	  of	  a	  
unique	  biochemical	  signature	  that	  is	  specifically	  recognised	  by	  53BP1.	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In	  order	  to	  fully	  characterise	  this	  interaction,	  M.	  Day	  also	  analysed	  a	  known	  γH2AX	  interacting	  
protein,	  MDC1	   [263].	   By	   performing	   fluorescence	   polarisation	   experiments	   using	   the	   γH2AX	  
phosphopeptide,	  this	  time	  titrated	  against	  the	  BRCT	  domains	  of	  MDC1,	  he	  demonstrated	  that	  
the	  BRCT	  domains	  of	  MDC1	   specifically	   recognise	   γH2AX	   (figure	  5.1d).	   The	  BRCT	  domains	  of	  
MDC1	   show	   a	   3.5-­‐fold	   higher	   affinity	   for	   γH2AX	   than	   those	   of	   53BP1	   with	   a	   calculated	  
dissociation	  constant	  (Kd)	  of	  0.4µM	  ±	  0.05.	  	  
M.	  Day	  also	  solved	  the	  X-­‐ray	  crystal	  structure	  of	  the	  BRCT	  domains	  of	  53BP1	  bound	  to	  the	  last	  
four	   amino	   acids	   of	   the	   γH2AX	   phosphopeptide	   (figure	   5.2a).	   Arginine	   1811	   of	   the	   BRCT	  
domains	   of	   53BP1	  mediates	   polar	   contacts	   between	   the	   amine-­‐containing	   functional	   group	  
and	  the	  carboxyl-­‐terminus	  of	  the	  γH2AX	  phosphopeptide,	  whilst	  lysine	  1814	  mediates	  contact	  
between	  the	  amine-­‐containing	  functional	  group	  and	  the	  phospho-­‐serine	  residue	  (figure	  5.2b).	  
Having	  identified	  the	  residues	  critical	  for	  mediating	  this	  interaction,	  M.	  Day	  was	  able	  to	  show	  
that	  by	  making	  either	  one	  of	  two	  charge	  reversal	  mutations	  (R1811E	  or	  K1814E),	  the	  specific	  
interaction	  observed	  by	  fluorescence	  polarisation,	  was	  abolished	  (figure	  5.1d).	  










Figure	   5.1	   53BP1	   BRCT	   domains	   interact	   speciﬁcally	   with	   γH2AX	  
phosphopep8de	  in	  vitro.	  Fluorescence	  polarisaAon	  performed	  by	  M.	  Day	  (Pearl	  
Lab)	  shows	  a)	  53BP1	  BRCT	  domain	  interacAon	  with	  γH2AX	  phosphopepAde	  with	  
and	   without	   pre-­‐treatment	   with	   λ-­‐phosphatase.	   b)	   InteracAon	   with	   KAP1	  
phosphopepAde.	  c)	   InteracAon	  with	  charge	  reversal	  of	   the	  C-­‐terminal	   tyrosine	  
or	   charge	   neutralisaAon	   with	   glycine.	   d)	   InteracAon	   of	   the	   BRCT	   domains	   of	  
MDC1	  with	   the	   γH2AX	   phosphopepAde	   d)	   BRCT	  mutants	   R1811E	   and	   K1814E	  




Figure	   5.2	   Crystal	   structure	   of	   γH2AX	   phosphopep8de	   bound	   to	   the	   BRCT	  
domains	  of	  53BP1.	  X-­‐ray	  crystallography	  performed	  by	  Ma?hew	  Day.	  a)	  shows	  
space	  ﬁlling	  model	  of	  the	  tandem	  BRCT	  domains	  of	  53BP1	  bound	  to	  the	  pSQEY	  
pepAde.	  b)	  shows	  detailed	  interacAon	  between	  the	  phosphate	  group	  and	  K1814	  




5.2.1	  The	  BRCT	  domains	  of	  53BP1	  co-­‐purify	  with	  γH2AX	  
Once	  it	  had	  been	  established	  that	  the	  BRCT	  domains	  of	  53BP1	  directly	  bind	  γH2AX	   in	  vitro,	   it	  
was	  necessary	   to	  demonstrate	   this	   interaction	   in	   vivo.	   In	  order	   to	  do	   this	   the	  BRCT	  domains	  
were	  cloned	   into	  an	  eYFP-­‐tagged	  vector	  downstream	  of	  a	  nuclear	   localisation	   signal	   (cloning	  
was	  performed	  by	  Dr	  Anthony	  Oliver).	  The	  two	  charge	  reversal	  mutants,	  R1811E	  and	  K1814E,	  
were	  also	  introduced	  into	  the	  same	  vector.	  The	  constructs	  along	  with	  an	  empty	  vector	  control	  
with	   just	   the	  eYFP	  and	  NLS	  alone,	  henceforth	   referred	   to	   as	   eYFP-­‐NLS-­‐BRCT	   (WT,	  R1811E	  or	  
K1814E),	  were	   transfected	   into	  HeLa	   cells	  with	   the	   aim	  of	   generating	   stable	   transfected	   cell	  
lines.	  	  
Stable	   cell	   lines	   expressing	   the	   YFP-­‐tagged	   constructs	   were	   generated	   by	   culturing	   cells	   in	  
selective	  medium	  48h	  after	  transfection.	  The	  constructs	  used	  contained	  a	  neomycin-­‐resistance	  
gene	   and	   the	   medium	   was	   supplemented	   with	   G418	   disulphate	   antibiotic	   48	   hours	   after	  
transfection.	  As	  a	  result,	  any	  surviving	  cells	  that	  could	  proliferate	  in	  the	  medium	  approximately	  
14	  days	   following	   transfection	  would	  have	  retained	  the	  plasmid	  and	  should	  express	   the	  YFP-­‐
NLS-­‐BRCT	  domain.	  Stable	  cell	  lines	  were	  generated	  for	  both	  YFP-­‐NLS-­‐BRCT	  (WT)	  and	  YFP-­‐NLS-­‐
BRCT	  (R1811E).	  	  
The	  stable	  cell	  lines	  were	  cultured	  and	  exposed	  to	  30Gy	  of	  ionising	  radiation	  and	  incubated	  for	  
a	   further	   hour	   before	   lysing.	   Dr	   Oliver	   performed	   a	   GFP-­‐trap	   experiment	   to	   purify	   the	  
recombinant	  BRCT	  domains	   from	   the	  mammalian	  cells.	   This	  enabled	   the	  analysis	  of	  proteins	  
co-­‐purifying	  with	   the	  BRCT	  domains	  under	  native	   conditions.	  Western	  analysis	   revealed	   that	  
γH2AX	   co-­‐purifies	  with	   the	  wild-­‐type	  BRCT	  domains	  but	  not	  with	   the	  R1811E	  mutant	   (figure	  
5.3).	  The	  abolition	  of	  this	  interaction	  as	  shown	  by	  co-­‐IP	  is	  consistent	  with	  and	  supplemented	  by	  
the	  earlier	  structural	  and	  in	  vitro	  data.	  	  	  	  
	   	  
Antony	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Figure	   5.3	   BRCT	   domains	   of	   53BP1	   can	   pull-­‐down	   γH2AX	   following	   damage.	   Stable	  
HeLa	  cell	  lines	  expressing	  YFP-­‐NLS-­‐BRCT	  wild	  type	  and	  R1811E	  were	  generated	  by	  G418	  
anAbioAc	  selecAon.	  Cell	   lines	  were	  cultured	  in	  4x	  20cm	  dishes	  before	   irradiaAon	  with	  
30Gy	   IR.	  Cells	  were	  allowed	  to	  recover	   for	  30	  minutes	  before	  harvesAng	  by	  scraping.	  
Performed	   by	  Dr	   A	  Oliver,	   the	   cell	   lysates	  were	   incubated	  with	  GFP-­‐trap	   resin	   along	  
with	  protease	  and	  phosphatase	  inhibitors.	  Retained	  protein	  was	  analysed	  by	  SDS-­‐PAGE	  
and	  Western	  blot	  probed	  for	  YFP	  using	  a	  polyclonal	  GFP	  anAbody	  and	  for	  γH2AX.	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5.2.2	  The	  BRCT	  domains	  in	  isolation	  can	  localise	  to	  sites	  of	  DNA	  damage	  
Once	  the	  interaction	  of	  the	  BRCT	  domains	  and	  γH2AX	  had	  been	  identified	  biochemically	  by	  co-­‐
purification	   from	   mammalian	   cells,	   it	   was	   then	   necessary	   to	   determine	   whether	   the	   BRCT	  
domains	  alone	  could	  localise	  to	  sites	  of	  DNA	  damage.	  	  
In	  order	  to	  test	  this,	  cells	  were	  transiently	  transfected	  with	  the	  BRCT	  domain	  constructs	  eYFP-­‐
NLS-­‐BRCT	  (WT,	  R1811E,	  K1814E	  or	  empty	  vector).	  The	  cells	  were	  pre-­‐treated	  for	  30	  minutes	  at	  
37°C	  with	  Hoechst	  stain.	  Hoechst	  intercalates	  between	  stacked	  base	  pairs	  in	  double	  stranded	  
DNA	  via	   the	  minor	  groove	   [264].	   The	  dye	  was	   then	  excited	  using	  a	  high-­‐power	  UVA	   laser	   to	  
induce	  DNA	  damage	  in	  a	  highly	  localised	  region	  within	  the	  cell	  nucleus.	  Following	  the	  induction	  
of	   damage,	   using	   a	   spinning-­‐disc	   confocal	   microscope,	   it	   was	   possible	   to	   track	   and	   record	  
changes	  in	  fluorescence	  intensity	  in	  real-­‐time.	  	  
Using	   this	   approach,	   it	   was	   established	   that	   53BP1-­‐BRCT	   domains	   alone	   are	   capable	   of	  
localising	  to	  sites	  of	  laser-­‐induced	  damage	  independently	  of	  domains	  required	  for	  recognition	  
of	  histone	  methylation	  and	  ubiquitination	  (figure	  5.4a).	  In	  order	  to	  confirm	  that	  double	  strand	  
breaks	  were	  generated	  by	  the	   laser,	  a	  control	  vector	  expressing	  the	  BRCT	  domains	  of	  MDC1,	  
eYFP-­‐NLS-­‐BRCT	   (MDC1)	   (previously	   shown	   to	   interact	   with	   γH2AX	   [263]),	   was	   included.	   As	  
demonstrated	  earlier,	  the	  BRCT	  domains	  of	  MDC1	  have	  a	  3.5-­‐fold	  higher	  affinity	  for	  the	  γH2AX	  
phosphopeptide.	  Interestingly,	  this	  increased	  affinity	  is	  apparent	  using	  this	  live-­‐cell	  assay,	  the	  
change	   in	   fluorescence	   intensity	   of	  MDC1-­‐BRCTs	   is	   nearly	   3-­‐fold	   higher	   than	   that	   of	   53BP1-­‐
BRCTs	  (figure	  5.4b).	  	  
Furthermore,	   cells	   transfected	   with	   either	   of	   the	   two	   BRCT	   mutant	   constructs	   (YFP-­‐NLS-­‐
R1811E	   or	   K1814E)	   fail	   localise	   to	   sites	   of	   damage	   as	   indicated	   by	   the	   negligible	   change	   in	  
fluorescence	   intensity	   following	  the	   introduction	  of	  DNA	  damage	   (figure	  5.4b).	  Failure	  of	   the	  
two	   mutant	   BRCT	   domains	   (R1811E	   and	   K1814E)	   to	   localise	   to	   sites	   of	   damage	   strongly	  
supports	   the	   hypothesis	   that	   this	   interaction	   is	   phosphorylation	   dependent	   and	   specifically	  
requires	  the	  interaction	  with	  the	  carboxyl	  group	  on	  the	  phosphopeptide.	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Figure	   5.4	   53BP1	   BRCT	   domains	   localise	   to	   DNA	   damage.	   a)	   HeLa	   cells	  were	   reverse	  
transfected	  with	  53BP1	  siRNA.	  48	  hours	  later	  cells	  were	  transfected	  with	  YFP-­‐NLS-­‐BRCT	  
constructs	   containing	   either	  wild-­‐type	   BRCT	   domains	   from	  53BP1	   or	  MDC1,	   an	   empty	  
vector	   containing	   a	   nuclear	   localisaAon	   signal	   (NLS)	   or	   one	   of	   the	   53BP1-­‐BRCT	   point	  
mutants.	   16	   hours	   aqer	   this	   and	   aqer	   pre-­‐sensiAsaAon	  with	   Hoechst	   stain	   cells	   were	  
damaged	   using	   laser	   micro-­‐irradiaAon.	   YFP	   was	   tracked	   over	   2	   minutes	   to	   observe	  
localisaAon	   to	   laser	   tracks.	   b)	   YFP	  was	   tracked	  over	  2	  minutes	   to	  observe	   localisaAon.	  
Fluorescence	  intensity	  proﬁles	  were	  generated	  using	  Slidebook6	  soqware	  (n=30	  from	  3	  
experimental	  repeats.	  Error	  bars	  show	  1	  standard	  deviaAon).	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5.2.3	  The	  BRCT	  domains	  localisation	  is	  dependent	  on	  kinase	  activity	  
To	  analyse	   the	  dependence	  of	   the	   localisation	  of	   the	  BRCT	  domains	  on	  phosphorylation,	   the	  
laser	  track	  experiments	  were	  repeated	  in	  cells	  that	  had	  been	  pre-­‐treated	  with	  caffeine	  1	  hour	  
prior	   to	   micro-­‐irradiation.	   High	   concentrations	   of	   caffeine	   have	   previously	   been	   shown	   to	  
inhibit	   the	   kinases	   required	   to	   phosphorylate	   γH2AX	   [265].	   Pre-­‐treating	   cells	   with	   8mM	  
caffeine	  prior	  to	  irradiation	  inhibits	  H2AX	  phosphorylation	  (figure	  5.5a).	  	  
Caffeine	   pre-­‐treatment	   of	   cells	   prior	   to	   laser-­‐induced	   irradiation	   prevented	   localisation	   of	  
eYFP-­‐NLS-­‐BRCT	  (WT)	  to	  regions	  of	  laser-­‐induced	  damage	  (figure	  5.5b).	  In	  order	  to	  characterise	  
this	  further,	  the	  checkpoint	  kinases	  ATM	  and	  DNA-­‐PK	  that	  are	  responsible	  for	  phosphorylating	  
H2AX	  in	  response	  to	  damage,	  were	  targeted	  using	  specific	  inhibitors.	  	  
These	  two	  kinases	  display	  functional	  redundancy	  since	  in	  the	  absence	  of	  ATM,	  DNA-­‐PK	  is	  able	  
to	   phosphorylate	   H2AX,	   albeit	   to	   a	   lesser	   extent	   than	   in	   the	   presence	   of	   ATM	   [266].	  
Additionally,	   inhibition	   of	   DNA-­‐PK	   alone	   does	   not	   to	   affect	   γH2AX	   focus	   formation	   [267].	   In	  
order	   to	   analyse	   the	   effect	   of	   inhibiting	   these	   kinases	   HeLa	   cells	   were	   treated	   with	   either	  
DMSO	   (control),	   KU99533	   (ATMi),	   NU	   7441	   (DNA-­‐PKi)	   or	   treated	   with	   both.	   Simultaneous	  
inhibition	   of	   ATM	   and	   DNA-­‐PK	   prevents	   phosphorylation	   of	   histone	   H2AX	   in	   response	   to	  
ionising	   radiation.	   A	   partial	   decrease	   in	   phosphorylation	   was	   observed	   after	   ATM	   inhibition	  
alone	  (figure	  5.6a).	  	  
Having	   established	   the	   concentrations	   of	   both	   inhibitors	   required	   to	   prevent	   the	  
phosphorylation	   of	   H2AX,	   it	   was	   then	   necessary	   to	   test	   whether,	   under	   conditions	   where	  
phosphorylation	  of	  H2AX	   is	   inhibitied,	  YFP-­‐NLS-­‐BRCT	  (WT)	  was	  still	  able	  to	   localise	  to	  sites	  of	  
damage	  induced	  by	  laser-­‐microirradiation.	  	  
Cells	   were	   treated	   as	   before	   with	   the	   additional	   pre-­‐treatment	   with	   specific	   inhibitors.	   The	  
results	  clearly	  indicate	  that	  when	  the	  kinases	  required	  for	  γH2AX	  generation	  are	  inhibited,	  the	  
BRCT	  domains	  of	  53BP1	  fail	  to	  localise	  to	  sites	  of	  damage	  (figure	  5.6b).	  Addition	  of	  the	  DNA-­‐PKi	  
does	  not	  affect	  localisation	  of	  the	  BRCT	  domains	  to	  sites	  of	  damage.	  However	  the	  addition	  of	  
ATMi	   alone	   significantly	   impairs	   localisation	   of	   YFP-­‐NLS-­‐BRCT	   (WT).	   Finally,	   by	   adding	   a	  
combination	  of	  both	  DNA-­‐PKi	  and	  ATMi	  localisation	  of	  the	  wild-­‐type	  BRCT	  domains	  to	  regions	  
of	  damage	  is	  completely	  abolished.	  These	  results	  are	  consistent	  with	  the	  earlier	  observations	  
that	  implicate	  γH2AX	  as	  a	  possible	  53BP1	  BRCT	  domain-­‐interacting	  candidate.	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Figure	   5.5	   YFP-­‐BRCT	   constructs	   fail	   to	   localise	   to	   caﬀeine	   treated	   cells.	   a)	   HeLa	  
cells	   were	   treated	   with	   the	   indicated	   concentraAon	   of	   caﬀeine	   1	   hour	   prior	   to	  
irradiaAon	  with	  3Gy	  IR.	  Cells	  were	  allowed	  to	  recover	  for	  30	  minutes	  aqer	  IR	  before	  
0.1%	   Triton	   extracAon	   and	   ﬁxaAon	   in	   0.4%	   PFA.	   Cells	   were	   immuno-­‐stained	   for	  
γH2AX	   and	   NBS1.	   b)	   HeLa	   cells	   were	   reverse	   transfected	   with	   53BP1	   siRNA.	   48	  
hours	  later	  cells	  were	  transfected	  with	  either	  an	  empty	  vector	  containing	  a	  nuclear	  
localisaAon	  signal	  (NLS)	  or	  YFP-­‐NLS-­‐53BP1-­‐BRCT	  constructs.	  15	  hours	  aqer	  this	  cells	  
were	   incubated	  with	  8mM	  caﬀeine	  for	  1	  hour	  prior	  to	   laser	  micro-­‐irradiaAon.	  YFP	  
was	  tracked	  over	  2	  minutes	  to	  observe	  localisaAon.	  Fluorescence	  intensity	  proﬁles	  
were	   generated	   using	   Slidebook6	   soqware	   (n=30	   from	   3	   experimental	   repeats.	  







Figure	   5.6	   53BP1	   BRCT	   domains	   localise	   to	   DNA	   damage	   dependent	   on	   kinase	  
ac8vity	  of	  ATM	  and	  DNA-­‐PK.	  a)	  HeLa	  cells	  were	  treated	  with	  either	  DNA-­‐Pki,	  ATMi	  or	  
both	   before	   ﬁxing	   and	   staining	   for	   γH2AX	   and	   NBS1	   b)	   HeLa	   cells	   were	   reverse	  
transfected	  with	   53BP1	   siRNA.	   48	   hours	   later	   cells	   were	   transfected	  with	   YFP-­‐NLS-­‐
BRCT	   constructs	   containing	   either	   a	   nuclear	   localisaAon	   signal	   alone	   (NLS)	   or	   wild-­‐
type	   53BP1-­‐BRCT	   domains	   (WT).	   15	   hours	   aqer	   this	   cells	   were	   treated	  with	   either	  
DNA-­‐Pki,	   ATMi	   or	   both	   for	   1	   hour	   prior	   to	   laser	   micro-­‐irradiaAon	   following	   pre-­‐
sensiAsaAon	   with	   Hoechst	   stain.	   YFP	   was	   tracked	   over	   2	   minutes	   to	   observe	  
localisaAon.	   Fluorescence	   intensity	   proﬁles	   were	   generated	   using	   Slidebook6	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5.2.4	  The	  localisation	  of	  the	  BRCT	  domains	  of	  53BP1	  to	  sites	  of	  DNA	  damage	  are	  
dependent	  on	  the	  presence	  of	  the	  Histone	  variant	  H2AX	  
Having	   shown	   that	   the	   localisation	   of	   the	   BRCT	   domains,	   in	   isolation,	   to	   sites	   of	   damage	   is	  
dependent	   on	   both	   specific	   recognition	   of	   a	   phosphopeptide	   and	   the	   activity	   of	   the	   kinases	  
required	   for	   phosphorylating	   H2AX	   in	   response	   to	   damage,	   it	   was	   then	   important	   to	   show	  
whether	   this	   localisation	  was	   also	   dependent	   on	   the	   histone	   variant	  H2AX.	   The	   laser	  micro-­‐
irradiation	  experiments	  with	  YFP-­‐NLS-­‐BRCT	  (WT)	  were	  repeated	  using	  H2AX	  -­‐/-­‐	  and	  H2AX	  +/+	  
mouse	  embryonic	  fibroblasts	  (MEFs).	  In	  the	  absence	  of	  the	  histone	  variant	  H2AX,	  and	  without	  
affecting	  any	  of	  the	  cellular	  kinases,	  the	  wild-­‐type	  53BP1	  BRCT	  domains	  fail	  to	  localise	  to	  tracks	  
produced	  by	  laser	  micro-­‐irradiation	  (figure	  5.7a	  and	  b).	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Figure	  5.7	  Loss	  of	  H2AX	  abolishes	  53BP1	  BRCT	  localisa8on	  to	  DSBs.	  a)	  H2AX	  
+/+	  and	  H2AX	  -­‐/-­‐	  MEFs	  were	  reverse	  transfected	  with	  53BP1	  siRNA.	  24	  hours	  
later	   cells	   were	   transfected	   with	   YFP-­‐NLS-­‐BRCT	   constructs	   containing	   either	  
wild-­‐type	  BRCT	  domains	   (WT)	  or	  a	  nuclear	   localisaAon	  signal	  alone	   (NLS).	  16	  
hours	   aqer	   this	   cells	   were	   damaged	   using	   laser	   micro-­‐irradiaAon.	   YFP	   was	  
tracked	   over	   2	   minutes	   to	   observe	   localisaAon.	   b)	   Fluorescence	   intensity	  
proﬁles	  were	  generated	  using	  Slidebook6	  soqware	  (n=30	  from	  3	  experimental	  
repeats.	  Error	  bars	  show	  1	  standard	  deviaAon).	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5.2.5	  Localisation	  of	  the	  BRCT	  domains	  does	  not	  result	  from	  dimerization	  with	  
endogenous	  53BP1	  
53BP1	   has	   been	   demonstrated	   to	   oligomerize	   through	   its	   oligomerization	   domain-­‐	   a	   region	  
upstream	   of	   the	   domains	   required	   for	   focus	   formation	   [268].	   However,	   the	   ability	   of	   the	  
Crb253BP1	   BRCT	   domains	   to	   co-­‐purify	   in	   S.	   pombe	   indicates	   that	   in	   yeast	   53BP1	   oligomerizes	  
through	   its	   BRCT	   domains	   [269].	   In	  mammalian	   cells,	   Lee	   et	   al	   demonstrated	   that	   the	   BRCT	  
domains	  of	  53BP1	  are	  also	  required	  for	  dimerization	  in	  addition	  to	  the	  oligomerization	  domain	  
[196].	  Importantly,	  they	  were	  also	  able	  to	  demonstrate	  that	  GST-­‐BRCT	  could	  oligomerize	  with	  
full-­‐length	   53BP1.	   As	   a	   result,	   it	   was	   necessary	   to	   test	   whether	   the	   localisation	   that	   was	  
observed	  using	  the	  YFP-­‐NLS-­‐BRCT	  construct	  occurred	  as	  a	  result	  of	  oligomerization	  of	  the	  BRCT	  
domains	  with	  endogenous	  53BP1.	  	  
All	   of	   the	   YFP-­‐NLS-­‐BRCT	   experiments	   were	   performed	   under	   conditions	   where	   53BP1	   was	  
depleted	  using	  RNAi.	  However,	  as	  RNAi	  is	  not	  100%	  effective	  the	  possibility	  remained	  that	  the	  
BRCTs	  could	   localise	  with	   the	  residual	   levels	  of	   the	  endogenous	  protein.	   It	  was	  hypothesised	  
that,	   if	   this	  were	   the	   case,	   the	   ability	   of	   the	   BRCT	   domains	   to	   localise	   to	   damage	  would	   be	  
enhanced	  when	  53BP1	  was	  not	  depleted	  as	  there	  would	  be	  more	  protein	  available	  to	  interact	  
with.	  In	  order	  to	  test	  this,	  HeLa	  cells	  were	  either	  depleted	  of	  53BP1	  by	  RNAi	  or	  left	  untreated.	  
48	  hours	  after	  this	  the	  cells	  were	  transfected	  with	  the	  YFP-­‐NLS-­‐BRCT	  (WT	  or	  Empty	  Vector)	  as	  
before.	  Protein	  localisation	  was	  analysed	  for	  3	  minutes	  following	  laser-­‐induced	  DNA	  damage.	  	  
The	  results	  indicate	  that	  there	  was	  no	  difference	  in	  the	  ability	  of	  the	  BRCT	  domains	  to	  localise	  
to	   damage	   when	   53BP1	   is	   depleted	   using	   RNAi	   versus	   untreated	   controls	   (figure	   5.8).	   This	  
indicates	  that	  localisation	  of	  the	  BRCT	  domains	  to	  damage	  was	  not	  a	  result	  of	  oligomerization	  
with	  the	  endogenous	  full-­‐length	  53BP1.	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Figure	   5.8	   Localisa8on	  of	   the	  BRCT	  domains	   does	   not	   result	   from	  oligomeriza8on	  
with	   endogenous	   53BP1.	  a)	  HeLa	   cells	  were	   either	   reverse	   transfected	  with	   53BP1	  
siRNA	  or	  a	  non-­‐targeAng	  control.	  48	  hours	  later	  cells	  were	  transfected	  with	  YFP-­‐NLS-­‐
BRCT	   constructs	   containing	   either	   wild-­‐type	   BRCT	   domains	   (WT)	   or	   a	   nuclear	  
localisaAon	  signal	  alone	  (NLS).	  Cells	  were	  pre-­‐treated	  with	  Hoechst	  stain	  prior	  to	  laser	  
micro-­‐irradiaAon.	   YFP	   was	   tracked	   over	   3	   minutes	   to	   observe	   localisaAon.	   b)	  
Fluorescence	  intensity	  proﬁles	  were	  generated	  using	  Slidebook6	  soqware	  (n=30	  from	  
3	  experimental	  repeats.	  Error	  bars	  show	  1	  standard	  deviaAon).	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5.2.6	  Mutation	  of	  the	  BRCT	  domain	  of	  53BP1	  by	  single	  point	  mutations	  causes	  a	  late	  
stage	  repair	  defect	  	  
Having	   shown	   that	  53BP1	  BRCT	  domains	  are	  capable	  of	   interacting	  with	  γH2AX	  both	   in	  vitro	  
and	  in	  vivo,	  experiments	  were	  undertaken	  to	  characterise	  any	  role	  that	  this	  interaction	  has	  in	  
the	  context	  of	  53BP1-­‐dependent	  DNA	  repair.	  	  
To	   do	   this,	   Dr	   Oliver	   Wilkinson	   (Watts	   lab)	   made	   two	   point	   mutations	   using	   site	   directed	  
mutagenesis	   within	   the	   BRCT	   domains	   of	   a	   full	   length	   HA-­‐53BP1	   siRNA-­‐resistant	   cDNA	  
construct	  (R1811E	  and	  K1814E).	  He	  utilised	  HeLa	  cells	  seeded	  at	  high	  confluence	  and	  depleted	  
them	  of	  endogenous	  53BP1	  using	  RNAi.	  Following	  this	  he	  transfected	  the	  cells	  with	  either	  the	  
wild-­‐type	  53BP1	  or	  one	  of	  the	  BRCT	  mutants.	  After	  the	  cells	  were	  allowed	  to	  express	  the	  cDNA	  
they	  were	  either	  left	  untreated	  or	  exposed	  to	  3Gy	  of	  ionising	  radiation.	  γH2AX	  foci	  were	  then	  
enumerated	  to	  study	  the	  repair	  kinetics	  of	  these	  cells.	  	  
Mutation	  of	  the	  BRCT	  domain	  of	  53BP1	  results	  in	  a	  ‘slow’	  kinetic	  repair	  defect	  as	  characterised	  
by	  a	  persistence	  of	  γH2AX	  foci	  at	  16	  and	  24	  hours	  following	  irradiation	  (figure	  5.9a)(performed	  
by	   Dr	   O.	  Wilkinson).	   It	   is	   proposed	   that	   these	   breaks	   represent	   a	   subset	   of	   DNA	   DSBs	   that	  
require	  more	   complex	   repair,	   occurring	  with	   slow	   repair	   kinetics	   [202,	   203].	   Dr	   Ross	   Cloney	  
(Watts	  Lab)	  consolidated	  these	  findings	  using	  U2OS	  cells	  (figure	  5.9b).	  These	  data	  corroborate	  
the	  findings	  by	  Noon	  et	  al	  [202]	  who	  demonstrated	  that	  deletion	  of	  the	  BRCT	  domain	  produces	  
a	   ‘slow’	  kinetic	  repair	  defect.	  Our	  data	  shows	  that	  this	  defect	   is	  attributable	  to	  the	  failure	  to	  
mediate	  a	  phospho-­‐specific	  interaction	  between	  53BP1-­‐BRCTs	  and	  their	  likely	  binding	  partner,	  
γH2AX.	  




































































Figure	   5.9	   53BP1	   BRCT	   domain	   mutants	   show	   a	   ‘slow’	   kine8c	   repair	   defect.	  
(Performed	  by	  Dr.	  Oliver	  Wilkinson).	  a)	  HeLa	  cells	  were	  reverse	  transfected	  with	  
53BP1	   siRNA.	   48	   hours	   later	   cells	   were	   transfected	   with	   an	   siRNA	   resistant	  
construct	  containing	  wild-­‐type	  HA-­‐53BP1	  or	  one	  of	  the	  BRCT	  mutants.	  16	  hours	  
later	  cells	  were	  exposed	  to	  3Gy	  ionising	  radiaAon	  and	  allowed	  to	  recover	  for	  the	  
indicated	   Ame	   before	   ﬁxing	   and	   staining	   for	   HA	   and	   γH2AX.	   γH2AX	   foci	   were	  
enumerated	   for	   25	   cells.	   Error	   bars	   show	   1	   standard	   deviaAon	   over	   3	  
experimental	   repeats	   b)	   U2OS	   cells	   processed	   as	   in	   a.	   (Performed	   by	   Dr.	   Ross	  
Cloney)	   (n=25	   error	   bars	   represent	   1	   standard	   deviaAon	   over	   3	   experimental	  










5.2.7	  53BP1	  BRCT	  domain	  mutants	  do	  not	  affect	  localisation	  of	  the	  MRN	  complex	  at	  
late	  stage	  timepoints	  
A	   single	   point	   mutation	   (either	   R1811E	   or	   K1814E)	   within	   the	   BRCT	   domain	   of	   53BP1	  
recapitulates	   the	   ‘slow’	   repair	   defect	   observed	   by	   Noon	   et	   al	   [202].	   In	   order	   to	   investigate	  
possible	  implications	  of	  disrupting	  this	   interaction,	   it	  was	  necessary	  to	  test	  the	  localisation	  of	  
other	   key	   mediators	   in	   the	   DNA	   damage	   response.	   Deletion	   of	   the	   BRCT	   domains	   has	  
previously	  been	  shown	  to	  disrupt	  the	  localisation	  of	  both	  pATM	  and	  the	  MRN	  complex	  [202].	  	  
The	   MRN	   complex	   (comprising	   Mre11,	   Rad50	   and	   Nbs1)	   is	   recruited	   rapidly	   to	   DSBs	   and	  
recognises	  broken	  DNA	  ends	  directly	  [270].	  The	  MRN	  complex	  is	  recruited	  to	  DSBs	  prior	  to	  the	  
recruitment	   of	   53BP1	   and	   the	   generation	   of	   γH2AX.	   After	   initial	   DSB	   recognition,	   the	  MRN	  
complex	   is	   capable	   of	   mediating	   several	   further	   interactions	   with	   mediator	   proteins	   to	  
facilitate	   the	   DNA	   damage	   response.	   The	   MRN	   complex	   activates	   the	   checkpoint	   kinase,	  
triggering	   autophosphorylation	   of	   ATM	   [271],	   which	   in	   turn	   phosphorylates	   γH2AX.	   MDC1	  
recognises	  γH2AX	  through	  its	  BRCT	  domains	  [263]	  and	  in	  turn,	  MDC1	  recruits	  more	  of	  the	  MRN	  
complex.	   This	   cycle	   facilitates	   the	   spreading	   of	   the	   γH2AX	   along	   the	   chromatin,	   flanking	   the	  
regions	   surrounding	   the	   break.	   Following	   on	   from	   this,	   53BP1	   is	   recruited	   by	   histone	   post-­‐
translational	  modifications-­‐	  ubiquitination	  of	  histone	  H2A	  and	  dimethylation	  of	  histone	  H3	  [9,	  
181].	  	  
Given	   the	   importance	  of	   these	   two	  mediators	   (MRN	  and	  pATM)	   for	   the	  progression	  of	  DNA	  
damage	   repair,	   immunofluorescence	   was	   used	   to	   analyse	   whether	   the	   localisation	   of	   these	  
mediators	  was	  affected	   in	  cells	   transfected	  with	   the	  53BP1	  BRCT	  domain	  mutants.	  The	  BRCT	  
domains	  of	  53BP1	  have	  been	  shown	  to	  be	  involved	  in	  phospho-­‐independent	  interactions	  with	  
the	   MRN	   complex	   through	   Rad50	   [259].	   Since	   the	   MRN	   is	   complex	   required	   prior	   to	   the	  
recruitment	  of	  pATM,	  it	  was	  necessary	  to	  test	  whether	  the	  interaction	  of	  53BP1	  with	  Rad50	  is	  
disrupted	  by	  mutation	  of	  the	  BRCT	  domains	  of	  53BP1.	  	  
HeLa	  cells	  were	  treated	  as	  before	  by	  depleting	  the	  endogenous	  53BP1	  using	  RNAi	  followed	  by	  
transfection	   with	   either	   the	   53BP1	   wild-­‐type	   or	   one	   of	   the	   mutants	   (R1811E,	   K1814E	   or	  
Y1502L-­‐Tudor	  domain)	  constructs.	  A	  HA-­‐53BP1	  construct	  with	  a	  point	  mutation	  located	  within	  
the	  Tudor	  domain	  was	  also	   included:	  mutation	  of	   the	  Tudor	  domain	  abolishes	   localisation	  of	  
53BP1	  to	  IRIF.	  In	  order	  to	  generate	  comparable	  numbers	  of	  γH2AX	  foci	  after	  24	  hours,	  due	  to	  
the	  repair	  defect	  observed	  in	  figure	  5.9,	  both	  the	  mock-­‐treated	  and	  cells	  transfected	  with	  the	  
wild-­‐type	   construct	   were	   exposed	   to	   8Gy	   ionising	   radiation,	   whereas	   the	   mutants	   were	  
exposed	   to	   just	   3Gy	   as	   used	   by	   Noon	   et	   al	   [202].	   This	   was	   to	   ensure	   that	   all	   samples	   had	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between	  5	  and	  10	  breaks	  per	  cell	  24	  hours	  after	  irradiation.	  The	  cells	  were	  immunostained	  for	  
HA	  (53BP1)	  to	  identify	  transfected	  cells	  and	  NBS1.	  	  
Localisation	  of	   the	  MRN	  complex	  was	  not	  disrupted	  by	   the	   introduction	  of	   the	  53BP1	  BRCT-­‐
R1811E	  or	  K1814E	  mutants	  (figure	  5.10).	  This	  contrasts	  with	  the	  deletion	  of	  the	  BRCT	  domain	  
or	   transfection	   with	   the	   Tudor	   domain	   mutant,	   which	   does	   impair	   MRN	   localisation.	   This	  
shows	   that	   the	  mutations	   are	   specific	   to	   the	   phosphorylation-­‐dependent	   interactions	   of	   the	  
BRCT	  domains.	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Figure	  5.10	  53BP1	  BRCT	  domain	  mutants	  co-­‐localise	  to	  sites	  of	  damage	  recognised	  by	  
the	  MRN	   complex.	   HeLa	   cells	  were	   reverse	   transfected	  with	   53BP1	   siRNA.	   48	   hours	  
later	   cells	  were	   transfected	  with	   an	   siRNA	   resistant	   construct	   containing	   either	  wild-­‐
type	  HA-­‐53BP1	  or	  one	  of	  the	  BRCT	  or	  Tudor	  domain	  mutants.	  16	  hours	  aqer	  this	  cells	  
were	  exposed	  to	  either	  8Gy	  for	  Mock	  and	  WT	  or	  3Gy	  ionising	  radiaAon	  for	  the	  mutants	  




5.2.8	  53BP1	  BRCT	  domain	  mutants	  fail	  to	  localise	  pATM	  at	  late	  stage	  timepoints	  
Having	  established	  that	  the	  MRN	  complex	  localised	  normally	  to	  sites	  of	  DNA	  damage	  with	  the	  
53BP1	   BRCT	   domain	  mutants,	   it	   was	   necessary	   to	   examine	   whether	   pATM	   localisation	   was	  
disrupted.	  The	  experiment	  was	  repeated	  with	  staining	  for	  HA	  (53BP1)	  and	  pATM.	  Interestingly,	  
both	  point	  mutations	  result	  in	  a	  failure	  to	  localise	  pATM	  at	  late	  stage	  time-­‐points	  (figure	  5.11).	  
It	  can	  be	  seen	  that	  despite	  normal	  53BP1	  focus	  formation,	  pATM	  completely	  fails	  to	  localise	  to	  
sites	   of	   damage	   and	   phenocopies	   the	   53BP1-­‐depleted	   cells	   and	   those	   transfected	   with	   the	  
53BP1	  Tudor	  domain	  mutant	  Y1502L	  (which	  fails	  to	  form	  foci).	  	  
In	  order	  to	  quantify	  the	  localisation	  of	  both	  pATM	  and	  MRN,	  the	  fluorescence	  intensity	  of	  each	  
was	  measured	   at	   loci	   in	   the	   cell	   marked	   by	   the	   presence	   of	   a	   53BP1	   focus,	   via	   the	   HA	   tag	  
(figure	  5.12).	  Furthermore,	   to	  account	   for	   the	  variability	   in	  expression	  produced	  by	   transient	  
transfections	   intensities	   of	   the	  HA-­‐	   (53BP1)	   foci	  were	   also	  measured.	   All	   three	   fluorescence	  
channels	  were	  normalised	  to	  the	  average	  focus	  intensity	  of	  the	  cells	  transfected	  with	  the	  wild-­‐
type	  53BP1	  construct.	  The	  intensities	  of	  HA	  foci	  were	  consistent	  across	  all	  experiments	  and	  all	  
foci	   analysed,	   indicating	   that	   there	   were	   similar	   levels	   of	   expression	   of	   the	   exogenous	  
constructs.	   The	   pATM	   localisation	   defect	   produced	   by	   the	   53BP1	   BRCT	   domain	   mutants	  
resulted	   in	   ~50%	   reduction	   in	   fluorescence	   intensity	   at	   sites	  marked	  by	   a	  HA	   (53BP1)	   focus.	  
The	  53BP1	  BRCT	  point	  mutants	  (R1811E	  and	  K1814E)	  fail	  to	  localise	  pATM	  but	  do	  still	  localise	  
the	  MRN	  complex.	  Finally,	  as	  noted	  before,	  depletion	  of	  53BP1	  alone	  or	  transfection	  with	  the	  
53BP1	  tudor	  domain	  mutant	  does	  impair	  MRN	  complex	  localisation.	  
To	  investigate	  this	  further	  it	  was	  important	  to	  establish	  the	  time	  following	  irradiation	  at	  which	  
phosphorylated	  ATM	  is	  no	  longer	  localised	  at	  the	  site	  of	  damage.	  Due	  to	  there	  being	  no	  defect	  
in	  γH2AX	  foci	  formation	  it	  was	  thought	  that	  pATM	  was	  likely	  to	  be	  concentrated	  and	  localised	  
at	   the	   sites	   of	   damage	   early	   on	   before	   displaying	   the	   defective	   pan-­‐nuclear	   distribution.	  
53BP1-­‐depleted	   HeLa	   cells	   were	   transfected	   with	   either	   the	   wild-­‐type	   or	   K1814E	   mutant	  
constructs	   and	   were	   fixed	   and	   stained	   for	   HA	   and	   pATM	   30	   minutes	   and	   1	   hour	   following	  
irradiation.	  The	  results	   indicate	   that	  pATM	  fails	   to	   localise	   to	  damage	  as	  early	  as	  30	  minutes	  
following	   damage	   when	   the	   BRCT	   domain	   is	   mutated	   (figure	   5.13).	   This	   suggests	   that	   the	  
recruitment	  and	  activation	  of	  pATM	  to	  in	  order	  to	  phosphorylate	  H2AX	  is	  highly	  transient	  and	  
that	  the	  retention	  of	  the	  kinase	  to	  chromatin	  is	  likely	  achieved	  by	  a	  separate	  BRCT-­‐dependent	  
set	  of	  interactions.	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Figure	   5.11	   53BP1	   BRCT	   domain	   mutants	   fail	   to	   localise	   pATM	   to	   sites	   of	   DNA	  
damage.	   HeLa	   cells	  were	   reverse	   transfected	  with	   53BP1	   siRNA.	   48	   hours	   later	   cells	  
were	   transfected	   with	   an	   siRNA	   resistant	   construct	   containing	   either	   wild-­‐type	  
HA-­‐53BP1	  or	  one	  of	  the	  BRCT	  or	  Tudor	  domain	  mutants.	  16	  hours	  aqer	  this	  cells	  were	  
exposed	  to	  either	  8Gy	  for	  Mock	  and	  WT	  or	  3Gy	  ionising	  radiaAon	  for	  the	  mutants	  and	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Figure	  5.12	  53BP1	  BRCT	  domain	  mutants	  co-­‐localise	  to	  sites	  of	  damage	  recognised	  by	  
the	  MRN	  complex	  but	   fail	   to	   localise	  pATM.	  Cells	  were	  processed	  as	   in	  5.9	  and	  5.10	  
with	  cells	  stained	  for	  HA,	  pATM	  and	  NBS1.	  Foci	  intensity	  was	  measured	  using	  Soqworx	  
soqware	  suite.	  Foci	  were	  marked	  by	   the	  presence	  of	  53BP1	  via	   the	  HA	   tag.	   Intensity	  
values	   were	   normalised	   to	   wild-­‐type	   foci	   intensity	   for	   NBS1,	   pATM	   and	   HA.	   Graph	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1	  hour	  post-­‐IR	  
Figure	   5.13	   53BP1	   BRCT	   domain	   mutants	   fail	   to	   localise	   pATM	   to	   sites	   of	  
damage	   as	   early	   as	   30	   minutes	   aber	   irradia8on.	   HeLa	   cells	   were	   reverse	  
transfected	   with	   53BP1	   siRNA.	   48	   hours	   later	   cells	   were	   transfected	   with	   an	  
siRNA	   resistant	   construct	   containing	   wild-­‐type	   HA-­‐53BP1	   or	   one	   of	   the	   BRCT	  
mutants.	   16	   hours	   aqer	   this	   cells	   were	   exposed	   3Gy	   ionising	   radiaAon	   and	  
allowed	   to	   recover	   for	   the	   indicated	   Ame	   before	   staining	   for	   HA	   and	   pATM.	  
Scale	  bar	  =	  10μm.	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5.2.9	  Depletion	  of	  KAP-­‐1	  by	  RNAi	  rescues	  the	  ‘slow’	  kinetic	  repair	  defect	  caused	  by	  
BRCT	  domain	  mutants	  
As	   mentioned	   in	   section	   4.2.9	   in	   order	   to	   repair	   complex	   breaks,	   via	   ‘slow’	   kinetic	   repair,	  
pATM-­‐dependent	  phosphorylation	  of	  KAP-­‐1	  on	  S824	  is	  required	  [202,	  203].	  Phosphorylation	  of	  
KAP-­‐1	   acts	   to	   promote	   chromatin	   relaxation	   and	   accessibility	   to	   DSB	   sites.	   It	   was	   therefore	  
decided	  to	  test	  whether	  the	  ‘slow’	  kinetic	  repair	  defect	  produced	  by	  the	  53BP1	  BRCT	  mutants	  
that	   results	   in	   a	   failure	   to	   localise	   pATM	   described	   above,	   is	   due	   to	   an	   inability	   to	  
phosphorylate	  KAP-­‐1	  to	  promote	  chromatin	  relaxation.	  	  
HeLa	  cells	  were	  either	  depleted	  of	  53BP1	  as	  before	  or	  dual	  depleted	  of	  both	  53BP1	  and	  KAP-­‐1.	  
As	   described	   above,	   siRNA	   resistant	   constructs	   were	   transfected	   into	   either	   53BP1	   only-­‐
depleted	  or	  double-­‐depleted	  backgrounds.	  Cells	  were	  then	  exposed	  to	  3Gy	  ionising	  radiation,	  
allowed	  to	  recover	  for	  the	  indicated	  time	  before	  fixing	  and	  staining	  for	  HA	  (53BP1)	  and	  γH2AX.	  
Finally,	  γH2AX	  foci	  were	  enumerated	  to	  indicate	  the	  number	  of	  breaks	  present	  within	  the	  cell	  
at	  that	  time.	  	  
Depletion	  of	  KAP-­‐1	  rescues	  the	  ‘slow’	  kinetic	  repair	  defect	  produced	  by	  mutation	  of	  the	  BRCT	  
domains	   of	   53BP1	   (figure	   5.14).	   As	   before,	   53BP1-­‐depleted	   cells	   and	   those	   transfected	  with	  
the	  53BP1	  BRCT-­‐K1814E	  mutant	   show	  a	   ‘slow’	  kinetic	   repair	  defect.	  This	   is	  overcome	  by	   the	  
additional	  depletion	  of	  KAP-­‐1	  as	  the	  number	  of	  persistent	  γH2AX	  foci	   is	  close	  to	  wild-­‐type	  or	  
untreated	   levels.	   This	   supports	   the	   hypothesis	   that	   the	   heterochromatin	   structure	   acts	   as	   a	  
barrier	  to	  repair	  for	  a	  subset	  of	  breaks	  that	  require	  BRCT-­‐dependent	  pATM	  localisation.	  	  	  






































Figure	  5.14	  siRNA	  deple8on	  of	  KAP-­‐1	  rescues	  the	  ‘slow’	  kine8c	  repair	  caused	  
by	   muta8on	   of	   the	   BRCT	   domains	   of	   53BP1.	   HeLa	   cells	   were	   reverse	  
transfected	   with	   53BP1	   and/or	   KAP-­‐1	   siRNA.	   48	   hours	   later	   cells	   were	  
transfected	  with	  an	  siRNA	  resistant	  construct	  containing	  wild-­‐type	  HA-­‐53BP1	  or	  
one	   of	   the	   BRCT	  mutants.	   16	   hours	   later	   cells	   were	   exposed	   to	   3Gy	   ionising	  
radiaAon	  and	  allowed	  to	  recover	  for	  the	   indicated	  Ame	  before	  staining	  for	  HA	  
and	   γH2AX.	   The	   graph	   shows	   average	   number	   of	   γH2AX	   foci	   per	   cell	   (n=25).	  
Error	  bars	  show	  1	  standard	  deviaAon	  over	  3	  experimental	   repeats.	   (note:	  This	  
experiment	   was	   performed	   at	   the	   same	   Ame	   as	   ﬁgure	   4.10	   with	   the	   same	  









5.2.10	  53BP1	  BRCT	  domain	  localisation	  to	  damage	  is	  independent	  of	  the	  chromatin	  
environment	  
Given	  the	  influence	  of	  KAP-­‐1	  on	  chromatin	  structure	  and	  how	  this	  affects	  the	  kinetics	  of	  repair,	  
it	  was	   important	   to	   test	  whether	   the	   chromatin	  environment	  has	   any	  bearing	  on	   the	  53BP1	  
BRCT-­‐γH2AX	  interaction.	  To	  investigate	  this,	  HeLa	  cells	  were	  either	  depleted	  of	  53BP1	  only	  or	  
dual-­‐depleted	   of	   53BP1	   and	   KAP-­‐1.	   Next,	   the	   cells	   were	   transfected	  with	   the	   YFP-­‐NLS-­‐BRCT	  
(WT)	   constructs	  used	  earlier.	   Cells	  were	  pre-­‐sensitised	  with	  Hoechst	  before	   the	   induction	  of	  
damage	  using	  a	  high-­‐power	  UVA	  laser.	  	  
Depletion	  of	  KAP-­‐1	  did	  not	  affect	   the	  ability	  of	   the	  YFP-­‐NLS-­‐BRCT	   (WT)	   to	   localise	   to	   sites	  of	  
damage	  (figure	  5.15).	  Both	  with	  and	  without	  KAP-­‐1	  RNAi,	  the	  change	  in	  intensity	  measured	  at	  
sites	   of	   damage	   was	   approximately	   7%	   indicating	   that	   the	   interaction	   between	   the	   BRCT	  
domain	  of	   53BP1	  and	   γH2AX	  occurs	   irrespective	  of	   the	   chromatin	   structure	   surrounding	   the	  
break	  site.	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Figure	  5.15	  YFP-­‐BRCT	  domains	  of	  53BP1	  localise	  to	  damage	  irrespec8ve	  the	  of	  
chroma8n	  environment.	  HeLa	  cells	  were	  reverse	  transfected	  with	  either	  53BP1	  
or	  53BP1	  and	  KAP1	  siRNA.	  48	  hours	  later	  cells	  were	  transfected	  with	  either	  YFP-­‐
NLS	  or	   YFP-­‐NLS-­‐BRCT	   constructs.	   16	  hours	   later	   cells	  were	  pre-­‐sensiAzed	  with	  
Hoechst	   stain	   and	   exposed	   to	   laser	  micro-­‐irradiaAon.	   YFP	  was	   tracked	   over	   2	  
minutes	   to	  observe	   localisaAon	   to	   laser	   tracks.	   Fluorescence	   intensity	   proﬁles	  
were	  generated	  using	  Slidebook6	  	  soqware	  (n=30	  from	  4	  experimental	  repeats.	  




5.2.11	  53BP1	  BRCT	  domain	  mutants	  fail	  to	  re-­‐position	  53BP1	  to	  the	  periphery	  of	  the	  
IRIF	  during	  S	  and	  G2-­‐phase	  
53BP1	   is	   physically	   repositioned	   to	   the	   periphery	   of	   IRIF	   relative	   to	   BRCA1	   to	   allow	   end	  
resection	   in	   S-­‐	   and	   G2-­‐phase	   cells	   [210].	   Experiments	   were	   undertaken	   to	   test	   whether	  
mutations	  within	  the	  γH2AX	  binding	  site	  in	  the	  BRCT	  domains	  of	  53BP1	  affect	  the	  antagonistic	  
relationship	   between	   53BP1	   and	   BRCA1.	   More	   specifically,	   given	   the	   newly	   identified	  
interaction	  of	  the	  BRCT	  domains	  and	  γH2AX,	  the	  relative	  positions	  of	  53BP1	  and	  BRCA1	  in	  IRIF	  
were	  analysed.	  	  
To	  test	  this	  R	  Cloney	  (Watts	  lab)	  used	  a	  similar	  experimental	  format	  as	  before,	  depleting	  HeLa	  
cells	   of	   endogenous	   53BP1	   by	   RNAi	   followed	   by	   transfection	   with	   either	   the	   wild-­‐type	   or	  
mutant	   53BP1	   BRCT	   constructs.	   The	   cells	   were	   then	   exposed	   to	   1Gy	   ionising	   radiation.	  
Following	   irradiation,	   the	   cells	   were	   incubated	   for	   a	   further	   8	   hours	   to	   allow	   DSB	   repair	  
progression.	   High-­‐resolution	   z-­‐stack	   images	  were	   taken.	   The	   images	  were	   then	   deconvolved	  
using	  SoftworX	  software	  suite.	  Imaris	  software	  was	  used	  to	  render	  z-­‐stacks	  into	  3-­‐dimentional	  
images	  (figure	  5.16a).	  
Fluorescence	  intensity	  profiles	  were	  measured	  from	  deconvolved	  z-­‐stack	  images	  by	  drawing	  a	  
single	   line	   intersecting	   the	   middle	   of	   the	   IRIF.	   30	   profiles	   over	   three	   experiments	   were	  
normalised	  to	  their	  highest	   intensity	  and	  positioned	  such	  that	  the	  highest	   intensity	  of	  BRCA1	  
was	  positioned	  at	  zero.	  Endogenous	  and	  wild-­‐type	  transfected	  53BP1	  show	  focal	  expansion	  of	  
~0.5µm	   in	   both	   directions	   from	   the	   IRIF	   centre	   8	   hours	   following	   irradiation.	   Analysis	   of	  
individual	  focus	  examples	  reveals	  that	  the	  wild-­‐type	  53BP1	  construct	  does	  not	  create	  a	  precise	  
ring	   surrounding	   BRCA1.	   Instead,	   expanded	   53BP1	   lobes	   can	   be	   observed	   on	   either	   side	   of	  
BRCA1.	  Further	  work	  will	  be	  required	  to	  determine	  the	  significance	  of	  this	  observation.	  	  
As	  can	  be	  seen	  from	  the	  analysis,	  53BP1	  fails	  to	  reposition	  at	  the	  periphery	  of	   IRIF	  when	  the	  
phospho-­‐specific	  binding	  activity	  of	  the	  BRCT	  domain	  is	  disrupted	  (figure	  5.16a	  and	  b).	  Instead,	  
53BP1	  remains	  localised	  to	  the	  core	  of	  the	  IRIF.	  	  
As	  53BP1	  is	  not	  removed	  from	  the	  core	  of	  the	  IRIF	  in	  cells	  transfected	  with	  the	  BRCT	  mutants,	  
it	  was	  proposed	  that	  this	  might	  hinder	  progression	  from	  NHEJ	  to	  HR-­‐driven	  repair.	  In	  order	  to	  
test	   whether	   HR	   was	   affected	   by	   mutation	   of	   the	   BRCT	   domain,	   R	   Cloney	   used	   U2OS	   cells	  
stably	  expressing	  a	  DR-­‐GFP	  construct.	  	  
After	   depletion	   of	   53BP1,	   the	   cells	   were	   co-­‐transfected	   with	   both	   the	   wild-­‐type	   or	   mutant	  
53BP1	   constructs	   along	  with	   an	   ISce-­‐I	   expression	   plasmid.	   ISce-­‐I	   introduces	   a	   double	   strand	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break	  within	  the	   inactive	  GFP	  gene.	  As	  before,	   if	   the	  cell	  attempts	  to	  repair	  this	  break	  by	  HR	  
the	  inactive	  GFP	  is	  resected,	  thereby	  removing	  an	  in-­‐frame	  stop	  codon	  from	  the	  GFP	  gene.	  The	  
downstream	  repair	  template,	  a	  N-­‐	  and	  C-­‐terminally	  truncated	  variant	  of	  the	  GFP	  gene	  can	  be	  
used	  to	  restore	  the	  active	  GFP	  gene,	  which	  is	  under	  the	  control	  of	  a	  promoter	  [272].	  Repair	  by	  
HR	  can	  then	  be	  analysed	  by	  fluorescence	  activated	  cell	  sorting.	  	  
R	   Cloney	   found	   that	   despite	   a	   failure	   to	   reposition	   53BP1	   containing	   a	   mutation	   in	   the	  
phospho-­‐peptide	  binding	  site,	  there	  was	  not	  a	  defect	   in	  HR	  (figure	  5.17).	  However,	  given	  the	  
influence	  of	   the	  chromatin	  environment	  on	   the	  efficacy	  of	   repair,	  using	  a	   reporter	   construct	  
that	   is	   likely	   integrated	   in	   a	   region	   of	   euchromatin	   is	   probably	   not	   a	   suitable	   method	   to	  
characterise	  this	  type	  of	  homology-­‐mediated	  repair.	  	  






















































Figure	   5.16	   53BP1	   BRCT	   mutants	   are	   not	   displaced	   by	   BRCA1	   and	   fail	   to	  
reposi8on	   to	   the	   periphery	   of	   IRIF	   in	   G2	   cells.	   HeLa	   cells	   were	   reverse	  
transfected	   with	   53BP1	   siRNA.	   48	   hours	   later	   cells	   were	   transfected	   with	   an	  
siRNA	   resistant	   construct	   containing	   wild-­‐type	   HA-­‐53BP1	   or	   one	   of	   the	   BRCT	  
mutants.	  16	  hours	  aqer	  this	  cells	  were	  exposed	  to	  either	  3Gy	  (Mock	  and	  WT)	  or	  
1Gy	   IR	   for	  mutants	  and	  allowed	   to	   recover	   for	  8	  hours	  before	  staining	   for	  HA	  
and	  BRCA1.	  a)	  High	  resoluAon,	  deconvolved	  Z-­‐stack	  images	  were	  obtained	  and	  
rendered	   using	   Imaris.	   b)	   QuanAtaAve	  measurements	   of	   intensity	   across	   foci	  























Figure	   5.17	  53BP1	  BRCT	  mutants	  do	  not	   show	  a	  HR	  defect.	   (Performed	  by	  Dr.	   Ross	  
Cloney).	   U20S	   cells	  with	   a	   stably	   integrated	   DR-­‐GFP	   construct	  with	   an	   Isce-­‐I	   cut	   site	  
were	  reverse	  transfected	  with	  53BP1	  siRNA.	  24	  hours	  later	  cells	  were	  transfected	  with	  
an	   siRNA	   resistant	   construct	   containing	   wild-­‐type	   HA-­‐53BP1	   or	   one	   of	   the	   BRCT	  
mutants	  alongside	  a	  plasmid	  encoding	  Isce-­‐I.	  Cells	  were	  incubated	  for	  48	  hours	  before	  
trypsinisaAon	   and	   analysis	   by	   ﬂow	   cytometry.	   Results	   show	   %	   of	   cells	   that	   are	   GFP	  
posiAve	  (average	  of	  3	  experiments,	  error	  bars	  show	  1	  standard	  deviaAon).	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5.2.12	  Re-­‐positioning	  of	  53BP1	  in	  S	  and	  G2	  phase	  is	  dependent	  on	  ATR	  kinase	  
activity	  
Having	   demonstrated	   that	   disruption	   of	   the	   phospho-­‐specific	   binding	   activity	   of	   the	   BRCT	  
domains	  of	  53BP1	  affected	  its	  re-­‐localisation,	  it	  was	  necessary	  to	  further	  characterise	  the	  role	  
of	  phosphorylation	  in	  mediating	  this	  repositioning	  event.	  Since	  the	  repositioning	  occurs	  several	  
hours	  after	  the	  creation	  of	  the	  damage,	  it	  was	  hypothesised	  that	  there	  might	  be	  a	  secondary	  
phosphorylation	   event	   that	   directs	   53BP1	   away	   from	   the	   focus	   core.	   Caffeine	  was	   added	   to	  
cells	  after	  the	  initial	  phosphorylation	  event,	  required	  to	  phosphorylate	  γH2AX,	  to	  determine	  if	  
the	  repositioning	  of	  53BP1	  requires	  a	  secondary	  phosphorylation	  event.	  	  	  
In	  order	  to	  do	  this	  the	  HeLa	  cells	  were	  exposed	  to	  ionising	  radiation	  to	  introduce	  double	  strand	  
breaks.	  The	  cells	  were	  treated	  with	  8mM	  caffeine	  to	  block	  any	  further	  H2AX	  phosphorylation.	  
The	   addition	   of	   caffeine	  was	   staggered	   from	   30	  minutes	   (i.e.	   after	   the	   initial	  wave	   of	   H2AX	  
phosphorylation)	  to	  6	  hours	  after	  irradiation.	  The	  cells	  were	  allowed	  to	  recover	  for	  a	  period	  of	  
8	  hours	  before	  fixing	  and	  staining	  for	  53BP1	  and	  BRCA1.	  Unlike,	  previous	  experiments	  53BP1	  
was	  visualised	  using	  an	  antibody	  directed	  to	  the	  endogenous	  protein,	  rather	  than	  via	  a	  HA-­‐tag	  
on	   an	   exogenously	   introduced	   construct.	   Deconvolved	   high-­‐resolution	   z-­‐stack	   images	   were	  
taken	  and	  as	  before	  intensity	  profiles	  were	  measured	  from	  30	  foci	  over	  3	  experiments.	  	  
The	   results	   show	   that	   repositioning	  of	  53BP1	   from	   the	   core	  of	   the	   focus	   in	   S-­‐	   and	  G2-­‐phase	  
cells	   is	   firstly	   a	   kinase-­‐dependent	   event	   and	   secondly,	   that	   this	   kinase-­‐dependent	  
phosphorylation	  event	  occurs	  after	  the	  initial	  wave	  of	  phosphorylation	  observed	  immediately	  
following	   damage	   (figure	   5.18a	   and	   b).	   Additionally,	   the	   repositioning	   of	   53BP1	   occurs	  
between	  6	  to	  8	  hours	  following	  the	  introduction	  of	  DNA	  damage.	  As	  demonstrated	  earlier,	  the	  
majority	   of	   DSBs	   generated	   were	   repaired,	   using	   fast	   kinetics,	   between	   6	   and	   16	   hours	  
following	   irradiation.	   The	   results	   indicate	   that	   the	  majority	   of	   53BP1	   focal	   expansion	   occurs	  
between	  6-­‐8	  hours	  after	  irradiation.	  	  
Finally,	  we	  wanted	  to	  identify	  the	  kinase	  responsible	  for	  the	  second	  wave	  of	  phosphorylation.	  
The	  above	  experiment	  was	   repeated	  using	  either	  an	  ATMi	   (Ku55933)	  or	  an	  ATRi	   (ATR	  kinase	  
inhibitor	  II)	  in	  place	  of	  the	  caffeine	  used	  before.	  	  
Unexpectedly	   the	   ATM	   inhibitor,	   which	   had	   been	   previously	   demonstrated	   to	   significantly	  
reduce	   γH2AX	   foci	   formation	   after	   DNA	   damage,	   did	   not	   affect	   53BP1	   repositioning	   after	  
irradiation.	  However,	  treatment	  with	  an	  ATR	  inhibitor	  did	  prevent	  the	  repositioning	  of	  53BP1	  
in	  S-­‐	  and	  G2-­‐phase	  cells	  (figure	  5.19	  and	  figure	  5.20).	  This	  suggests	  that	  there	  is	  a	  role	  for	  ATR	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in	  the	  reorganisation	  of	  IRIF	  at	  later	  time	  points	  following	  irradiation	  but	  does	  not	  rule	  out	  the	  
possibility	  of	  ATR-­‐dependent	  phosphorylation	  of	  H2AX	  to	  facilitate	  the	  repositioning	  of	  53BP1.	  	  









-­‐1.5	   -­‐0.5	   0.5	   1.5	  




-­‐1.5	   -­‐0.5	   0.5	   1.5	  




-­‐1.5	   -­‐0.5	   0.5	   1.5	  




-­‐1.5	   -­‐0.5	   0.5	   1.5	  

























Figure	   5.18	   Reposi8oning	   of	   53BP1	   in	   G2-­‐phase	   cells	   is	   a	   kinase	   dependent	  
event.	  HeLa	  cells	  were	  exposed	  to	  3Gy	  ionising	  radiaAon.	  Cells	  were	  allowed	  to	  
recover	   for	   the	   indicated	   Ame	   before	   the	   addiAon	   of	   8mM	   caﬀeine.	   8	   hours	  
aqer	   the	   iniAal	   damage	   cells	   were	   ﬁxed	   and	   immunostained	   for	   53BP1	   and	  
BRCA1.	  a)	  Deconvolved	  z-­‐stack	  images	  were	  obtained	  b)	  intensity	  proﬁles	  across	  
foci	   were	   generated	   using	   soqWoRx	   soqware	   (n=30	   average	   shown	   over	   3	  
experiments	  with	  1	  standard	  deviaAon).	  Scale	  bar	  =	  5µm.	  








Figure	  5.19	  ATR	  kinase	  ac8vity	  is	  required	  for	  53BP1	  reposi8oning	  in	  G2	  phase	  
cells.	  HeLa	  cells	  were	  exposed	  to	  1Gy	  of	   ionising	  radiaAon.	  Cells	  were	  allowed	  
to	  recover	  for	  the	  30	  minutes	  before	  the	  addiAon	  of	  either	  Ku55933	  (ATMi)	  or	  
ATR	   kinase	   inhibitor	   II.	   8	   hours	   aqer	   the	   iniAal	   damage	   cells	   were	   ﬁxed	   and	  
immunostained	   for	   53BP1	   (red)	   and	   BRCA1	   (green).	   High-­‐resoluAon	   z-­‐stack	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Figure	   5.20	   ATR	   kinase	   ac8vity	   is	   required	   immediately	   prior	   to	   53BP1	  
reposi8oning	  in	  G2	  phase	  cells.	  HeLa	  cells	  were	  processed	  as	  in	  5.18	  inhibitors	  
were	  added	  at	  the	  indicated	  Ames.	  8	  hours	  following	  irradiaAon	  cells	  were	  ﬁxed	  
and	  stained	  for	  BRCA1	  and	  53BP1.	  IRIF	  intensity	  proﬁles	  were	  measured	  across	  
foci	   using	   soqWoRx	   soqware	   suite	   (n=30	   average	   shown	   over	   3	   experiments	  




Our	   investigations	   have	   shown	   that	   the	   BRCT	   domains	   of	   53BP1	   interact	   specifically	   and	  
directly	   with	   γH2AX	   in	   vitro	   using	   a	   combination	   of	   fluorescence	   polarisation	   and	   X-­‐ray	  
crystallography.	  Using	  the	  X-­‐ray	  crystal	  structure	  it	  was	  possible	  to	  identify	  residues	  critical	  for	  
mediating	   this	   interaction	   and	   as	   a	   result,	   make	   specific	   point	   mutations	   to	   abolish	   this	  
interaction.	  	  
Furthermore,	  by	  isolating	  the	  BRCT	  domains	  of	  53BP1	  fused	  to	  an	  eYFP-­‐fluorescent	  reporter	  it	  
was	  possible	   to	  observe	   and	  quantify	   the	   intrinsic	   ability	   of	   the	  BRCT	  domains	   to	   localise	   to	  
sites	  of	  laser-­‐induced	  damage.	  Importantly,	  this	  localisation	  was	  not	  the	  result	  of	  dimerization	  
of	  the	  BRCT	  domain	  with	  residual	  endogenous	  53BP1.	  Additionally,	  by	  making	  one	  of	  two	  point	  
mutations	  or	  by	   targeting	   the	  kinases	   responsible	   for	  phosphorylating	  H2AX,	   the	   localisation	  
was	   abolished	   and	   demonstrates	   that	   the	   in	   vivo	   interaction	   is	   also	   phosphorylation	  
dependent.	  	  
Although	   these	   data	   allude	   to	   γH2AX	   being	   the	   interacting	   partner	   with	   which	   the	   BRCT	  
domains	  of	  53BP1	  interact,	  the	  failure	  of	  the	  mutant	  BRCT	  domains	  to	  localise	  to	  laser-­‐induced	  
damage	  only	   indicates	  dependence	  on	  a	  phosphorylated	   target,	  but	  does	  not	   indicate	  which	  
target	  protein.	  The	  same	  is	  true	  when	  the	  activity	  of	  the	  checkpoint	  kinases,	  ATM	  and	  DNA-­‐PK,	  
are	   inhibited.	   The	   failure	   to	   localise	   the	   BRCT	   domain	   to	   sites	   of	   damage	   indicates	   that	  
phosphorylation	   by	   ATM	   and	   DNA-­‐PK	   is	   required,	   but	   as	   these	   kinases	   are	   responsible	   for	  
phosphorylating	   hundreds	   of	   proteins	   within	   the	   cell,	   it	   does	   not	   rule	   out	   another	  
phosphorylated	  target	  being	  responsible	  for	  the	  localisation.	  	  
Furthermore,	   the	   failure	   to	   localise	   YFP-­‐NLS-­‐BRCT	   (WT)	   in	   H2AX	   -­‐/-­‐	  MEFs	   clearly	   indicates	   a	  
dependence	   of	   H2AX,	   however	   the	   possibility	   remains	   that	   loss	   of	   this	   histone	   variant	  may	  
result	  in	  the	  additional	  loss	  of	  multiple	  protein	  interaction	  networks	  associated	  with	  the	  γH2AX	  
which	  could	  ultimately	  prevent	  the	  localisation	  of	  the	  BRCT	  domains.	  	  	  	  	  
One	   of	   the	   limitations	   of	   using	   the	   YFP-­‐NLS-­‐BRCT	   reporter	   constructs	   is	   the	   overexpression	  
produced	   by	   the	   CMV	   promoter	   used	   to	   drive	   expression.	   This	   promoter	   caused	   the	   entire	  
nucleus	  to	  display	  a	  fluorescent	  signal.	  As	  a	  result,	  it	  was	  not	  possible	  to	  visualise	  localisation	  
of	   the	   constructs	   using	   damage	   induced	   by	   ionising	   radiation,	   this	   is	   likely	   due	   to	   the	  
expression	   level	   of	   the	   YFP-­‐NLS-­‐BRCT	   (WT)	  being	   far	   higher	   than	   the	  endogenous	   level.	   This	  
could	  also	  result	  from	  the	  competition	  of	  53BP1	  with	  MDC1	  as	  mentioned	  earlier.	  As	  a	  result,	  
more	  concentrated	  damage	  was	  generated	  using	  a	  high	  power	  UVA	  laser.	  Even	  with	  the	  more	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highly	  concentrated	  damage,	  the	  change	  in	  localisation	  of	  the	  YFP	  signal	  was	  very	  small	  (as	  low	  
as	  5-­‐7%).	  	  
In	  order	  to	  establish	  whether	  the	  competition	  with	  MDC1	  was	  the	  reason	  for	  the	  small	  change	  
in	   localisation,	   it	   would	   be	   necessary	   to	   deplete	   MDC1	   by	   siRNA	   prior	   to	   analysing	   the	  
recruitment	   kinetics	   of	   YFP-­‐NLS-­‐BRCT	   (WT).	   However,	   depletion	   of	  MDC1	  would	   disrupt	   the	  
MDC1-­‐MRN-­‐ATM-­‐γH2AX	   positive	   feedback	   loop	   required	   for	   γH2AX	   spreading	   along	   the	  
chromatin,	   it	  would	   therefore	  be	  unlikely	   that	   the	  wild	   type	  BRCT	  domains	  would	   localise	  to	  
sites	  laser-­‐induced	  damage	  under	  these	  conditions.	  	  
Further	  work	  will	  be	  required	  to	  analyse	  the	  interactions	  of	  the	  BRCT	  domains	  of	  both	  MDC1	  
and	   53BP1	   at	   endogenous	   expression	   levels	   and	   fully	   characterise	   the	   competition	   between	  
these	   two	   proteins.	   Genome	   editing	   techniques,	   such	   as	   CRISPR,	   could	   be	   used	   to	   create	  
mutations	   in	   the	   TP53BP1	   gene	   under	   the	   control	   of	   the	   endogenous	   promoter.	   The	   same	  
techniques	   could	   also	   be	   employed	   to	   tag	   the	   gene	   with	   a	   GFP	   reporter	   gene	   to	   analyse	  
recruitment	  kinetics	  in	  real-­‐time.	  	  	  	  
Thirdly,	  by	  knocking	  down	  endogenous	  53BP1	  and	  transfecting	  cells	  with	  constructs	  containing	  
our	  mutants	  we	  were	  able	  to	  demonstrate	  that	  the	  phospho-­‐specific	  interactions	  of	  the	  BRCT	  
domains	  are	  required	  for	  repair	  of	  ‘slow’	  kinetic	  or	  complex	  DSBs.	  The	  repair	  defect	  occurs	  due	  
to	  a	   failure	   to	   retain	  pATM	  at	   the	   sites	  of	  damage	   independently	  of	  MRN	   localisation.	  Using	  
dual	   RNAi	   depletion	   we	   were	   able	   rescue	   the	   repair	   defect	   by	   targeting	   the	   downstream	  
chromatin	  effector,	  KAP-­‐1.	  	  
Following	  the	  generation	  of	  CRISPR	  engineered	  cell	  lines,	  it	  would	  be	  necessary	  to	  confirm	  that	  
the	  same	  repair	  defects	  and	   localisation	  defects	  are	  still	  observed.	  Given	  the	  varied	  range	  of	  
important	  roles	  mediated	  by	  KAP-­‐1	  in	  regulating	  and	  protecting	  the	  genome	  [273]	  it	  would	  be	  
important	  to	  confirm	  that	  the	  rescue	  produced	  by	  the	  depletion	  of	  KAP-­‐1,	  results	  directly	  from	  
phosphorylation	   of	   KAP-­‐1	   by	   pATM.	   By	   using	   genome	   engineering	   techniques,	   an	   un-­‐
phosphorylatable	   mutant	   (S824A)	   and	   a	   phosphomimetic	   mutant	   (S824D/E)	   could	   be	  
generated	   under	   the	   control	   of	   the	   endogenous	   promoters.	   Enumerating	   γH2AX	   as	   before,	  
with	   these	   new	   cell	   lines	   would	   indicate	   whether	   the	   repair	   defect	   is	   solely	   due	   to	   the	  
defective	  KAP-­‐1	  phosphorylation	  by	  pATM.	  
Finally,	   by	   analysing	   the	   repositioning	   of	   53BP1	   in	   S-­‐	   and	   G2-­‐phase	   IRIF	   it	   has	   been	  
demonstrated	  that	  a	  phospho-­‐specific	  interaction,	  mediated	  by	  the	  BRCT	  domains	  of	  53BP1,	  is	  
required	  for	  repositioning	  of	  53BP1	  from	  the	  core	  of	  the	  IRIF	  to	  the	  periphery.	  Further	  to	  this,	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it	   was	   possible	   to	   show	   that	   this	   defect	   is	   phenocopied	   by	   the	   inhibition	   of	   ATR	   kinase	  
following	   damage.	   As	   ATR	   potentially	   regulates	   a	   number	   of	   downstream	   proteins	   by	   post-­‐
translational	  modification,	  it	  will	  be	  necessary	  to	  further	  characterise	  the	  role	  of	  this	  kinase	  in	  
the	  repositioning	  of	  53BP1	  and	  whether	  this	  acts	  downstream	  of	  the	  BRCT-­‐γH2AX	  interaction.	  	  




6.1	  Investigating	  the	  role	  of	  SUMOylation	  of	  eukaryotic	  translation	  
initiation	  factors	  
As	   the	   role	  of	   SUMOylation	   in	   regulating	   eIFs	   is	   discussed	  predominantly	   in	   section	  3.3,	   this	  
section	  will	  focus	  on	  the	  future	  directions	  of	  this	  project	  in	  relation	  to	  further	  characterisation	  
of	  the	  role	  of	  SUMOylation	  in	  mediating	  the	  response	  to	  cellular	  stress.	  	  	  
Looking	   at	   the	   future	   direction	   for	   this	   project	   it	  would	   be	   important	   establish	  whether	   the	  
introduction	   of	   an	   unSUMOylatable	   mutant	   affects	   miRNA-­‐mediated	   mRNA	   silencing.	  
Collaborative	  work	  from	  M.	  Bushell	  (University	  of	  Leicester)	  has	  since	  shown	  that	  mutation	  of	  
K226	   in	   eIF4A2	   does	   not	   impair	   miRNA-­‐mediated	   mRNA	   silencing	   using	   a	   let7	   luciferase	  
reporter	  assay.	  In	  order	  to	  further	  characterise	  the	  role	  of	  SUMO,	  it	  would	  be	  useful	  to	  create	  
unSUMOylatable	  eIF4A	  mutants	  under	  the	  control	  of	  their	  endogenous	  promoters	  using	  gene-­‐
editing	   techniques.	   The	   generation	   of	   these	   cell	   lines	   would	   be	   an	   invaluable	   tool	   to	  
characterise	  any	  changes,	  while	  more	   importantly	  not	  producing	  any	  artificial	   change	  due	   to	  
the	  over-­‐	  or	  under-­‐expression	  of	  exogenously	  introduced	  plasmid	  constructs.	  	  
Firstly,	  it	  would	  need	  to	  be	  established	  whether	  or	  not	  K216	  is	  the	  sole	  target	  of	  SUMOylation	  
of	  eIF4A1	   in	  mammalian	  cells.	   Following	  on	   from	  this,	   and	   the	  generation	  of	  a	  mutant	  using	  
gene	  editing,	  polysome	  fractionation	  and	  mRNAseq	  could	  be	  used	  to	  identify	  which	  transcripts	  
within	   the	  cell	   are	  being	  actively	   translated.	  Further	   to	   this,	  any	  change	   in	   the	  mRNAs	  being	  
targeted	   for	   translation	   in	   response	   to	   stress	   granule	   formation	   could	   be	   quantified	   and	  
normalised	   to	   the	  cellular	  mRNA	   levels.	  Additionally,	  any	  decrease	   in	   the	  number	  of	  actively	  
translated	  genes	  between	   the	  mutant	  and	  wild-­‐type	  eIF4A1	  with	  and	  without	  pre-­‐treatment	  
with	  a	  stress	  granule	  inducing	  agent	  would	  help	  elucidate	  whether	  SUMOylation	  of	  translation	  
factors	  acts	  to	  promote	  stress	  granule	  formation.	  	  
In	  the	  case	  of	  eIF4A2,	  given	  that	  the	  unSUMOylatable	  mutant	  does	  not	  affect	  miRNA-­‐mediated	  
mRNA	  silencing,	  a	  polySUMO-­‐eIF4A2	  fusion	  protein	  could	  be	  introduced	  into	  mammalian	  cells.	  
Analysis	   of	   how	   readily	   this	   fusion	   protein	   is	   incorporated	   into	   stress	   granules	   under	   stress	  
conditions	   could	   further	   consolidate	   this	   function	   of	   SUMO.	   	   As	  mentioned	   earlier,	   the	  mild	  
phenotype	  observed	  may	  result	  from	  group	  protein	  interactions	  by	  a	  number	  of	  SUMOylated	  
proteins.	  As	  a	  result,	  mutation	  of	  all	  of	  the	  SUMOylation	  sites	  identified	  in	  the	  eIF4F	  complex	  




6.2	  Characterisation	  of	  the	  phospho-­‐specific	  interactions	  between	  
53BP1	  and	  TopBP1	  and	  their	  role	  in	  DNA	  DSB	  repair	  
In	   this	  project,	   it	   has	  been	  determined	   that	   two	  phosphorylation	   sites	  within	   the	  N-­‐terminal	  
region	  of	  53BP1,	  S366	  and	  T670,	  are	   required	   for	   interaction	  between	  53BP1	  and	  TopBP1	   in	  
G1-­‐phase	   cells.	   Both	   S366	   and	   T670	   are	   phosphorylated	   in	   response	   to	   damage	   in	   vivo.	  
Furthermore,	   failure	  to	  phosphorylate	  either	  site	  disrupts	  co-­‐localisation	  between	  53BP1	  and	  
TopBP1	  in	  G1-­‐phase	  cells,	  as	  observed	  by	  immunofluorescence	  and	  impairs	  the	  direct	  physical	  
interaction	   of	   these	   two	   proteins,	   as	   observed	   by	   immunoprecipitation.	   Cells	   that	   cannot	  
mediate	   the	   interaction	   between	   53BP1	   and	   TopBP1	   fail	   to	   sustain	   G1-­‐phase	   arrest	   and	  
prevent	   entry	   into	   S-­‐phase	   while	   DNA	   damage	   persists	   (figure	   6.1).	   Concomitantly,	   cells	  
expressing	   these	   phosphorylation	   site	   mutants	   fail	   to	   repair	   a	   subset	   of	   DNA	   breaks	  
representative	   of	   the	   heterochromatic	   proportion	   of	   DNA	   DSBs.	   However,	   no	   defect	   was	  
observed	   in	   localisation	   of	   the	   checkpoint	   kinase,	   pATM	   or	   in	   the	   S-­‐	   and	   G2-­‐phase	  
repositioning	  of	  53BP1.	  	  
By	   analysing	   the	   co-­‐localisation	   of	   53BP1	   with	   TopBP1,	   it	   was	   possible	   to	   determine	   that	  
mutation	   of	   either	   phosphorylation	   site	   within	   53BP1,	   mutation	   of	   either	   S366A	   or	   T670A,	  
resulted	  in	  impaired	  recruitment	  of	  TopBP1	  to	  DNA	  DSBs.	  The	  53BP1-­‐S366A	  mutation	  appears	  
to	  abolish	  co-­‐localisation	  with	  TopBP1	  foci	  present	  within	  the	  cells,	  however	  the	  53BP1-­‐T670A	  
mutation	   appears	   to	   disrupt	   TopBP1	   foci	   formation	   altogether.	   This	   is	   consistent	   with	   the	  
observations	  of	  Cescutti	  et	  al	  [193]	  who	  showed	  that	  the	  removal	  of	  the	  BRCT	  domains	  0,	  1-­‐2	  
from	   the	   N-­‐terminus	   of	   TopBP1	   prevented	   its	   co-­‐localisation	   with	   both	   53BP1	   and	   RPA.	  
Furthermore,	   they	   also	   demonstrated	   that	   deletion	   of	   TopBP1	   BRCT	   domains	   4-­‐5	   did	   not	  
prevent	  focus	  formation	  in	  response	  to	  damage,	  but	  did	  significantly	  impair	  co-­‐localisation	  of	  
TopBP1	  and	  53BP1.	  This	   suggests	   that	  despite	  both	  phosphorylation	   sites	  being	   required	   for	  
interaction	   of	   53BP1	   with	   TopBP1	   there	   may	   yet	   be	   some	   functional	   difference	   of	  
phosphorylating	  each	  residue.	  	  
Furthermore,	  it	  remains	  to	  be	  determined	  which	  kinase(s)	  are	  required	  for	  phosphorylation	  of	  
S366	   and	   T670A.	   As	   the	   phosphopeptide	   sequence	   is	   comprised	   of	   a	   phosphorylated-­‐
serine/threonine	   followed	   by	   a	   proline	   residue,	   the	   kinase	   responsible	   for	   phosphorylating	  
these	   residues	   is	   potentially	   a	   cyclin-­‐dependent	   kinase	   [274].	   This	   would	   also	   be	   consistent	  
with	   the	  observations	  made	   in	  S.	  pombe,	  whereby	  Crb253BP1	   is	  phosphorylated	  on	   threonine-­‐
187	  by	  CDK	   in	  order	   to	   interact	  with	  Rad4TopBP1	   [238].	  This	  could	  be	  analysed	  by	  pre-­‐treating	  
cells	   with	   specific	   kinase	   inhibitors	   to	   determine	   which	   kinase	   is	   required	   to	   phosphorylate	  
these	   sites	   following	   damage.	   It	   will	   be	   of	   importance	   to	   note	   whether	   the	   same	   kinase	   is	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responsible	   for	   the	   phosphorylation	   of	   S366	   and	   T670	   or	  whether	   phosphorylation	   of	   these	  
residues	   requires	   the	   activity	   of	   two	   separate	  protein	   kinases.	   Furthermore,	   it	   could	   also	  be	  
the	  case	  that	  phosphorylation	  of	  one	  residue	  may	  be	  dependent	  on	  the	  prior	  phosphorylation	  
of	  the	  other,	  as	  is	  the	  case	  in	  S.	  pombe,	  whereby	  the	  phosphorylation	  of	  T187	  by	  CDK	  requires	  
prior	  phosphorylation	  of	  both	  T215	  and	  T235	  [238].	  
One	   interesting	  point	   to	  note	   is	   that	  despite	  a	   failure	  to	  recruit	  TopBP1	  to	   IRIF	  when	  53BP1-­‐
T670	   is	  mutated	   to	   alanine,	   cells	   treated	  with	   siRNA	  oligonucleotides	   targeting	   53BP1	   alone	  
are	  still	  able	  to	  form	  TopBP1	  foci.	  One	  explanation	  for	  this	  phenomenon	  is	  that	  in	  cells	  where	  
endogenous	  53BP1	  has	  been	  depleted,	   the	  cells	  are	  unable	   to	  protect	   the	  broken	  DNA	  ends	  
from	  being	  resected	  [190].	  This	  in	  turn	  would	  allow	  RPA	  to	  bind	  to	  any	  newly	  generated	  single	  
stranded	  regions	  of	  DNA	  [275].	   In	  these	  examples,	  TopBP1	  may	  still	  be	  recruited	  through	  the	  
conventional	   interaction	   with	   ATR	   through	   ATRIP	   and	   RPA	   [221].	   This	   RPA-­‐dependent	  
recruitment	  of	  TopBP1	  to	  sites	  of	  damage	  may	  be	  distinct	  from	  circumstances	  in	  which	  53BP1	  
is	   present	   and	   prevents	   generation	   of	   ssDNA,	   but	   cannot	   associate	   with	   TopBP1	   in	   a	  
phosphorylation-­‐dependent	  manner.	  This	  may	  also	  serve	  to	  account	  for	  the	  decreased	  number	  
of	   TopBP1	   foci	   present	   in	   53BP1-­‐depleted	   cells,	   as	   TopBP1	   localisation	   may	   be	   limited	   to	  
breaks	  that	  have	  undergone	  extensive	  end	  resection.	  In	  order	  to	  determine	  whether	  this	  is	  in	  
fact	  the	  case,	  co-­‐localisation	  of	  TopBP1	  foci	  with	  RPA	  in	  53BP1-­‐depleted	  G1-­‐phase	  cells	  could	  
be	  analysed.	  	  
Alternatively,	   in	   cells	   with	   53BP1	   present,	   it	   would	   be	   interesting	   to	   determine	   whether	  
TopBP1,	  53BP1	  and	  RPA	  co-­‐localise	  to	  DNA	  damage	  in	  G1-­‐phase	  cells.	  If	  RPA	  is	  not	  present	  in	  
IRIF	  where	  53BP1	  and	  TopBP1	  co-­‐localise,	  it	  would	  suggest	  that	  the	  role	  of	  this	  interaction	  is	  to	  
recruit	  TopBP1	  in	  the	  absence	  of	  RPA-­‐coated	  ssDNA.	  	  
Additionally,	  by	  analysing	  the	  number	  of	  γH2AX	  foci	  per	  cell	  in	  HeLa	  cells	  following	  exposure	  to	  
ionising	   radiation,	   it	  was	   demonstrated	   that	   53BP1-­‐depleted	   cells	   transfected	  with	   either	   of	  
the	  phosphorylation	  site	  mutants	  (53BP1-­‐S366A,	  -­‐T670A	  or	  double	  mutant)	  display	  a	  defect	  in	  
DSB	   repair.	   A	   subset	   of	   the	   total	   number	   of	   breaks	   (~15%)	   remained	   unrepaired	   24	   hours	  
following	  exposure	  to	   ionising	  radiation.	  The	  defect	  observed	  reflects	  the	  failure	  to	  complete	  
the	  ‘slow’	  kinetic	  DSB	  repair	  representative	  of	  the	  heterochromatic	  proportion	  of	  DSBs	  [202].	  
Further	   to	   this,	   additional	   depletion	   of	   KAP-­‐1,	   the	   downstream	   mediator	   required	   for	  
chromatin	   relaxation,	   bypasses	   the	   ‘slow’	   kinetic	   repair	   defect.	   This	   suggests	   that	   there	   is	   a	  
requirement	  for	  TopBP1	  localisation	  for	  repair	  of	  53BP1-­‐dependent	  DSBs	  comparable	  to	  those	  
requiring	  ATM	  for	  repair,	  but	  not	  acting	  through	  ATM	  localisation	  [203].	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Interestingly,	   TopBP1	   has	   been	   shown	   to	   localise	   ATM	   through	   interactions	   with	   the	   MRN	  
complex	  in	  Xenopus	  egg	  extracts.	  In	  these	  extracts,	  ATM-­‐dependent	  phosphorylation	  of	  S1131	  
is	   required	   for	   full	   activation	   of	   ATR	  by	   TopBP1,	   however	   the	   interaction	  with	  MRN	  has	   not	  
been	  demonstrated	  in	  humans	  [221,	  276].	  In	  mammalian	  cells	  however,	  TopBP1	  is	  required	  for	  
full	  activation	  of	  ATR	  via	  its	  ATR-­‐activation	  domain	  [229].	  As	  a	  result	  it	  would	  also	  be	  important	  
to	  analyse	  whether	  ATR,	  or	  its	  downstream	  target	  Chk1,	  are	  activated	  in	  response	  to	  damage	  
in	   G1-­‐phase	   cells	   with	   the	   phosphorylation	   site	   mutants.	   Research	   has	   only	   tentatively	  
suggested	   a	   role	   for	   ATR	   in	   G1-­‐phase	   cells	   as	   treatment	   with	   ATR	   inhibitors	   increases	   cell	  
sensitivity	   to	   ionising	   radiation-­‐induced	   killing	   [239].	   Furthermore,	   ATR	   foci	   have	   been	  
observed	  in	  G1-­‐phase	  cells	  following	  exposure	  to	  ionising	  radiation.	  Analysis	  of	  the	  recruitment	  
kinetics	   of	   ATR	   show	   its	   accumulation	   over	   two	   hours,	   comparable	   to	   that	   of	   TopBP1	  
recruitment,	  which	  appears	  1-­‐2	  hours	  following	  damage	  and	  peaking	  at	  approximately	  4	  hours	  
after	  DNA	  damage	  [193,	  277].	  
The	  interaction	  of	  53BP1	  with	  TopBP1	  is	  also	  required	  to	  mediate	  G1-­‐S	  phase	  checkpoint	  arrest	  
in	  response	  to	  DNA	  damage.	  Although	  the	  exact	  role	  of	  TopBP1	  in	  this	  process	  remains	  to	  be	  
established,	  it	  has	  been	  demonstrated	  that	  TopBP1	  regulates	  replication	  origin	  firing	  during	  S-­‐
phase	  and	  that	  TopBP1	  is	  required	  for	  intra-­‐S	  phase	  checkpoint	  arrest	  by	  suppressing	  the	  firing	  
of	   ‘late’	   replication	  origins	   [223,	  224].	   It	   is	  possible	   that	   localisation	  of	  TopBP1	   to	   IRIF	   in	  G1-­‐
phase	  cells	  serves	  to	  deplete	  the	  available	  pool	  of	  TopBP1	  capable	  of	  licencing	  DNA	  replication	  
and	   thereby	  preventing	  entry	   into	   S-­‐phase.	  However,	   this	   is	   unlikely	   as	  depletion	  of	   TopBP1	  
alone	  results	  in	  a	  failure	  to	  maintain	  G1-­‐phase	  cell-­‐cycle	  arrest	  following	  DNA	  damage	  [193].	  	  
There	   is	   second	   mechanism	   by	   which	   TopBP1	   may	   regulate	   S-­‐phase	   entry.	   Conventionally,	  
CDK2	   bound	   to	   cyclin-­‐E	   governs	   entry	   into	   S-­‐phase	   by	   phosphorylating	   Rb	   (Retinoblastoma	  
protein),	  which	  would	  otherwise	  suppress	  the	  activity	  of	  the	  transcription	  factor,	  E2F-­‐1	  [278].	  
E2F-­‐1	   activates	   transcription	   of	   a	   number	   of	   genes	   required	   to	   promote	   entry	   into	   S-­‐phase	  
[279].	  Furthermore,	  it	  has	  been	  demonstrated	  that	  overexpression	  of	  E2F-­‐1	  alone	  is	  enough	  to	  
stimulate	   cells	   to	   enter	   S-­‐phase	   [280].	   Importantly,	   TopBP1	   interacts	   directly	   with	   E2F-­‐1	  
through	   TopBP1-­‐BRCT	   domain	   6	   and	   suppresses	   the	   transcriptional	   activity	   of	   E2F-­‐1	   by	   re-­‐
localising	   it	   to	   IRIF	   [281].	  Ultimately	   this	   suggests	   that	   in	  G1-­‐phase	   cells,	   phosphorylation	   of	  
53BP1	  on	  S366	  and	  T670	  are	  required	  for	  recruitment	  of	  TopBP1	  to	  IRIF	  in	  order	  to	  re-­‐localise	  
and	   suppress	   the	   transcriptional	  activity	  of	  E2F-­‐1	  and	  prevent	  entry	   into	  S-­‐phase	  while	  DSBs	  
are	  present.	   In	  order	   to	  determine	   if	   this	   is	   the	  case,	   it	  would	  be	  necessary	  to	  deplete	  E2F-­‐1	  
from	   cells	   expressing	   the	   53BP1	   phosphorylation	   site	   mutants.	   If	   G1-­‐S	   phase	   arrest	   is	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dependent	  on	  downstream	  regulation	  of	  E2F-­‐1	  by	  TopBP1,	   the	  additional	  depletion	  of	  E2F-­‐1	  
should	   restore	   the	   G1-­‐S	   phase	   checkpoint	   in	   cells	   expressing	   the	   53BP1	   phosphorylation	  
mutants.	  	  
Finally,	  by	  analysing	  53BP1	  repositioning	  in	  G2-­‐phase	  cells	  and	  the	  ability	  to	  perform	  HR	  using	  
a	   GFP-­‐reporter	   assay	   it	   was	   possible	   to	   demonstrate	   that	   neither	   of	   these	   phosphorylation	  
mutants	  appears	  to	  impair	  the	  progression	  towards	  HR-­‐mediated	  repair,	  or	  HR	  itself,	  following	  
exposure	   to	   ionising	   radiation.	   This	   further	   strengthens	   the	   idea	   that	   the	   G1-­‐phase	   specific	  
interaction	  between	  53BP1	  and	  TopBP1	  is	  limited	  to	  the	  repair	  of	  complex	  of	  breaks	  solely	  by	  
NHEJ.	  
	   	  
Progression	  into	  S-­‐phase	  while	  DNA	  DSBs	  
are	  present	  
Figure	   6.1	   Proposed	   model	   for	   the	   role	   of	   the	   G1-­‐phase	   phosphorylaAon-­‐
dependent	  interacAon	  between	  53BP1	  and	  TopBP1.	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6.3	  Determining	  the	  phospho-­‐specific	  interactions	  of	  the	  BRCT	  
domains	  of	  53BP1	  and	  their	  role	  in	  DNA	  damage	  repair	  	  
In	  this	  project,	  it	  has	  been	  demonstrated	  that	  the	  BRCT	  domains	  of	  53BP1	  interact	  specifically	  
and	  directly	  with	  γH2AX	  in	  vitro.	  In	  vivo,	  localisation	  of	  the	  BRCT	  domains	  to	  sites	  of	  damage	  is	  
phosphorylation-­‐dependent,	  requires	  the	  histone	  variant	  H2AX	  and	  the	  kinase	  activity	  of	  both	  
ATM	  and	  DNA-­‐PK	  following	  damage.	  	  
While	  this	  work	  was	  being	  undertaken,	  the	  53BP1	  BRCT-­‐γH2AX	  interaction	  was	  also	  identified	  
by	   another	   research	   group	   by	   performing	   the	   reciprocal	   experiments	   i.e.	   co-­‐purification	   of	  
proteins	  with	   a	   γH2AX	  peptide.	   Further	   validation	  of	   this	   interaction	  by	   this	   research	   group,	  
suggested	  that	  mutation	  of	  K1814	  to	  methionine	   impairs	   recruitment	  of	   full-­‐length	  53BP1	  to	  
sites	  of	  laser	  induced	  damage,	  although	  the	  affect	  was	  less	  severe	  than	  in	  cells	   lacking	  MDC1	  
(which	  would	  fail	  to	  propagate	  the	  γH2AX	  signal)	  [282,	  283].	  This	  suggests	  that	  the	  recruitment	  
of	   full-­‐length	   53BP1	   to	   sites	   of	   DNA	   damage	   may	   be	   directly	   influenced	   by	   the	   ability	   to	  
recognise	   γH2AX.	   However	   the	   decrease	   in	   the	   rate	   of	   53BP1	   recruitment	   when	   the	   BRCT	  
domains	  are	  mutated	   is	  quite	  small	  and	  potentially	  difficult	  to	  detect	  without	  analysing	   large	  
numbers	  of	  cells.	  	  	  
The	   in	  vitro	   interaction	  data	   indicate	   that	   the	  BRCT	  domains	  of	  MDC1	  have	  a	  3.5-­‐fold	  higher	  
affinity	  for	  the	  γH2AX	  phosphopeptide	  than	  those	  of	  53BP1	  (Kd=0.4µM	  ±	  0.05	  for	  MDC1-­‐BRCTs	  
and	  1.4µM	  ±	  0.14	  for	  53BP1-­‐BRCTs).	  This	  suggests	  that	  at	  the	  molecular	  level	  MDC1	  is	  capable	  
of	  out-­‐competing	  53BP1	  for	  γH2AX.	  This	   is	  not	  surprising	  given	  that	   the	   interaction	  of	  MDC1	  
with	   γH2AX	   is	   required,	   prior	   to	   53BP1	   recruitment,	   for	   the	   spreading	   of	   the	   γH2AX	   signal	  
along	   the	   chromatin	  via	  additional	   recruitment	  of	  MRN	  and	  pATM	   [263,	  283,	  284].	   It	   is	  only	  
after	  this	  that	  53BP1	  is	  recruited	  through	  a	  combination	  of	  histone	  methylation	  and	  damage-­‐
induced	   ubiquitination	   [9,	   10].	   Given	   the	  weaker	   affinity	   of	   the	   BRCT	   domains	   of	   53BP1	   for	  
γH2AX	   it	   may	   be	   that	   this	   interaction	   only	   becomes	   physiologically	   important	   at	   this	   later	  
stage.	  	  
Further	   investigation	   could	   be	   undertaken	   to	   establish	   the	   specific	   dynamics	   of	   both	   53BP1	  
and	  MDC1	  to	  elucidate	  the	  potential	  antagonism.	  This	  could	  be	  analysed	  by	  transfecting	  cells	  
with	  fluorescently	  labelled	  MDC1	  and	  53BP1.	  Live-­‐cell	  imaging	  could	  be	  utilised	  to	  determine,	  
in	  real-­‐time,	  whether	  MDC1	  is	  retained	  at	  the	  break	  following	  damage	  or	  if	  there	  is	  a	  handover	  
to	  allow	  53BP1	  access	  to	  the	  chromatin	  via	  γH2AX	  binding.	  	  
The	  BRCT	  domains	  of	  53BP1	  mediate	  multiple	  phosphorylation-­‐independent	  interactions	  with	  
p53,	  Rad50	  and	  EXPAND1	  [196,	  197,	  258,	  285].	  Having	  characterised	  further	   interaction	  with	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γH2AX,	   it	  would	  be	  necessary	   to	  determine	  whether	   this	   interaction	   is	  mutually	  exclusive	  or	  
whether	  the	  BRCT	  domains	  are	  capable	  of	  mediating	  several	  phosphorylation-­‐dependent	  and	  -­‐
independent	  interactions	  simultaneously.	  	  
Mutations	  that	  impair	  the	  γH2AX-­‐binding	  of	  the	  BRCT	  domains	  of	  53BP1	  also	  disrupt	  pATM	  but	  
not	  MRN	   localisation.	  This	   is	   significant	  as	  previously	   it	  has	  been	   shown	   that	  deletion	  of	   the	  
BRCT	  domains	   impair	   the	   localisation	  of	  both	  ATM	  and	  MRN	  [202].	   Interestingly,	   it	  has	  been	  
demonstrated	   that	   ATM	   can	   localise	   to	   IRIF	   in	   the	   absence	   of	   MRN	   and	   Ku70	   [286].	   This	  
suggests	  that	  multiple	  interactions	  may	  be	  possible	  within	  the	  cell	  to	  localise	  ATM	  to	  the	  sites	  
of	   damage	   without	   the	   requirement	   for	   the	   conventional	   MDC1-­‐MRN-­‐ATM	   interaction	   and	  
could	  also	  begin	  to	  explain	  why	  localisation	  of	  pATM,	  but	  not	  MRN,	  is	  affected	  [283].	  
In	   this	  project,	   it	  has	  also	  been	  established	  that	  an	   inability	   to	  mediate	   the	  phosphorylation-­‐
dependent	  interactions	  of	  the	  BRCT	  domains	  of	  53BP1	  results	  in	  a	  persistence	  of	  γH2AX	  foci	  at	  
later	  time	  points,	  comparable	  to	  inhibition	  of	  ATM	  and	  representative	  of	  the	  heterochromatic	  
proportion	  of	  DSBs	  [202].	  	  Furthermore,	  these	  breaks	  are	  repaired	  by	  downregulation	  of	  KAP-­‐1	  
(figure	   6.2).	   ATM-­‐dependent	   phosphorylation	   of	   SUMOylated	   KAP1	   is	   required	   to	   release	  
CHD3,	   a	   chromatin	   remodeler,	   from	   regions	   of	   heterochromatin	   in	   order	   to	   promote	  
relaxation	   of	   heterochromatin	   [203].	   Interestingly,	   Artemis	   the	   DNA	   endonuclease	   is	   also	  
required	   for	   resolution	   of	  DSBs	   that	   display	   ‘slow’	   kinetics	   repair,	   but	   acts	   independently	   of	  
KAP-­‐1	   phosphorylation	   [267].	   These	   results	   suggest	   that	   although	   repair	   of	   heterochromatic	  
breaks	   requires	   signalling	   though	   53BP1	   and	   ATM,	   there	  may	   be	   a	   number	   of	   downstream	  
effector	   proteins	   required	   to	   both	   remodel	   chromatin	   and	   process	   the	   broken	   DNA	   ends	   in	  
preparation	  for	  repair.	  	  	  
In	   addition	   to	   the	   role	   of	   repair	   of	   heterochromatic	   DSBs	   in	   G1-­‐phase	   cells,	   it	   has	   been	  
demonstrated	  that	  there	   is	  a	  defect	   in	  53BP1	  repositioning	   in	  S-­‐	  and	  G2-­‐phase	  cells,	  a	  defect	  
that	  is	  recapitulated	  by	  the	  inhibition	  of	  ATR	  checkpoint	  kinase	  following	  on	  from	  early	  break	  
processing	  events	  (figure	  6.3).	  Further	  work	  will	  be	  required	  to	  demonstrate	  whether	  a	  failure	  
to	  reposition	  53BP1	  to	  the	  periphery	  of	  BRCA1	  marked	  IRIF	  confers	  a	  repair	  defect.	  Using	  a	  DR-­‐
GFP	   reporter	   assay	  no	  defect	   in	  HR	  was	  observed.	   It	   is	   likely	  however,	   that	  using	  a	   reporter	  
construct	   upstream	   of	   the	   repair	   template	   may	   not	   reflect	   the	   complexity	   required	   for	  
complete	   homology-­‐mediated	   repair,	   which	   under	   normal	   physiological	   conditions	   may	   be	  
hindered	  by	  the	  chromatin	  environment.	  One	  way	  of	  visualising	  the	  progression	  to	  HR	  would	  
be	  stain	  for	  Rad51	  foci	  using	   immunofluorescence.	   If	  a	  failure	  to	  reposition	  53BP1	  blocks	  the	  
progression	   towards	  HR-­‐mediated	   repair,	   it	  would	  be	  expected	   that	  Rad51	   foci	  would	   fail	   to	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form.	  Furthermore,	   it	  would	  be	  possible	   to	  correlate	  any	   failure	   to	   form	  Rad51	   foci	  with	   the	  
chromatin	  environment	  by	  co-­‐immunostaining	  for	  other	  markers	  of	  heterochromatin	  such	  as	  
HP1α	  [287].	  
Given	  that	  both	  deletion	  of	  the	  BRCT	  domains	  of	  53BP1	  and	  the	  inhibition	  of	  ATR	  produce	  the	  
same	   repositioning	   defect,	   it	   would	   be	   important	   to	   examine	   whether	   the	   roles	   of	   these	  
proteins	  are	  epistatic.	  If	  inhibition	  of	  ATR	  in	  combination	  with	  the	  53BP1	  BRCT	  mutant	  did	  not	  
result	  in	  synthetic	  lethality	  or	  a	  more	  severe	  defect,	  it	  could	  be	  concluded	  that	  these	  proteins	  
function	  in	  the	  same	  repair	  pathway.	  This	  would	  also	  suggest	  that	  one	  of	  two	  scenarios	  exist	  
within	  the	  cell,	  either	  ATR	  phosphorylates	  H2AX	  in	  response	  to	  damage	  in	  S-­‐	  and	  G2	  phase	  or	  
the	  BRCT	  domains	  of	  53BP1	  are	  required	  for	  additional	  processing	  of	  DSBs	  prior	  to	  activation	  
of	  ATR	  following	  damage.	  	  
Although	  phosphorylation	  of	  H2AX	  in	  response	  to	  ionising	  radiation	  primarily	  occurs	  by	  ATM,	  
ATR	  has	  been	  shown	  to	  be	  required	  for	  H2AX	  phosphorylation	  during	  replicative	  stress	  [288].	  If	  
the	  role	  of	  ATR	   in	  this	  process	   is	  to	  phosphorylate	  H2AX,	   it	  would	  suggest	  that	  there	  may	  be	  
cross-­‐talk	  between	  these	  apparent	  damage-­‐specific	  responses.	  	  
Alternatively,	   the	   requirement	   for	   ATR	   kinase	   could	   be	   further	   downstream.	   Previous	  
investigation	   has	   shown	   that	   a	   handover	   event	   exists	   between	   ATM	   and	   ATR	   kinase	   in	  
response	  to	  DNA	  damage	  that	  is	  dependent	  on	  the	  presence	  of	  single	  stranded	  DNA	  [289].	  As	  
demonstrated	   in	   figure	  5.10,	  mutation	  of	   the	  BRCT	  domain	  of	  53BP1	  prevents	   localisation	  of	  
pATM	  following	  damage.	  As	  a	  result,	   it	  would	  be	  necessary	  to	  test	  whether	  the	  repositioning	  
of	  53BP1	  requires	  pATM	  for	  early	  break	  processing.	  Previous	  investigation	  has	  shown	  that	  ATM	  
is	  required	  to	  stimulate	  nucleases	  MRE11	  and	  CtIP	  [290].	  Furthermore,	  DNA	  end	  resection	  is	  a	  
prerequisite	   for	   full	   ATR	   activation	   via	   the	   recruitment	   of	   ATRIP	   to	   RPA	   which	   binds	  
unprotected	  single	  stranded	  DNA	  [291].	  The	  ability	  of	  the	  cells	  to	  resect	  DNA	  ends	  could	  also	  
be	   analysed	   by	   RPA	   focus	   formation.	   If	   the	   BRCT	   domain	   mutants	   block	   end	   resection	   by	  
preventing	  the	  repositioning	  of	  53BP1,	  it	  would	  be	  expected	  that	  RPA	  foci	  would	  fail	  to	  form	  in	  
these	   cells.	   This	  would	   theoretically	   contrast	  with	   depletion	   of	   endogenous	   53BP1	   alone,	   in	  
where	  the	  cells	  would	  be	  unable	  to	  protect	  the	  DNA	  ends	  from	  resection	  and	  would	  show	  RPA	  
foci.	  Additionally,	  as	  the	  nuclease	  activity	  of	  Mre11	  is	  regulated	  by	  phosphorylation,	  Western	  
analysis	  could	  also	  be	  used	  to	   investigate	  phosphorylation	  of	  Mre11	   in	  cells	   transfected	  with	  
the	  mutant	   53BP1	  BRCT	  domains	   and	   those	   treated	  with	   an	  ATR	   inhibitor	   [148].	   This	  would	  
help	  to	  determine	  whether	  the	  repair	  of	  heterochromatic	  breaks	  in	  S-­‐	  and	  G2-­‐phase	  are	  a	  two-­‐
phase	  process	  requiring	  initial	  processing	  with	  ATM	  followed	  by	  later	  activity	  by	  ATR.	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To	  further	  examine	  the	  role	  of	  53BP1	  and	  ATR	  and	  to	  establish	  whether	  the	  activity	  of	  ATR	  is	  
downstream	  of	  53BP1,	   it	  would	  be	  necessary	   to	  use	   immunofluorescence	   to	  assess	  whether	  
ATR	  is	  still	  recruited	  to	  these	  sites	  of	  damage	  when	  the	  BRCT	  domain	  is	  mutated.	  It	  is	  possible	  
that	  a	  failure	  to	  reposition	  53BP1	  at	  the	  periphery	  of	  the	   IRIF	  would	  block	  end-­‐resection	  and	  
subsequent	  ATR	  recruitment.	  Further	  work	  would	  be	  required	  to	  elucidate	  the	  ATR-­‐dependent	  
process	  required	  for	  DSB	  resolution	  in	  S-­‐	  and	  G2-­‐phase	  cells.	  
Interestingly,	  in	  D.	  melanogaster,	  researchers	  have	  shown	  that	  that	  depletion	  of	  ATR	  results	  in	  
a	   persistence	   of	   H2Av	   foci	   within	   DAPI-­‐bright	   regions	   of	   nuclei.	   The	   DAPI-­‐bright	   regions	   of	  
DNA,	   co-­‐stained	   with	   HP1a,	   mark	   areas	   of	   heterochromatin.	   Following	   damage,	   DSBs	   are	  
resected	   and	   repositioned	   to	   the	   periphery	   of	   the	   region	   by	   expansion	   of	   the	  HP1a	   domain	  
prior	  to	  Rad51	  foci	  formation	  and	  additional	  processing	  for	  repair	  [292].	  This	  suggests	  that	  ATR	  
may	  have	  some	  role	  in	  regulating	  factors	  required	  for	  repositioning	  the	  DSBs	  to	  the	  periphery	  
of	  the	  heterochromatic	  regions.	  	  
As	   ATR	   checkpoint	   kinase	   phosphorylates	   a	   number	   of	   downstream	   target	   proteins,	   it	   is	  
important	  to	  consider,	  if	  not	  H2AX,	  which	  proteins	  acting	  downstream	  are	  phosphorylated	  by	  
ATR	  kinase.	  A	  number	  of	  downstream	  factors	  have	  been	  shown	  to	  be	  required	  for	  53BP1	  IRIF	  
expansion,	   including	   BRCA1,	   CtIP,	   SETDB1,	   SUV39	   and	  HP-­‐1	   [210,	   211].	   The	   requirement	   for	  
CtIP,	   a	   known	   target	  of	  ATR	  kinase,	   indicates	   that	  53BP1	   IRIF	  expansion	   is	   concomitant	  with	  
long-­‐range	   DNA	   end	   resection	   and	   suggests	   a	   role	   for	   ATR	   immediately	   prior	   to	   53BP1	   IRIF	  
expansion,	  as	  seen	  in	  figure	  5.20	  by	  delaying	  ATR	  inhibitor	  addition	  [293].	  Further	  work	  will	  be	  
required	   to	   establish	   which	   of	   the	   chromatin	   remodelling	   proteins,	   if	   any,	   require	  
phosphorylation	  by	  ATR	  kinase	  and	  discern	  the	  individual	  and	  collective	  contributions	  of	  both	  
chromatin	  compaction	  and	  relaxing	  factors	  in	  promoting	  DSB	  repair.	  	  If	  chromatin-­‐remodelling	  
factors	  required	  for	  repair	  of	  heterochromatic	  DSBs	  are	  regulated	  by	  ATR,	  this	  could	  suggest	  a	  
mechanism	  by	  which	  TopBP1	  is	  required	  for	  the	  ‘slow’	  kinetic	  repair	  in	  G1-­‐phase	  cells.	  	  
Ultimately,	   the	   future	  direction	  of	   this	  project	  will	   concern	  piecing	   together	   the	  networks	  of	  
interactions	  between	  53BP1,	  MDC1	  and	  pATM	   in	  order	   to	  understand	  why	   the	  53BP1-­‐BRCT-­‐
γH2AX	  interaction	  is	  required	  to	  retain	  phosphorylated	  ATM	  at	  sites	  of	  DSBs.	  Further	  work	  will	  
be	   required	   to	   establish	   the	   requirement	   for	   TopBP1	   in	   the	   resolution	   of	   heterochromatic	  
breaks.	   Lastly,	   in	   S-­‐	   and	   G2-­‐phase	   cells	   further	   work	   will	   also	   be	   required	   to	   establish	   the	  
sequence	  of	  events	  in	  the	  preparation	  of	  DSBs	  marked	  for	  repair	  by	  HR	  and	  the	  potential	  role	  
of	  the	  BRCT	  domains	  of	  53BP1	  and	  ATR	  in	  regulating	  this	  repair	  pathway.	  	  	  
‘Slow’	  kineAc	  DSB	  repair	  
Figure	  6.2	  Proposed	  model	   for	   resoluAon	  of	  heterochromaAc	  breaks	   requiring	  
the	  phospho-­‐speciﬁc	  interacAons	  between	  53BP1	  BRCT	  domain	  and	  γH2AX.	  	  
HeterochromaAc	  DSB	  






‘Long-­‐range’	  DNA	  end	  resecAon	  
Homologous	  
Template	  
Figure	  6.3	  Proposed	  model	  for	  resoluAon	  of	  S-­‐	  and	  G2-­‐	  phase	  heterochromaAc	  
breaks	   desAned	   for	   repair	   by	  HR.	   53BP1	   needs	   to	   be	   reposiAoned	   relaAve	   to	  
BRCA1	   to	   permit	   long-­‐range	   end	   resecAon.	   DNA	   outlined	   in	   red	   marks	   the	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Abstract
SUMO is a small post-translational modifier, that is attached to lysine residues in target proteins. It acts by altering protein-
protein interactions, protein localisation and protein activity. SUMO chains can also act as substrates for ubiquitination,
resulting in proteasome-mediated degradation of the target protein. SUMO is removed from target proteins by one of a
number of specific proteases. The processes of sumoylation and desumoylation have well documented roles in DNA
metabolism and in the maintenance of chromatin structure. To further analyse the role of this modification, we have
purified protein complexes containing the S. pombe SUMO protease, Ulp2. These complexes contain proteins required for
ribosome biogenesis, RNA stability and protein synthesis. Here we have focussed on two translation initiation factors that
we identified as co-purifying with Ulp2, eIF4G and eIF3h. We demonstrate that eIF4G, but not eIF3h, is sumoylated. This
modification is increased under conditions that produce cytoplasmic stress granules. Consistent with this we observe partial
co-localisation of eIF4G and SUMO in stressed cells. Using HeLa cells, we demonstrate that human eIF4GI is also sumoylated;
in vitro studies indicate that human eIF4GI is modified on K1368 and K1588, that are located in the C-terminal eIF4A- and
Mnk-binding sites respectively.
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Introduction
Sumoylation is a post-translational protein modification that is
required for numerous processes within cells, including transcrip-
tion, chromosome segregation, DNA damage responses, cell
signalling and meiosis (reviewed in [1–7]). At the molecular level
it functions by altering the surface of target molecules to affect
protein-protein interactions e.g. of PCNA (proliferating cell
nuclear antigen) and Srs2 (a DNA helicase) [8,9], by altering the
intracellular localisation of proteins e.g. of RanGAP [10], or by
changing the conformation of target proteins (e.g. in the case of
thymine DNA glycosylase [11]). SUMO chains attached to target
proteins can also be ubiquitinated and thus result in proteolysis of
the target.
SUMO is a small ubiquitin-like modifier that is attached to
lysine residues in target proteins. The yeasts Schizosaccharomyces
pombe and Saccharomyces cerevisiae both have a single gene for
SUMO: pmt3 and SMT3, respectively, while mammals have four,
SUMO-1, -2, -3 and -4 (although the role of SUMO-4 is not well
defined). SUMO-2 and -3 are 97% identical to each other and
about 50% identical to SUMO-1 (reviewed in [1]). SUMO is
produced as a precursor protein that needs to be cleaved into the
mature form in order to act as a substrate in the sumoylation
reaction. Processing of SUMO requires a specific SUMO-protease
[12–14], and involves the removal of a small number of amino
acids from the C-terminus of precursor SUMO to reveal a Gly-
Gly motif. Mature SUMO is then activated by the formation of a
thioester bond between the C-terminal glycine residue and a
cysteine residue in one subunit of the SUMO activating enzyme
(E1). From here SUMO is passed to the SUMO conjugating
enzyme (E2), where it again forms a thioester bond with another
cysteine residue. SUMO can then be attached to one or more
lysine residues in the target protein. In some cases, one of a small
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number of SUMO ligases (E3) is required for conjugation. In
many cases the lysine is contained within the consensus motif
yKxE, where y is a hydrophobic amino acid, and x is any amino
acid. SUMO can be added to target proteins as a monomer or as
poly-SUMO in the form of chains. The removal of SUMO from
target proteins or dismantling of SUMO chains occurs via the
action of SUMO-specific proteases [14,15].
In S. cerevisiae there are two SUMO proteases, Ulp1 and Ulp2,
both of which can deconjugate SUMO from target proteins, but
which have different target specificities [12]. Only Ulp1 is capable
of processing precursor SUMO to the mature form [12,15]. Ulp1
and Ulp2 are differently localised within the cell: Ulp1 is located at
nuclear pores, while Ulp2 is located mainly within the nucleus
[15]. Mammalian cells have six SUMO-specific proteases
(SENPs). These are also differentially localised within cells and
have different abilities to cleave precursor SUMO and to
deconjugate SUMO from targets e.g. [16,17]. The S. pombe Ulp1
protease has been characterised and shown to process SUMO to
the mature form, and like S. cerevisiae Ulp1, to be located at the
nuclear periphery [13]. However, little is known about Ulp2 in this
organism.
Translation initiation factors, which play key roles in cell
survival and oncogenesis [18–22], can be modified by sumoylation
[6,7,23–31]. Protein synthesis is carried out in three stages
(initiation, elongation and termination), with the initiation stage
of translation generally accepted as a major site of regulation of
gene expression in mammalian cells [18–22]. This step in protein
synthesis is regulated by a family of proteins, the initiation factors
[18,21,22] which interact with each other and the mRNA. These
proteins modulate the binding of mRNA to the ribosome, a
process facilitated by the assembly of the cap binding protein
(eIF4E), a helicase (eIF4A) and a scaffold protein (eIF4G), to form
the eIF4F complex (eIF4E/eIF4A/eIF4G). The eIF4G scaffold
protein possesses domains that interact with eIF4E, eIF4A, eIF3
and the poly(A) binding protein (PABP) [18,20–22]. The activity of
the eIF4F complex is regulated by a family of proteins, the eIF4E
binding proteins (4E-BPs). Using a conserved motif, 4E-BPs
compete with eIF4G for a common surface on eIF4E and inhibit
eIF4F assembly. In mammalian cells, activation of the mechanistic
target of rapamycin (mTORC1) leads to the multi-site phosphor-
ylation of 4E-BP1 [18,22,32] preventing 4E-BP1 from binding to
eIF4E and thereby allowing formation of the eIF4F initiation
complex and ribosomal recruitment of mRNA [18,21,22]. More
recently, phosphorylated human eIF4E has been shown to be
modified by sumoylation on five lysine residues [33]. Consistent
with a role in modulating protein-protein interactions [34],
sumoylation did not interfere with mRNA recognition but
enhanced eIF4F complex level assembly on the mRNA cap,
promoting the expression of ornithine decarboxylase, c-myc and
Bcl-2, thereby driving the anti-apoptotic and oncogenic activity of
eIF4E [33].
Since the majority of SUMO in cells is present in the nucleus,
much of the work undertaken to understand the role of
sumoylation has focussed on its role in regulating events associated
with DNA metabolism, such as the maintenance of chromatin
structure, recombination and DNA damage responses [3,5,8,9].
More recently it has been demonstrated that sumoylation is
required in the nucleolus to regulate ribosome biogenesis e.g. [35].
In order to obtain a fuller understanding of the role of sumoylation
we have begun to investigate the protein-protein interactions and
localisation of the mostly uncharacterised S. pombe SUMO
protease, Ulp2. Our results from gel filtration and immunofluo-
rescence studies indicate that Ulp2 is present in at least two high
Mr complexes, which are distinct from the nuclear pore complex
that contains Ulp1. We demonstrate that it co-purifies with a
number of proteins, many of which are involved in RNA
metabolism or protein synthesis. We have investigated whether
two of these proteins, eIF4G and eIF3h, are sumoylated, with the
result that we observe SUMO modification of eIF4G but not
eIF3h. Exposure of cells to conditions that lead to the formation of
stress granules, results in increased sumoylation of eIF4G, and
partial co-localisation of eIF4G and SUMO in the cytoplasm.
Finally, we demonstrate that human eIF4G is sumoylated in HeLa
cells, by both SUMO-1 and SUMO-2.
Materials and Methods
Strains and plasmids
The strains used in this work are described in Table 1. The
strains containing myc-, HA or TAP-tagged ulp1, ulp2, pli1, eIF4G
and eIF3h were created using the method of Bahler et al [36].
pREP41-His-SUMO was constructed by cloning the pmt3 ORF
into pREP41-His (created in this study). The S. pombe and human
eIF4G and eIF4GI constructs, Sp C-term, N-FAG, M-FAG and
C-FAG contain different fragments of the eIF4G/eIF4GI Orfs
cloned into pET15b [37]. HeLa cell lines stably transfected with
His-SUMO-1 and His-SUMO-2 were gifts from Prof R Hay
(University of Dundee) [38,39].
Ulp2 expression and assay
The ulp2 ORF was amplified from cDNA, by PCR and cloned
into pFastBacHTa (GibcoBRL). Recombinant baculoviruses were
generated according to GibcoBRL instructions. 50 ml infected
cells were lysed in 50 mM Tris HCl pH 8, 5 mM b-mercapto-
ethanol, 1% nonidet, 1 mM PMSF. Ulp2 protein was purified
using Talon resin. Ulp2 activity assays were conducted as
described for Ulp1 [13].
Protein purification methods
His-tagged SUMO was recovered from S. pombe and human
whole cell extracts under denaturing conditions with Ni2+ agarose
beads. Cell extracts were prepared as follows: 108 cells (S. pombe) or
6–86106 cells (Hela) were washed in ice cold water before being
lysed by vortexing in 1.85 M NaOH, 7.5% v/v b-mercaptoeth-
anol. The lysate was incubated on ice for 20 min after which TCA
was added to a final concentration of 25%. Following a further
20 min incubation on ice, precipitated proteins were collected by
centrifugation and resuspended and solubilised in 1 ml buffer A
(6 M guanidinium HCl, 0.1 M NaH2PO4, 10 mM Tris-HCl,
pH 8). Insoluble material was removed by centrifugation. The cell
extract was then incubated with Ni2+ agarose (Novagen) in Buffer
A in the presence of 0.05% Tween-20, 150 mM imidazole.
Purification on Ni2+ agarose was carried out according to the
manufacturer’s instructions. Samples were analysed by SDS-
PAGE and Western blotting. His-tagged S. pombe and human
eIF4GI fragments for in vitro sumoylation assays were purified from
E. coli using Ni2+ agarose according to the manufacturer’s
instructions.
For gel filtration, 200 ml logarithmically growing cells were
harvested, washed and then broken in 1 ml ice cold lysis buffer
(45 mM HEPES pH 7.8, 300 mM KCl, 5 mM MgCl2, 5 mM
EDTA, 5 mM EGTA, 12 mM NaF, 10% glycerol, 80 mM b-
glycerophosphate, 0.1 mM sodium orthovanadate, 1 mM PMSF,
1 mM DTT, supplemented with Roche complete protease
inhibitor). The extract was clarified by two rounds of centrifuga-
tion at 20,000 rpm for 10 min. 1.5 mg protein was loaded onto
either a Superdex 200 or Superose 6 column pre-equilibrated in
S. pombe Ulp2
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lysis buffer. 0.5 ml fractions were collected and 15 ml of each was
analysed by SDS PAGE.
For TAP-purification, 60 l ulp2-TAP cells were grown to mid-log
phase, harvested and frozen at 280uC until required. Ulp2-TAP
was purified using a modification of the method described by
Seraphin et al. [40]. Specifically, the cells were broken in a 6850
freezer mill in 20 mM Tris-HCl, pH 7.5, 10 mM NaCl, 1 mM
DTT, 0.5 mM EDTA, 2 mM MgCl2, 0.1 mM NaF, 0.1%
Nonidet NP40, 1 mM PMSF, 5 mM sodium orthovanadate,
80 mM b-glycerophosphate, 10 mM N-ethylmaleimide, supple-
mented with Roche complete protease inhibitor. All subsequent
procedures were carried out at 4uC. The cell extract was
centrifuged twice for 1 h at 10,000 rpm. Samples were pre-
cleared by incubation with 200 ml Dynabeads for 30 min to
remove proteins that bound non-specifically to the beads. The
extracts were incubated with 300 ml IgG-coated Dynabeads for
2 h. The beads were collected and washed extensively before
being resuspended in TEV buffer (50 mM Tris-HCl pH 8.0,
0.5 mM EDTA, 1 mM DTT) with 250 units AcTEV protease
(Invitrogen) for 3 h. The IgG-coated Dynabeads were removed
from the preparation and Ulp2-TAP containing complexes were
snap frozen in liquid nitrogen.
In vitro sumoylation assay
Recombinant His-tagged S. pombe eIF4G and human eIF4GI
fragments were purified from E. coli and tested for sumoylation in
an in vitro sumoylation assay as described elsewhere [41]. SUMO-
TRGG (Pmt3-L109R,GG: the mature form of S. pombe SUMO
containing a trypsin cleavage site immediately upstream of the
diglycine motif) was used in the assay to facilitate the identification
of the sumoylation sites by mass spectrometry.
Immunological methods
Western analysis was carried out as described previously [13].
Production of anti-SUMO and anti-eIF4GI (against the KRERK
epitope) antisera has been described elsewhere [41,42], anti-myc
antibodies for immunofluorescence were purified from cell
supernatant (cell line CRL1729, from ATCC) using protein G-
sepharose or were from Santa Cruz (sc-40), anti-HA antisera were
from Santa Cruz (sc-7392) and monoclonal anti-tubulin antibodies
were from Sigma (T5168). Immunofluorescence was undertaken
as described in Moreno et al. [43]. Cells were observed using an
Applied Precision Deltavision Spectris microscope using deconvo-
lution software.
Mass spectrometry
Complexes purified by purification of TAP-Ulp2 were analysed
by SDS PAGE. Protein bands were visualised by staining with
colloidal Coommassie, excised and subjected to trypsin in-gel
digestion essentially as described by Schevchenko et al. [44]. The
supernatant from the digested samples was removed and acidified
to 0.1% TFA, dried down, and reconstituted in 0.1% TFA prior to
LC MS/MS analysis. Each sample was loaded and desalted at a
flow rate of 5 ml/min on a C18 trap column (200 mm ID x 1 cm,
5 mm PepMap 100, Dionex) in buffer A (acetonitrile (2% v/v):
water (97.9% v/v): formic acid (0.1% v/v)). The tryptic peptides
were fractionated on a C18 reverse phase column (75 mm ID x
25 cm, 3 mm PepMap 100, Dionex) using an Ultimate U3000
nano-LC system (Dionex) and a 2 hr linear gradient from 95%
buffer A to 50% buffer B (acetonitrile (95% v/v): water (4.9% v/v):
formic acid (0.1% v/v) at a flow rate of 300 nl/min. Eluted
peptides were directly analysed by tandem mass spectrometry
using a LTQ Orbitrap XL hybrid FTMS (ThermoScientific)
operated in parallel acquisition IDA mode with nominal resolution
of 60,000 (FWHM) at m/z 400 for MS1 and the top six most
abundant multiply charged ions being selected for CID fragmen-
tation in the linear ion trap followed by dynamic exclusion for
90 secs.
Derived MS/MS data were searched against the S. pombe subset
of the UniProt Knowledgebase release 15.13 database using
Sequest version SRF v. 5 as implemented in Bioworks v 3.3.1
(Thermo Fisher Scientific), assuming carboxyamidomethylation
(Cys), deamidation (Asn and Gln) and oxidation (Met) as variable
modifications and using a peptide tolerance of 10 ppm and a
fragment ion tolerance of 0.8 Da. One missed cleavage was
allowed and filtering criteria used for positive protein identifica-
tions were Xcorr values greater than 1.9 for +1 spectra, 2.2 for +2
spectra and 3.75 for +3 spectra and a delta correlation (DCn) cut-
off of 0.1.
Table 1. List of strains.
Strain Genotype Reference
Sp.011 ade6-704, leu1-32, ura4-D18, h2 [72]
Sp.611 ulp1-myc:kan, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.614 ulp2-myc:kan, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.658 ulp1::ura4, ade6-704, leu1-32, ura4-D18, h2 [13]
Sp.723 pli1-myc:kan, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.874 pmt3-GG:ura4, ade6-704, leu1-32, ura4-D18, h2 This study
sp.851 ulp1::ura4, pmt3-GG:ura4, ade6-704, leu1-32, ura4-D18, h2 This study
sp.855 ulp2::ura4, pmt3-GG:ura4, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.1470 ulp2-TAP, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.2047 eIF3h-HA:Nat, ade6-704, leu1-32, ura4-D18, h+ This study
Sp.2048 ulp2-myc:kan, eIF3h-HA:Nat, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.2068 ulp2-myc:kan, eIF4G-HA:Nat, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.2085 ulp2::kan, ade6-704, leu1-32, ura4-D18, h2 This study
Sp.2088 eIF4G-HA:Nat, ade6-704, leu1-32, ura4-D18, h+ This study
doi:10.1371/journal.pone.0094182.t001
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For the identification of sumoylation sites, reduction and
alkylation were instead performed using TCEP and MMTS
respectively as previously described [45] and bioinformatics
analysis following conversion of LTQ-Orbitrap (.raw) raw data
files to Mascot generic format (MGF) via Mascot Distiller (Matrix
Science) performed essentially as described by Chicooree et al.
[46] using the MASCOT search engine with the UniProt
Knowledgebase release 15.13 database with the S. pombe subset
as selected taxonomy. Precursor ion tolerances were again set at
10 ppm and MS/MS peptide ion tolerance to 0.8 Da, and the
same variable modifications assumed. However, two missed
trypsin cleavages were allowed.
Following trypsin digestion, cleavage of the SUMO moiety was
expected to leave a Gly-Gly isotag on modified residues. The GG
isotag (on lys) was accordingly also searched as a variable
modification. Following MASCOT searches, putative sites of
SUMOylation were noted and the relevant raw MS/MS spectra
subsequently examined manually to confirm presence of the
modification (the GG isotag).
Results
Biochemical characterisation of S. pombe Ulp2
A comparison of the S. pombe Ulp2 sequence was made with
those of the two S. cerevisiae SUMO proteases, Ulp1 and Ulp2 [47].
Since S. pombe Ulp2 more closely resembles S. cerevisiae Ulp2
(required solely for deconjugating SUMO from high Mr SUMO-
containing species) than it does Ulp1 (which is required for both
processing and deconjugating), it is likely that the main activity of
S. pombe Ulp2 is in deconjugating SUMO from sumoylated targets
rather than in processing SUMO to the mature form. Before
proceeding to analyse the localisation or protein-protein interac-
tions of Ulp2, we first confirmed its proposed biochemical activity.
His-tagged Ulp2 was purified from insect cells as described in
Materials and Methods. Using assays we described previously [13],
we demonstrate that Ulp2 is significantly less able than Ulp1 to
process SUMO to the mature form (Figure 1A, lane 2 (Ulp1) and
lane 3 (Ulp2)), but is capable of deconjugating SUMO from high
Mr species in an N-ethylmaleimide- (NEM)-dependent manner
(Figure 1B). These results confirm that like S. cerevisiae Ulp2, S.
pombe Ulp2 is a cysteine protease whose main function is in
deconjugating SUMO from target proteins.
Deletion of the ulp2 gene results in a severe growth
defect and sensitivity to a range of stresses
Deletion of pmt3 (which encodes SUMO), hus5 (the gene
encoding the SUMO-conjugating enzyme, E2), rad31 (which
encodes one sub-unit of the SUMO activating enzyme, E1) or ulp1
(another SUMO-specific protease gene) results in severe growth
and morphological abnormalities [13,48–50]. We therefore wished
to determine whether disrupting the ulp2 gene has any effect on
cell growth or viability. Disruption of the gene is not lethal.
However, ulp2-d cells form very small colonies and show distinct
morphological abnormalities resembling hus5 and rad31 mutants
(data not shown). Comparison of SUMO-containing species in
ulp1-d and ulp2-d cells (Figure 1C, lanes 3 and 4) supports the
notion that the main function of Ulp2 is in the removal or
dismantling of high Mr SUMO-containing species, rather than in
processing precursor SUMO. Provision of the mature form of
SUMO (Pmt3-GG) in ulp1-d cells (lane 5) results in the
incorporation of SUMO into high Mr species (unlike the situation
in ulp1-d cells, lane 3), while in ulp2-d cells (lane 6), the level of high
Mr species is slightly increased.
To begin to identify cellular processes involving Ulp2, we tested
whether ulp2-d cells are sensitive to the DNA synthesis inhibitor,
hydroxyurea (HU) and other stresses (Figure 1D), and compared
these responses to those of ulp1-d,pmt3-GG cells (where the mature
form of SUMO is provided, so that cells are only defective in the
deconjugating activity of Ulp1). Since ulp2-d and ulp1-d,pmt3-GG
cultures contain a high proportion of dead cells, it was necessary to
plate more cells for these strains compared to wild type
(approximately 10 fold). These data indicate that ulp2-d cells are
temperature sensitive, unlike the ulp1-d,pmt3-GG strain, but similar
to the S. cerevisiae ulp2D strain [51], and sensitive to the DNA
synthesis inhibitor, hydroxyurea (HU, 2 mM). They are also
sensitive to the protein synthesis inhibitor, cycloheximide (CHX,
10 and 20 mg/ml) and KCl (1 M) indicating that Ulp2 likely has
roles in numerous cellular processes.
Ulp2 is present in high molecular weight complexes
Throughout most of the cell cycle, Ulp1 is associated with the
nuclear envelope [13], and specifically with the nuclear pore
complex [52,53]. To determine whether Ulp2 is also part of a high
Mr complex we undertook gel filtration analysis. Figure 2A
indicates that, as expected, Ulp1 elutes in the void volume,
consistent with it being present in a high Mr complex. Ulp2 also
elutes in the void volume like Ulp1, but additionally, it is present in
fractions corresponding to an approximate Mr of 670 kDa. This
suggests that Ulp2 is likely to be present in at least two different
complexes. In contrast to the results obtained for Ulp1 and Ulp2,
Pli1, an E3 SUMO ligase [54], does not elute in these high Mr
fractions, implying that it likely exists in cells as a monomer or
possibly a dimer.
Ulp2 is located in both the nucleus and cytoplasm, but is
predominantly nuclear
Since a proportion of Ulp2 co-elutes with Ulp1 in the void
volume, we wished to determine whether some or all of the Ulp2
co-localises with Ulp1 in cells, i.e. is at the nuclear periphery. We
therefore analysed the localisation of Ulp2. Figure 3 indicates that
Ulp2 is present in foci that are predominantly nuclear, with a small
proportion in the cytoplasm. Little if any Ulp2 is located at the
nuclear periphery. Thus the location of Ulp2 is distinct from that
of Ulp1 [13], indicating that it is unlikely to be part of nuclear pore
complexes. In many cases, Ulp2 co-localises with SUMO. Ulp1
undergoes distinct changes in localisation during the cell cycle, its
localisation changing from the nuclear periphery where it is for
most of the cell cycle, to the region between the separating DNA
masses during mitosis [13]. In contrast, the location of Ulp2
appears to be relatively unchanged in cells at different cell cycle
stages. For example, during mitosis (Figure 3, TRITC panel, cells
labelled 4), a time when Ulp1 relocalises, the distribution of
intranuclear Ulp2 foci is very similar to that observed at other
times in the cell cycle (cells labelled 1–3) and is unchanged.
Ulp2 co-purifies with proteins associated with RNA
metabolism and protein synthesis
To begin to identify the nature of the complexes observed in
Figure 2, we C-terminally-tagged Ulp2 with TAP in the genome
(ulp2-TAP) and isolated the tagged protein and associated proteins
as described in Materials and Methods. Protein complexes were
analysed by SDS PAGE (Figure 4) and fractions excised from the
gel for mass spectrometric analysis. As shown in Table S1 and
Table 2, the majority of the proteins identified are associated with
RNA metabolism, such as RNA processing, ribosome biogenesis
or initiation of translation. To ensure that these proteins co-
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purified specifically with Ulp2, a parallel purification was
undertaken using Rad9-TAP, and from cells expressing the TAP
tag alone (Figure S1). Rad9 is a member of the 9-1-1 complex
required for the DNA integrity checkpoint [55], and would not be
expected to interact with a the same proteins as those that interact
with Ulp2. Very little protein co-purified with the TAP-tag alone,
while purification of Rad9-TAP yielded a quite different set of
bands. Most of the proteins co-purifying with Rad9 were
associated with DNA metabolism as expected (data not shown)
and only one protein, glyceraldehyde 3-phosphate dehydrogenase,
was common to the Ulp2-TAP and Rad9-TAP preparations.
A number of proteins required for ribosome biogenesis,
including some of those we identified by mass spectrometry, have
recently been demonstrated to be sumoylated (Table 2) [6,7,23–
27,56–58]. However, little is known about the effect of sumoyla-
tion on the function of translation factors. We therefore selected
two translation initiation factors, eIF4G and eIF3h for further
study. The analysis of some of the other factors will be described
elsewhere. eIF4G has been well characterised in S. cerevisiae and
mammalian cells [18,22] and to some extent in S. pombe [59].
eIF4G acts as a scaffold protein as part of the eIF4F complex to
recruit mRNA to the ribosome for translation [21], while eIF3h is
a non-core subunit of the eIF3 complex linking eIF4F/mRNA to
the ribosome in mammalian cells [60]. Gel filtration analysis of
whole cell extracts from cells containing Ulp2-myc and either
eIF4G-HA or eIF3h-HA indicates that the majority of eIF4G co-
elutes with Ulp2 (Figure 2B). In contrast, eIF3h elutes in multiple
Figure 1. Analysis of Ulp2 function. A. Assay for SUMO-processing activity. Lanes 1–4 contain full length SUMO, lane 5 SUMO-GG. Lanes 1,5,
unincubated controls, lanes 2–4 were incubated at 20uC for 2 h following addition of 0.72 mg Ulp1 (lane 2), 2.32 mg Ulp2 (lane 3) or 2 ml buffer (lane
4). Proteins were analysed by SDS PAGE followed by staining with Coommassie Brilliant Blue. B. Assay for de-conjugating activity. S. pombe cell
extracts were prepared using standard native extraction procedures. Extracts were incubated at 20uC for 2 h (lanes 1–6), lane 1 5 ml of fraction from
extract from E. coli cells transformed with empty vector, equivalent in volume to the Ulp2-containing fraction from ulp2-transformed cells, lane 2
0.6 mg Ulp2, lane 3 1.2 mg Ulp2, lane 4 2.4 mg (5 ml) Ulp2, lane 5 4.8 mg Ulp2, lane 6 1.2 mg Ulp2 pre-incubated with 5 mM NEM, lane 7 total cell extract
without incubation at 20uC. Assays were analysed by Western blotting with anti-SUMO antisera. C. Western analysis of total cell extracts using anti-
SUMO antisera. Both the separating and stacking gels (6% polyacrylamide in the stacking gel) were blotted. D. Ten microlitre of 10 fold serial dilutions
of cells were plated onto YEP agar plates with or without additives as indicated. 10x amount of cells of ulp2-d and ulp1-d,pmt3-GG were used
compared to wild type.
doi:10.1371/journal.pone.0094182.g001
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Figure 2. Ulp2 is present in high Mr complexes. Analysis of complexes by gel filtration. A. Total cell extracts from ulp1-myc, ulp2-myc or pli1-myc
strains were analysed on a Sephadex 200 column, and fractions were western blotted with anti-myc antibodies. B. Total cell extracts from ulp2-
myc,eIF4G-HA and ulp2-myc,eIF3h-HA strains were analysed on a Superose 6 column, fractions were western blotted with anti-myc and anti-HA
antibodies.
doi:10.1371/journal.pone.0094182.g002
Figure 3. Ulp2 is localised predominantly within the nucleus. A. Cells containing myc-tagged ulp2 as the sole copy of the ulp2 gene were
incubated with anti-myc antisera (mouse monoclonal) and anti-SUMO antisera (rabbit polyclonal) followed by TRITC-conjugated anti-mouse IgG
antisera, FITC-conjugated anti-rabbit IgG antisera and DAPI. Merge = overlay of TRITC (red), FITC (green) and DAPI (blue) staining. 1: early G2 cells,
2,3: late G2 cells, 4: mitotic cells, 5: S phase cells. Bar = 5 mm.
doi:10.1371/journal.pone.0094182.g003
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fractions, suggesting it is present in several different sized
complexes.
eIF4G, but not eIF3h, is sumoylated in S. pombe
One possibility to explain the interaction of eIF4G and eIF3h
with the SUMO protease Ulp2 is that they are themselves
modified by SUMO. In order to determine whether this is the
case, cells containing genomic copies of HA-tagged eIF4G or
eIF3h were co-transformed with pREP41-His-SUMO. His-tagged
SUMO was purified on Ni2+ agarose. Denaturing conditions (with
6 M guanidinium HCl in the binding buffer, followed by 6 M
urea, 300 mM imidazole washes) were used to ensure that
sumoylation of the individual proteins was being observed, rather
than that of other components of the eIF4F or eIF3 complexes).
Figure 5A, shows that eIF4G is specifically recovered in the
presence of His-tagged SUMO (lane 1), but not in the absence of
His-tagged SUMO (lane 2), indicating that it is sumoylated in S.
pombe. In contrast, eIF3h is not recovered in either the absence or
presence of His-tagged SUMO (Figure 5B), indicating that this
translation factor is not sumoylated in fission yeast. Its co-
purification with Ulp2 may thus be through the interaction of
Ulp2 with other member(s) of the eIF3 complex.
Conditions that induce stress granules affect the
localisation and sumoylation of eIF4G
Since one of the functions of sumoylation is to affect protein
localisation, we next investigated whether eIF4G and SUMO co-
localise. Figure 6 shows that in untreated cells, as has been shown
previously [61], the majority of eIF4G is cytoplasmic as expected
for a translation initiation factor. As has been observed in S.
cerevisiae and human cells [62,63], a small amount of eIF4G is also
present in the nucleus, where it is proposed to couple RNA
processing events in the nucleus with translation in the cytoplasm.
In contrast to the situation with eIF4G, the majority of the SUMO
protein is present in the nucleus (Figures 3 and 6). We observe that
a significant proportion of the nuclear eIF4G co-localises with
SUMO, suggesting sumoylation of eIF4G may have a role in
regulating RNA processing or localisation.
Protein synthesis can be inhibited by a variety of factors. For
example, cycloheximide (CHX) interacts with ribosomes and
inhibits the elongation step, while exposure of S. pombe cells to 1 M
KCl inhibits protein synthesis by the sequestration of translation
initiation factors and mRNA into cytoplasmic stress granules [64].
Following treatment with CHX, eIF4G staining is slightly more
punctate than in untreated cells, while the pattern of SUMO
staining is unchanged. In these cells, there is a low level of
colocalisation of eIF4G and SUMO in the nucleus. Interestingly,
exposure of cells to CHX results in distorted nuclei. The reason for
this is not known, but it could be due to disruption of RNA
processing and/or localisation by CHX.
In S. pombe and mammalian cells eIF4G and eIF4GI respec-
tively, are among the translation factors present in stress granules
[61,65,66]. To investigate stress granule formation in S. pombe, we
exposed cells to 1 M KCl. In these cells, eIF4G is present in fewer,
but quite bright, punctate cytoplasmic foci (Figure 6). This pattern
of staining is similar to what has been observed for stress granules
in S. pombe, and in particular, what has previously been observed
for eIF4G in this organism [61,64]. In these cells, there was
occasional co-localisation of the two proteins in the cytoplasm and
this appeared to reflect the appearance of eIF4G and SUMO in
the same granule.
Figure 4. Purification of Ulp2-TAP. SDS-PAGE of Ulp2-Tap and
associated proteins. TEV = TEV protease, used to cleave Ulp2 from TAP
tag. Numbers refer to gel slices analysed by mass spectrometry.
doi:10.1371/journal.pone.0094182.g004
Table 2. Summary of proteins identified by mass spectrometry that co-purified with TAP-Ulp2.
Function Protein
Translation eIF2a, eIF2b, eIF3a, eIF3b, eIF3c, eIF3c, eIF3h, eIF4G, EF1a EF2B, eEF3B, EF2, Pabp
RNA synthesis Rpa1, Rpa2,
RNA processing Rrp5, SPAC694.02, Exo2, Dhp1, Upf1, SPBC19G7.10C, Nop2, Dbp2, Prp19, Sla1,
Ribosome biogenesis aconitate hydrolase/mitochondrial ribosomal protein subunit L49, SPAC22G7.05, SPAC1142.04(Noc2 predicted), Hsc1/Sks2, Rpl301,
Rpl302, Rml2
DNA metabolism Tcg1, Rfc5,
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Another protein known to be present in stress granules is polyA-
binding protein (PABP) [61]. We therefore compared the
localisation of eIF4G and PABP in cells exposed to 1 M KCl.
We observe PABP in large cytoplasmic granules, which are
different to those we observe in cells only containing HA-tagged
eIF4G-HA (Figure S2A and Figure 6). Curiously, in some of the
cells that contain both eIF4G-HA and PABP-RFP, eIF4G is now
also present in large granules where it co-localises with PABP.
Further analysis of PABP-RFP containing cells indicated that a
proportion of the SUMO is mislocalised to the cytoplasm (Figure
S2B). This suggests that C-terminal RFP-tagging of PABP may
affect its function and/or localisation.
Following exposure to 1 M KCl, we noticed that there was less
staining of both eIF4G and SUMO compared to that in untreated
cells. Western analysis of eIF4G and SUMO levels indicates that
in response to 1 M KCl the levels of both proteins are significantly
reduced (Figure 5C). The reason for this is unknown, but may be
due to the fact that a proportion of the eIF4G and SUMO is
insoluble and not recovered in the extract. Alternatively, and in
our view the more likely explanation, we propose that in response
to this stress, there is increased proteolysis of both proteins.
We next investigated whether sumoylation of eIF4G is affected
by exposure of cells to either CHX (100 mg/ml) or KCl (1 M).
Figure 7A indicates that there is an increase in sumoylation in
response to KCl, with levels of sumoylation unaffected by exposure
to CHX, when compared to levels in untreated cells (with relative
levels being 1:1:1.5; wt, CHX-treated, KCl-treated, respectively).
These data suggest that sumoylation of eIF4G may be associated
with stress granule formation and/or proteolysis of the translation
initiation factor.
Human eIF4GI is sumoylated
In order to analyse the role of sumoylation of S. pombe eIF4G we
investigated the possibility of testing the protein for ability to be
sumoylated in our in vitro sumoylation assay, as this could help us
identify the sumoylated lysine residue(s). However, two factors
make this identification difficult. Firstly, in order to purify protein
for an in vitro sumoylation assay, we would need to clone the full
length S. pombe eIF4G cDNA. We have previously observed that
Figure 5. eIF4G, but not eIF3h, is sumoylated. His-tagged SUMO was expressed in cells containing genomically tagged (HA) copies of eIF4G (A)
and eIF3h (B). WCE = whole cell extract, PD = Ni2+-agarose pull down. Blots were probed with anti-HA or anti-SUMO antisera. C. Western blot of
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plasmids containing the N-terminus of the S. pombe eIF4G coding
sequence cannot be tolerated in E. coli [59], so that full length
eIF4G cannot be expressed in E. coli. The reason for this is
unknown, but may be due to the presence of a highly repeated
sequence within the eIF4G coding sequence. Secondly, this highly
repeated sequence (present in the coding sequence in the S. pombe,
but not in the S. cerevisiae or human proteins) contains 16 repeats of
a perfect sumoylation site consensus motif (AKRE), which would
likely make identification of the site(s) difficult, even if we were able
to express the full length protein. We therefore expressed a C-
terminal fragment (comprising aa 970–1403), which contains
eIF4E, eIF4A and eIF3 binding sites (Figure 7B) and tested this in
our in vitro sumoylation assay. We did not observe any sumoylation
of this fragment, implying that sumoylation likely occurs in the N-
terminus of the protein.
To further analyse the role of sumoylation we set out to
determine whether human eIF4GI is sumoylated and if so, to
identify the sumoylation site(s) in this protein. We used HeLa cell
lines stably transfected with either His-SUMO-1 or His-SUMO-2
[38,39]. His-tagged SUMO was recovered from cell extracts
prepared under denaturing conditions. Figure 7C indicates that
eIF4GI is not recovered from extracts of cells that do not contain
His-tagged SUMO (lane1), but is isolated from extracts of cells
containing His-SUMO-1 (lane 2) and to a lesser extent from cells
expressing His-SUMO-2 (lane 3). This confirms that, like S. pombe
eIF4G, human eIF4GI is sumoylated.
We next sought to identify the sumoylation sites on human
eIF4GI. In order to facilitate our analysis, we used three different
human eIF4G fragments, N-FAG, M-FAG and C-FAG (Figure 7B,
[37]). These protein fragments were purified from E. coli and tested
in our in vitro sumoylation assay (data not shown). Slow migrating
forms of eIF4G were excised from gels and analysed by mass
spectrometry. Two sumoylation sites were identified: K1368 and
K1588 (Figure 7D). These map to two domains of eIF4GI which
interact with eIF4A and the protein kinase, Mnk1, respectively
[18,21,22]. These results suggest that sumoylation may affect the
interaction of eIF4GI with these two proteins.
Discussion
In order to analyse the role of S. pombe Ulp2, we purified Ulp2-
TAP-containing complexes. We identified proteins involved in
RNA synthesis or processing, ribosome biogenesis and translation.
This is consistent with recent reports that a number of proteins
required for ribosome biogenesis and RNA processing are
sumoylated [6,67,68]. While this manuscript was in preparation,
Figure 6. Effect of cycloheximide and KCl on localisation of eIF4G and SUMO. Cells containing eIF4G-HA, untreated (UT) or exposed to CHX
(100 mg/ml) or KCl (1 M) as indicated, were incubated with anti-SUMO antisera (green) and anti-HA antisera (red). Bar = 5 mm. Bottom panel, regions
indicated by boxes in panel above. Arrows indicate sites of colocalisation of SUMO and eIF4G.
doi:10.1371/journal.pone.0094182.g006
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a global analysis of the SUMO system interactome in S. cerevisiae
identified a range of proteins including a number required for
ribosome biogenesis and rRNA processing that interact with Ulp2
[69]. Additionally, the nucleolar SUMO-specific protease, SENP3,
has been demonstrated to reverse the SUMO modification of
nucleophosmin to be required for rRNA processing [70].
Although a number of translation factors, required for both the
initiation and elongation steps of protein synthesis, have been
identified in global screens as being sumoylated e.g. [23–28,30,31],
little is known about the role of sumoylation of these proteins. This
is in contrast to the situation with the role of sumoylation in
ribosome biogenesis. We therefore focussed our attention on two
S. pombe translation initiation factors in our list of Ulp2-interactors:
Figure 7. Human eIF4G is sumoylated. A. S. pombe cells containing His-tagged SUMO and HA-tagged eIF4G as indicated were treated with CHX
(100 mg/ml) or KCl (1 M), and His-tagged SUMO pulled down, and analysed as in Figure 5. B. Comparison of human and eIF4G proteins, indicating
protein binding domains: PABP= polyA binding protein, 4E = eIF4E, 4A = eIF4A, 3 = eIF3, Mnk = MAP kinase-interacting kinase 1. C. Whole cell
extracts (WCE) and Ni2+ pull-down (PD) from extracts of HeLa cells stably transfected with His-tagged SUMO-1 (S1) or SUMO-2 (S2) or nothing (-).
Western blots probed with anti-eIF4GI (KRERK epitope) antisera. D. Representative eIF4G ion mass spectra (MS/MS spectra) showing identification of
the in vitro sites of sumoylation.
doi:10.1371/journal.pone.0094182.g007
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eIF4G and eIF3h. Both proteins are known to be present in high
Mr complexes, with eIF4G being part of the eIF4F complex while
eIF3h is part of the eIF3 complex [22]. We demonstrate here that
eIF4G, but not eIF3h is sumoylated in vivo. These results are
supported by the genome-wide analyses of sumoylated proteins
that have been undertaken, that indicate that eIF4G is sumoylated
[24,28] but which have not to date identified eIF3h as a
sumoylation target.
As the most prominent role of translation initiation factors is in
cytoplasmic protein synthesis, we began by investigating whether
Ulp2 is associated with polysomes. However, we observed that
while Ulp2 migrated at the same position in sucrose gradients as
polysomes, it was still present in these fractions under conditions
(2.5 mM EDTA) where polysomes were disrupted, indicating that
the majority of Ulp2 is not associated with actively translating
polysomes (data not shown). This result confirms our gel filtration
analysis and localisation studies, and indicates that Ulp2 is present
in very high molecular weight complexes, but discounts the
possibility that Ulp2 is associated with actively translating
polysomes.
The role of sumoylation of translation factors has not been well
studied, apart from that of eIF4E [29,33]. eIF4E is an mRNA cap-
binding protein, and one of the proteins that interacts with eIF4G
to form the eIF4F complex [22]. eIF4E is regulated by
phosphorylation and by interaction with eIF4E-binding proteins
(4E-BPs). Sumoylation of eIF4E on five lysines is promoted by its
phosphorylation at S209, and results in its dissociation from 4E-
BP1. Sumoylation did not interfere with mRNA recognition but
enhanced eIF4F complex assembly on the mRNA cap, promoting
the expression of ornithine decarboxylase, c-myc and Bcl-2,
driving the anti-apoptotic and oncogenic activity of eIF4E [33]. As
phosphorylation of eIF4E has been shown to play a role in
selective nuclear export of mRNA [71], it is likely that sumoylation
of eIF4E occurs in the nucleus and/or as it emerges into the
cytoplasm
We have shown that in response to osmotic stress (1 M KCl),
conditions that induce stress granules in fission yeast, the overall
levels of SUMO and eIF4G are reduced. We have also shown that
under these conditions, there is increased sumoylation of eIF4G.
The role of this modification is not known. Our results suggest two
possible scenarios: the first being that sumoylation is targeting
eIF4G for degradation, possibly via the action of a SUMO-
targeted ubiquitin ligase (STUbL). The second possibility is that
sumoylation may be targeting eIF4G to stress granules. Further
work is needed to distinguish between these two possibilities.
The two sumoylation sites in human eIF4GI that we have
identified are not conserved in fission yeast eIF4G, as this protein
lacks the C-terminal domains present in human eIF4GI
(Figure 7B). Their positions suggest that sumoylation of this
protein may be affecting interactions of eIF4GI with eIF4A and
Mnk1. eIF4A is a DEAD-box protein that participates in
translation initiation and binds to eIF4GI [18,21,22]. Functioning
as an ATP-dependent RNA helicase, eIF4A is believed to unwind
secondary structure in the 59-untranslated region of mRNAs to
enable ribosome scanning. The RNA-stimulated ATPase and
ATP-dependent helicase activities of eIF4A are enhanced by its
interaction with two domains on eIF4GI, one in the C-terminus
and one in the middle domain [18,22]. Interaction and subsequent
recycling of eIF4A from the eIF4G/eIF4A complex stimulates the
eIF4A helicase activity required for the mRNA scanning process.
It is possible that sumoylation of eIF4GI either directly or
indirectly affects the interaction with eIF4A, thereby regulating
translation initiation. Mnk1 is a kinase which binds at the extreme
C-terminus of eIF4GI and regulates the phosphorylation of eIF4E
at Ser209 [18,21,22]. Phosphorylated eIF4E has been shown to be
modified by sumoylation on five lysine residues [33] promoting
eIF4F complex formation and specific protein synthesis [33].
Sumoylation of K1588 on eIF4GI could prevent the binding of
Mnk1, reduce eIF4E phoshorylation and thereby abrogate
sumoylation of eIF4E and specific mRNA translation. As
phosphorylation of eIF4E is associated with tumour cell formation
and increased resistance of tumour cells to apoptosis, sumoylation
of eIF4GI at this site could provide a novel and undiscovered
mechanism to regulate cell growth and proliferation in mamma-
lian cells. Further work needs to be done to address this.
In conclusion, our results demonstrate that S. pombe and human
eIF4GI are both sumoylated, and that in S. pombe this modification
is increased under conditions that promote the formation of stress
granules. We have also identified the target lysine residues that are
used for sumoylation in vitro in human eIF4GI. It will be of interest
to determine whether these sites are also used in vivo, and to
identify the role of this sumoylation.
Supporting Information
Figure S1 Comparison of proteins co-purifying with
Ulp2-Tap and Rad9-Tap. Extracts from cells expressing Ulp2-
Tap, Rad9-Tap (Methods S1) or Tap alone were subjected to the
same purification procedure and analysed by SDS-PAGE followed
by staining with colloidal coommassie.
(TIF)
Figure S2 Colocalisation of eIF4G with PABP. A. Strain
containing eIF4G-HA and PABP-RFP stained with anti-HA and
anti-RFP antisera. Secondary antisera: anti-rabbit FITC conju-
gated, anti-mouse TRITC-conjugated. B. Strains containing either
eIF4G-HA or Pabp-RFP (Methods S1) as indicated, stained with
anti-SUMO antisera.
(TIF)
Table S1 Identity of proteins co-purifying with Ulp2-
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Regulation of protein synthesis is of fundamental
importance to cells. It has a critical role in the control of gene
expression, and consequently cell growth and proliferation.
The importance of this control is supported by the fact that
protein synthesis is frequently upregulated in tumor cells. The
major point at which regulation occurs is the initiation stage.
Initiation of translation involves the interaction of several
proteins to form the eIF4F complex, the recognition of the
mRNA by this complex, and the subsequent recruitment of
the 40S ribosomal subunit to the mRNA. This results in the
formation of the 48S complex that then scans the mRNA for
the start codon, engages the methionyl-tRNA and eventually
forms the mature 80S ribosome which is elongation-
competent. Formation of the 48S complex is regulated by the
availability of individual initiation factors and through speciﬁc
protein-protein interactions. Both of these events can be
regulated by post-translational modiﬁcation by ubiquitin or
Ubls (ubiquitin-like modiﬁers) such as SUMO or ISG15. We
provide here a summary of translation initiation factors that
are modiﬁed by ubiquitin or Ubls and, where they have been
studied in detail, describe the role of these modiﬁcations and
their effects on regulating protein synthesis.
Introduction
Initiation of protein synthesis
Protein synthesis is of fundamental importance in cells and its
regulation is crucial for the continued viability of organisms. The
process comprises 3 stages: initiation, elongation and termina-
tion. Of these, initiation is generally considered to be one of the
major regulatory steps of gene expression in mammalian cells.
Initiation requires the function of a number of translation initia-
tion factors (Fig. 1), several of which have key roles in cell sur-
vival and oncogenesis. These proteins modulate the binding of
mRNA to the ribosome, a process facilitated by the assembly of
the cap binding protein (eIF4E), a helicase (eIF4A) and a scaffold
protein (eIF4G), to form the eIF4F complex (eIF4E/eIF4A/
eIF4G).1-3 The eIF4G scaffold protein possesses domains that
interact with eIF4E, eIF4A, eIF3 and the poly(A) binding pro-
tein, PABP.1-4 PABP itself is regulated by interaction with other
proteins; binding of Paip1 to PABP stimulates protein synthesis
while interaction with Paip2 is inhibitory to translation.5,6 The
activity of the eIF4F complex is regulated by a family of proteins,
the eIF4E binding proteins (4E-BPs). Using a conserved motif,
4E-BPs compete with eIF4G for a common surface on eIF4E
and inhibit eIF4F assembly. In mammalian cells, activation of
the mechanistic target of rapamycin (mTORC1) leads to phos-
phorylation of 4E-BP1 in a hierarchical manner. This promotes
protein synthesis by releasing eIF4E and enabling eIF4F complex
assembly on the m7GTP cap of mRNA, mediating 40S ribo-
somal subunit binding by a bridging interaction between eIF4G
and eIF3.1-3
In most organisms there is more than one isoform of most of
these translation initiation factors. For example, there are 3 iso-
forms of eIF4A, eIF4G and PABP.7-9 In some cases the functions
of the isoforms are indistinguishable, in others there are indica-
tions that the different isoforms display mRNA-specific regula-
tion.7-9 Further work will be required to uncover the full range of
functions and specificities of these isoforms.
Ubiquitin like proteins
Ubiquitin-like proteins (Ubls) comprise a family of structur-
ally related proteins. The different members of the family share
sequence similarities, and in particular the proteins contain a
conserved b-grasp fold consisting of 5 b sheets and one a helix.10
Ubiquitin is a 76 amino acid protein and is the most highly con-
served member of the Ubl family, with 96% identity between
yeast and human ubiquitin. SUMO (small ubiquitin-like modi-
fier) is less conserved between species and contains a longer,
more variable N-terminal extension than ubiquitin being around
100–110 amino acids in total length.11 ISG15, between 155–
165 amino acids in length, contains 2 ubiquitin-like domains.12
It was the first member of the family to be identified and, unlike
ubiquitin and SUMO, is present only in vertebrates. The gene
was so named because it was observed to be an interferon stimu-
lated gene encoding a 15 kDa protein.13 Most members of the
Ubl family are synthesized as precursor proteins that need to be
processed to a mature form to reveal a di-glycine motif at the
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Figure 1. For ﬁgure legend, see page e959366-3.
























C-terminus that is required for activation and subsequent con-
jugation of the Ubl to target proteins. The exception to this
is ISG15 in fish and bovine species where the protein is syn-
thesized in the mature form.14 Ubls are attached to one or
more lysine residues in target proteins. There are no known
consensus sequences for conjugation sites for ubiquitin and
ISG15. However SUMO is frequently, although not always,
attached to lysine residues present within the consensus
sequence cKxE, where c D a hydrophobic amino acid and x
is any amino acid.11
Ubiquitylation
Ubiquitin can be covalently attached to lysine residues in tar-
get proteins as a monomer or in the form of chains. This occurs
via the activity of a number of proteins, the E1 (ubiquitin acti-
vating enzyme), E2 (ubiquitin conjugating enzyme) and E3
(ubiquitin ligase) proteins (Fig. 2). In most organisms there is a
single E1, around 40 E2s and hundreds of E3s (reviewed
in15,16). Ubiquitin is produced as a precursor protein that is
processed to the mature form by one of a small number of spe-
cific ubiquitin proteases, to reveal a diglycine motif at the C-ter-
minus. Ubiquitin is then activated in an ATP-dependent
manner, by the formation of a thioester bond between the C-ter-
minal glycine residue and a cysteine residue on the E1 activating
enzyme. From here it is passed to an E2 ubiquitin conjugating
enzyme, again, via the formation of a thioester bond between the
C-terminal glycine residue and a cysteine residue. Attachment of
ubiquitin requires one of a large number of E3 ubiquitin ligases,
which in many cases interact directly with target proteins, but
which in some instances interact with targets via an adaptor pro-
tein. In the main, the E3s provide the specificity for the modifi-
cation. Ubiquitin chain formation occurs via lysine residues
within ubiquitin itself, and also requires the activities of the E1,
E2 and E3 enzymes. The most common linkages are via K11,
K48 and K63.17,18 Ubiquitin can be removed from targets by
the actions of deubiquitinating enzymes (DUBs). Ubiquityla-
tion has 2 main roles: targeting of proteins for proteolysis and
modification of protein function. The best studied role of ubiq-
uitylation is its targeting of proteins for proteasome-mediated
degradation. This involves the recognition of K11- and K48-
linked ubiquitin chains by the 26S proteasome.19 However,
there is a rapidly expanding literature on other roles for ubiqui-
tylation. For example ubiquitylation of PCNA is required for
the recruitment of an error-prone polymerase to undertake
translesion DNA synthesis e.g,20 while ubiquitylation of mem-
brane proteins is required for endocytosis and ubiquitylation of
PIN2 is required for vacuolar sorting (reviewed in21). In these
cases the modification involves a single ubiquitin or K63-linked
chains.
Sumoylation
The process of sumoylation is very similar to that of ubiqui-
tylation, involving SUMO-specific E1 (SUMO activating
enzyme), E2 (SUMO conjugating enzyme) and E3 (SUMO
ligase) proteins.11 There is a single E1 (a heterodimer), a single
E2 (Ubc9) and to date around 12 E3s have been identified.
Unlike ubiquitylation, an E3 is not always required for modifi-
cation, as the E2 is in some cases sufficient, and can provide a
degree of target specificity.22 Like ubiquitin, SUMO can be
attached to proteins either as a monomer or in the form of
poly-SUMO chains.11 Sumoylation affects protein-protein
interactions,23,24 protein activity25 and protein localization.26
In addition, SUMO chains interact with STUbLs (SUMO-tar-
geted ubiquitin ligases) that bring about ubiquitylation of the
target protein and associated SUMO chains, resulting in pro-
teasome–mediated proteolysis.27
ISGylation
ISG15 is conjugated to target proteins in a manner similar to
that of ubiquitin and SUMO.28 ISG15 expression and modifica-
tion (ISGylation) are activated by Type I interferon (IFN), which
is one of a number of critical cytokines in the innate immune
response. As is the case for ubiquitin and SUMO, there are pro-
teases that are specific for processing ISG15 and deconjugating it
from target proteins (e.g., USP43,29) and a specific E1 enzyme
for ISG15.29 However, some of the E2s (e.g., UbcH8) and E3s
(e.g., Efp—the partner of UbcH8, and HHARI—the human
homolog of Drosophila ariadne) involved in ISGylation also
appear to be involved in ubiquitylation.30,31
Identiﬁcation of Ubl Attachment Sites and the Roles
of Modiﬁcation
Early methods for the identification of modified sites involved
site-directed mutagenesis of individual lysine residues in target
proteins, followed by analysis in vitro or in vivo to determine
whether modification still occurred. While this has been success-
ful in some cases (e.g.,32) in many cases it has been problematic
since other lysine residues are frequently used instead of the nor-
mal sites in the mutant proteins. More recently, mass spectrome-
try has been used successfully for site identification (e.g.,33). This
involves the cleavage of modified proteins by trypsin or other
suitable protease to release peptides from the target. This method
is facilitated by having a protease cleavage site close to the C-ter-
minal diglycine motif attached to the target, so that only a few
extra amino acids remain attached to the modified site. Modifica-
tion sites are thus detected by the identification of peptides that
are increased in Mr by an amount dependent on the position of
the cleavage site within the Ubl.
Figure 1. (See previous page). Formation of the 48S preinitiation complex. eIF1, 1A and 3 interact with the 40S ribosomal subunit. This then interacts
with eIF5 and the ternary complex (eIF2-GTP-Met-tRNA) to form the 43S complex. In parallel, eIF4E and eIF4A are recruited by eIF4G to form the eIF4F
complex. The availability of eIF4E is controlled by 4E-BP1, which in turn is regulated by phosphorylation by mTOR. The eIF4F complex binds to the cap
on mRNA along with Poly(A)-binding protein (PABP) and eIF4B. PABP is regulated via interactions with 2 PABP proteins, PAIP1 and PAIP2. The 43S com-

























Analysis of the role of the modifications is hampered by the
fact that frequently, only low levels of modified forms are
observed in cells. The reason for this could be that the modifica-
tions are transient, are labile, or as in the case of poly-ubiquityla-
tion and poly-sumoylation, are targeting the protein for
proteasome-mediated destruction. It is also possible that modifi-
cation may be confined to target molecules in a particular cellular
location. Additionally, it is proposed that this form of post-trans-
lational modification is not like modifications such as phosphory-
lation—i.e., an on/off switch. For example, in the case of
SUMO, it is proposed that in some cases modification results in
a change in conformation of the target protein that is maintained
even after desumoylation occurs. Thus analysis of the roles of
these modifications has lagged behind analysis of the function of
other types of modifications.
Identification of the roles of the modifications has been under-
taken, in the main using in vitro assays to look at relative binding
abilities of wild type and unsumoylatable mutant proteins for
their binding partners e.g.,32 or by introduction of mutant cod-
ing sequences into cells to determine the effect of inability to
modify a particular protein. This is relatively straightforward in
yeast where a mutant copy can be integrated in the genome as
Figure 2. Ubiquitylation pathway. E1 D Ubiquitin activating enzyme, E2 D ubiquitin conjugating enzyme, E3 D ubiquitin ligase, DUB D deubiquitylating
enzyme. Ubiquitin is activated by the formation of a ubiquitin-adenylate before forming a thioester bond with a cysteine residue in the E1 ubiquitin acti-
vating enzyme. Ubiquitin is passed to an E2 ubiquitin conjugating enzyme, again forming a thioester bond. Target proteins are recognized by E3 ubiqui-
tin ligases, either directly or via an adaptor, and ubiquitin is attached via the formation of an e-amino bond. Ubiquitin can be attached to target proteins
either as a monomer, or in the form of ubiquitin chains. Ubiquitin can be removed from target proteins by the action of one of a number of DUBs.
























the sole copy of the coding sequence e.g.,34 In mammalian cells,
the mutant sequence can be introduced by transfection, but is
dependent on having cells where the gene has been knocked out
or where siRNA depletion is efficient. Depletion of the any of
the enzymes in the conjugation pathway would be likely to affect
multiple targets and would not be appropriate.
Role of Modiﬁcation by Ubiquitin or Ubls
in Translation Initiation Factors
A series of recent proteomic screens have identified numerous
translation initiation factors that are modified by either ubiquitin
or SUMO, or in many cases, by both (Table 1). Additionally,
some of the screens have identified the lysine residues required
for the modification. Early studies involved the overexpression of
the modifier, but recently more refined methods using diGly cap-
ture techniques have been used to identify sites when the
modifier is expressed at endogenous levels e.g.35,36 These studies
use mass spectrometry to identify diGly-modified peptides
obtained by trypsin digestion of cellular proteins. A list of modi-
fied sites can be found at PhosphoSitePlus37 (http://www.
phosphosite.org/home). In many cases, individual lysine residues
are identified as a single ‘hit’, making them less likely target sites
than lysine residues that are highly represented, as for example is
observed in eIF4A and eIF4G proteins.
More detailed studies on the role of modification of a number
of the individual proteins by ubiquitin, SUMO and in one case,
ISG15 have also been reported. We summarize here what is
known about the roles of these post-translational modifications
and how they might affect translation rates in mammalian cells.
eIF4E
Regulation of eIF4E levels is important for normal cell
growth, as disruption of its expression or its over-production
leads to aberrant cell growth or oncogenesis.38 Additionally,
Table 1. Proteins identiﬁed in proteomic screens as being modiﬁed by ubiquitin or SUMO
Initiation factor Ubiquitin SUMO Reference
eIF1A Hs Ubiquitin*Mm Ubiquitin Rn SUMO-3 35,36,58,59
eIF2A Hs Ubiquitin*Mm Ubiquitin Hs SUMO-2*At SUMO 35,55,59,80
eIF2a Hs Ubiquitin*Mm Ubiquitin Dm SUMO 36,56,59
eIF2B-b Hs Ubiquitin*Mm Ubiquitin Hs SUMO-1/2 36,59,81
eIF2b Hs Ubiquitin*Mm Ubiquitin At SUMO*Sc SUMO-1 36,59,80,82
eIF2 subunit 1 Hs Ubiquitin*Mm Ubiquitin Rn SUMO-3 35,58,59
eIF2g Hs Ubiquitin*Mm Ubiquitin Dm SUMO*Hs SUMO-1*Hs SUMO-2/3*Sc SUMO 35,36,56,57,59,82,83, *
eIF5B* Hs Ubiquitin*Mm Ubiquitin Hs SUMO-2*Hs SUMO-1* 55,59,61(A)
eIF3A Hs Ubiquitin*Mm Ubiquitin*Rn Ubiquitin Hs SUMO-2*Hs SUMO-1 36,55,59,61(B)*
eIF3B Hs Ubiquitin*Mm Ubiquitin Hs SUMO-2 35,55,59
eIF3C Hs Ubiquitin*Mm Ubiquitin Hs SUMO 1/2 35,59,81
eIF3D Hs Ubiquitin*Mm Ubiquitin Rn SUMO-3 35,58,59
eIF3E Hs Ubiquitin*Mm Ubiquitin Hs SUMO-1/2 35,59,81
eIF3F Hs Ubiquitin*Mm Ubiquitin 59,74(C)
eIF3G Hs Ubiquitin*Mm Ubiquitin 35,36,59
eIF3H Hs Ubiquitin*Mm Ubiquitin*Rn Ubiquitin 35,36,59(D)*
eIF3I Hs Ubiquitin Sc SUMO*Hs SUMO-1/2 35,36,59,60,82–84
eIF3J Hs Ubiquitin*Mm Ubiquitin 36,59
eIF3K Hs Ubiquitin*Mm Ubiquitin 35,36*
eIF3L Hs Ubiquitin*Mm Ubiquitin 35,59
eIF3M Hs Ubiquitin*Mm Ubiquitin Hs SUMO-1 35,59,83
eIF3X Hs SUMO-2 55
eIF4A1 Hs Ubiquitin*Mm Ubiquitin*Rn Ubiquitin Dm SUMO*Rn SUMO-3*Hs SUMO-1/2*At SUMO 35,36,55–62(D)
eIF4A2 Hs Ubiquitin*Mm Ubiquitin Hs SUMO-1 35,59,61
eIF4E Hs Ubiquitin*Mm Ubiquitin Hs SUMO-1 36,46,59
eIF4GI Hs Ubiquitin*Mm Ubiquitin Hs SUMO-1/2 36,57,59,61
eIF4GII Hs Ubiquitin 35
eIF4GIII Hs Ubiquitin*Mm Ubiquitin 35,36
eIF5A Hs Ubiquitin*Mm Ubiquitin*Rn Ubiquitin Hs SUMO-1/2 35,59,83(D)
PABP1 Hs Ubiquitin*Mm Ubiquitin Hs SUMO-2*Sc SUMO 35,55,57,59,85
PABP4 Hs Ubiquitin*Mm Ubiquitin Hs SUMO-2 35,55,59
Hs: human, Rn: rat, Mm: mouse, Sc: S. cerevisiae, At: Arabidospsis. (A) (2010) CST Curation Set: 9913; Year: 2010; SILAC: N; Biosample/Treatment: AMO-1(cell
line)/Velcade; Disease: -; Speciﬁcity of Antibody Used to Purify Peptides prior to MS2: anti-UbK Antibody Used to Purify Peptides prior to MS2: Ubiquitin
(D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoafﬁnity Beads Cat#: 1990. (B) (2008) CST Curation Set: 3970;
Year: 2008; SILAC: N; Biosample/Treatment: brain(tissue)/untreated; Disease: -; Speciﬁcity of Antibody Used to Purify Peptides prior to MS2: anti-UbK.
(C) (2009) CST Curation Set: 8668; Year: 2009; SILAC: N; Biosample/Treatment: RPMI-8266(cell line)/Velcade; Disease: -; Speciﬁcity of Antibody Used to Purify
Peptides prior to MS2: anti-UbK Antibody Used to Purify Peptides prior to MS2: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin
Branch Motif (K-e-GG) Immunoafﬁnity Beads Cat#: 1990. (D) (2007) CST Curation Set: 3578; Year: 2007; SILAC: N; Biosample/Treatment: brain(tissue)/ischemia

























eIF4E protein levels increase during differentiation e.g.,39 eIF4E
is both mono- and poly-ubiquitylated40,41 and this has been
demonstrated to occur mainly on K159.40 This modification is
enhanced by the E3 ubiquitin ligase, Chip (carboxy terminus of
Hsp-70 interacting protein) which is known to have a role in reg-
ulating protein quality control.42 A mutant form of eIF4E that is
unable to interact with eIF4G or 4E-BP1 is more highly ubiqui-
tylated than wild type eIF4E. This results in increased degrada-
tion by the proteasome of the mutant form, consistent with a
role for ubiquitylation of eIF4E in a quality control process,
removing inactive forms of the protein from the cell.40 A role for
ubiquitylation in quality control is supported by a number of
observations. First, that binding of eIF4E to 4E-BP1 (eIF4E
binding protein that is also regulated by ubiquitylation—see
below) suppresses ubiquitylation and degradation and that only
non-ubiquitylated eIF4E binds eIF4G. Second, overexpression of
4E-BP1 prevents ubiquitin-mediated degradation of eIF4E.
Third, heat shock (45C 10 min, conditions that would result in
a degree of protein misfolding) also induces ubiquitylation of
eIF4E, as does exposure to another form of stress, cadmium
chloride.41
While poly-ubiquitylation clearly has a role in targeted
destruction of eIF4E, little work has been performed to deter-
mine whether there is a different role for mono-ubiquitylation in
regulating levels or subcellular localization of eIF4E. In contrast,
the biological significance of eIF4E phosphorylation and its effect
on translation have been studied over many years; however, the
role of phosphorylation in modulating the activity of the protein
is still not completely understood, although enhanced levels of
eIF4E phosphorylation are associated with a number of human
tumors.43,44 Biophysical studies have suggested that phosphoryla-
tion of eIF4E decreases its affinity for the mRNA cap of mRNA,
possibly allowing rapid recycling of eIF4E between competing
mRNAs.45 However, it has also been suggested that phosphoryla-
tion of S209 causes a retractable salt bridge to form with K159
(the ubiquitylation site) which leads to increased binding of
capped mRNA.40 Mutation of K159 to alanine but not arginine,
reduces association with cap analogs, indicating that a positive
charge is required at this position. Despite the fact that the
K159R mutant cannot be ubiquitylated, it has been proposed
that mono-ubiquitylation may stabilize the distance between
S209 and K159, or that ubiquitin itself may form part of the
bridge between S209 and K159.40
eIF4E is also modified by SUMO,32,46 in a process that is pro-
moted by HDAC2 (histone deacetylase 2).46 Sumoylation occurs
on several lysine residues, namely K36, 49, 162, 206 and 212.
Interestingly, unlike what has been observed with a number of
other proteins, such as IkBa and PCNA,34,47 sumoylation and
ubiquitylation of eIF4E do not occur on the same lysine residues.
Sumoylation of eIF4E is dependent on phosphorylation, but the
reverse is not true: inability to sumoylate eIF4E does not affect
its ability to be phosphorylated.32 Sumoylation results in the
induction of translation of a subset of mRNAs required for cell
proliferation and apoptosis. A mutant form of eIF4E that cannot
be sumoylated is still able to bind m7GTP, indicating that cap-
binding is unaffected. However, compared with wild type
protein, the mutant form binds significantly better to 4E-BP1
than it does to eIF4G, and is unable to form stable eIF4F com-
plexes. It has been suggested that sumoylation induces a confor-
mational change in eIF4E producing a change in interaction
surfaces resulting in release from 4E-BP1 and promoting interac-
tion with eIF4G. The inability of the mutant protein to be
sumoylated results in an increase in the amount of eIF4E inter-
acting with 4E-BP1.32 While overexpression of wild type eIF4E
in NIH-3T3 cells results in increased expression of eIF4E-
regulated genes, this is not observed when unsumoylatable eIF4E
is overexpressed.32 At this time is unclear whether sumoylation of
eIF4E has any effect of global rates of translation or rates of
export of specific mRNAs from the nucleus.
4EHP
4EHP, also known as eIF4E2, binds to the m7GTP cap in a
manner similar to that of eIF4E. However, unlike eIF4E, it does
not bind eIF4G and therefore does not allow ribosome recruit-
ment. It thus competes with eIF4E for the mRNA and prevents
translation.48 It is targeted for ubiquitylation49 and interestingly,
also for modification with another Ubl, ISG15.50 Curiously, the
E3 ligase HHARI, which has recently been shown to be a marker
of cellular proliferation,51 stimulates both ubiquitylation and
ISGylation of 4EHP.49,50 Proteomic studies have identified
K239 as a ubiquitylation site, but this has not been verified in a
detailed study. In contrast, ISGylation, which occurs on K134
and K222, has been analyzed in some detail.50 Binding studies
indicate that ISGylated 4EHP has a higher affinity for m7GTP
than the unmodified form. It has been proposed that this modifi-
cation is used by cells to inhibit translation of specific mRNAs in
innate immune responses. Interestingly, despite its similarity to
4EHP, eIF4E is not ISGylated.
4E-BP Family
The eIF4E binding proteins (4E-BPs) are key regulators of
protein synthesis.1-3 As their name suggests, they function by
interacting with eIF4E. This inhibits eIF4E function by prevent-
ing it from interacting with eIF4G to form the mature eIF4F
complex. The 4E-BP proteins are phosphorylated following acti-
vation of mTORC1, in response to changes in growth condi-
tions, and interaction of eIF4E with 4E-BP1 and -2 occurs with
the hypophosphorylated form.1-5 A key factor in the regulation
of translation initiation is that the relative levels of eIF4E and
4E-BP1 and -2 are highly controlled.52 The hypophosphorylated
form, but not the hyperphosphorylated form, of 4E-BP1 is unsta-
ble if not bound to eIF4E. Under these conditions, 4E-BP1 is
ubiquitylated and targeted for proteasome-mediated proteoly-
sis.52,53 The role of ubiquitylation was identified following some
rather unexpected results obtained when knockdown of eIF4E
using shRNA was demonstrated to have no effect on protein syn-
thesis.52 This was subsequently shown to be due to concomitant
degradation of 4E-BP1, which resulted in the release of eIF4E
molecules to compensate for the loss brought about by the
reduced expression. K57, a lysine residue conserved between all 3
4E-BPs, was identified by the Sonenberg lab as the ubiquitylation
site in 4E-BP1,52 and a screen of an siRNA library identified the
























KLHL25-CUL3 as the E3 ubiquitin ligase responsible for 4E-
BP1 degradation. Knockdown of KLHL25 resulted in a decrease
in translation, consistent with it having a role in controlling levels
of 4E-BP1.52
Proteasome activity (presumed to be a result of poly-ubiquity-
lation) has also been demonstrated to be required for the forma-
tion of a truncated form of 4E-BP1 (tr4E-BP) in murine erythro-
leukemia (MEL) cells containing activated p53.54 This truncated
form is 3 kDa smaller than full-length protein, is unphosphory-
lated and relatively stable. It also binds to eIF4E in preference to
the full-length protein. It has been proposed that the production
of this p53-induced form may be contributing to the ability of
p53 to regulate apoptosis and malignancy.
eIF4A
Two isoforms of eIF4A have been identified in proteomic
screens as being modified by ubiquitin and SUMO.35,36,55-62 In
contrast to what is observed with some of the other initiation fac-
tors, modified peptides from both eIF4A1 and eIF4A2 are highly
abundant in the proteomic screens designed to identify ubiquity-
lation sites, implying that modification is likely to have a key role
(s) in the regulation of the function of these 2 proteins. In the
ubiquitin screens, most of the modified sites identified in the
human eIF4A proteins were also observed in the mouse proteins,
suggesting that they are likely to be true ‘hits’ and not false posi-
tives. Interestingly, eIF4A2 (but not eIF4A1) and translational
repression have both been shown to be essential for miRNA-
mediated gene regulation.63 However, the post-translational
modification of these proteins by ubiquitin or Ubls has not been
analyzed in detail and to date there are no reports on whether it
affects the activity of the eIF4A protein or miRNA-mediated
translational control.
In a role unrelated to its function in translation, ubiquityla-
tion of Drosophila eIF4A has been shown to be linked with
Decapentaplegic (Dpp) signaling.64 Additionally, rice DRM2
(required for RNA-directed DNA methylation) interacts with
eIF4A via its ubiquitin associated (UBA) domain, (although
whether this occurs with a ubiquitylated form has not been
analyzed).65
eIF4G
There are 3 isoforms of the scaffold protein, eIF4G, eIF4GI-
III. As observed with eIF4A, diGly-modified peptides from these
proteins are abundant in proteomic screens designed to identify
ubiquitylation sites,35,36,57,59,61 and again most are observed in
both the human and mouse proteins. In eIF4GI these sites (6 in
total, 4 common to both human and mouse) map to lysine resi-
dues occurring between amino acids 593–925 which map close
to, or in the region of, the eIF4E and eIF4A/3 binding sites. The
abundance of these modified tryptic fragments and their position
in the protein suggests that this post-translational modification is
likely to be important for regulating the functions of these pro-
teins, possibly by affecting the interaction of eIF4G with other
members of the eIF4F complex. Again, these modifications have
not been analyzed in detail and to date there are no reports on
whether they affect the activity of eIF4GI. In addition to this
modification by ubiquitin, eIF4GI has been shown to be sumoy-
lated in both fission yeast and human cells.66 Sumoylation of S.
pombe eIF4G is increased following exposure of cells to 1 M KCl
or arsenite, conditions which result in the formation of stress
granules. In vitro sumoylation studies have identified 2 sumoyla-
tion sites in mammalian eIF4GI, K1368 and K1588, residing in
the eIF3/4A binding site and the Mnk-binding domain, respec-
tively. (Mnks (MAP kinase-interacting kinases) are kinases which
bind to the C-terminus of eIF4G and phosphorylate eIF4E
which is bound to the N-terminus of eIF4G.67) These data sug-
gest that sumoylation may be affecting interactions of eIF4GI
with associated proteins, e.g., eIF4E, and possibly the assembly
of eIF4G into stress granules.
Paip2
Poly(A)-binding protein (PABP) is regulated through the
interaction with 2 proteins, Paip1 and Paip2.5,6 Paip1, which
also interacts with eIF3g, is eIF4G-like and is stimulatory for
translation, while Paip2 represses PABP function by decreasing
the affinity of PABP for polyadenylated mRNA, thus inhibiting
translation. Paip1 and Paip2 both have 2 domains, PAM1 and
PAM2 which interact with PABP. This interaction occurs
through RRM-1 and PABC domains, respectively.68 Addition-
ally, PAM2 is capable of interacting with EDD (a member of the
HECT domain family of E3 ubiquitin ligases) which also con-
tains a PABC domain.69 In cells where levels of PABP are
depleted, Paip2A is ubiquitylated in an EDD-dependent manner
prior to proteasome-mediated degradation.70 Interestingly, the
affinity of the PAM2 domain of Paip2 for the PABC domain of
PABP is greater than that of the affinity for the PABC of EDD.
Thus, it is proposed that interaction of PABP with Paip2 com-
petes with EDD for interaction with PAM2 on Paip2, and that
this normally prevents ubiquitylation of Paip2.70 However, in
apparently contradictory work, it has been demonstrated that
during human cytomegalovirus infection PABP levels rise con-
comitantly with the levels of both Paip2 and EDD1. The reason
for this is not known, but it has been proposed that it may pro-
vide cells with a process to allow rapid changes in protein levels if
necessary.71 Paip2B is also polyubiquitylated, although at a
somewhat lower level that Paip2, and is hence more stable.72
eIF3
Proteomic studies have identified many of the eIF3 subunits
as targets for ubiquitylation and/or sumoylation. However, inde-
pendent of these studies, eIF3f is the only eIF3 subunit where the
function of these modifications has been studied in any detail.
eIF3f is a non-core subunit of the eIF3 complex. It can act both
as a repressor and as an enhancer of translation (reviewed in73).
Its role as a translational enhancer came to light in a study on
muscle atrophy.74 Here, eIF3f is ubiquitylated by the MAFbnx/
Atrogin1 protein which is a muscle-specific F-box protein ubiq-
uitin E3 ligase.75 This E3 is upregulated and essential for acceler-
ated muscle protein loss in a number of disorders.76
Ubiquitylation of eIF3f occurs on multiple (6) lysines in the C-
terminus74 and results in its ubiquitin-mediated proteolysis in

























MAFbnx and eIF3f are detected in the nucleus.75 It has been pro-
posed that this ubiquitylation may be associated with the rapid
downregulation of certain proteins during muscle atrophy. eIF3f
also interacts with the ubiquitin E3 ligase TRC8 to inhibit pro-
tein synthesis. The mechanism by which this occurs is unknown,
but it has been proposed that TRC8 targets an eIF3 subunit for
ubiquitylation.77 Unrelated to its role in translation, eIF3f can
act as a deubiquitylating enzyme (DUB). In this capacity it is
capable of deubiquitylating, and thus contributing to the activa-
tion of, the Notch signaling receptor in Drosophila.78
Interestingly, recent work has shown that eIF3e is involved in
eIF4E phosphorylation; Mnk1 binding to eIF4F is dependent on
eIF3e, and eIF3e is sufficient to promote Mnk1-binding to
eIF4G.79 As eIF3e is modified by both ubiquitylation and
sumoylation, it would be interesting to know if these modifica-
tions of eIF3e also have a role in controlling eIF4E
phosphorylation.
Summary
In conclusion, despite the fact that numerous translation initi-
ation factors have been shown to be ubiquitylated and/or sumoy-
lated in proteomic screens, relatively little is known about the
effects of the modifications on the functions of individual pro-
teins. In part this is due to the transient nature of these modifica-
tions, e.g., in many cases of sumoylation, less than 5% of a
particular protein is modified at any one time, and the sumoy-
lated species appear to be very labile in certain organisms due to
highly active SUMO-specific proteases. Additionally, since ubiq-
uitylation targets proteins for destruction, analysis of ubiquity-
lated proteins, other than in the presence of a proteasome
inhibitor, is difficult.
The recent use of proteomic screens to identify modified pro-
teins and the modified site(s) suggests that there are many more
cases where post-translational modification by ubiquitin or Ubls
is likely to affect translation initiation factors. For example,
sumoylation of eIF4A1/2 might have a role in regulating both
the unwinding of mRNA secondary structure and the ability of
eIF4A2 to mediate miRNA-dependent gene expression in mam-
malian cells. Further work on these modifications is required to
fully elucidate their effect on individual proteins and on transla-
tional control of gene expression as a whole.
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53BP1 plays multiple roles in mammalian DNA dam-
age repair, mediating pathway choice and facilitating
DNA double-strand break repair in heterochromatin.
Although it possesses a C-terminal BRCT2 domain,
commonly involved in phospho-peptide binding in
other proteins, initial recruitment of 53BP1 to sites
of DNA damage depends on interaction with histone
post-translational modifications—H4K20me2 and
H2AK13/K15ub—downstream of the early gH2AX
phosphorylation mark of DNA damage. We now
show that, contrary to current models, the 53BP1-
BRCT2 domain binds gH2AX directly, providing a
third post-translational mark regulating 53BP1 func-
tion. We find that the interaction of 53BP1 with
gH2AX is required for sustaining the 53BP1-depen-
dent focal concentration of activated ATM that
facilitates repair of DNA double-strand breaks in het-
erochromatin in G1.INTRODUCTION
TP53 binding protein 1 (53BP1) is a large multi-domain protein
with multiple roles in the DNA damage response (Panier and
Boulton, 2014; Zimmermann and de Lange, 2014). Following
DNA damage and activation of the DNA-damage-responsive
protein kinase ATM, 53BP1 is recruited rapidly to nuclear foci
(Schultz et al., 2000) containing the primary mark of DNA
damage—phosphorylation of Ser139 close to the C terminus of
the histone H2A variant—H2AX (Rogakou et al., 1998), generally
known as gH2AX. Although 53BP1 has a C-terminal tandem
BRCT domain (BRCT2), which in its orthologs, Saccharomyces
cerevisiae Rad9p and Schizosaccharomyces pombe Crb2, me-
diates binding to the equivalents of gH2AX (Hammet et al.,
2007; Kilkenny et al., 2008), the role of the 53BP1-BRCT2 domain
remains controversial. Although some studies indicated an inter-action with gH2AX (Stewart et al., 2003;Ward et al., 2003), others
have contradicted this (Stucki et al., 2005;Ward et al., 2006), and
a significant role for this domain in the DNA damage response
has been largely discounted (Bothmer et al., 2011; Callen
et al., 2013).
Current models suggest that 53BP1 recruitment to ionizing ra-
diation induced nuclear foci (IRIF) depends only indirectly on
gH2AX and is instead mediated by two other post-translational
modifications: (1) H2AK13/15-anchored ubiquitin chains (Fra-
det-Turcotte et al., 2013) generated by the E3 ubiquitin ligases
RNF8 and RNF168, which are themselves recruited by MDC1,
whose BRCT2 domain interaction with gH2AX is required for its
own recruitment (Bekker-Jensen and Mailand, 2010; Pinder
et al., 2013); and (2) direct interaction of the tandem Tudor do-
mains of 53BP1 with dimethylated H4K20 (Botuyan et al.,
2006) exposed by release of JMJD2A and L3MBTL1 following
their ubiquitylation by RNF8 and RNF168 (Acs et al., 2011; Mal-
lette et al., 2012).
We have re-examined the role of the 53BP1-BRCT2 domain
and show unambiguously that it is a competent binding module
for phosphorylated peptides with a clear specificity for the DNA-
damage marker gH2AX, and in isolation from other parts of
53BP1 is sufficient for localization to sites of DNA damage in
cells associated with gH2AX.
Structure-based mutational disruption of gH2AX binding by
53BP1 interferes with the 53BP1-dependent localization of
pATM required for repair of DNA damage in regions of hetero-
chromatin and results in a defect in the slow phase of DNA break
repair in G1. These data add a third histone post-translational
mark to the ligand repertoire of 53BP1, and a clear functional
role for phosphopeptide binding by its BRCT2 domain.RESULTS AND DISCUSSION
53BP1-BRCT2 Binds gH2AX In Vitro
Comparison of the tandem BRCT domains of 53BP1 with those
of MDC1 (Rodriguez et al., 2003; Stucki et al., 2005) and Crb2
(Kilkenny et al., 2008) shows strong conservation of residuesCell Reports 13, 1–9, December 15, 2015 ª2015 The Authors 1
Figure 1. 53BP1 BRCT2 Domain Binds gH2AX
(A) Fluorescence polarization assay (closed circle) showing binding of His6-SUMO-53BP1-BRCT2 to a fluorescein-tagged phosphopeptide (Flu-
SGGKKATQApSQEY) corresponding to the last 13 residues of gH2AX. Data are means of four replicates with error bars showing 1 SD, and the KD (1.4 mM ± 0.15)
was calculated by least-squares fitting of a one-site binding model. Removal of the phosphate group on Ser139 by addition of l-phosphatase (open circle)
abrogates the interaction. The dashed line indicates a signal level consistent with non-specific interaction.
(B) As (A) but for His6-SUMO-MDC1-BRCT2 binding to the fluorescein-tagged gH2AX phosphopeptide.
(legend continued on next page)
2 Cell Reports 13, 1–9, December 15, 2015 ª2015 The Authors
Please cite this article in press as: Baldock et al., ATM Localization and Heterochromatin Repair Depend on Direct Interaction of the 53BP1-BRCT2
Domain with gH2AX, Cell Reports (2015), http://dx.doi.org/10.1016/j.celrep.2015.10.074
Please cite this article in press as: Baldock et al., ATM Localization and Heterochromatin Repair Depend on Direct Interaction of the 53BP1-BRCT2
Domain with gH2AX, Cell Reports (2015), http://dx.doi.org/10.1016/j.celrep.2015.10.074implicated in specific binding of phosphorylated histone H2A
tails. To determine whether 53BP1 shared this property, we
measured the binding of the isolated 53BP1-BRCT2 segment
to a fluorescently labeled phosphopeptide (fluorescein-
SGGKKATQApSQEY) corresponding to the last 13 residues of
human gH2AX, by fluorescence polarization (see Experimental
Procedures). 53BP1-BRCT2 bound the phosphopeptide with a
KD of 1.4 mM (Figure 1A), an affinity 3.5-fold lower than
MDC1-BRCT2 (KD = 0.4 mM) when measured under the same
experimental conditions (Figure 1B), but well within the range
that is highly likely to be physiologically functional. The dephos-
phorylated H2AX peptide showed no significant binding (Fig-
ure 1A), nor did a comparable phosphopeptide from another pro-
tein (KAP1-pS824: fluorescein-GYG-SLPGAGLSpSQELSGG),
showing the interaction is both phospho-dependent and
sequence specific (Figure 1C).
Given that gH2AX is not the only phosphorylated ligand bound
specifically by other BRCT2 domains, we further defined the pa-
rameters of phosphopeptide recognition by 53BP1-BRCT2. A
gH2AX peptide with an amidated C terminus (H2AX-pS139-
NH2 or with an additional glycine (H2AX-pS139-Gly) bound
53BP1-BRCT2 far less tightly than the peptide with the free
charged a-carboxyl (Figure 1D). (Although the phosphorylated
serine in human H2AX is encoded by codon 140 of the H2AFX
gene, the initiator methionine is removed, and therefore not
generally counted in the prevalent literature. For consistency,
we here refer to this residue as Ser139.) We also explored the ef-
fect on binding to 53BP1-BRCT2 of phosphorylation of H2AX-
Tyr142, believed to mediate a switch between DNA repair and
apoptosis (Cook et al., 2009). An H2AX peptide phosphorylated
on Tyr142 bound far less tightly than the gH2AX peptide, as did a
peptide bis-phosphorylated on both Ser139 and Tyr142 (Fig-
ure 1E). These data reinforce the conclusion that the canonical
DNA-damage-responsive mark gH2AX is a specific ligand of
53BP1-BRCT2.
To further characterize the interaction, we determined the
crystal structure of 53BP1-BRCT2 in complex with the core
DNA-binding domain of P53 and a short ‘‘pSQEY’’ peptide cor-
responding to the last four residues of gH2AX (Figure 1F; Table
S1). The phosphopeptide bound in a similar conformation to its
interaction with the BRCT2 domain of MDC1, with the phosphate
group on gH2AX-Ser139 bound by the side chain of 53BP1-
Thr1737, the peptide backbone of Met1738, and the side chains
of Lys1773 and Lys1814 (Figure 1G). The side-chain carboxyl of(C) As (A) but with a fluorescein-tagged phosphopeptide derived from the major
2010). No binding was observed.
(D) As (A) but for gH2AX peptides in which the C-terminal a-carboxyl group of Tyr1
residue (open circle). Both modifications substantially reduce the affinity, and no
(E) As (A) but for H2AX peptides in which the side chain of Tyr142 is phospho
phosphorylation (open circle). In both cases, phosphorylation of Tyr142 substan
(F) Overview of crystal structure of a phosphopeptide corresponding to the last f
binding domain of P53, which is required for crystallogenesis, makes no interact
(G) Detail of interactions made by the tail of gH2AX with the 53BP1-BRCT2 doma
reflect their relative position within the protein sequence. The basic side chains of
interactions with the acidic phosphate of gH2AX-pSer139 and the a-carboxyl of
(A) and (C).
(H) As (A) but showing binding of the fluorescent gH2AX peptide to His6-SUMO
mutation (open circle).gH2AX-Glu141 interacts with the peptide backbone of 53BP1-
Arg1811, while the a-carboxyl of gH2AX-Tyr142 forms ionic
and hydrogen bonding interactions with the side chain of
53BP1-Arg1811, explaining the strong preference for an
unblocked C terminus in our binding assays (Figure 1D). The
side chain of Tyr142 protrudes into a hydrophobic pocket
lined by the side chains of Leu1887, Asn1883, and the main
chain of Arg1813, an interaction that would be precluded by
its phosphorylation. Consistent with the structure, charge
reversal mutation of Lys1814, which interacts with the phos-
phate on H2AX-pSer139, or Arg1811, which binds the
a-carboxyl of H2AX-Tyr142, abrogated interaction of 53BP1-
BRCT2 with the gH2AX phosphopeptide (Figure 1H). As the
BRCT2 domain of 53BP1 is a dimer in solution, like that of its
yeast homolog Crb2 (Kilkenny et al., 2008), we confirmed that
dimerization was not affected by the phospho-bindingmutations
(Figure S1).
53BP1-BRCT2 Binds gH2AX in Cells
To determine whether the in vitro interaction that we observed
for 53BP1-BRCT2 is reflected in its behavior in cells, we trans-
fected HeLa cells with an eYFPNLS-53BP1-BRCT2 construct.
Laser micro-irradiation of the nuclei of live transfected cells
caused a distinct time-dependent accumulation of fluorescence
along the laser track, consistent with recruitment of the tagged
53BP1-BRCT2 construct to sites of DNA damage; a construct
lacking the BRCT2 segment or with mutations that abolish
gH2AX binding in vitro did not (Figures 2A and 2B; Movies S1
and S2). Although it was not possible to directly image gH2AX
formation in live HeLa cells, recruitment of MDC1-BRCT2 to
the laser tracks confirms the presence of gH2AX (Movies S3),
and clear gH2AX foci could be readily visualized in fixed cells
following irradiation. The lower intensity of the recruited
53BP1-BRCT2 compared to MDC1-BRCT2 is consistent with
the lower affinity of 53BP1-BRCT2 for gH2AX we measured
in vitro. Pre-treatment of the cells with KU55933, a specific inhib-
itor of ATM, substantially diminished gH2AX focus formation on
irradiation, and this was further decreased by a DNA-PK inhibitor
NU7441 (Figure 2C). When HeLa cells expressing the eYFPNLS-
53BP1-BRCT2 construct were similarly pre-treated, recruitment
of fluorescence to the laser stripe was greatly diminished, and
with addition of NU7441, effectively abolished (Figure 2D).
Consistent with this, the eYFPNLS-53BP1-BRCT2 construct did
not localize to sites of DNA damage in mouse embryonicATM phosphorylation site on the heterochromatin protein KAP-1 (Noon et al.,
42 is modified by either amidation (closed circle) or addition of a further glycine
KD could be determined.
rylated, either alone (closed circle) or in the presence of the gH2AX Ser139
tially diminished binding to His6-SUMO-53BP1-BRCT2.
our residues of gH2AX bound to the BRCT2 domain of 53BP1. The core DNA-
ion with the gH2AX peptide and is omitted for clarity.
in. Carbon atoms in gH2AX are white; those of 53BP1 are rainbow colored to
53BP1 residues Lys1814 and Arg1811 provide neutralizing hydrogen bonding
Tyr142, which are both required for binding of gH2AX to 53BP1-BRCT2; see
-53BP1-BRCT2 with either an R1811E mutation (closed circle) or a K1814E
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immunoprecipitated the wild-type eYFPNLS-53BP1-BRCT2
construct from HeLa cell extracts and were able to detect a
co-precipitating gH2AX signal in western blots that was greatly
diminished in immunoprecipitates of eYFPNLS-53BP1-BRCT2
with the R1811E mutation that abrogates gH2AX binding
in vitro (Figure 2G).
Taken together, these structural, biochemical, and cellular ob-
servations provide compelling evidence that the BRCT2 segment
of 53BP1 has an inherent ability to localize to sites of DNA dam-
age independently of other regions of the protein, and that this
recruitment, which depends on phosphorylation of H2AX by
DNA-damage-responsive PIKK kinases, is mediated by the
clearly demonstrated ability of 53BP1-BRCT2 to bind gH2AX
both specifically and directly.
Phospho-Binding by 53BP1-BRCT2 Regulates pATM
Focal Localization
Having demonstrated the ability of 53BP1 to bind gH2AX
directly, we sought to determine whether this ability contributed
to any of the known roles of 53BP1 in the DNA damage
response.
53BP1 is required for the focal localization of activated ATM,
autophosphorylated on Ser1981 (Bakkenist and Kastan, 2003),
and MRE11-RAD50-NBS1 (MRN) complexes at sites of DNA
damage, and in the consequent activation of ATM checkpoint
signaling (DiTullio et al., 2002; Mochan et al., 2004; Lee et al.,
2010; Panier and Boulton, 2014). Consistent with this, small
interfering RNA (siRNA) knockdown of 53BP1 in HeLa cells
substantially diminished recruitment of activated pATM and
MRN (visualized by NBS1), to nuclear ionizing radiation-
induced foci (IRIF), with both of these proteins displaying a
diffuse pan-nuclear distribution following irradiation (Figures 3
and S3).
Wild-type siRNA-resistant HA-tagged 53BP1 expressed in
these knockdown cells, formed distinct foci itself following irra-
diation, and restored NBS1 and pATM foci that co-localized
with those of 53BP1. However, a 53BP1 construct completely
lacking the BRCT2 domain still formed foci of its own but failed
to restore NBS1 and pATM foci. By contrast 53BP1 constructs
in which the BRCT2 domain was present but contained muta-Figure 2. 53BP1 BRCT2 Domain Localizes to DNA Damage through Ph
(A) HeLa cells were reverse transfected with 53BP1 siRNA. 48 hr later, cells were
containing either wild-type or mutant BRCT domains, or eYFP-SV40NLS-MDC1-B
line indicated by the white arrowheads, and images were recorded over 3 min. S
(B) eYFP fluorescence was tracked over 3 min to observe localization. Profiles
Slidebook6 software (n = 30 from three experimental repeats). Error bars, 1 SD.
(C) Cells were treated with either KU55933 (ATMi), NU7441 (DNA-PKi), or both for
before fixing and staining for gH2AX. Scale bar, 10 mm.
(D) Cells were processed as before with the addition of either DNA-PKi, ATMi, o
over 3 min to observe localization. Fluorescence intensity profiles were generat
bars, 1 SD.
(E) H2AX+/+ and H2AX/ mouse embryonic fibroblasts were reverse transfecte
SV40NLS-53BP1-BRCT2 construct or the eYFP-SV40NLS control. 16 hr after thi
tracked over 3 min to observe localization. Scale bar, 10 mm.
(F) Fluorescence intensity profiles from (E) were generated using Slidebook6 sof
(G) eYFP-SV40NLS-53BP1-BRCT2 was immunoprecipitated using GFP-trap bea
eYFP-SV40NLS-53BP1-BRCT2 or gH2AX detected by western blot. Inputs represtions that disrupt binding to gH2AX (R1811E, K1814E) were
able to recruit NBS1 into co-incident foci but had no effect
on pATM, which retained the diffuse staining evident in the
53BP1 knockdown cells. A defect in pATM focus formation
was evident with the K1814E mutant as early as 30 min post-
irradiation (Figure S3B). A 53BP1 construct with a Tudor
domain mutation (Y1502L) that abolishes recruitment to DNA
damage (Huyen et al., 2004; Botuyan et al., 2006) eliminated
53BP1 foci and did not restore focal concentration of either
NBS1 or pATM.
These data confirm previous observations that 53BP1 facili-
tates focal concentration of NBS1 (and thereby MRN) and
pATM at DNA breaks in G1 but show that in both cases
this is dependent on the BRCT2 domain, and that focal recruit-
ment of pATM is specifically dependent on the ability of that
domain to interact with gH2AX. These data also indicate a
function for the 53BP1-BRCT2 in mediating an additional
link between MRN complexes and chromatin modification,
via its phosphorylation-independent interaction with RAD50
(Paull, 2015) and its phosphorylation-dependent interaction
with gH2AX.
Phospho-Binding by 53BP1-BRCT2 Contributes to
Heterochromatin Repair
Double-strand break (DSB) repair in heterochromatin occurs
more slowly than in euchromatin and requires 53BP1-depen-
dent retention of pATM and consequent phosphorylation of
the silencing factor KAP1/TRIM28 (Noon et al., 2010), which
promotes its release with consequent relaxation of the
heterochromatin. HeLa cells contact-inhibited in G0/G1, and
transfected with 53BP1 siRNA, displayed significantly higher
numbers of gH2AX foci 16–24 hr after irradiation than mock-
transfected cells, or knockdown cells expressing a wild-type
53BP1 construct (Figure 4A). Consistent with their inability to
localize pATM (Figure 3B), 53BP1 constructs lacking the
BRCT2 domain or with gH2AX-binding defective mutations
failed to rescue the knockdown phenotype and resulted in
significantly increased levels of gH2AX foci at later time points
(Figures 4B and S4). Simultaneous knockdown of KAP1, whose
phosphorylation depends on pATM localization, reduced the
number of persistent gH2AX foci seen with these mutantsospho-Specific Interactions
transfected with eYFP-SV40NLS or eYFP-SV40NLS-53BP1-BRCT2 constructs
RCT2. 16 hr after this cells were damaged using laser micro-irradiation along a
cale bar, 10 mm.
of fluorescence intensity along the laser track in (A) were generated using
1 hr prior to irradiation with 3 Gy of IR. Cells were incubated for a further 30 min
r both for 1 hr prior to laser micro-irradiation. eYFP-fluorescence was tracked
ed using Slidebook6 software (n = 30 from three experimental repeats). Error
d with 53BP1 siRNA. 24 hr later, cells were transfected with either the eYFP-
s, cells were damaged using laser micro-irradiation. eYFP fluorescence was
tware (n = 30 from three experimental repeats). Error bars, 1 SD.
ds (ChromoTek), from benzonase-treated, g-irradiated HeLa cell lysates, and
ent 1/1,000 of the total sample used in the immunoprecipitation.
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Figure 3. Co-localization of pATM Is Dis-
rupted in 53BP1-BRCT2 Phospho-Binding
Mutants
(A) HeLa cells were reverse transfected with
53BP1 siRNA. 48 hr later, cells were transfected
with an siRNA-resistant construct containing wild-
type HA-53BP1, one of the BRCT mutants, or a
Tudor domain mutant (Y1502L). 16 hr after this,
cells were exposed to either 8 Gy for mock and
wild-type (WT) or 3 Gy of ionizing radiation for the
mutants and allowed to recover for 24 hr before
staining for HA and NBS1. Scale bar, 5 mm.
(B) As (A) but stained for pATM.
(C) Cells processed in (A) and (B) were analyzed by
measuring foci intensity of HA, pATM, and NBS1
(n = 30). Foci intensities were normalized to the
average wild-type foci intensity for their respective
channel. Normalized HA foci intensities from cells
transfected with either WT or BRCT mutants in-
dicates comparable expression of the plasmid
constructs. Graph shows average of three exper-
iments with 1 SD.
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persistent foci were due to damage sites in heterochromatin
(Goodarzi et al., 2008).
Biological Roles of 53BP1 Binding to gH2AX
To date, BRCT2 domains of three mammalian proteins—
MCPH1, PTIP, and MDC1—have been found to specifically
recognize the primary mark of DNA damage, gH2AX (Yan
et al., 2011; Stucki et al., 2005; Singh et al., 2012). Our
data show unambiguously that this is a property shared6 Cell Reports 13, 1–9, December 15, 2015 ª2015 The Authorsby the BRCT2 domain of 53BP1, and
that this interaction plays a role in the
biological functions of 53BP1—a very
similar conclusion was reached by
Kleiner et al. (2015). This observation
further strengthens the idea that 53BP1
is the functional ortholog of the fission
yeast and budding yeast proteins Crb2
and Rad9p (Hammet et al., 2007; Kil-
kenny et al., 2008).
Although the ability of the BRCT2
domain of 53BP1 to bind gH2AX contrib-
utes to efficient repair of DNA damage, it
is not required for initial recruitment of
53BP1 to IRIF in the immediate response
to DNA damage in G1. 53BP1 recruitment
is downstream of recognition of gH2AX
by MDC1, whose BRCT2 domain has a
higher affinity for gH2AX. Nonetheless,
once recruited to damaged chromatin
53BP1’s interaction with gH2AX would
be favored by its interaction with the other
post-translational modifications it recog-
nizes, and the gH2AX interaction might
only become functionally significant at a
later stage of the IRIF-centered repairprocesses or in specific situations such as the repair of damage
in heterochromatin, as we show here.
Recruitment and retention of 53BP1 at sites of DNA damage
facilitates co-localization and retention of other factors required
for signaling and repair (Panier and Boulton, 2014). In the case of
MRN, this is mediated by a phospho-independent interaction
between RAD50 and the 53BP1-BRCT2 (Lee et al., 2010). Re-
gions within the MRN complex have, in turn, been implicated in
recruiting and activating ATM at sites of DNA damage (Paull,
2015), but it is not clear what role these play in retaining pATM
Figure 4. Slow Repair of Damage in Hetero-
chromatin Is Defective in 53BP1-BRCT2
Phospho-Binding Mutants
(A) HeLa cells were reverse transfected with
53BP1 siRNA. 48 hr later, cells were transfected
with an siRNA-resistant construct containing wild-
type HA-tagged 53BP1 or one of the BRCT mu-
tants. 16 hr later, cells were exposed to 3 Gy of
ionizing radiation and allowed to recover for the
indicated time before staining for HA-53BP1 and
gH2AX. Higher numbers of gH2AX foci were
evident 24 hr after irradiation in siRNA-treated cells
and siRNA-treated cells transfected with 53BP1
mutant constructs.
(B) Quantitation of gH2AX focus persistence.
Graphs show the mean of three experiments; error
bars, 1 SD. 53BP1 constructs lacking the BRCT
domain or with point mutations that abrogate
gH2AX binding in vitro show significantly higher
levels of persistent gH2AX foci than wild-type
(one-way ANOVA).
(C) As (A) but with 53BP1 and/or KAP-1 siRNA.
Persistence of significantly higher levels of gH2AX
foci in the presence of 53BP1 mutants is sup-
pressed when KAP-1 is also knocked down, indi-
cating that persistence is due to a defect in KAP-1
phosphorylation by ATM as a result of the failure of
the 53BP1 mutants to localize pATM to hetero-
chromatinized sites of damage.
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that focal concentration and retention of pATM at slowly repaired
sites of DNA damage in G1 (Noon et al., 2010) is independent of
MRN recruitment but dependent on 53BP1 recruitment and,Cell Reports 13, 1–9significantly, the histone modifications it
engages with. Thus, while removal of the
ability of 53BP1 to bind gH2AX does not
affect focal co-localization of MRN and
53BP1, it substantially reduces pATM
localization, which, in turn, results in a
defect in DSB repair in heterochromatin.
These data highlight a role for the
53BP1-BRCT2 domain in reinforcing links
between MRN complexes and chromatin
modification, via its phosphorylation-
independent interaction with RAD50
(Noon et al., 2010) and its phosphoryla-
tion-dependent interaction with gH2AX.
The means by which 53BP1 facilitates
pATM concentration and retention in
IRIFs remains unclear. There is little indi-
cation in the literature of a direct interac-
tion of ATM with 53BP1, although both
proteins have well-documented interac-
tions with other proteins in common.
The dependence we demonstrate here
on 53BP1’s ability to bind gH2AX sug-
gests that this is likely to involve complex
features of local chromatin conformation
and histone modifications and furtherwork will be required to define this. It is highly likely that other
of the myriad functions of 53BP1 will also involve this hitherto
disregarded property of 53BP1, and work is ongoing to uncover
and characterize these., December 15, 2015 ª2015 The Authors 7
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See the Supplemental Experimental Procedures for full details.
Protein Expression and Purification
Proteins for biochemical and structural analysis were expressed in E. coli and
purified by affinity and conventional chromatography.
Fluorescence Polarization Experiments
Binding to BRCT2 domains was determined using fluorescein-labeled pep-
tides and His6-SUMO-BRCT2 fusion proteins. Dissociation constants (KD)
were determined by non-linear regression to a one site-specific bindingmodel.
Crystallization, X-Ray Diffraction Data Collection, Phasing, Model
Building, and Refinement
Crystals of P53Core/53BP1-BRCT2 were grown by vapor diffusion and
soaked with the gH2AX-pS139 peptide (pSQEY) for 60 min prior to plunge-
freezing in liquid nitrogen. Diffraction data were collected at the Diamond
Synchrotron Lightsource, and the structure was determined by molecular
replacement.
Tissue Culture, Cell Lines, and Reagents
HeLa, H2AX+/+, and H2AX/ mouse embryonic fibroblast (MEF) cells were
cultured in DMEM supplemented with 10% (v/v) fetal calf serum (FCS), peni-
cillin, streptomycin, and L-glutamine. Caffeine (Sigma-Aldrich) was used at a
final concentration of 10 mM. ATMi (KU55933, Abcam), DNA-PKi (NU7441,
Santa Cruz Biotechnology), and ATRi (ATR-kinase inhibitor II, Merck Millipore)
were all used at a concentration of 10 mM, except for the CHK1 inhibitor UCN-
01 (Sigma-Aldrich) that was used at a concentration of 200 nM. Cells were irra-
diated using a Caesium137 gamma source.
siRNA Depletion of 53BP1/KAP-1 and siRNA-Resistant Expression
of 53BP1
HeLa cells were seeded at high confluence onto 35-mm plates and reverse
transfected with either 53BP1-siRNA or negative control oligonucleotides
diluted into serum free media Cells were cultured for a further 48 hr for efficient
depletion. Subsequently cells were transfected with 53BP1 constructs
rendered siRNA-resistant by three silent point mutations in the 53BP1 cDNA
clone in pCMH6K (A231G, A234G, and A237C) (Noon et al., 2010) and incu-
bated for a further 16 hr before irradiation.
Antibodies
All antibodies used were from standard commercial sources (see the Supple-
mental Experimental Procedures for full details).
Immunofluorescence
Cells were fixed on coverslips and washed three times before incubation at
room temperature with the primary antibodies. Cells were washed a further
three times before incubation with the secondary, fluorophore-coupled, anti-
bodies, and washed a final three times before mounting on glass slides with
DAPI mounting media.
Live-Cell Imaging and UV-Laser Microirradiation
Cells were seeded at low confluence before 53BP1 depletion by siRNA, and
eYFP-SV40NLS-53BP1-BRCT2 plasmid constructs were transfected into cells.
Cells were incubated for 20 min with 100 mg/ml Hoechst 34580 prior to excita-
tion with a 405-nm laser. Protein localization was tracked over 3 min using a
488-nm laser.
GFP-Trap
Stable cell lines were generated for HeLa cells transfected with wild-type or
R1811E mutant forms of the eYFP-SV40NLS-53BP1-BRCT2 expression
construct. Cellular lysates were generated by re-suspension of frozen pellets,
and incubated with GFP-Trap A resin. Retained protein was detected by
chemiluminescent western blot.8 Cell Reports 13, 1–9, December 15, 2015 ª2015 The AuthorsACCESSION NUMBERS
The accession number for the crystallographic data reported here is PDB:
5ECG.
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Supplemental Information includes Supplemental Experimental Procedures,
four figures, one table, and three movies and can be found with this article
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